ID	Source	Molecule	Alias (molecule)	DNA/mRNA/Protein	State (molecule)	Modifier	Alias (modifier)	Relationship	Drug (Therapy)	Alias (drug)	Model	H	Cases	Reference	Notes1	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	17-AAG	Tanespimycin (17-allylamino-17-demethoxygeldanamycin)	3	1		"Da Rocha Dias S, Cancer Res 2005, 65:10686-91"	17-AAG is a HSP90 inhibitor2	Melanoma	GSK3B		mRNA	downregulated by	GSK3B siRNA		sensitivity to	Sorafenib	Nexavar (R)	3	1		"Panka DJ, J Biol Chem 2008, 283:726-32"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor"6	Melanoma	TYRO3	"Sky, TYRO3 protein tyrosine kinase "	mRNA	downregulated by	TYRO3 siRNA		sensitivity to	Cisplatin	CDDP	3	1		"Zhu S, Proc Natl Acad Sci USA 2009, 106:17025-30"	TYRO3 inhibition by siRNA (small interfering RNA) increases the therapeutic effect of cisplatin. TYRO3 induces MITF-M expression in a SOX10-dependent manner in melanoma cells11	Endothelial cells	CXCR1		mRNA	expressed			sensitivity to	CXCR1 siRNA		4	1		"Singh S, Int J Cancer 2010, 126:328-36"	"Inhibition of CXCR1 (receptor for IL-8, an angiogenic factor) expression by small interfering RNA has therapeutic effect"12	Melanoma	KIT 	c-KIT	DNA	mut V560A (exon 11)			sensitivity to	Sorafenib	Nexavar (R)	5	1	1	"Quintas-Cardama A, Nat Clin Pract Oncol 2008, 5:737-40"	Mucosal melanoma; no active control trial (historical comparison). Sorafenib: BRAF CRAF VEGFR PDGFR inhibitor16	Melanoma	KIT 	c-KIT	DNA	mut K642E (exon 13)			sensitivity to	Imatinib	Gleevec (R)	5	1	1	"Lutzky J, Pigment Cell Melanoma Res 2008, 21:492-3"	Mucosal melanoma; no active control trial (historical comparison)20	Melanoma	ERBB3	HER3	mRNA	downregulated by	HER3 siRNA		sensitivity to	Dacarbazine	DTIC	3	1		"Reschke M, Clin Cancer Res 2008, 14:5188-97"	HER3 silencing increases DTIC activity23	Melanoma	HERG	KCNH2	mRNA	expressed			sensitivity to	HERG siRNA		3	1		"Afrasiabi E, Cell Signal 2010, 22:57-64"	HERG siRNA reduces cell proliferation and migration. HERG is a potassium voltage-gated channel family24	Melanoma	E2F1	E2F1 transcription factor	mRNA	expressed			sensitivity to	E2F1 siRNA		4	1		"Alla V, J Natl Cancer Inst 2010, 102:127-33 "	"E2F1 siRNA effect is abolished by blocking the EGFR pathway: thus, E2F1 acts by transactivating EGFR"25	Melanoma	KIT 	c-KIT	protein	expressed			sensitivity to	Imatinib	Gleevec (R)	3	1		"All-Ericsson C, Invest Ophthalmol Vis Sci 2004, 45:2075-82"	"Uveal melanoma; no KIT mutations found. The results confirm that c-Kit is vastly expressed in uveal melanoma, suggest that the c-Kit molecular pathway may be important in uveal melanoma growth, and point to its use as a target for therapy with imatinib (STI571)"27	Melanoma	KIT 	c-KIT	DNA	mut D820Y			sensitivity to	Sunitinib	Sutent (R)	3	1		"Ashida A, Int J Cancer 2009, 124:862-8"	"Acral lentiginous melanoma. Sunitinib is a small molecule inhibitor of various receptor tyrosine kinases such as VEGFR, PDGFR, KIT, RET. A significant growth suppressive effect of sunitinib was observed in an acral melanoma cell line harboring the D820Y mutation "28	Melanoma	KIT 	c-KIT	DNA	mut D820Y			no relationship with	Imatinib	Gleevec (R)	3	0		"Ashida A, Int J Cancer 2009, 124:862-8"	"Acral lentiginous melanoma. While imatinib did not affect the proliferation of SM3 cells, sunitinib showed marked growth inhibition against this cell harboring the D820Y mutation "31	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 		expressed			resistance to	Temozolomide	TMZ	3	-1		"Augustine CK, Clin Cancer Res 2009, 15:502-10"	"MGMT showed a significant correlation with temozolomide sensitivity (MGMT activity, P < 0.0001; MGMT expression, P ≤ 0.0001). "32	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	active (high activity)			resistance to	Temozolomide	TMZ	3	-1		"Augustine CK, Clin Cancer Res 2009, 15:502-10"	"MGMT showed a significant correlation with temozolomide sensitivity (MGMT activity, P < 0.0001; MGMT expression, P ≤ 0.0001). "33	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	DNA	methylated			no relationship with	Temozolomide	TMZ	3	0		"Augustine CK, Clin Cancer Res 2009, 15:502-10"	No correlation was observed between MGMT promoter methylation status at the target regions evaluated and response to temozolomide 34	Melanoma	EPAC		mRNA	expressed			sensitivity to	EPAC siRNA		3	1		"Baljinnyam E, Am J Physiol Cell Physiol 2009, 297:C802-13"	Silencing of EPAC (an effector molecule of cAMP) inhibits melanoma cell migration35	Melanoma	Mcl-1			expressed			resistance to	ARC		3	-1		"Bhat UG, Cell Cycle 2008, 7:1851-5"	ARC is a transcriptional inhibitor (nucleoside analog)37	Melanoma	Mcl-1			expressed			resistance to	Siomycin A		3	-1		"Bhat UG, Cell Cycle 2008, 7:1851-5"	Siomycin A: FoxM1 inhibitor40	Melanoma	KIT 	c-KIT	DNA	amplified (gene)			sensitivity to	Imatinib	Gleevec (R)	5	1	1	"Carvajal RD, J Clin Oncol 27:15s, 2009 (suppl; abstr 9001)"	Acral and mucosal melanoma; no active control trial (historical comparison). Imatinib: KIT inhibitor41	Melanoma	KIT 	c-KIT	DNA	mut ? (exon 11)			sensitivity to	Imatinib	Gleevec (R)	5	1	3	"Carvajal RD, J Clin Oncol 27:15s, 2009 (suppl; abstr 9001)"	Acral and mucosal melanoma; no active control trial (historical comparison)42	Melanoma	BRAF	B-Raf	DNA	mut V600E			no relationship with	Sorafenib	Nexavar (R)	5	0	34	"Eisen T, Br J Cancer 2006, 95:581-6"	"Tumor response was not associated with BRAF mutation. Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor"43	Melanoma	BRAF	B-Raf	DNA	mut V600E			no relationship with	Sorafenib	Nexavar (R)	5	0	37	"Min CJ, J Clin Oncol 2008, 26: abstract 9072"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. Tumor response was minimal both in mutated and wild type BRAF patients"44	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	RAF-265		4	1		"Fecher LA, Pigment Cell Melanoma Res 2008, 21:410-1"	RAF 265 is a BRAF inhibitor45	Melanoma	BRAF	B-Raf	DNA	mut V600E			resistance to	Sorafenib	Nexavar (R)	3	-1		"McDermott U, Proc Natl Acad Sci USA 2007, 104:19936-41"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor"46	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	AZ628		3	1		"McDermott U, Proc Natl Acad Sci USA 2007, 104:19936-41"	AZ628 is a BRAF inhibitor47	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	PLX4032	RG7204	3	1		"Sala E, Mol Cancer Res 2008, 6:751-9"	PLX4032 is a BRAF inhibitor with high selectivity for mutated BRAF V600E48	Melanoma	BRAF	B-Raf	DNA	mut D595G			sensitivity to	Sorafenib	Nexavar (R)	4	1		"Smalley KS, Oncogene 2009, 28:85-94"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor"49	Melanoma	BRAF	B-Raf	DNA	mut G469E			sensitivity to	Sorafenib	Nexavar (R)	3	1		"Smalley KS, Oncogene 2009, 28:85-94"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor"50	Melanoma	BRAF	B-Raf	DNA	mut V600E			resistance to	Sorafenib	Nexavar (R)	3	-1		"Smalley KS, Oncogene 2009, 28:85-94"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor"51	Melanoma	BRAF (V600E)	B-Raf (V600E)	mRNA	downregulated by	BRAF V600E siRNA		sensitivity to	MITF siRNA		3	1		"Kido K, Cancer Sci 2009, 100:1863-9"	"In an in vitro model of human melanoma, silencing of MITF synergically increases the cytotoxic effect of BRAF V600E silencing"52	Melanoma	MITF	Microphthalmia-associated transcription factor 	mRNA	downregulated by	MITF siRNA		sensitivity to	BRAF V600E siRNA		3	1		"Kido K, Cancer Sci 2009, 100:1863-9"	"In an in vitro model of human melanoma, silencing of MITF synergically increases the cytotoxic effect of BRAF V600E silencing"53	Melanoma	KIT 	c-KIT	DNA	amplified (gene)			sensitivity to	Imatinib	Gleevec (R)	5	1	1	"Hodi FS, J Clin Oncol 2008, 26:2046-51"	Mucosal melanoma; no active control trial (historical comparison)54	Melanoma	"KIT, PDGFR"		protein	expressed			no relationship with	Imatinib	Gleevec (R)	5	0	12	"Hofmann UB, Clin Cancer Res 2009, 15:324-9"	"Uveal melanoma. In this phase II trial of imatinib for the treatment of advanced uveal melanoma, no objective response was observed, despite the fact that c-KIT was overexpressed in 55% of primary tumors and in 76% of metastatic samples (no KIT mutations found), and SCF was overexpressed in 43% of primary tumors and in 58% of metastatic samples"55	Melanoma	KIT 	c-KIT	protein	wild type			resistance to	Imatinib	Gleevec (R)	3	-1		"Jiang X, Clin Cancer Res 2008, 14:7726-32"	Imatinib mesylate had no effects on three cutaneous melanoma cell lines known to be KIT wild type56	Melanoma	KIT 	c-KIT	DNA	wild type			resistance to	Imatinib	Gleevec (R)	3	-1		"Jiang X, Clin Cancer Res 2008, 14:7726-32"	Mucosal melanoma.Mucosal melanoma cells exhibited imatinib sensitivity correlating with KIT mutational status (imatinib decreased proliferation and was cytotoxic to KIT mutated but not wild type melanoma cells)57	Melanoma	"KIT, PDGFR "		protein	expressed			no relationship with	Imatinib	Gleevec (R)	5	0	21	"Kim KB, Br J Cancer 2008, 99:734-40"	"Twenty-one patients whose melanoma expressed at least one PTK (c-kit, platelet-derived growth factor receptors, c-abl, or abl-related gene) were treated with 400 mg of imatinib twice daily. One patient with acral lentiginous melanoma and high KIT expression showed response. Imatinib at the studied dose had minimal clinical efficacy as a single-agent therapy for metastatic melanoma"59	Melanoma	KIT 	c-KIT	protein	expressed			no relationship with	Imatinib	Gleevec (R)	3	0		"Knight LA, Anticancer Drugs 2006, 17:649-55"	"No correlation of effect was noted with c-Kit, platelet-derived growth factor receptor-alpha or platelet-derived growth factor receptor-beta expression, assessed by immunohistochemistry"60	Melanoma	KIT 	c-KIT	protein	wild type			sensitivity to	Imatinib	Gleevec (R)	3	1		"Lefevre G, J Biol Chem 2004, 279:31769-79"	Uveal melanoma; no KIT mutations found61	Melanoma	KIT 	c-KIT	protein	expressed			no relationship with	Imatinib	Gleevec (R)	3	0		"Mayorga ME, Melanoma Res 2006, 16:127-35"	"Imatinib: small molecule inhibitor of tyrosine kinase receptors (TKR) such as KIT and PDGFR. This study supports an antiproliferative effect of imatinib (STI571) on cultured human cutaneous melanoma-derived cell lines: however, no relationship could be established between the expression of c-Kit, ABL, PDGFR-alpha or PDGFR-beta and the response of cell lines to STI571. The identification of an unknown target of STI571 in human cutaneous melanoma cells would allow the selection of patients who could benefit from this treatment"62	Melanoma	KIT 	c-KIT	protein	expressed			no relationship with	Imatinib	Gleevec (R)	4	0		"McGary EC, J Invest Dermatol 2004, 122:400-5"	Imatinib: small molecule inhibitor of tyrosine kinase receptors (TKR) such as KIT and PDGFR63	Melanoma	KIT 	c-KIT		uncharacterized			no relationship with	Imatinib	Gleevec (R)	5	0	13	"Penel N, Invest New Drugs 2008, 26:561-5"	Uveal melanoma (molecularly unselected patients)64	Melanoma	"KIT, PDGFR "		protein	expressed			no relationship with	Imatinib	Gleevec (R)	5	0	16	"Ugurel S, Br J Cancer 2005, 92:1398-405"	"This study did not reveal an efficacy of imatinib in advanced metastatic melanoma, regardless of the expression pattern of the imatinib target molecules c-Kit and PDGFR"65	Melanoma	KIT 	c-KIT	protein	wild type			resistance to	Imatinib	Gleevec (R)	3	-1		"Ugurel S, Br J Cancer 2005, 92:1398-405"	The melanoma cell lines showed a heterogenous expression of the imatinib target molecules without functional mutations in the corresponding amino-acid sequences. In vitro imatinib treatment of the cell lines showed no antiproliferative effect66	Melanoma	KIT 	c-KIT	DNA	mut L576P (exon 11)			resistance to	Imatinib	Gleevec (R)	3	-1		"Woodman SE, Mol Cancer Ther 2009, 8:2079-85"	"In vitro testing showed that the cell viability of the L576P mutant cell line was not reduced by imatinib, nilotinib, or sorafenib small molecule KIT inhibitors"67	Melanoma	KIT 	c-KIT	DNA	mut L576P (exon 11)			sensitivity to	Dasatinib		5	1	2	"Woodman SE, Mol Cancer Ther 2009, 8:2079-85"	"Mucosal melanoma. Two metastatic melanoma patients with the L576P KIT mutation were treated with dasatinib, including one patient previously treated with imatinib. Both patients had marked reduction (>50%) and elimination of tumor F18-fluorodeoxyglucose (FDG)-avidity by positron emission tomography (PET) imaging after dasatinib treatment. These data support the selective inhibitory effect of dasatinib against cells harboring the most common KIT mutation in melanoma, and thus has therapeutic implications for acrallentiginous, chronic sun-damaged, and mucosal melanomas"68	Melanoma	KIT 	c-KIT	DNA	mut L576P (exon 11)			sensitivity to	Dasatinib		3	1		"Woodman SE, Mol Cancer Ther 2009, 8:2079-85"	"The mutant melanoma cell line was sensitive to dasatinib. These data support the selective inhibitory effect of dasatinib against cells harboring the most common KIT mutation in melanoma, and thus has therapeutic implications for acrallentiginous, chronic sun-damaged, and mucosal melanomas"69	Melanoma	KIT 	c-KIT		uncharacterized			no relationship with	Imatinib	Gleevec (R)	5	0	26	"Wyman K, Cancer 2006, 106:2005-11"	Metastatic melanoma (molecularly unselected patients): no objective tumor response was observed71	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	active (high activity)			resistance to	Fotemustine		3	-1		"Christmann M, Int J Cancer 2001, 92:123-9"	"Determination of O6-methylguanine-DNA methyltransferase (MGMT) activity showed that MeWo cells that acquired resistance to fotemustine upon repeated treatment with the drug display high MGMT activity, whereas the parental cell line had no detectable MGMT"73	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	"mRNA, protein"	expressed			resistance to	Fotemustine		3	-1		"Christmann M, Int J Cancer 2001, 92:123-9"	"Compared with control cells, both MGMT mRNA and MGMT protein were expressed at a high level in fotemustine resistant cells"74	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	DNA	methylated			resistance to	Fotemustine		3	-1		"Christmann M, Int J Cancer 2001, 92:123-9"	There was only an insignificant difference in the CpG methylation pattern of the MGMT promoter whereas a clear hypermethylation in the body of the gene was observed in fotemustine resistant cells: MGMT gene (not promoter) hypermethylation leads to MGMT overexpression and thus chemoresistance76	Melanoma	Caveolin-1	Cav-1	mRNA	expressed			sensitivity to	Cav-1 siRNA		3	1		"Felicetti F, Int J Cancer 2009, 125:1514-22"	Cav-1 knockdown by siRNA has therapeutic activity in this model77	Melanoma	FGF-2	Fibroblast growth factor 2 (bFGF)	protein	expressed			no relationship with	Docetaxel		3	0		"Fontijn D, Mol Cancer Ther 2007, 6:2807-15"	bFGF overexpression can result in resistance against temozolomide mediated by demethylation of the O6-methylguanine-DNA-methyltransferase promoter78	Melanoma	FGF-2	Fibroblast growth factor 2 (bFGF)	protein	expressed			no relationship with	Doxorubicin	Adriamycin (R)	3	0		"Fontijn D, Mol Cancer Ther 2007, 6:2807-15"	bFGF overexpression can result in resistance against temozolomide mediated by demethylation of the O6-methylguanine-DNA-methyltransferase promoter79	Melanoma	FGF-2	Fibroblast growth factor 2 (bFGF)	protein	expressed			resistance to	Temozolomide	TMZ	3	-1		"Fontijn D, Mol Cancer Ther 2007, 6:2807-15"	bFGF overexpression can result in resistance against temozolomide mediated by demethylation of the O6-methylguanine-DNA-methyltransferase promoter81	Melanoma	NQO1	NADPH quinone oxidoreductase		downregulated			resistance to	17-AAG	Tanespimycin (17-allylamino-17-demethoxygeldanamycin)	3	-1		"Gaspar N, Cancer Res 2009, 69:1966-75"	Decreased expression of NQO1 is associated with resistance to 17-AAG82	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	expressed			resistance to	6-thioguanine		3	-1		"Gefen N, Cancer Biol Ther 2010, 9:49-55"	Acquired resistance to 6-thioguanine in melanoma cells involves the repair enzyme O6-methylguanine-DNA methyltransferase (MGMT)86	Melanoma	SCF		protein	expressed			no relationship with	Imatinib	Gleevec (R)	5	0	12	"Hofmann UB, Clin Cancer Res 2009, 15:324-9"	"Uveal melanoma. In this phase II trial of imatinib for the treatment of advanced uveal melanoma, no objective response was observed, despite the fact that c-KIT was overexpressed in 55% of primary tumors and in 76% of metastatic samples (no KIT mutations found), and SCF was overexpressed in 43% of primary tumors and in 58% of metastatic samples"93	Melanoma	S100A2		mRNA	expressed			sensitivity to	Rexinoid + Rosiglitazone		3	1		"Klopper JP, PPAR Res 2010, 2010:729876"	"Rexinoid: RXR ligand. Rosiglitazone: PPAR ligand. Overexpression of S100A2 enhanced the effect of rexinoid and thiazolidinedione (TZD) treatment while inhibition of S100A2 expression attenuated the response to rexinoid/TZD treatment, suggesting that S100A2 is necessary for optimal response to RXR and PPARgamma activation by respective ligands "94	Melanoma	PDGFRA	PDGF receptor alpha	protein	expressed			no relationship with	Imatinib	Gleevec (R)	3	0		"Knight LA, Anticancer Drugs 2006, 17:649-55"	"No correlation of effect was noted with c-kit, platelet-derived growth factor receptor-alpha or platelet-derived growth factor receptor-beta expression, assessed by immunohistochemistry"95	Melanoma	PDGFRB	PDGF receptor beta	protein	expressed			no relationship with	Imatinib	Gleevec (R)	3	0		"Knight LA, Anticancer Drugs 2006, 17:649-55"	"No correlation of effect was noted with c-kit, platelet-derived growth factor receptor-alpha or platelet-derived growth factor receptor-beta expression, assessed by immunohistochemistry"96	Melanoma	Syndecan-2		mRNA	expressed			sensitivity to	Syndecan-2 siRNA		3	1		"Lee JH, J Biol Chem 2009, 284:27167-75"	"Overexpression of syndecan-2 enhanced migration and invasion of melanoma cells, whereas the opposite was observed when syndecan-2 levels were knocked down using small inhibitory RNAs"101	Melanoma	JUN	c-JUN	mRNA	expressed			sensitivity to	JUN siRNA		4	1		"Lopez-Bergami P, J Biol Chem 2010, 285:903-13"	c-JUN upregulates PDK1 transcription which increases AKT and PKC activity by phosphorylation102	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	expressed			resistance to	Dacarbazine based chemotherapy		5	-1	79	"Ma S, Br J Cancer 2003, 89:1517-23"	There was an inverse relationship between MGMT expression and clinical response to DTIC-based chemotherapy103	Host	MGMT	O-6-methylguanine-DNA methyltransferase 	DNA	polymorphism I143V			no relationship with	Dacarbazine based chemotherapy		5	0	79	"Ma S, Br J Cancer 2003, 89:1517-23"	There was no evidence that these variants decreased the MGMT DNA repair activity compared to the wild-type protein104	Host	MGMT	O-6-methylguanine-DNA methyltransferase 	DNA	polymorphism K178R			no relationship with	Dacarbazine based chemotherapy		5	0	79	"Ma S, Br J Cancer 2003, 89:1517-23"	There was no evidence that these variants decreased the MGMT DNA repair activity compared to the wild-type protein105	Host	MGMT	O-6-methylguanine-DNA methyltransferase 	DNA	polymorphism L84F			no relationship with	Dacarbazine based chemotherapy		5	0	79	"Ma S, Br J Cancer 2003, 89:1517-23"	There was no evidence that these variants decreased the MGMT DNA repair activity compared to the wild-type protein106	Melanoma	Galectin-1		mRNA	downregulated by	Galectin-1 siRNA		sensitivity to	Temozolomide	TMZ	2	1		"Mathieu V, J Invest Dermatol 2007, 127:2399-410"	"Galectin-1 protects from TMZ likely because it reduces the lysosomal release of cathepsin-B, which mediates autophagy (a process promoted by TMZ)"107	Melanoma	PDGFRA	PDGF receptor alpha	protein	expressed			no relationship with	Imatinib	Gleevec (R)	3	0		"Mayorga ME, Melanoma Res 2006, 16:127-35"	"Imatinib: small molecule inhibitor of tyrosine kinase receptors (TKR) such as KIT and PDGFR. This study supports an antiproliferative effect of imatinib (STI571) on cultured human cutaneous melanoma-derived cell lines: however, no relationship could be established between the expression of c-Kit, ABL, PDGFR-alpha or PDGFR-beta and the response of cell lines to STI571. The identification of an unknown target of STI571 in human cutaneous melanoma cells would allow the selection of patients who could benefit from this treatment"108	Melanoma	PDGFRB	PDGF receptor beta	protein	expressed			no relationship with	Imatinib	Gleevec (R)	3	0		"Mayorga ME, Melanoma Res 2006, 16:127-35"	"Imatinib: small molecule inhibitor of tyrosine kinase receptors (TKR) such as KIT and PDGFR. This study supports an antiproliferative effect of imatinib (STI571) on cultured human cutaneous melanoma-derived cell lines: however, no relationship could be established between the expression of c-Kit, ABL, PDGFR-alpha or PDGFR-beta and the response of cell lines to STI571. The identification of an unknown target of STI571 in human cutaneous melanoma cells would allow the selection of patients who could benefit from this treatment"110	Melanoma	PDGFR	PDGF receptor	protein	expressed			no relationship with	Imatinib	Gleevec (R)	4	0		"McGary EC, J Invest Dermatol 2004, 122:400-6"	Imatinib: small molecule inhibitor of tyrosine kinase receptors (TKR) such as KIT and PDGFR111	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	expressed			resistance to	Temozolomide	TMZ	3	-1		"Mhaidat NM, Br J Cancer 2007, 97:1225-33"	Inhibition of MGMT with O6-benzylguanine resulted in decrease in cell viability and this correlated with western blot analysis of MGMT levels in the melanoma cells113	Melanoma	p53	TP53	DNA	wild type (vs mutated)			sensitivity to	Temozolomide	TMZ	3	1		"Mhaidat NM, Br J Cancer 2007, 97:1225-33"	Melanoma cells with wild type p53 had much reduced viability in the presence of TMZ compared to melanoma cells with mutated p53115	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	expressed			no relationship with	Temozolomide	TMZ	5	0	50	"Middleton MR, Br J Cancer 1998, 78:1199-202"	Measurements of pretreatment levels of MGMT in melanoma biopsies did not predict for response to temozolomide117	Plasma/serum	LDH		protein	expressed			resistance to	Biochemotherapy		5	-1	135	"Minor DR, Oncologist 2009, 14:995-1002"	Original: normal levels are associated with sensitivity to biochemotherapy120	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	active (high activity)			resistance to	Fotemustine		3	-1		"Naumann SC, Br J Cancer 2009, 100:322-33"	"The O(6)-methylguanine-DNA methyltransferase (MGMT) activity in the cell lines was between 0 and 1100 fmol mg(-1) protein, and there was a correlation between MGMT activity and the level of resistance to TMZ and fotemustine"121	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	active (high activity)			resistance to	Temozolomide	TMZ	3	-1		"Naumann SC, Br J Cancer 2009, 100:322-33"	"The O(6)-methylguanine-DNA methyltransferase (MGMT) activity in the cell lines was between 0 and 1100 fmol mg(-1) protein, and there was a correlation between MGMT activity and the level of resistance to TMZ and fotemustine"124	Melanoma	p53	TP53	DNA	wild type (vs mutated)			resistance to	Fotemustine		3	-1		"Naumann SC, Br J Cancer 2009, 100:322-33"	"Melanoma lines expressing p53 wild-type were more resistant to TMZ and fotemustine than p53 mutant melanoma lines, which is in marked contrast to previous data reported for glioma cells treated with TMZ"125	Melanoma	p53	TP53	DNA	wild type (vs mutated)			resistance to	Temozolomide	TMZ	3	-1		"Naumann SC, Br J Cancer 2009, 100:322-33"	"Melanoma lines expressing p53 wild-type were more resistant to TMZ and fotemustine than p53 mutant melanoma lines, which is in marked contrast to previous data reported for glioma cells treated with TMZ"126	Melanoma	ROR2	Receptor tyrosine kinase-like orphan receptor 2	mRNA	expressed			sensitivity to	ROR2 siRNA		2	1		"O'Connell MP, Oncogene 2010, 29:34-44"	Reduction of ROR2 (which mediates Wnt5A signaling in melanoma cells) results in a decrease in the invasion and metastasis of melanoma cells in vivo129	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	mRNA	upregulated by	MGMT genetic engineering		resistance to	Temozolomide	TMZ	3	-1		"Passagne I, Toxicol Appl Pharmacol 2006, 211:97-105"	O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin-C130	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	mRNA	upregulated by	MGMT genetic engineering		sensitivity to	Mitomycin-C	MMC	3	1		"Passagne I, Toxicol Appl Pharmacol 2006, 211:97-105"	O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin-C131	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	mRNA	upregulated by	MGMT genetic engineering		resistance to	Fotemustine		3	-1		"Passagne I, Toxicol Appl Pharmacol 2006, 211:97-106"	O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin-C134	Melanoma	PAEP	Progestagen associated endometrial protein	mRNA	expressed			sensitivity to	PAEP siRNA		4	1		"Ren S, J Cell Mol Med 2010, 14:1432-42"	Silencing of PAEP shows anti-melanoma activity in a xenograft model136	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	expressed			no relationship with	Temozolomide	TMZ	5	0	49	"Rietschel P, J Clin Oncol 2008, 26:2299-304"	"In this phase II study of extended-dose TMZ in patients with advanced melanoma, tumor response did not correlate with MGMT expression or promoter methylation, suggesting that other resistance mechanisms are important"137	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	DNA	methylated			no relationship with	Temozolomide	TMZ	5	0	49	"Rietschel P, J Clin Oncol 2008, 26:2299-304"	"In this phase II study of extended-dose TMZ in patients with advanced melanoma, tumor response did not correlate with MGMT expression or promoter methylation, suggesting that other resistance mechanisms are important"139	Melanoma	FKBP51	FK506 binding protein 51	mRNA	downregulated by	FKBP51 siRNA		sensitivity to	Radiotherapy		4	1		"Romano S, Cell Death Differ 2010, 17:145-57"	Radiotherapy effect is increased by FKBP51 siRNA and thus FKBP51 is defined by the authors a radiotherapy resistance molecule141	Endothelial cells	Laminin-421		protein	expressed			sensitivity to	Laminin antibody (antagonist)		3	1		"Saito N, Pigment Cell Melanoma Res 2009, 22:601-10"	"In an in vitro model, antibody blockage of lymphatic endothelial cell laminin-421 inhibits migratory ability of melanoma cells"142	Melanoma	gp100	Pmel-17	mRNA	downregulated by	gp100 siRNA		sensitivity to	Methotrexate	MTX	3	1		"Sánchez del Campo L, Pigment Cell Melanoma Res 2009, 22:588-600"	Inhibition of melanosome related protein gp100 leads to reduced drug sequestration into melanosomes and following drug exocytosis through the folate receptor alpha154	Melanoma	"CDK4, KIT"			expressed			sensitivity to	Imatinib	Gleevec (R)	4	1		"Smalley KS, Cancer Res 2008, 68:5743-52"	Cell lines overexpressing both CDK4 and KIT are sensitive to imatinib157	Melanoma	CRAF	C-Raf		expressed			sensitivity to	Sorafenib	Nexavar (R)	4	1		"Smalley KS, Oncogene 2009, 28:85-94"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. CRAF seems to act through Bcl-2"158	Melanoma	ERK		protein	phosphorylated (activated)			sensitivity to	Sorafenib	Nexavar (R)	3	1		"Smalley KS, Oncogene 2009, 28:85-94"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor"159	Melanoma	S100B			expressed			sensitivity to	Pentamidine (S100B inhibitor)		3	1		"Smith J, Anticancer Drugs 2010, 21:181-5"	Pentamidine (antibiotic used against Pneumocystis Carinii and Trypanosoma Cruzi) inhibits S100B that binds to and inhibits p53162	Melanoma	mTOR	Mammalian target of rapamycin		expressed			sensitivity to	Rapamycin	Sirolimus	4	1		"Thallinger C, Pharmacology 2008, 82:233-8"	"The oral rapamycin treatment had an antineoplastic effect, ranging from 35 to 78% tumor weight reduction compared with the saline group"163	Melanoma	Tyrosinase			expressed			sensitivity to	Dacarbazine + Quercetin		3	1		"Thangasamy T, Cell Oncol 2008, 30:371-87"	Tyrosinase overexpression promotes ATM-dependent p53 phosphorylation by quercetin and sensitizes melanoma cells to dacarbazine168	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	expressed			no relationship with	Fotemustine		5	0	34	"Voelter V et al, Int J Cancer 2008, 123:1215-8"	Uveal melanoma. These results do not support MGMT methylation status or protein expression as predictive markers for treatment outcome to intra-arterial chemotherapy with alkylating agents169	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	DNA	methylated			no relationship with	Fotemustine		5	0	34	"Voelter V et al, Int J Cancer 2008, 123:1215-8"	Uveal melanoma. These results do not support MGMT methylation status or protein expression as predictive markers for treatment outcome to intra-arterial chemotherapy with alkylating agents173	Melanoma	gp100	Pmel-17		expressed			resistance to	Cisplatin	CDDP	3	-1		"Xie T, Cancer Res 2009, 69:992-9"	Expression of gp100 (involved in melanin metabolism ) antagonizes cisplatin activity. These data provide the first direct evidence that melanosomal regulatory genes influence drug sensitivity and that the presence of mature melanosomes likely contributes to melanoma resistance to therapy. The melanoma MelFB lost gp100/Pmel17 expression through immunoselection; the congenic cell line MelFB + gp100/Pmel17 was derived from MelFB by the transduction of gp100/Pmel17 into MelFB175	Melanoma	TRAILR1	DR4		expressed			sensitivity to	TRAIL		3	1		"Zhang XD, Cancer Res 1999, 59:2747-53"	Surface expression of TRAIL-R1 and -R2 (but not TRAIL-R3 and -R4) showed an overall correlation with TRAIL-induced apoptosis176	Melanoma	TRAILR2	DR5		expressed			sensitivity to	TRAIL		3	1		"Zhang XD, Cancer Res 1999, 59:2747-53"	Surface expression of TRAIL-R1 and -R2 (but not TRAIL-R3 and -R4) showed an overall correlation with TRAIL-induced apoptosis178	Melanoma	TYRO3	"Sky, TYRO3 protein tyrosine kinase "	mRNA	expressed			sensitivity to	TYRO3 siRNA		4	1		"Zhu S, Proc Natl Acad Sci USA 2009, 106:17025-30"	The receptor protein tyrosine kinase TYRO3 is an upstream regulator of MITF expression (TYRO3 induces MITF-M expression in a SOX10-dependent manner in melanoma cells). Its knockdown shows antimelanoma activity in a xenograft model179	Melanoma	TYRO3	"Sky, TYRO3 protein tyrosine kinase "	mRNA	downregulated by	TYRO3 siRNA		sensitivity to	Docetaxel		3	1		"Zhu S, Proc Natl Acad Sci USA 2009, 106:17025-30"	The receptor protein tyrosine kinase TYRO3 is an upstream regulator of MITF expression (TYRO3 induces MITF-M expression in a SOX10-dependent manner in melanoma cells). Its knockdown shows synergistic activity with docetaxel180	Melanoma	TYRO3	"Sky, TYRO3 protein tyrosine kinase "	mRNA	downregulated by	TYRO3 siRNA		no relationship with	Temozolomide	TMZ	3	0		"Zhu S, Proc Natl Acad Sci USA 2009, 106:17025-30"	The receptor protein tyrosine kinase TYRO3 is an upstream regulator of MITF expression (TYRO3 induces MITF-M expression in a SOX10-dependent manner in melanoma cells)181	Melanoma	GPNMB		protein	expressed			sensitivity to	CR011-vcMMAE		3	1		"Qian X, Mol Oncol 2008, 2:81-93"	"CR011-vcMMAE is a fully human monoclonal antibody to the extracellular domain of GPNMB, conjugated the cytotoxic agent monomethylauristatin E (MMAE)"182	Melanoma	ADK	Adenosine kinase	mRNA	downregulated by	ADK siRNA		resistance to	FAdo	Kinetin-riboside	3	-1		"Cabello CM, Biochem Pharmacol 2009, 77:1125-38"	FAdo is a purine derivative. Pharmacological and siRNA-based genetic inhibition of adenosine kinase (ADK) suppressed FAdo cytotoxicity and also prevented ATP depletion and p21 upregulation suggesting the importance of bioconversion of FAdo into the nucleotide form required for drug action184	Melanoma	CD147	Basigin		expressed			sensitivity to	CD147 siRNA		4	1		"Kanekura T, J Dermatol Sci 2010, 57:149-54"	"In a nude mouse model of pulmonary metastasis from melanoma, the metastatic potential of CD147-expressing melanoma cells injected into the tail vein is abolished by CD147 silencing"190	Melanoma	Argininosuccinate synthetase			expressed			resistance to	Arginine deiminase	ADI	3	-1		"Tsai WB, Mol Cancer Ther 2009, 8:3223-33"	"The sensitivity of melanoma to ADI treatment is based on its auxotrophy for arginine due to a lack of argininosuccinate synthetase (AS) expression, the rate-limiting enzyme for the de novo biosynthesis of arginine; induction of AS expression is associated with resistance to ADI"191	Melanoma	MEK1		DNA	mut P124L			resistance to	AZD6244		5	-1	1	"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6"	AZD6244 is a MEK inhibitor. The mutation found in a drug resistant human melanoma was demonstrated to be responsible for drug resistance in an in vitro human model192	Melanoma	MEK1		DNA	mut I103N			resistance to	AZD6244		3	-1		"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6"	AZD6244 is a MEK inhibitor193	Melanoma	MEK1		DNA	mut L115P			resistance to	AZD6244		3	-1		"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6"	AZD6244 is a MEK inhibitor194	Melanoma	MEK1		DNA	mut F129L			resistance to	AZD6244		3	-1		"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6"	AZD6244 is a MEK inhibitor195	Melanoma	MEK1		DNA	mut V211D			resistance to	AZD6244		3	-1		"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6"	AZD6244 is a MEK inhibitor196	Melanoma	MEK1		DNA	mut Q56P			resistance to	AZD6244		3	-1		"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6"	AZD6244 is a MEK inhibitor197	Melanoma	MEK1		DNA	mut P124L			resistance to	CI-1040	PD184352	3	-1		"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6"	CI-1040 is a MEK inhibitor198	Melanoma	MEK1		DNA	mut I103N			resistance to	CI-1040	PD184352	3	-1		"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6"	CI-1040 is a MEK inhibitor199	Melanoma	MEK1		DNA	mut L115P			resistance to	CI-1040	PD184352	3	-1		"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6"	CI-1040 is a MEK inhibitor200	Melanoma	MEK1		DNA	mut F129L			resistance to	CI-1040	PD184352	3	-1		"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6"	CI-1040 is a MEK inhibitor201	Melanoma	MEK1		DNA	mut V211D			resistance to	CI-1040	PD184352	3	-1		"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6"	CI-1040 is a MEK inhibitor202	Melanoma	MEK1		DNA	mut Q56P			resistance to	CI-1040	PD184352	3	-1		"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6"	CI-1040 is a MEK inhibitor203	Melanoma	MEK1		DNA	mut P124L			resistance to	PLX 4720		3	-1		"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6"	PLX 4720 is a BRAF inhibitor (MEK mutation causes cross-resistance to this drug)204	Melanoma	MEK1		DNA	mut Q56P			resistance to	PLX 4720		3	-1		"Emery CM, Proc Natl Acad Sci USA 2009, 106:20411-6"	PLX 4720 is a BRAF inhibitor (MEK mutation causes cross-resistance to this drug)205	Melanoma	BRG1	SWI/SNF chromatin remodeling complex catalytic subunit		expressed			resistance to	Cisplatin	CDDP	3	-1		"Keenen B, Oncogene 2010, 29:81-92"	Re-introduction of BRG1 in BRG1-deficient SK-MEL5 cells enhanced expression of differentiation-specific MITF target genes and resistance to cisplatin206	Melanoma	ALK2		protein	expressed			sensitivity to	BMP7		3	1		"Na YR, Cancer Sci 2009, 100:2218-25"	"ALK2: BMP receptor. BMP7 treatment only slightly reduced cell growth rate, but induced mesenchymal-epithelial transition and reduced the invasion and migration ability"209	Melanoma	Noxa		mRNA	downregulated by	Noxa siRNA		resistance to	Obatoclax + Tunicamycin		3	-1		"Jiang CC, Neoplasia 2009, 11:945-55"	Tunicamycin is an endoplasmic reticulum (ER) stress inducer. Obatoclax is a BH3 mimetic (Mcl-1 inhibitor)211	Melanoma	Mcl-1		mRNA	downregulated by	Mcl-1 siRNA		sensitivity to	ABT-737		3	1		"Keuling AM, PLoS One 2009, 4:e6651"	"ABT-737 is a small molecule inhibitor of Bcl-2, Bcl-xL and Bcl-W. RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma, which is caspase-8 dependent"212	Melanoma	Caspase-8			expressed			sensitivity to	ABT-737 + Mcl-1 siRNA		3	1		"Keuling AM, PLoS One 2009, 4:e6651"	Basal levels of caspase-8 and Bid correlate with treatment sensitivity213	Melanoma	Bid			expressed			sensitivity to	ABT-737 + Mcl-1 siRNA		3	1		"Keuling AM, PLoS One 2009, 4:e6651"	Basal levels of caspase-8 and Bid correlate with treatment sensitivity214	Melanoma	DEK		mRNA	downregulated by	DEK siRNA		sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Khodadoust MS, Cancer Res 2009, 69:6405-13"	DEK (which is often upregulated in melanoma) transactivates Mcl-1216	Melanoma	STAT1	Signal transducer and activator of transcription 1 		expressed			resistance to	Doxorubicin	Adriamycin (R)	2	-1		"Khodarev NN, PLoS One 2009, 4:e5821"	"STAT1-high tumor cells also demonstrate resistance to IFN-gamma (IFNg), ionizing radiation and doxorubicin relative to parental B16F1 and low expressors of the IFN/STAT1 pathway (STAT1-low genotype)"217	Melanoma	STAT1	Signal transducer and activator of transcription 1 		expressed			resistance to	Radiotherapy		2	-1		"Khodarev NN, PLoS One 2009, 4:e5821"	"STAT1-high tumor cells also demonstrate resistance to IFN-gamma (IFNg), ionizing radiation and doxorubicin relative to parental B16F1 and low expressors of the IFN/STAT1 pathway (STAT1-low genotype)"218	Melanoma	STAT1	Signal transducer and activator of transcription 1 		expressed			resistance to	IFN gamma		2	-1		"Khodarev NN, PLoS One 2009, 4:e5821"	"STAT1-high tumor cells also demonstrate resistance to IFN-gamma (IFNg), ionizing radiation and doxorubicin relative to parental B16F1 and low expressors of the IFN/STAT1 pathway (STAT1-low genotype)"219	Melanoma	XBP-1			expressed			resistance to	Vincristine		3	-1		"Jiang CC, Neoplasia 2009, 11:436-47"	XBP-1 (an ER stress response protein) activates AKT. These results identify activation of the PI3K/Akt pathway by XBP-1-mediated signaling of the unfolded protein response as a resistance mechanism against docetaxel and vincristine in melanoma cells under ER stress220	Melanoma	XBP-1			expressed			resistance to	Docetaxel		3	-1		"Jiang CC, Neoplasia 2009, 11:436-47"	XBP-1 (an ER stress response protein) activates AKT. These results identify activation of the PI3K/Akt pathway by XBP-1-mediated signaling of the unfolded protein response as a resistance mechanism against docetaxel and vincristine in melanoma cells under ER stress221	Melanoma	ID2	Inhibitor of DNA binding 2		expressed			resistance to	TGF beta		3	-1		"Schlegel NC, Pigment Cell Melanoma Res 2009, 22:445-53"	Id2 suppression of p15 counteract TGFbeta-mediated growth inhibition of melanoma cells222	Melanoma	Tyrosinase			expressed			sensitivity to	TMECG	Epicatechin-3-gallate derivative	3	1		"Sánchez-del-Campo L, Mol Pharm 2009, 6:883-94"	TMECG is an anticancer prodrug (dihydrofolate reductase - DHFR - inhibitor; antifolate agent) activated by tyrosinase223	Melanoma	FLIP	c-FLIP		expressed			resistance to	Celastrol		1	-1		"Kim Y, Biotechnol Lett 2009, 31:945-52"	Celastrol is a triterpene with anti-oxidant and anti-inflammatory properties. Celastrol-resistant B16F10 melanoma cells had a higher expression level of c-FLIP(L) and Snail as compared with a sensitive cell line224	Melanoma	SLUG	Snail		expressed			resistance to	Celastrol		1	-1		"Kim Y, Biotechnol Lett 2009, 31:945-52"	Celastrol is a triterpene with anti-oxidant and anti-inflammatory properties. Celastrol-resistant B16F10 melanoma cells had a higher expression level of c-FLIP(L) and Snail as compared with a sensitive cell line227	Melanoma	BMF		DNA	mut A69P			sensitivity to	CI-1040	PD184352	3	1		"VanBrocklin MW, Cancer Res 2009, 69:1985-94"	"This mutation reduces BMF interaction with DLC2, which sequesters BMF to the cytoskeleton and in turn inhibits apoptosis"228	Melanoma	BMF		mRNA	downregulated by	BMF siRNA		resistance to	CI-1040	PD184352	3	-1		"VanBrocklin MW, Cancer Res 2009, 69:1985-94"	CI-1040: MEK inhibitor. BMF expression is necessary for MEK inhibition to be therapeutically effective229	Melanoma	B-catenin	Beta catenin	mRNA	downregulated by	B-catenin siRNA		sensitivity to	Decitabine	"5-AZA, 5-aza-2'-deoxycytidine "	3	1		"Halaban R, PLoS One 2009, 4:e4563"	Beta-catenin seems to act through MITF transactivation230	Melanoma	Clusterin			expressed			sensitivity to	Decitabine	"5-AZA, 5-aza-2'-deoxycytidine "	3	1		"Halaban R, PLoS One 2009, 4:e4563"	Decitabine induces clusterin expression (by demethylation) in sensitive melanoma cells and thus is proposed as a marker of sensitivity to 5-AZA233	Melanoma	ABCB8		mRNA	downregulated by	ABCB8 siRNA		sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Elliott AM, Mol Cancer Res 2009, 7:79-87"	"ABCB8 mediates the resistance to doxorubicin (but not other drugs) in melanoma cells, likely by protecting the mitochondrial genome"234	Melanoma	ABCB8		mRNA	downregulated by	ABCB8 siRNA		no relationship with	Paclitaxel	Taxol	3	0		"Elliott AM, Mol Cancer Res 2009, 7:79-87"	"ABCB8 mediates the resistance to doxorubicin (but not other drugs) in melanoma cells, likely by protecting the mitochondrial genome"235	Melanoma	ABCB8		mRNA	downregulated by	ABCB8 siRNA		no relationship with	Cisplatin	CDDP	3	0		"Elliott AM, Mol Cancer Res 2009, 7:79-87"	"ABCB8 mediates the resistance to doxorubicin (but not other drugs) in melanoma cells, likely by protecting the mitochondrial genome"236	Melanoma	ABCB8		mRNA	downregulated by	ABCB8 siRNA		no relationship with	5-Fluorouracil	5-FU	3	0		"Elliott AM, Mol Cancer Res 2009, 7:79-87"	"ABCB8 mediates the resistance to doxorubicin (but not other drugs) in melanoma cells, likely by protecting the mitochondrial genome"237	Melanoma	TGFBI			expressed			sensitivity to	Decitabine	"5-AZA, 5-aza-2'-deoxycytidine "	3	1		"Halaban R, PLoS One 2009, 4:e4563"	Decitabine induces TGFBI expression (by demethylation) in sensitive melanoma cells and thus is proposed as a marker of sensitivity to 5-AZA238	Melanoma	Tubulin beta class III	TUBB3		expressed			resistance to	Paclitaxel	Taxol	3	-1		"Akasaka K, J Invest Dermatol 2009, 129:1516-26"	20% of samples were TUBB3 negative and HDAC inhibition can restore TUBB3 expression239	Melanoma	STAT3	Signal transducer and activator of transcription 3 	protein	phosphorylated (Ser-727)			sensitivity to	Oncostatin-M	OSM	3	1		"Lacreusette A, J Pathol 2009, 217:665-76"	Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin-M resistance in metastatic melanoma cells242	Melanoma	ICAM1	Intercellular adhesion molecule 1		expressed			resistance to	Lymphocyte lysis (immunotherapy)		3	-1		"Hamai A, Cancer Res 2008, 68:9854-64"	ICAM1 seems to act though activation of PI3K/AKT pathway243	Melanoma	STAT5	Signal transducer and activator of transcription 5 		expressed			sensitivity to	STAT5 dominant negative		3	1		"Hassel JC, Melanoma Res 2008, 18:378-85"	"Inhibition of STAT5 activity leads to melanoma apoptosis, likely by decreasing Bcl-xL expression; since STAT5 is activated by IFN, STAT5 phosphorylation might be a marker of IFN resistance"245	Melanoma	AMFR	"Autocrine motility factor receptor, gp78"	protein	targeted by	AMF	Autocrine motility factor (phosphoglucose isomerase)	sensitivity to	Paclitaxel	Taxol	2	1		"Kojic LD, PLoS One 2008, 3:e3597"	"Paclitaxel is selectively targeted to melanoma cells by AMF, which is the ligand of gp78 (which is overexpressed in malignant cells)"246	Melanoma	MFG-E8	Milk fat globule EGF-8		expressed			resistance to	Etoposide	VP-16	1	-1		"Jinushi M, Cancer Res 2008, 68:8889-98"	Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and Twist signaling in the tumor microenvironment250	Melanoma	GRP78	Glucose regulated protein 78	mRNA	downregulated by	GRP78 siRNA		sensitivity to	Cisplatin	CDDP	3	1		"Jiang CC, Carcinogenesis 2009, 30:197-204"	Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells251	Melanoma	GRP78	Glucose regulated protein 78	mRNA	downregulated by	GRP78 siRNA		sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Jiang CC, Carcinogenesis 2009, 30:197-204"	Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells255	Melanoma	FcgammaRIIB1			expressed			resistance to	ADCC		1	-1		"Cassard L, Int J Cancer 2008, 123:2832-9"	ADCC: NK cell-mediated antibody-dependent cellular cytotoxicity256	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	U0126	MEK inhibitor	3	1		"Smalley KS, Oncogene 2009, 28:85-94"	U0126: MEK inhibitor257	Melanoma	BRAF	B-Raf	DNA	mut K601E			sensitivity to	U0126	MEK inhibitor	3	1		"Smalley KS, Oncogene 2009, 28:85-94"	U0126: MEK inhibitor258	Melanoma	BRAF	B-Raf	DNA	mut D595G			resistance to	U0126	MEK inhibitor	3	-1		"Smalley KS, Oncogene 2009, 28:85-94"	U0126: MEK inhibitor259	Melanoma	BRAF	B-Raf	DNA	mut G469E			resistance to	U0126	MEK inhibitor	3	-1		"Smalley KS, Oncogene 2009, 28:85-94"	U0126: MEK inhibitor260	Melanoma	Cyclin D1		DNA	amplified (gene)			resistance to	SB590885		3	-1		"Smalley KS, Mol Cancer Ther 2008, 7:2876-83"	"SB590885 is a BRAF inhibitor. Increased cyclin D1 from genomic amplification contributes to BRAF inhibitor resistance of BRAF V600E-mutated melanomas, particularly in the context of a CDK4 mutation/overexpression"261	Melanoma	CDK4	Cyclin dependent kinase-4	DNA	mut K22Q			no relationship with	SB590885		3	0		"Smalley KS, Mol Cancer Ther 2008, 7:2876-83"	SB590885 is a BRAF inhibitor262	Melanoma	CDK4	Cyclin dependent kinase-4	DNA	mut R24C			no relationship with	SB590885		3	0		"Smalley KS, Mol Cancer Ther 2008, 7:2876-83"	SB590885 is a BRAF inhibitor263	Melanoma	CDK4	Cyclin dependent kinase-4	DNA	mut R24L			no relationship with	SB590885		3	0		"Smalley KS, Mol Cancer Ther 2008, 7:2876-83"	SB590885 is a BRAF inhibitor264	Melanoma	SOCS1	Suppressor of cytokine signaling 1	mRNA	downregulated by	SOCS1 siRNA		sensitivity to	IFN gamma		1	1		"Takahashi Y, Cancer Sci 2008, 99:1650-5"	IFN gamma-induced high SOCS-1 gene expression in B16-BL6 cells significantly interferes with the antiproliferative effect of IFN gamma265	Melanoma	AKT	PKB		expressed			sensitivity to	Sertraline		4	1		"Reddy KK, Pigment Cell Melanoma Res 2008, 21:451-6"	Sertraline (an antidepressant acting as selective seretonin reuptake inhibitor) inhibits AKT phosphorylation and has anti-melanoma activity266	Melanoma	Mcl-1		mRNA	downregulated by	Mcl-1 siRNA		sensitivity to	Tunicamycin		3	1		"Jiang CC, Cancer Res 2008, 68:6708-17"	Tunicamycin is an endoplasmic reticulum (ER) stress inducer267	Melanoma	Mcl-1		mRNA	downregulated by	Mcl-1 siRNA		sensitivity to	Thapsigargin		3	1		"Jiang CC, Cancer Res 2008, 68:6708-17"	Thapsigargin is an endoplasmic reticulum (ER) stress inducer268	Melanoma	Puma		mRNA	downregulated by	Puma siRNA		resistance to	Tunicamycin		3	-1		"Jiang CC, Cancer Res 2008, 68:6708-17"	Tunicamycin is an endoplasmic reticulum (ER) stress inducer269	Melanoma	Noxa		mRNA	downregulated by	Noxa siRNA		resistance to	Thapsigargin		3	-1		"Jiang CC, Cancer Res 2008, 68:6708-17"	Thapsigargin is an endoplasmic reticulum (ER) stress inducer270	Melanoma	Puma		mRNA	downregulated by	Puma siRNA		resistance to	Thapsigargin		3	-1		"Jiang CC, Cancer Res 2008, 68:6708-17"	Thapsigargin is an endoplasmic reticulum (ER) stress inducer271	Melanoma	Noxa		mRNA	downregulated by	Noxa siRNA		resistance to	Tunicamycin		3	-1		"Jiang CC, Cancer Res 2008, 68:6708-17"	Tunicamycin is an endoplasmic reticulum (ER) stress inducer272	Melanoma	Bcl-2		mRNA	downregulated by	Bcl-2 siRNA		sensitivity to	Mebendazole		3	1		"Doudican N, Mol Cancer Res 2008, 6:1308-15"	"Mebendazole (an anthelmintic drug) seems to act through Bcl-2 phosphorylation, which prevents Bcl-2 interaction with pro-apoptotic protein Bax"273	Melanoma	Noggin		mRNA	downregulated by	Noggin siRNA		sensitivity to	BMP7		4	1		"Hsu MY, Lab Invest 2008, 88:842-55"	BMP7 acts as an autocrine growth inhibitor in melanocytic cells and advanced melanoma cells may escape from BMP7-induced inhibition through concomitant aberrant expression of Noggin (BMP antagonist)274	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	AZ628		3	1		"Montagut C, Cancer Res 2008, 68:4853-61"	AZ628: RAF selective inhibitor275	Melanoma	CRAF	C-Raf		expressed			resistance to	AZ628		3	-1		"Montagut C, Cancer Res 2008, 68:4853-61"	AZ628: RAF selective inhibitor276	Melanoma	CRAF	C-Raf		expressed			sensitivity to	Geldanamycin		3	1		"Montagut C, Cancer Res 2008, 68:4853-61"	Geldanamycin: HSP90 inhibitor (which promotes CRAF degradation)277	Melanoma	CEACAM1			expressed			resistance to	Lymphocyte lysis (immunotherapy)		3	-1		"Markel G, Immunology 2009, 126:186-200"	"Surviving melanoma cells increase their surface CEACAM1 expression, which in turn confers enhanced resistance against fresh tumor-infiltrating lymphocytes (TIL)"278	Immune cells	T-bet		mRNA	downregulated by	T-bet knockout		resistance to	NK cell lysis (immunotherapy)		2	-1		"Werneck MB, J Immunol 2008, 180:8004-10"	T-bet is essential for NK-mediated cross-talk between innate and adaptive immune responses to metastatic disease279	Melanoma	BRAF	B-Raf	DNA	mut V600E			resistance to	Actinomycin-D		3	-1		"Sheridan C, J Biol Chem 2008, 283:22128-35"	"Oncogenic BRAF causes chemoresistance by promoting ERK-dependent inactivation of Bad and Bim, which in turn causes apoptosis inhibition"280	Melanoma	BRAF	B-Raf	DNA	mut V600E			resistance to	Daunorubicin		3	-1		"Sheridan C, J Biol Chem 2008, 283:22128-35"	"Oncogenic BRAF causes chemoresistance by promoting ERK-dependent inactivation of Bad and Bim, which in turn causes apoptosis inhibition"281	Melanoma	BRAF	B-Raf	DNA	mut V600E			resistance to	Cisplatin	CDDP	3	-1		"Sheridan C, J Biol Chem 2008, 283:22128-35"	"Oncogenic BRAF causes chemoresistance by promoting ERK-dependent inactivation of Bad and Bim, which in turn causes apoptosis inhibition"282	Melanoma	CENPB		mRNA	expressed			resistance to	Irinotecan	CPT-11	3	-1		"Gao K, Int J Oncol 2008, 32:1343-9"	Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells283	Melanoma	H2AFX		mRNA	expressed			resistance to	Irinotecan	CPT-11	3	-1		"Gao K, Int J Oncol 2008, 32:1343-9"	Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells284	Melanoma	MCM5		mRNA	expressed			resistance to	Irinotecan	CPT-11	3	-1		"Gao K, Int J Oncol 2008, 32:1343-9"	Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells285	Melanoma	ZADH1		mRNA	expressed			resistance to	Irinotecan	CPT-11	3	-1		"Gao K, Int J Oncol 2008, 32:1343-9"	Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells286	Melanoma	NGB		mRNA	expressed			resistance to	Irinotecan	CPT-11	3	-1		"Gao K, Int J Oncol 2008, 32:1343-9"	Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells287	Melanoma	IGF1	Insulin-like growth factor 1	mRNA	downregulated by	IGF1 siRNA		sensitivity to	TRAIL		3	1		"Hilmi C, J Invest Dermatol 2008, 128:1499-505"	"IGF1 acts through upregulation of Bcl-2, Bcl-xL and survivin"288	Melanoma	IGF1	Insulin-like growth factor 1	mRNA	downregulated by	IGF1 siRNA		sensitivity to	Staurosporine		3	1		"Hilmi C, J Invest Dermatol 2008, 128:1499-505"	"IGF1 acts through upregulation of Bcl-2, Bcl-xL and survivin"289	Melanoma	HMW-MAA	"gp240, CSPG4, NG2, High molecular weight melanoma associated antigen"	mRNA	downregulated by	HMW-MAA siRNA		sensitivity to	Cisplatin	CDDP	3	1		"Chekenya M, Oncogene 2008, 27:5182-94"	HMW-MAA inhibition seems to act through inhibition of alpha3beta1 integrin/PI3K signaling 290	Melanoma	HMW-MAA	"gp240, CSPG4, NG2, High molecular weight melanoma associated antigen"	mRNA	downregulated by	HMW-MAA siRNA		sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Chekenya M, Oncogene 2008, 27:5182-94"	HMW-MAA inhibition seems to act through inhibition of alpha3beta1 integrin/PI3K signaling 293	Melanoma	MITF	Microphthalmia-associated transcription factor 	mRNA	expressed			sensitivity to	MITF siRNA		3	1		"Dynek JN, Cancer Res 2008, 68:3124-32"	MITF seems to act through Livin upregulation294	Melanoma	mTOR	Mammalian target of rapamycin		expressed			resistance to	TGF beta		3	-1		"Hong F, Mol Cell 2008, 30:701-11"	"mTOR overexpression activates both Akt and SGK1, causing TGF-beta resistance through impaired nuclear import and cytoplasmic accumulation of p27"295	Melanoma	Syntenin	MDA-9	mRNA	expressed			sensitivity to	Syntenin antisense construct		4	1		"Boukerche H, Proc Natl Acad Sci USA 2008, 105:15914-9"	"Syntenin seems to act through c-SRC activation, which promotes the formation of an active FAK/c-Src signaling complex, leading to enhanced tumor cell invasion and metastatic spread"296	Melanoma	PARP-1	Poly ADP-ribose polymerase 1	mRNA	downregulated by	PARP-1 siRNA		sensitivity to	Temozolomide	TMZ	2	1		"Tentori L, Eur J Cancer 2008, 44:1302-14"	Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity298	Melanoma	ASK1		mRNA	downregulated by	ASK1 siRNA		resistance to	Noxa gene therapy		3	-1		"Hassan M, Oncogene 2008, 27:4557-68"	"Noxa forced expression not only triggered the classical mitochondrial caspase cascade, but also resulted in the activation of the pro-apoptotoc ASK1/JNK/p38 pathway"299	Melanoma	ABCB5		mRNA	expressed			resistance to	Doxorubicin	Adriamycin (R)	3	-1		"Frank NY, Cancer Res 2005, 65:4320-33"	"Besides expression/sensitivity correlation, ABCB5 inhibition (by a neutralizing antibody) leads to increased sensitivity to doxorubicin "301	Melanoma	Bad		mRNA	downregulated by	Bad siRNA		resistance to	BRAF knockdown		3	-1		"Boisvert-Adamo K, Oncogene 2008, 27:3301-12"	Bad inhibition reduces the anoikis of melanoma cells depleted of BRAF (BRAF protects from apoptosis through Bad inhibition by phosphorylation)302	Melanoma	ARC		mRNA	downregulated by	ARC siRNA		sensitivity to	Thapsigargin		3	1		"Chen LH, Cancer Res 2008, 68:834-42"	ARC inhibits endoplasmic reticulum (ER) stress induced apoptosis (caused by thapsigargin)303	Melanoma	ARC		mRNA	downregulated by	ARC siRNA		sensitivity to	Tunicamycin		3	1		"Chen LH, Cancer Res 2008, 68:834-42"	ARC inhibits endoplasmic reticulum (ER) stress induced apoptosis (caused by tunicamycin)304	Melanoma	Mcl-1		mRNA	downregulated by	Mcl-1 siRNA		sensitivity to	CD95 ligand	FAS ligand	3	1		"Chetoui N, Mol Cancer Res 2008, 6:42-52"	Mcl-1 might inhibit melanoma cell killing by immune cells306	Melanoma	Proteasome			expressed			sensitivity to	Bortezomib	Velcade (R)	3	1		"Sorolla A, Br J Dermatol 2008, 158:496-504"	Bortezomib is a proteasome inhibitor307	Melanoma	Proteasome			expressed			sensitivity to	ALLN		3	1		"Sorolla A, Br J Dermatol 2008, 158:496-504"	ALLN is a proteasome inhibitor308	Melanoma	Proteasome			expressed			sensitivity to	MG-132	Proteasome inhibitor	3	1		"Sorolla A, Br J Dermatol 2008, 158:496-504"	MG-132 is a proteasome inhibitor309	Melanoma	Proteasome			expressed			sensitivity to	Epoxomicin		3	1		"Sorolla A, Br J Dermatol 2008, 158:496-504"	Epoxomicin is a proteasome inhibitor311	Melanoma	MYC	c-Myc	mRNA	downregulated by	MYC antisense oligo		sensitivity to	Doxorubicin	Adriamycin (R)	4	1		"Pastorino F, J Control Release 2008, 126:85-94"	"In vivo experiments revealed that liposomal formulations of c-Myc antisense and DXR, both delivered via liposomes targeted with a monoclonal antibody against the disialoganglioside GD(2), led to the most pronounced delay in tumor growth when administered in a sequential manner"312	Melanoma	Tubulin beta class III	TUBB3		expressed			resistance to	Docetaxel		3	-1		"Mhaidat NM, FEBS Lett 2008, 582:267-72"	"Sensitive cells showed low levels of class III beta-tubulin with little microtubular incorporation, whereas class III beta-tubulin expression was higher in resistant cells. These results suggest that phenotypic expression of beta-tubulin class III in melanoma may help identify patients with melanoma that can respond to taxanes "313	Melanoma	FLIP	c-FLIP	mRNA	downregulated by	FLIP siRNA		sensitivity to	TRAIL		3	1		"Geserick P, Oncogene 2008, 27:3211-20"	FLIP may mediate melanoma resistance to apoptosis induced by immune cells314	Melanoma	FLIP	c-FLIP	mRNA	downregulated by	FLIP siRNA		sensitivity to	CD95 ligand	FAS ligand	3	1		"Geserick P, Oncogene 2008, 27:3211-20"	FLIP may mediate melanoma resistance to apoptosis induced by immune cells315	Melanoma	p73		DNA	methylated			sensitivity to	Cisplatin	CDDP	3	1		"Shen L, Cancer Res 2007, 67:11335-43"	p73 is a p53 homologue; p73 gene silencing is associated with chemosensitivity316	Melanoma	p73		DNA	methylated			sensitivity to	BCNU		3	1		"Shen L, Cancer Res 2007, 67:11335-43"	p73 is a p53 homologue; p73 gene silencing is associated with chemosensitivity317	Melanoma	p73		DNA	methylated			sensitivity to	Carboplatin		3	1		"Shen L, Cancer Res 2007, 67:11335-43"	p73 is a p53 homologue; p73 gene silencing is associated with chemosensitivity319	Melanoma	PRAME		mRNA	downregulated by	PRAME siRNA		sensitivity to	Retinoic acid	13-cis retinoic acid	4	1		"Epping MT, Cell 2005, 122:835-47"	PRAME inhibits the RAR (retinoic acid receptor) pathway320	Melanoma	PRAME		mRNA	downregulated by	PRAME siRNA		sensitivity to	PXD101		4	1		"Epping MT, Proc Natl Acad Sci USA 2007, 104:17777-82"	PXD101 is a HDAC inhibitor321	Melanoma	PRAME		mRNA	downregulated by	PRAME siRNA		sensitivity to	Trichostatin A	HDAC inhibitor	3	1		"Epping MT, Proc Natl Acad Sci USA 2007, 104:17777-82"	TSA is a HDAC inhibitor322	Melanoma	PRAME		mRNA	downregulated by	PRAME siRNA		sensitivity to	Butyric acid	HDAC inhibitor	3	1		"Epping MT, Proc Natl Acad Sci USA 2007, 104:17777-82"	Butyrate is a HDAC inhibitor326	Melanoma	GRP78	Glucose regulated protein 78	mRNA	downregulated by	GRP78 siRNA		sensitivity to	Tunicamycin		3	1		"Jiang CC, Cancer Res 2007, 67:9750-61"	siRNA knockdown of GRP78 increased ER stress-induced caspase-4 activation and apoptosis327	Melanoma	GRP78	Glucose regulated protein 78	mRNA	downregulated by	GRP78 siRNA		sensitivity to	Thapsigargin		3	1		"Jiang CC, Cancer Res 2007, 67:9750-61"	siRNA knockdown of GRP78 increased ER stress-induced caspase-4 activation and apoptosis328	Melanoma	p73		mRNA	upregulated by	p73 genetic engineering		sensitivity to	Cisplatin	CDDP	4	1		"Tuve S, Apoptosis 2006, 11:235-43"	Adenovirus-mediated TA-p73beta gene transfer increases chemosensitivity of human malignant melanomas329	Melanoma	p73		mRNA	upregulated by	p73 genetic engineering		sensitivity to	Doxorubicin	Adriamycin (R)	4	1		"Tuve S, Apoptosis 2006, 11:235-43"	Adenovirus-mediated TA-p73beta gene transfer increases chemosensitivity of human malignant melanomas330	Melanoma	p73 delta	p73 isoform delta	mRNA	expressed			sensitivity to	p73 delta gapmer		4	1		"Emmrich S, Mol Cancer 2009, 8:61"	p73 delta gapmer is a locked nucleic acid (LNA) antisense oligonucleotide (ASO) that inhibits expression of p73 delta (an oncogenic isoform of p73) while sparing full length p73 (tumor suppressor gene of the p53 family)331	Melanoma	p53	TP53	DNA	wild type (vs mutated)			sensitivity to	DW1/2		3	1		"Smalley KS, Cancer Res 2007, 67:209-17"	DW1/2 is a GSK3 beta inhibitor that activates wild type p53 (not mutated p53) by decreasing HDM2 (MDM2) levels332	Melanoma	HDM2	MDM2		expressed			sensitivity to	Nutlin-3		3	1		"Smalley KS, Cancer Res 2007, 67:209-17"	Nutlin-3 is a HDM2 (MDM2) inhibitor (MDM2 is a p53 inhibitor)333	Melanoma	NFkB	Nuclear factor kappa B	protein	active (high activity)			no relationship with	TRAIL		3	0		"Kurbanov BM, Oncogene 2007, 26:3364-77"	Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NFkB but is related to downregulation of initiator caspases and DR4334	Melanoma	TRAILR1	DR4		expressed			sensitivity to	TRAIL		3	1		"Kurbanov BM, Oncogene 2007, 26:3364-77"	Results were based on both expression and siRNA experiments335	Melanoma	Caspase-8			expressed			sensitivity to	TRAIL		3	1		"Kurbanov BM, Oncogene 2007, 26:3364-77"	Results were based on both expression and siRNA experiments336	Melanoma	Caspase-10			expressed			sensitivity to	TRAIL		3	1		"Kurbanov BM, Oncogene 2007, 26:3364-77"	Results were based on both expression and siRNA experiments340	Melanoma	Bcl-2		mRNA	downregulated by	Bcl-2 siRNA		sensitivity to	TRAIL		3	1		"Chawla-Sarkar M, Cell Death Differ 2004, 11:915-23"	"Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis"341	Melanoma	FLIP	c-FLIP	mRNA	downregulated by	FLIP siRNA		sensitivity to	TRAIL		3	1		"Chawla-Sarkar M, Cell Death Differ 2004, 11:915-23"	"Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis"342	Melanoma	XIAP		mRNA	downregulated by	XIAP siRNA		sensitivity to	TRAIL		3	1		"Chawla-Sarkar M, Cell Death Differ 2004, 11:915-23"	"Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis"343	Melanoma	Survivin	BIRC5	mRNA	downregulated by	Survivin siRNA		sensitivity to	TRAIL		3	1		"Chawla-Sarkar M, Cell Death Differ 2004, 11:915-23"	"Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis"344	Melanoma	Livin	ML-IAP	mRNA	expressed			sensitivity to	Livin antisense oligonucleotide		3	1		"Kasof GM, J Biol Chem 2001, 276:3238-46"	Transfection of an antisense construct against livin could trigger apoptosis specifically in cell lines expressing livin mRNA345	Melanoma	Survivin	BIRC5	mRNA	expressed			resistance to	Vaccine (allogeneic)		5	-1	63	"Takeuchi H, Int J Cancer 2005, 117:1032-8"	Impossible to determine whether survivin acts as a prognostic or predictive marker346	Melanoma	Survivin	BIRC5		expressed			sensitivity to	TAT-Surv-T34A		4	1		"Yan H, Oncogene 2006, 25:6968-74"	TAT-Surv-T34A is a cell permeable survivin dominant-negative mutant 348	Melanoma	Bcl-2			expressed			resistance to	Ceramidase inhibitors		3	-1		"Raisova M, FEBS Lett 2002, 516:47-52"	"Ceramidase inhibitors (D-e-MAPP, D-NMAPPD) act by increasing ceramide levels"349	Melanoma	MITF	Microphthalmia-associated transcription factor 		expressed			sensitivity to	dnMITF gene therapy		3	1		"McGill GG, Cell 2002, 109:707-18"	dnMITF (dominant negative MITF) seems to act mainly through Bcl-2 downregulation (MITF upregulates Bcl-2 expression)351	Melanoma	Mcl-1		mRNA	downregulated by	Mcl-1 siRNA		sensitivity to	Bortezomib	Velcade (R)	3	1		"Qin JZ, Cancer Res 2006, 66:9636-45"	In this model bortezomib seems to act by increasing NOXA levels354	Melanoma	Bcl-2/Bax ratio			expressed			resistance to	CD95 ligand	FAS ligand	3	-1		"Raisova M, J Invest Dermatol 2001, 117:333-40"	High Bcl-2 combined with low Bax expression predicts low sensitivity to FasL apoptosis355	Melanoma	TNFR1	TNF receptor 1	DNA	methylated			resistance to	TNF	Tumor necrosis factor	3	-1		"Kaminski R, Oncol Rep 2004, 12:509-16"	Results obtained by re-expressing TNFR1 with demethylating agent 5-aza-2'-deoxycytidine 358	Melanoma	Bim		mRNA	downregulated by	Bim siRNA		resistance to	TRAIL + SBHA		3	-1		"Gillespie S, Apoptosis 2006, 11:2251-65"	Bim inhibition reduces the therapeutic effect of this combination regimen359	Melanoma	GALNT14		mRNA	expressed			resistance to	TRAIL		3	-1		"Wagner KW, Nat Med 2007, 13:1070-7"	GALNT14 causes glycosylation of TRAILR362	Melanoma	AIF	Apoptosis inducing factor	mRNA	downregulated by	AIF siRNA		resistance to	U0126	MEK inhibitor	3	-1		"Wang YF, Clin Cancer Res 2007, 13:4934-42"	"U0126: MEK inhibitor. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1"363	Melanoma	Puma		mRNA	downregulated by	Puma siRNA		resistance to	U0126	MEK inhibitor	3	-1		"Wang YF, Clin Cancer Res 2007, 13:4934-42"	"U0126: MEK inhibitor. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1"364	Melanoma	Bim		mRNA	downregulated by	Bim siRNA		resistance to	U0126	MEK inhibitor	3	-1		"Wang YF, Clin Cancer Res 2007, 13:4934-42"	"U0126: MEK inhibitor. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1"365	Melanoma	Mcl-1		mRNA	downregulated by	Mcl-1 siRNA		sensitivity to	U0126	MEK inhibitor	3	1		"Wang YF, Clin Cancer Res 2007, 13:4934-42"	"U0126: MEK inhibitor. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1"366	Melanoma	RSK1	Ribosomal S6 kinase (RS6K)	protein	phosphorylated (activated)			resistance to	PD98059	MEK inhibitor	3	-1		"Eisenmann KM, Cancer Res 2003, 63:8330-7"	"PD98059 is a MEK1 inhibitor. MEK phosphorylates and activates ERK, which phosphorylates and activates RSK (which phosphorylates and inhibits Bad)"367	Melanoma	Bad		DNA	mut S75A			sensitivity to	PD98059	MEK inhibitor	3	1		"Eisenmann KM, Cancer Res 2003, 63:8330-7"	"PD98059 is a MEK1 inhibitor. Mutated Bad cannot be phosphorylated (and thus inactivated) by RSK. MEK phosphorylates and activates ERK, which phosphorylates and activates RSK (which phosphorylates and inhibits Bad)"368	Melanoma	AIF	Apoptosis inducing factor	mRNA	downregulated by	AIF siRNA		resistance to	Sorafenib	Nexavar (R)	3	-1		"Panka DJ, Cancer Res 2006, 66:1611-9"	"Sorafenib (BRAF, CRAF, VEGFR and PDGFR inhibitor) is active against melanoma cells in which AIF mediates apoptosis (is independent of Bad phosphorylation status)"369	Melanoma	AKT	PKB	protein	phosphorylated (Ser-473)			sensitivity to	Wortmannin		3	1		"Dhawan P, Cancer Res 2002, 62:7335-42"	Wortmannin is a PI3K inhibitor (PI3K activates AKT by phosphorylation). Constitutive activation of Akt in melanoma leads to upregulation of NFkB and tumor progression372	Melanoma	PAF	Platelet activating factor		expressed			resistance to	Etoposide	VP-16	2	-1		"Heon Seo K, Cancer Res 2006, 66:4681-6"	PAF activates NFkB which leads to upregulation of antiapoptotic factors Bcl-2 and Bcl-xL376	Melanoma	IKK	IKB kinase		expressed			sensitivity to	BMS-345541	NFkB inhibitor	4	1		"Yang J, Clin Cancer Res 2006, 12(3 Pt 1):950-60"	Inhibition of constitutive IKK activity by BMS-345541 resulted in the reduction of NFkB activity377	Melanoma	BRAF	B-Raf	mRNA	downregulated by	BRAF siRNA		resistance to	TNF	Tumor necrosis factor	3	-1		"Gray-Schopfer VC, Cancer Res 2007, 67:122-9"	"TNF induces NFkB activity, which antagonizes BRAF inhibition"378	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	Sorafenib	Nexavar (R)	4	1		"Karasarides M, Oncogene 2004, 23:6292-8"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. Oncogenic mutationally activated BRAF acts through ERK activation"379	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	CI-1040	PD184352	4	1		"Solit DB, Nature 2006, 439:358-62"	CI-1040 is a MEK inhibitor. Mutation of BRAF is associated with enhanced and selective sensitivity to MEK inhibition when compared to either BRAF wild-type cells or cells harboring a RAS mutation389	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	PLX 4720		4	1		"Tsai J, Proc Natl Acad Sci USA 2008, 105:3041-6"	PLX 4720 is a BRAF inhibitor with high selectivity for mutated BRAF V600E (compared to wild type)390	Melanoma	HSP90			expressed			sensitivity to	17-AAG	Tanespimycin (17-allylamino-17-demethoxygeldanamycin)	4	1		"Grbovic OM, Proc Natl Acad Sci USA 2006, 103:57-62"	17-AAG is a HSP90 inhibitor. Both CRAF and mutated BRAF V600E (not wild type BRAF) require HSP90 for stability391	Melanoma	BRAF	B-Raf	DNA	mut V600E			no relationship with	17-AAG	Tanespimycin (17-allylamino-17-demethoxygeldanamycin)	3	0		"Grbovic OM, Proc Natl Acad Sci USA 2006, 103:57-62"	17-AAG is a HSP90 inhibitor that works against melanoma cells independently of the BRAF mutational status (mutated vs wild type)392	Melanoma	BRAF	B-Raf	DNA	mut V600E			no relationship with	17-AAG	Tanespimycin (17-allylamino-17-demethoxygeldanamycin)	5	0	15	"Solit DB, Clin Cancer Res 2008, 14:8302-7"	"No objective responses were observed, either in BRAF mutant or wild type tumors"395	Endothelial cells	"VEGFR2, FGFR, PDGFRB"			expressed			sensitivity to	SU6668		4	1		"Laird AD, Cancer Res 2000, 60:4152-60"	SU6668 is a multikinase inhibitor396	Melanoma	"RAS (KRAS, NRAS, HRAS)"		DNA	wild type (vs mutated)			no relationship with	R115777	Tipifarnib	3	0		"End DW, Cancer Res 2001, 61:131-7"	"R115777 is a farnesyl transferase inhibitor (FTI) that blocks RAS activity, independently of RAS (any gene: KRAS, NRAS, HRAS) mutational status"397	Melanoma	Farnesyl transferase (RAS)			expressed			sensitivity to	R115777	Tipifarnib	4	1		"End DW, Cancer Res 2001, 61:131-7"	R115777 is a farnesyl transferase inhibitor (FTI) that blocks RAS activity. In this model a cell line with wild type RAS was used398	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	BRAF siRNA		3	1		"Hingorani SR, Cancer Res 2003, 63:5198-202"	"When present, BRAF(V599E) appears to be essential for melanoma cell viability and transformation and, therefore, represents an attractive therapeutic target in the majority of melanomas that harbor the mutation"400	Melanoma	Bcl-2			expressed			resistance to	TRAIL + U0126		3	-1		"Zhang XD, Oncogene 2003, 22:2869-81"	Over expression of Bcl-2 blocked TRAIL-induced apoptosis in the presence of U0126401	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	U0126	MEK inhibitor	4	1		"Sharma A, Cancer Res 2006, 66:8200-9"	"U0126 is a MEK inhibitor. When BRAF is mutated (V600E), targeting MEK is more effective than targeting BRAF with sorafenib"402	Melanoma	BRAF	B-Raf	DNA	mut V600E			no relationship with	Sorafenib	Nexavar (R)	4	0		"Sharma A, Cancer Res 2006, 66:8200-9"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. When BRAF is mutated (V600E), targeting MEK (with U0126) is more effective than targeting BRAF with sorafenib"403	Melanoma	AKT	PKB	protein	phosphorylated (Ser-473)			sensitivity to	Akt-DN gene therapy		3	1		"Jetzt A, Cancer Res 2003, 63:6697-706"	Akt-DN: dominant negative AKT. Authors used different cell lines: one melanoma cell line with low AKT activity was resistant to treatment; those with high AKT activity were sensitive404	Melanoma	AKT3	PKB	protein	phosphorylated (Ser-473)			sensitivity to	AKT3 siRNA		4	1		"Stahl JM, Cancer Res 2004, 64:7002-10"	In this model AKT activity was high due to PTEN loss. Isoform specific siRNA showed that AKT3 is the best target409	Melanoma	BRAF	B-Raf	DNA	mut V600E			no relationship with	Sorafenib + Rapamycin		3	0		"Molhoek KR, J Transl Med 2005, 3:39"	BRAF mutational status has no impact on the response to this treatment410	Melanoma	Noxa		mRNA	downregulated by	Noxa antisense oligo		resistance to	Bortezomib	Velcade (R)	3	-1		"Qin JZ, Cancer Res 2005, 65:6282-93"	Noxa is required for bortezomib (proteasome inhibitor) anti-melanoma activity411	Melanoma	Noxa		mRNA	downregulated by	Noxa siRNA		resistance to	Bortezomib	Velcade (R)	4	-1		"Fernandez Y, Cancer Res 2005, 65:6294-304"	Noxa is a new biomarker to gauge the efficacy of bortezomib specifically in tumor cells (bortezomib had no effect on normal cells)413	Melanoma	IKK	IKB kinase		expressed			sensitivity to	IKK ribozyme		2	1		"Yang J, Cancer Res 2007, 67:3127-34"	"Transgenic melanoma cells with constitutively activated HRAS were used. HRAS activates IKK, which activates NFkB"414	Melanoma	Mcl-1		mRNA	downregulated by	Mcl-1 antisense oligo		sensitivity to	Dacarbazine	DTIC	4	1		"Thallinger C, J Invest Dermatol 2003, 120:1081-6"	Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model415	Melanoma	Bcl-xL		mRNA	downregulated by	Bcl-xL antisense oligo		sensitivity to	Cisplatin	CDDP	3	1		"Heere-Ress E, Int J Cancer 2002, 99:29-34"	Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy416	Melanoma	"Bcl-2, Bcl-xL"			expressed			sensitivity to	Oligonucleotide 4625		3	1		"Gautschi O, J Natl Cancer Inst 2001, 93:463-71"	Oligonucleotide 4625 is a bispecific antisense oligo that targets Bcl-2 and Bcl-xL417	Melanoma	Bcl-xS		mRNA	upregulated by	Bcl-xS genetic engineering		sensitivity to	Etoposide	VP-16	3	1		"Hossini AM, FEBS Lett 2003, 553:250-6"	Bcl-xS has pro-apoptotic activity as opposed to its isoform Bcl-xL418	Melanoma	Bcl-xS		mRNA	upregulated by	Bcl-xS genetic engineering		sensitivity to	Pamidronate		3	1		"Hossini AM, FEBS Lett 2003, 553:250-6"	Bcl-xS has pro-apoptotic activity as opposed to its isoform Bcl-xL419	Melanoma	Bcl-xS		mRNA	upregulated by	Bcl-xS genetic engineering		sensitivity to	Ceramide		3	1		"Hossini AM, FEBS Lett 2003, 553:250-6"	Bcl-xS has pro-apoptotic activity as opposed to its isoform Bcl-xL420	Melanoma	Bcl-xL		mRNA	upregulated by	Bcl-xL genetic engineering		resistance to	CD95 ligand	FAS ligand	3	-1		"Hossini AM, FEBS Lett 2003, 553:250-6"	Bcl-XL protected from apoptosis caused via CD95/Fas stimulation421	Melanoma	Tyrosinase			expressed			sensitivity to	CD95 ligand gene therapy		3	1		"Fecker LF, J Invest Dermatol 2005, 124:221-8"	Tyrosinase promoter controlled gene therapy inducing CD95 ligand overexpression causes melanoma specific cytotoxicity422	Melanoma	Bcl-xAK		mRNA	upregulated by	Bcl-xAK genetic engineering		sensitivity to	Etoposide	VP-16	3	1		"Hossini AM, Oncogene 2006, 25:2160-9"	Bcl-xAK has pro-apoptotic activity as opposed to its isoform Bcl-xL423	Melanoma	Bcl-xAK		mRNA	upregulated by	Bcl-xAK genetic engineering		sensitivity to	Pamidronate		3	1		"Hossini AM, Oncogene 2006, 25:2160-9"	Bcl-xAK has pro-apoptotic activity as opposed to its isoform Bcl-xL424	Melanoma	Bcl-xAK		mRNA	upregulated by	Bcl-xAK genetic engineering		sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Hossini AM, Oncogene 2006, 25:2160-9"	Bcl-xAK has pro-apoptotic activity as opposed to its isoform Bcl-xL425	Melanoma	Bcl-xAK		mRNA	upregulated by	Bcl-xAK genetic engineering		sensitivity to	CD95 antibody (agonist)		3	1		"Hossini AM, Oncogene 2006, 25:2160-9"	Bcl-xAK has pro-apoptotic activity as opposed to its isoform Bcl-xL426	Melanoma	Bik	Nbk	mRNA	upregulated by	Bik genetic engineering		sensitivity to	Etoposide	VP-16	3	1		"Oppermann M, Oncogene 2005, 24:7369-80"	"Conditional expression of Nbk/Bik by applying the inducible tetracycline-responsive expression system triggered apoptosis and enhanced sensitivity to proapoptotic stimuli as to agonistic CD95 activation and to chemotherapeutics etoposide, doxorubicin and pamidronate"427	Melanoma	Bik	Nbk	mRNA	upregulated by	Bik genetic engineering		sensitivity to	Pamidronate		3	1		"Oppermann M, Oncogene 2005, 24:7369-80"	"Conditional expression of Nbk/Bik by applying the inducible tetracycline-responsive expression system triggered apoptosis and enhanced sensitivity to proapoptotic stimuli as to agonistic CD95 activation and to chemotherapeutics etoposide, doxorubicin and pamidronate"428	Melanoma	Bik	Nbk	mRNA	upregulated by	Bik genetic engineering		sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Oppermann M, Oncogene 2005, 24:7369-80"	"Conditional expression of Nbk/Bik by applying the inducible tetracycline-responsive expression system triggered apoptosis and enhanced sensitivity to proapoptotic stimuli as to agonistic CD95 activation and to chemotherapeutics etoposide, doxorubicin and pamidronate"429	Melanoma	Bik	Nbk	mRNA	upregulated by	Bik genetic engineering		sensitivity to	CD95 antibody (agonist)		3	1		"Oppermann M, Oncogene 2005, 24:7369-80"	"Conditional expression of Nbk/Bik by applying the inducible tetracycline-responsive expression system triggered apoptosis and enhanced sensitivity to proapoptotic stimuli as to agonistic CD95 activation and to chemotherapeutics etoposide, doxorubicin and pamidronate"430	Melanoma	L1-CAM		mRNA	downregulated by	L1-CAM siRNA		sensitivity to	Cisplatin	CDDP	3	1		"Lee SB, J Invest Dermatol 2010, 130:763-73"	"L1-CAM is released by ADAM10, which is overexpressed in melanoma metastasis as compared to primary melanoma"431	Melanoma	"Bcl-2, Bcl-xL, Mcl-1"			expressed			sensitivity to	Gossypol		3	1		"Shelley MD, Anticancer Drugs 2000, 11:209-16"	"Gossypol inhibits Bcl-2, Bcl-xL and Mcl-1"432	Melanoma	Bim		mRNA	upregulated by	Bim genetic engineering		sensitivity to	Radiotherapy		2	1		"Kashiwagi H, Ann Surg Oncol 2007, 14:1763-71"	"Authors administered TAT-Bim, a peptide that contains two domains, a peptide transduction domain derived from the HIV-1 TAT protein and a biological effector domain, the BH3 domain from the pro-apoptotic Bcl-2 family member Bim"438	Plasma/serum	LDH		protein	expressed			resistance to	Oblimersen + Dacarbazine		5	-1	771	"Bedikian AY, J Clin Oncol 2006, 24:4738-45"	Patients with normal LDH levels showed a significantly better overall survival than those with high levels (subgroup analysis within a phase III RCT); whether this relates to the association of LDH with survival or with response to therapy is unclear439	Melanoma	CDK	Cyclin dependent kinase		uncharacterized			no relationship with	Flavopiridol		5	0	17	"Burdette-Radoux S, Invest New Drugs 2004, 22:315-22"	Flavopiridol is a CDK inhibitor. Metastatic melanoma. No objective response was observed. CDK expression/activity was not determined440	Melanoma	AKT	PKB		uncharacterized			no relationship with	Perifosine		5	0	18	"Ernst DS, Invest New Drugs 2005, 23:569-75"	Perifosine is an AKT inhibitor. Metastatic melanoma. No objective response was observed. AKT expression/activity was not determined. No preclinical data are available441	Melanoma	CDKN2A	"p16, INK4A"		expressed			resistance to	Flavopiridol		3	-1		"Robinson WA, Melanoma Res 2003, 13:231-8"	Melanoma cells lacking p16 are more sensitive than those expressing p16. Flavopiridol inhibits CDK and seems to act as p16 in p16 negative cells442	Melanoma	mTOR	Mammalian target of rapamycin		uncharacterized			no relationship with	Temsirolimus	"CCI-779, Torisel (R)"	5	0	33	"Margolin K, Cancer 2005, 104:1045-8"	CCI-779 is a mTOR inhibitor. One partial response was observed. mTOR expression/activity was not determined444	Melanoma	Proteasome			uncharacterized			no relationship with	Bortezomib	Velcade (R)	5	0	27	"Markovic SN, Cancer 2005, 103:2584-9"	Bortezomib is a proteasome inhibitor (acts mainly through NFkB inhibition). No objective tumor response was observed. Metastatic melanoma. Proteasome/NFkB expression/activity was not determined 453	Melanoma	PRAS40		mRNA	downregulated by	PRAS40 siRNA		sensitivity to	Staurosporine		4	1		"Madhunapantula SV, Cancer Res 2007, 67:3626-36"	PRAS40 is an AKT3 target. Staurosporine is a pro-apoptotic agent456	Melanoma	YB-1	Y box binding protein 1	mRNA	downregulated by	YB-1 siRNA		sensitivity to	Cisplatin	CDDP	3	1		"Schittek B, Int J Cancer 2007, 120:2110-8"	YB-1 is a transcription/translation factor regulating the expression of proliferation and apoptosis related genes457	Melanoma	YB-1	Y box binding protein 1	mRNA	downregulated by	YB-1 siRNA		sensitivity to	Etoposide	VP-16	3	1		"Schittek B, Int J Cancer 2007, 120:2110-8"	YB-1 is a transcription/translation factor regulating the expression of proliferation and apoptosis related genes458	Melanoma	MAGE-A		protein	expressed			resistance to	Etoposide	VP-16	3	-1		"Monte M, Proc Natl Acad Sci USA 2006, 103:11160-5"	"MAGE-A acts through p53 inhibition in p53 wild type melanoma cells (the MAGE/p53 complex recruits HDAC3, which downregulates the transactivation function of p53)"460	Melanoma	TG2	Transglutaminase 2		expressed			sensitivity to	TG2 siRNA		3	1		"Fok JY, Mol Cancer Ther 2006, 5:1493-503"	TG2 seems to act through integrin-mediated cell survival signaling pathways461	Melanoma	Bcl-2		mRNA	expressed			no relationship with	Oblimersen		3	0		"Lai JC, Mol Cancer Ther 2005, 4:305-15"	"Oblimersen can induce apoptosis in melanoma cell lines, but this effect appears independent of Bcl-2 expression (instead, caspases appear necessary)"463	Melanoma	ABCB5		mRNA	downregulated by	ABCB5 siRNA		sensitivity to	Camptothecin		3	1		"Huang Y, Cancer Res 2004, 64:4294-301"	"Accordingly, ABCB5 is defined as melanoma chemoresistance molecule"464	Melanoma	ABCB5		mRNA	downregulated by	ABCB5 siRNA		sensitivity to	5-Fluorouracil	5-FU	3	1		"Huang Y, Cancer Res 2004, 64:4294-301"	"Accordingly, ABCB5 is defined as melanoma chemoresistance molecule"465	Melanoma	ABCB5		mRNA	downregulated by	ABCB5 siRNA		no relationship with	Mitoxantrone		3	0		"Huang Y, Cancer Res 2004, 64:4294-301"	"As regards mitoxantrone, ABCB5 was not found to be a melanoma chemoresistance molecule"466	Melanoma	GSTM1	Glutathione S-transferase M1		expressed			resistance to	Chlorambucil		3	-1		"Depeille P, Mol Pharmacol 2004, 65:897-905"	Results were based on both expression and inhibition experiments467	Melanoma	"GSTM1, MRP1"			expressed			resistance to	Vincristine		3	-1		"Depeille P, Mol Pharmacol 2004, 65:897-905"	Results were based on both expression and inhibition experiments. GSTM1 and MRP1 act synergically to cause resistance to vincristine468	Melanoma	TYRP2	DCT		expressed			resistance to	Radiotherapy		3	-1		"Pak BJ, Oncogene 2004, 23:30-8"	Results were based on both expression and forced expression experiments470	Melanoma	E2F1	E2F1 transcription factor	mRNA	upregulated by	E2F1 genetic engineering		sensitivity to	Etoposide	VP-16	3	1		"Dong YB, Cancer Res 2002, 62:1776-83"	Forced expression of transcription factor E2F1 (viral vector) chemosensitizes melanoma cells471	Melanoma	E2F1	E2F1 transcription factor	mRNA	upregulated by	E2F1 genetic engineering		sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Dong YB, Cancer Res 2002, 62:1776-83"	Forced expression of transcription factor E2F1 (viral vector) chemosensitizes melanoma cells472	Melanoma	E2F1	E2F1 transcription factor	mRNA	upregulated by	E2F1 genetic engineering		no relationship with	Cisplatin	CDDP	3	0		"Dong YB, Cancer Res 2002, 62:1776-83"	Forced expression of transcription factor E2F1 via viral vector473	Melanoma	E2F1	E2F1 transcription factor	mRNA	upregulated by	E2F1 genetic engineering		no relationship with	5-Fluorouracil	5-FU	3	0		"Dong YB, Cancer Res 2002, 62:1776-83"	Forced expression of transcription factor E2F1 via viral vector474	Melanoma	Topoisomerase II beta	TOP2B	protein	expressed			no relationship with	Doxorubicin	Adriamycin (R)	3	0		"Satherley K, J Pathol 2000, 192:174-81"	Uveal melanoma475	Melanoma	ABCB1	"MDR1, P-gp"	protein	expressed			no relationship with	Doxorubicin	Adriamycin (R)	3	0		"Satherley K, J Pathol 2000, 192:174-81"	Uveal melanoma476	Melanoma	LRP	Major vault protein	protein	expressed			no relationship with	Doxorubicin	Adriamycin (R)	3	0		"Satherley K, J Pathol 2000, 192:174-81"	Uveal melanoma477	Melanoma	ABCC1	MRP1	protein	expressed			no relationship with	Doxorubicin	Adriamycin (R)	3	0		"Satherley K, J Pathol 2000, 192:174-81"	Uveal melanoma478	Melanoma	ABCB1	"MDR1, P-gp"	protein	expressed			no relationship with	Vincristine		3	0		"Satherley K, J Pathol 2000, 192:174-81"	Uveal melanoma479	Melanoma	LRP	Major vault protein	protein	expressed			no relationship with	Vincristine		3	0		"Satherley K, J Pathol 2000, 192:174-81"	Uveal melanoma480	Melanoma	ABCC1	MRP1	protein	expressed			no relationship with	Vincristine		3	0		"Satherley K, J Pathol 2000, 192:174-81"	Uveal melanoma481	Melanoma	p53	TP53	mRNA	expressed			sensitivity to	Vindesine		3	1		"Kern MA, Anticancer Res 1997, 17(6D):4359-70"	Decreasing levels of p53 mRNA correlated with increased chemoresistance482	Melanoma	p53	TP53	mRNA	expressed			sensitivity to	Etoposide	VP-16	3	1		"Kern MA, Anticancer Res 1997, 17(6D):4359-70"	Decreasing levels of p53 mRNA correlated with increased chemoresistance483	Melanoma	p53	TP53	mRNA	expressed			sensitivity to	Fotemustine		3	1		"Kern MA, Anticancer Res 1997, 17(6D):4359-70"	Decreasing levels of p53 mRNA correlated with increased chemoresistance484	Melanoma	ABCC1	MRP1	mRNA	expressed			resistance to	Daunomycin		3	-1		"Berger W, Int J Cancer 1997, 71:108-15"	"The sensitivity of melanoma cell lines to daunomycin (DM) and doxorubicin (DOX), but not to vinblastine (VBL), etoposide (VP-16) and cisplatin (CDDP), analysed by an MTT-based survival assay, were inversely correlated with MRP-gene expression"485	Melanoma	ABCC1	MRP1	mRNA	expressed			resistance to	Doxorubicin	Adriamycin (R)	3	-1		"Berger W, Int J Cancer 1997, 71:108-15"	"The sensitivity of melanoma cell lines to daunomycin (DM) and doxorubicin (DOX), but not to vinblastine (VBL), etoposide (VP-16) and cisplatin (CDDP), analysed by an MTT-based survival assay, were inversely correlated with MRP-gene expression"486	Melanoma	ABCC1	MRP1	mRNA	expressed			no relationship with	Vinblastine		3	0		"Berger W, Int J Cancer 1997, 71:108-15"	"The sensitivity of melanoma cell lines to daunomycin (DM) and doxorubicin (DOX), but not to vinblastine (VBL), etoposide (VP-16) and cisplatin (CDDP), analysed by an MTT-based survival assay, were inversely correlated with MRP-gene expression"487	Melanoma	ABCC1	MRP1	mRNA	expressed			no relationship with	Etoposide	VP-16	3	0		"Berger W, Int J Cancer 1997, 71:108-15"	"The sensitivity of melanoma cell lines to daunomycin (DM) and doxorubicin (DOX), but not to vinblastine (VBL), etoposide (VP-16) and cisplatin (CDDP), analysed by an MTT-based survival assay, were inversely correlated with MRP-gene expression"488	Melanoma	ABCC1	MRP1	mRNA	expressed			no relationship with	Cisplatin	CDDP	3	0		"Berger W, Int J Cancer 1997, 71:108-15"	"The sensitivity of melanoma cell lines to daunomycin (DM) and doxorubicin (DOX), but not to vinblastine (VBL), etoposide (VP-16) and cisplatin (CDDP), analysed by an MTT-based survival assay, were inversely correlated with MRP-gene expression"489	Melanoma	NRAS	N-Ras	DNA	mut codon 61			resistance to	Cisplatin	CDDP	4	-1		"Jansen B, Cancer Res 1997, 57:362-5"	Activating mutations of NRAS were associated to chemoresistance490	Melanoma	NRAS	N-Ras		expressed			no relationship with	Cisplatin	CDDP	4	0		"Jansen B, Cancer Res 1997, 57:362-5"	Overexpression of wt NRAS had no effect on chemosensitivity491	Melanoma	Glutathione S-transferase	GST	protein	expressed			no relationship with	Chemotherapy (miscellany)		5	0	39	"Schadendorf D, J Invest Dermatol 1995, 105:109-12"	"Different chemotherapeutics were used. No correlation was found between GST levels by immunohistochemistry and the course of tumor progression, between GST levels in metastases obtained before or during chemotherapy, or between GST levels and clinical response"492	Melanoma	CDKN2A	"p16, INK4A"	mRNA	expressed			sensitivity to	Melphalan + actinomycin-D		5	1	30	"Gallagher SJ, Neoplasia 2008, 10:1231-9"	Isolated limb infusion model. p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors493	Melanoma	BRAF	B-Raf	DNA	mut V600E			resistance to	Melphalan + actinomycin-D		5	-1	30	"Gallagher SJ, Neoplasia 2008, 10:1231-9"	Isolated limb infusion model. p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors494	Melanoma	ASNA1			expressed			sensitivity to	Cisplatin	CDDP	3	1		"Hemmingsson O, Cancer Chemother Pharmacol 2009, 63:491-9"	"Reduced ASNA1 expression is associated with significant inhibition of cell growth, increased apoptosis and increased sensitivity to cisplatin and arsenite"495	Melanoma	ASNA1			expressed			sensitivity to	Arsenic trioxide	ATO	3	1		"Hemmingsson O, Cancer Chemother Pharmacol 2009, 63:491-9"	"Reduced ASNA1 expression is associated with significant inhibition of cell growth, increased apoptosis and increased sensitivity to cisplatin and arsenite"496	Melanoma	GSTP1	Glutathione S-transferase P1	mRNA	downregulated by	GSTP1 siRNA		sensitivity to	Etoposide	VP-16	3	1		"Depeille P, Br J Cancer 2005, 93:216-23"	Lowering the GSTP1 level significantly increased (about 3.3-fold) the sensitivity of A375-ASPi1 cells to etoposide497	Melanoma	"GSTP1, MRP1"			downregulated by	GSTP1 siRNA + Sulphinpyrazone		sensitivity to	Etoposide	VP-16	3	1		"Depeille P, Br J Cancer 2005, 93:216-23"	"Combined inhibition of both GSTP1 and MRP1 (ABCC1) with siRNA and sulphinpyrazone, respectively, sensitizes melanoma cells to etoposide"498	Melanoma	CREB	cAMP response element binding protein		downregulated by	CREB dominant negative		sensitivity to	Radiotherapy		3	1		"Yang YM, Oncogene 1996, 12:2223-33"	"Through its transcriptional activity, CREB plays an important role in the acquisition of characteristic phenotypes of human melanoma cells including resistance to irradiation"499	Melanoma	CREB	cAMP response element binding protein		expressed			sensitivity to	CREB dominant negative		4	1		"Xie S, Oncogene 1997, 15:2069-75"	Silencing CREB using a dominant-negative form of CREB (KCREB) in MeWo metastatic melanoma cells decreases their tumorigenic and metastatic potentials in nude mice by downregulating expression of MMP-2 and MCAM/MUC18 and decreasing melanoma cell invasion through the basement membrane500	Melanoma	ATF2			downregulated by	ATF2 dominant negative		sensitivity to	Radiotherapy		3	1		"Ronai Z, Oncogene 1998, 16:523-31"	"Cells were transfected with ATF2 cDNA lacking the transactivation domain (ATF2(delta1-195)): these cells showed weaker transcriptional activities and an altered pattern of homo/hetero dimers (similar article by the same investigators: Bhoumik A, Clin Cancer Res 2001, 7:331-42)"501	Melanoma	ATF2			downregulated by	ATF2 dominant negative		sensitivity to	Mitomycin-C	MMC	3	1		"Ronai Z, Oncogene 1998, 16:523-31"	"Cells were transfected with ATF2 cDNA lacking the transactivation domain (ATF2(delta1-195)): these cells showed weaker transcriptional activities and an altered pattern of homo/hetero dimers (similar article by the same investigators: Bhoumik A, Clin Cancer Res 2001, 7:331-42)"502	Melanoma	ATF2			downregulated by	ATF2 dominant negative		sensitivity to	Cisplatin	CDDP	3	1		"Ronai Z, Oncogene 1998, 16:523-31"	"Cells were transfected with ATF2 cDNA lacking the transactivation domain (ATF2(delta1-195)): these cells showed weaker transcriptional activities and an altered pattern of homo/hetero dimers (similar article by the same investigators: Bhoumik A, Clin Cancer Res 2001, 7:331-42)"503	Melanoma	ATF2			downregulated by	ATF2 dominant negative		sensitivity to	Cytarabine	Cytosine arabinoside	3	1		"Ronai Z, Oncogene 1998, 16:523-31"	"Cells were transfected with ATF2 cDNA lacking the transactivation domain (ATF2(delta1-195)): these cells showed weaker transcriptional activities and an altered pattern of homo/hetero dimers (similar article by the same investigators: Bhoumik A, Clin Cancer Res 2001, 7:331-42)"504	Melanoma	CREB	cAMP response element binding protein		downregulated by	CREB dominant negative		sensitivity to	Thapsigargin		3	1		"Jean D, J Biol Chem 1998, 273:24884-90"	"Thapsigargin inhibits endoplasmic reticulum-dependent Ca2+ ATPase and thereby increases cytosolic Ca2+, which induces apoptosis"507	Melanoma	Bcl-2		mRNA	downregulated by	Bcl-2 siRNA		sensitivity to	Cisplatin	CDDP	3	1		"Wacheck V, Oligonucleotides 2003, 13:393-400"	"If siRNA compounds targeting Bcl-2 were combined with the apoptosis-inducing chemotherapeutic agent cisplatin, a massive increase in apoptotic cell death compared with controls was observed. Notably, the combination of Bcl2 siRNA and low-dose cisplatin resulted in a supra-additive effect, with nearly complete suppression of cell growth, whereas cell growth in cisplatin-only-treated cells was only moderately affected "509	Melanoma	"Bcl-2, SOD2"		mRNA	downregulated by	Bcl-2 antisense oligo + SOD2 antisense oligo		sensitivity to	TNF	Tumor necrosis factor	2	1		"Benlloch M, J Biol Chem 2006, 281:69-79"	"SOD: superoxide dismutase. By treating iB16M-Gln+ cells with a double anti-antisense therapy (Bcl-2 and SOD2 antisense oligodeoxynucleotides) and TNF-alpha, metastatic cell survival decreased to approximately 1%"510	Melanoma	Bcl-2		mRNA	downregulated by	Bcl-2 siRNA		sensitivity to	3p-siRNA		2	1		"Poeck H, Nat Med 2008, 14:1256-63"	"Anti-Bcl-2 3p-siRNA can both inhibit Bcl-2 expression and activate Rig-I, the immunostimulating cytosolic antiviral helicase retinoic acid-induced protein I"513	Melanoma	Clusterin			expressed			resistance to	Cisplatin	CDDP	3	-1		"Hoeller C, J Invest Dermatol 2005, 124:1300-7"	Results were obtained with both expression and inhibition experiments. Clusterin is defined as chemoresistance molecule514	Melanoma	Clusterin			expressed			resistance to	Paclitaxel	Taxol	3	-1		"Hoeller C, J Invest Dermatol 2005, 124:1300-7"	Results were obtained with both expression and inhibition experiments. Clusterin is defined as chemoresistance molecule515	Melanoma	Clusterin			expressed			resistance to	5-Fluorouracil	5-FU	3	-1		"Hoeller C, J Invest Dermatol 2005, 124:1300-7"	Results were obtained with both expression and inhibition experiments. Clusterin is defined as chemoresistance molecule516	Melanoma	Clusterin		mRNA	downregulated by	Clusterin antisense oligo		sensitivity to	Dacarbazine	DTIC	4	1		"Hoeller C, J Invest Dermatol 2005, 124:1300-7"	"To evaluate the effects of clusterin-antisense treatment in vivo, a SCID-mouse/human-melanoma xenotransplantation model was used. Pre-treatment of mice with the 2'MOE-modified clusterin antisense oligo was associated with a significantly improved tumor response to dacarbazine as compared with animals pretreated with a scrambled control oligonucleotide"517	Melanoma	MYC	c-Myc	mRNA	downregulated by	MYC antisense oligo		sensitivity to	Cisplatin	CDDP	3	1		"Leonetti C, Clin Cancer Res 1999, 5:2588-95"	Increase of cisplatin sensitivity by c-Myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin518	Melanoma	MYC	c-Myc	protein	expressed			resistance to	IFN alpha	IFN alpha (2b)	3	-1		"Tulley PN, Br J Ophthalmol 2004, 88:1563-7"	Uveal melanoma. The ATP chemosensitivity assay was used to study sensitivity to IFN-alpha-2b in freshly isolated cells from each of 45 tumor specimens519	Melanoma	MYC	c-Myc	mRNA	downregulated by	MYC antisense oligo		sensitivity to	Radiotherapy		3	1		"Bucci B, Clin Cancer Res 2005, 11:2756-67"	MYC downregulation sensitizes melanoma to radiation by inhibiting MLH1 and MSH2 expression. Sensitization is p53 independent521	Immune cells	CTLA4			uncharacterized			sensitivity to	Tremelimumab	"CTLA4 antibody (antagonist) CP-675,206"	5	1	84	"Camacho LH, J Clin Oncol 2009, 27:1075-81"	"Phase II trial. Eight (10%) of 84 response-assessable patients attained objective antitumor responses. Multiple infusions of tremelimumab were generally tolerable and demonstrated single-agent antitumor activity. Both phase II regimens generated durable tumor responses. Based on its more favorable safety profile, 15 mg/kg every 3 months was selected for further clinical testing"522	Host	CTLA4		DNA	polymorphism rs4553808			sensitivity to	Ipilimumab	CTLA4 antibody (antagonist)	5	1	152	"Breunis WB, J Immunother 2008, 31:586-90"	Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade523	Host	CTLA4		DNA	polymorphism rs11571327			sensitivity to	Ipilimumab	CTLA4 antibody (antagonist)	5	1	152	"Breunis WB, J Immunother 2008, 31:586-90"	Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade524	Host	CTLA4		DNA	polymorphism rs231775			sensitivity to	Ipilimumab	CTLA4 antibody (antagonist)	5	1	152	"Breunis WB, J Immunother 2008, 31:586-90"	Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade525	Host	CTLA4		DNA	polymorphism rs733618			no relationship with	Ipilimumab	CTLA4 antibody (antagonist)	5	0	152	"Breunis WB, J Immunother 2008, 31:586-90"	Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade526	Host	CTLA4		DNA	polymorphism rs5742909			no relationship with	Ipilimumab	CTLA4 antibody (antagonist)	5	0	152	"Breunis WB, J Immunother 2008, 31:586-90"	Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade527	Host	CTLA4		DNA	polymorphism rs3087243			no relationship with	Ipilimumab	CTLA4 antibody (antagonist)	5	0	152	"Breunis WB, J Immunother 2008, 31:586-90"	Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade528	Host	CTLA4		DNA	polymorphism rs7565213			no relationship with	Ipilimumab	CTLA4 antibody (antagonist)	5	0	152	"Breunis WB, J Immunother 2008, 31:586-90"	Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade531	Immune cells	CTLA4			uncharacterized			sensitivity to	Tremelimumab	"CTLA4 antibody (antagonist) CP-675,206"	5	1	29	"Ribas A, J Clin Oncol 2005, 23:8968-77"	Response rate: 14%532	Immune cells	CTLA4			uncharacterized			no relationship with	Tremelimumab	"CTLA4 antibody (antagonist) CP-675,206"	6	0	655	"Ribas A, J Clin Oncol 2008, 26: May 20 suppl, Abstract LBA9011"	Phase III RCT of tremelimumab versus physician choice (dacarbazine or temozolomide)533	Melanoma	p53 delta 40	p53 isoform delta 40		expressed			resistance to	Cisplatin	CDDP	3	-1		"Avery-Kiejda KA, Clin Cancer Res 2008, 14:1659-68"	"Indirect proof: this p53 isoform was shown to inhibit p53-dependent transcription activation of the p21 and PUMA promoters, suggesting that the expression of p53 delta40 may account for the aberrant function of p53 in melanoma, which may play a role in chemoresistance"534	Melanoma	DFNA5	ICERE-1	mRNA	expressed			sensitivity to	Etoposide	VP-16	3	1		"Lage H, FEBS Lett 2001, 494:54-9"	Reduced expression is associated with resistance and forced expression increases sensitivity535	Melanoma	MLH1		mRNA	expressed			sensitivity to	Cisplatin	CDDP	3	1		"Lage H, Int J Cancer 1999, 80:744-50"	Decreased expression associated with resistance536	Melanoma	MSH2		mRNA	expressed			sensitivity to	Cisplatin	CDDP	3	1		"Lage H, Int J Cancer 1999, 80:744-50"	Decreased expression associated with resistance537	Melanoma	MLH1		mRNA	expressed			sensitivity to	Etoposide	VP-16	3	1		"Lage H, Int J Cancer 1999, 80:744-50"	Decreased expression associated with resistance538	Melanoma	MSH2		mRNA	expressed			sensitivity to	Etoposide	VP-16	3	1		"Lage H, Int J Cancer 1999, 80:744-50"	Decreased expression associated with resistance539	Melanoma	MLH1		mRNA	expressed			sensitivity to	Fotemustine		3	1		"Lage H, Int J Cancer 1999, 80:744-50"	Decreased expression associated with resistance540	Melanoma	MSH2		mRNA	expressed			sensitivity to	Fotemustine		3	1		"Lage H, Int J Cancer 1999, 80:744-50"	Decreased expression associated with resistance541	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	mRNA	expressed			resistance to	Fotemustine		3	-1		"Lage H, Int J Cancer 1999, 80:744-50"	Increased expression associated with resistance546	Melanoma	DNMT1	DNA methyl transferase 1	mRNA	downregulated by	DNMT1 antisense oligo		sensitivity to	IFN alpha	IFN alpha (2b)	3	1		"Reu FJ, J Clin Oncol 2006, 24:3771-9"	Inhibition of DNMT1 seems to act through demethylation of pro-apoptotic genes such as IFN-induced XAF1547	Melanoma	DNMT1	DNA methyl transferase 2	mRNA	downregulated by	DNMT1 antisense oligo		sensitivity to	IFN beta		3	1		"Reu FJ, J Clin Oncol 2006, 24:3771-9"	Inhibition of DNMT1 seems to act through demethylation of pro-apoptotic genes such as IFN-induced XAF1548	Melanoma	JNK		protein	phosphorylated (activated)			sensitivity to	Docetaxel		3	1		"Mhaidat NM, Clin Cancer Res 2007, 13:1308-14"	"Docetaxel induces apoptosis by increasing levels of activated JNK, which phosphorylates and inhibits Bc-2"549	Melanoma	ERK		protein	phosphorylated (activated)			resistance to	Docetaxel		3	-1		"Mhaidat NM, Clin Cancer Res 2007, 13:1308-14"	"Docetaxel can induce ERK activation, which reduces apoptosis by phosphorylating and inhibiting BAD"550	Melanoma	FAK	Focal adhesion kinase	mRNA	downregulated by	FAK antisense oligo		sensitivity to	5-Fluorouracil	5-FU	3	1		"Smith CS, Melanoma Res 2005, 15:357-62"	Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines551	Melanoma	Gadd45a		mRNA	downregulated by	Gadd45a siRNA		sensitivity to	UVB	Ultraviolet B light	3	1		"Fayolle C, J Invest Dermatol 2008, 128:196-202"	Gadd45a activation protects melanoma cells from ultraviolet B-induced apoptosis552	Melanoma	Gadd45a		mRNA	downregulated by	Gadd45a siRNA		sensitivity to	Cisplatin	CDDP	3	1		"Fayolle C, J Invest Dermatol 2008, 128:196-202"	These observations suggest that Gadd45a inactivation could be a useful way to sensitize melanoma cells to chemotherapy553	Melanoma	Gadd45a		mRNA	downregulated by	Gadd45a siRNA		sensitivity to	Dacarbazine	DTIC	3	1		"Fayolle C, J Invest Dermatol 2008, 128:196-202"	These observations suggest that Gadd45a inactivation could be a useful way to sensitize melanoma cells to chemotherapy554	Melanoma	GGT	Gamma glutamyl transferase	mRNA	upregulated by	GGT genetic engineering		resistance to	Cisplatin	CDDP	3	-1		"Franzini M, Eur J Cancer 2006, 42:2623-30"	The plasma membrane enzyme gamma-glutamyltransferase (GGT) is regarded as critical for the maintenance of intracellular levels of glutathione (GSH)556	Melanoma	HDAC1	Histone deacetylase 1	mRNA	upregulated by	HDAC1 genetic engineering		resistance to	Butyric acid	HDAC inhibitor	3	-1		"Bandyopadhyay D, Cancer Res 2004, 64:7706-10"	Butyrate: HDAC inhibitor. Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway557	Melanoma	p53	TP53	mRNA	downregulated by	p53 siRNA		resistance to	Butyric acid	HDAC inhibitor	3	-1		"Bandyopadhyay D, Cancer Res 2004, 64:7706-10"	Sodium butyrate (an HDAC inhibitor) mediates apoptosis in melanoma cells through a p53-mediated pathway (including Bax upregulation)565	Melanoma	Rac1			downregulated by	Rac1 dominant negative		resistance to	Paclitaxel	Taxol	3	-1		"Lee SC, Proteomics 2007, 7:4112-22"	Dominant negative Rac1 attenuates paclitaxel-induced apoptosis in human melanoma cells through upregulation of heat shock protein 27 (HSP27)566	Melanoma	HSP70			expressed			resistance to	Cisplatin	CDDP	1	-1		"Schmitt E, Cancer Res 2006, 66:4191-7"	"Inhibition (by ADD70, a neutralizing peptide) of HSP70 ability to bind (and inhibit) proapoptotic factor AIF leads to chemosensitization"567	Melanoma	Survivin	BIRC5		expressed			resistance to	Photodynamic therapy	PDT	3	-1		"Ferrario A, Cancer Res 2007, 67:4989-95"	Dominant negative experiments570	Melanoma	hTERT			downregulated by	hTERT dominant negative		resistance to	Temozolomide	TMZ	3	-1		"Tentori L, Mol Pharmacol 2003, 63:192-202"	Inhibition of telomerase increases resistance of melanoma cells to temozolomide (but not to temozolomide combined with poly ADP-ribose polymerase inhibitor)571	Melanoma	hTERT			downregulated by	hTERT dominant negative		sensitivity to	Temozolomide + PARP inhibitor		3	1		"Tentori L, Mol Pharmacol 2003, 63:192-202"	"Inhibition of poly(ADP-ribose) polymerase (PARP), an enzyme involved in the repair of N-methylpurines, restored sensitivity of DN-hTERT clones (slowly growing) to TMZ"572	Melanoma	hTERT		protein	active (high activity)			no relationship with	Temozolomide	TMZ	3	0		"Tentori L, Mol Pharmacol 2003, 63:192-202"	Susceptibility to TMZ of melanoma lines derived from the same patient did not depend on basal telomerase activity573	Melanoma	hTERT			downregulated by	hTERT dominant negative		resistance to	Carmustine		3	-1		"Tentori L, Mol Pharmacol 2003, 63:192-202"	"Carmustine: chloroethylating agent; inhibition of telomerase by DN-hTERT resulted in reduced growth rate and increased resistance to TMZ and to the chloroethylating agent carmustine, increased sensitivity to cisplatin, and no change in response to tamoxifen or to a selective N3-adenine methylating agent "574	Melanoma	hTERT			downregulated by	hTERT dominant negative		sensitivity to	Cisplatin	CDDP	3	1		"Tentori L, Mol Pharmacol 2003, 63:192-202"	"Inhibition of telomerase by DN-hTERT resulted in reduced growth rate and increased resistance to TMZ and to the chloroethylating agent carmustine, but increased sensitivity to cisplatin"575	Melanoma	hTERT		protein	active (high activity)			no relationship with	Tamoxifen	Anti-estrogen	3	0		"Tentori L, Mol Pharmacol 2003, 63:192-202"	"Inhibition of telomerase by DN-hTERT resulted in reduced growth rate and increased resistance to TMZ and to the chloroethylating agent carmustine, increased sensitivity to cisplatin, and no change in response to tamoxifen or to a selective N3-adenine methylating agent "576	Melanoma	hTERT			expressed			resistance to	Cisplatin	CDDP	3	-1		"Biroccio A, Mol Pharmacol 2003, 63:632-8"	"Low hTERT expression cells are sensitive, while hTERT forced expression induces resistance "577	Melanoma	hTERT			expressed			resistance to	Trabectedin	"ET-743, Yondelis (R)"	3	-1		"Biroccio A, Mol Pharmacol 2003, 63:632-8"	"Low hTERT expression cells are sensitive, while hTERT forced expression induces resistance "578	Melanoma	Oxygen			low (hypoxia)			resistance to	Doxorubicin	Adriamycin (R)	3	-1		"Sanna K, Int J Cancer 1994, 58:258-62"	Hypoxia-induced drug resistance was present immediately after reoxygenation and tended to decrease with time but remained statistically significant even 42 hr after reoxygenation579	Melanoma	Oxygen			low (hypoxia)			resistance to	Methotrexate	MTX	3	-1		"Sanna K, Int J Cancer 1994, 58:258-62"	Hypoxia-induced drug resistance was present immediately after reoxygenation and tended to decrease with time but remained statistically significant even 42 hr after reoxygenation580	Melanoma	Oxygen			low (hypoxia)			resistance to	Doxorubicin	Adriamycin (R)	1	-1		"Matthews NE, J Natl Cancer Inst 2001, 93:1879-85"	"Nitric oxide mediates chemosensitivity in tumor cells, and hypoxia-induced drug resistance appears to result, in part, from downstream suppression of endogenous NO production. These results raise the possibility that administration of small doses of NO mimetics could be used as an adjuvant in chemotherapy"582	Melanoma	IGF1R	IGF1 receptor	mRNA	downregulated by	IGF1R siRNA		sensitivity to	Cisplatin	CDDP	3	1		"Yeh AH, Oncogene 2006, 25:6574-81"	"These results support development of IGF1R targeting as therapy for melanoma, regardless of the presence of activating mutations in the RAS-RAF pathway"583	Melanoma	IGF1R	IGF1 receptor	mRNA	downregulated by	IGF1R siRNA		sensitivity to	Temozolomide	TMZ	3	1		"Yeh AH, Oncogene 2006, 25:6574-81"	"These results support development of IGF1R targeting as therapy for melanoma, regardless of the presence of activating mutations in the RAS-RAF pathway"584	Melanoma	IL-8	Interleukin-8	protein	expressed			resistance to	Dacarbazine	DTIC	3	-1		"Lev DC, Mol Cancer Ther 2003, 2:753-63"	Dacarbazine causes transcriptional upregulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy585	Melanoma	VEGF	Vascular endothelial growth factor	protein	expressed			resistance to	Dacarbazine	DTIC	3	-1		"Lev DC, Mol Cancer Ther 2003, 2:753-63"	Dacarbazine causes transcriptional upregulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy587	Melanoma	Livin	ML-IAP	protein	expressed			resistance to	Etoposide	VP-16	3	-1		"Nachmias B, Cancer Res 2003, 63:6340-9"	"Using primary cultures derived from melanoma patients, the Authors found a correlation between Livin overexpression and in vitro drug resistance"588	Melanoma	Livin	ML-IAP	mRNA	downregulated by	Livin antisense oligo		sensitivity to	Cisplatin	CDDP	3	1		"Mousavi-Shafaei P, Anticancer Drugs 2006, 17:1031-9"	Antisense-mediated melanoma inhibitor of apoptosis protein downregulation sensitizes G361 melanoma cells to cisplatin593	Melanoma	Ubc9	SUMO E2-conjugating enzyme	mRNA	downregulated by	Ubc9 siRNA		sensitivity to	Cisplatin	CDDP	3	1		"Moschos SJ, Oncogene 2007, 26:4216-25"	Ubc9 plays a crucial role in preventing advanced-stage melanomas from undergoing CDDP-induced apoptosis594	Melanoma	Ubc9	SUMO E2-conjugating enzyme	mRNA	downregulated by	Ubc9 siRNA		sensitivity to	Paclitaxel	Taxol	3	1		"Moschos SJ, Oncogene 2007, 26:4216-25"	Ubc9 plays a crucial role in preventing advanced-stage melanomas from undergoing taxol-induced apoptosis595	Melanoma	Ubc9	SUMO E2-conjugating enzyme	mRNA	downregulated by	Ubc9 siRNA		no relationship with	Temozolomide	TMZ	3	0		"Moschos SJ, Oncogene 2007, 26:4216-25"	Ubc9 does not plays a crucial role in preventing advanced-stage melanomas from undergoing TMZ-induced apoptosis596	Melanoma	TYRP2	DCT		expressed			resistance to	Cisplatin	CDDP	3	-1		"Chu W, Oncogene 2000, 19:395-402"	Results based on both expression and forced expression experiments. TYRP2 overexpression may confer resistance specifically to DNA damaging agents597	Melanoma	TYRP2	DCT		expressed			resistance to	Carboplatin		3	-1		"Chu W, Oncogene 2000, 19:395-402"	Results based on both expression and forced expression experiments. TYRP2 overexpression may confer resistance specifically to DNA damaging agents598	Melanoma	TYRP2	DCT		expressed			resistance to	Methotrexate	MTX	3	-1		"Chu W, Oncogene 2000, 19:395-402"	Results based on both expression and forced expression experiments. TYRP2 overexpression may confer resistance specifically to DNA damaging agents599	Melanoma	TYRP2	DCT		expressed			no relationship with	Paclitaxel	Taxol	3	0		"Chu W, Oncogene 2000, 19:395-402"	Results based on both expression and forced expression experiments. TYRP2 overexpression may confer resistance specifically to DNA damaging agents601	Melanoma	TRAF2			downregulated by	TRAF2 dominant negative		sensitivity to	UVR	Ultraviolet radiation	3	1		"Ivanov VN, Oncogene 2001, 20:2243-53"	"The findings identify p38, TNFalpha and NFkB as key players that efficiently sensitize melanoma cells to UVR, ribotoxic (anisomycin) and radiomimetic chemicals-induced apoptosis in response to aberrant TRAF2 signaling"602	Melanoma	TRAF2			downregulated by	TRAF2 dominant negative		sensitivity to	Actinomycin-D		3	1		"Ivanov VN, Oncogene 2001, 20:2243-53"	"The findings identify p38, TNFalpha and NFkB as key players that efficiently sensitize melanoma cells to UVR, ribotoxic (anisomycin) and radiomimetic chemicals-induced apoptosis in response to aberrant TRAF2 signaling"603	Melanoma	TRAF2			downregulated by	TRAF2 dominant negative		sensitivity to	Anisomycin		3	1		"Ivanov VN, Oncogene 2001, 20:2243-53"	"The findings identify p38, TNFalpha and NFkB as key players that efficiently sensitize melanoma cells to UVR, ribotoxic (anisomycin) and radiomimetic chemicals-induced apoptosis in response to aberrant TRAF2 signaling"604	Melanoma	TRAF2			downregulated by	TRAF2 dominant negative		no relationship with	Cisplatin	CDDP	3	0		"Ivanov VN, Oncogene 2001, 20:2243-53"	"The findings identify p38, TNFalpha and NFkB as key players that efficiently sensitize melanoma cells to UVR, ribotoxic (anisomycin) and radiomimetic chemicals-induced apoptosis in response to aberrant TRAF2 signaling"605	Melanoma	TRAF2			downregulated by	TRAF2 dominant negative		no relationship with	Paclitaxel	Taxol	3	0		"Ivanov VN, Oncogene 2001, 20:2243-53"	"The findings identify p38, TNFalpha and NFkB as key players that efficiently sensitize melanoma cells to UVR, ribotoxic (anisomycin) and radiomimetic chemicals-induced apoptosis in response to aberrant TRAF2 signaling"606	Melanoma	Topoisomerase II alpha	TOP2A	DNA	mut Ala429del			resistance to	Etoposide	VP-16	3	-1		"Campain JA, Somat Cell Mol Genet 1995, 21:451-71"	"The acquisition of the mutant allele of topoisomerase IIalpha confers a selective advantage to cells in the presence of VP-16. As the drug concentration increased during the selection process, surviving sublines show preferential expression of the mutant topoisomerase IIalpha mRNA over that of the wild-type "608	Melanoma	Thioredoxin	TRX		expressed			resistance to	TNF	Tumor necrosis factor	3	-1		"Barral AM, Melanoma Res 2000, 10:331-43"	High intracellular expression of Trx and TrxR was directly correlated with the resistance to TNFalpha-induced cytotoxicity609	Melanoma	Thioredoxin reductase	TRXR		expressed			resistance to	TNF	Tumor necrosis factor	3	-1		"Barral AM, Melanoma Res 2000, 10:331-43"	High intracellular expression of Trx and TrxR was directly correlated with the resistance to TNFalpha-induced cytotoxicity610	Melanoma	Survivin	BIRC5		expressed			resistance to	Cisplatin	CDDP	3	-1		"Li H, Exp Eye Res 2006, 83:176-82"	"Uveal melanoma. Results based on both expression levels, forced expression and antisense oligo"611	Melanoma	Survivin	BIRC5		expressed			no relationship with	Cisplatin + Actinomycin-D		3	0		"Li H, Exp Eye Res 2006, 83:176-82"	Uveal melanoma. The combination of cisplatin and actinomycin-D significantly decreased survivin expression and enhanced the cisplatin-induced apoptosis of uveal melanoma cells in vitro612	Melanoma	Survivin	BIRC5		expressed			resistance to	TRAIL		3	-1		"Li H, Arch Ophthalmol 2005, 123:654-61"	Uveal melanoma613	Melanoma	Survivin	BIRC5	mRNA	downregulated by	Survivin antisense oligo		sensitivity to	TRAIL		3	1		"Li H, Arch Ophthalmol 2005, 123:654-61"	Uveal melanoma614	Melanoma	Survivin	BIRC5	mRNA	downregulated by	Survivin ribozyme		sensitivity to	Topotecan		4	1		"Pennati M, Carcinogenesis 2004, 25:1129-36"	Topotecan: topoisomerase I inhibitor615	Melanoma	STAT5	Signal transducer and activator of transcription 5 	mRNA	downregulated by	STAT5 siRNA		sensitivity to	IFN alpha		3	1		"Wellbrock C, Curr Biol 2005, 15:1629-39"	"IFN activates both STAT5 and STAT1: while STAT1 is necessary for IFN therapeutic effect, STAT5 reduces STAT1 activity. STAT5 is an IFN resistance molecule"616	Melanoma	STAT1/STAT3 (ratio)		protein	phosphorylated (activated)			sensitivity to	IFN alpha		5	1	21	"Wang W, Clin Cancer Res 2007, 13:1523-31"	Higher pSTAT1/pSTAT3 ratios in pretreatment tumor cells were associated with longer overall survival of patients treated with high dose IFN 617	Melanoma	SOCS3	Suppressor of cytokine signaling 3	mRNA	downregulated by	SOCS3 siRNA		sensitivity to	IL-6	Interleukin-6	3	1		"Komyod W, Mol Cancer Res 2007, 5:271-81"	SOCS3 inhibition seems to act through STAT1 activation by phosphorylation618	Melanoma	SOCS3	Suppressor of cytokine signaling 3	mRNA	downregulated by	SOCS3 siRNA		sensitivity to	Oncostatin-M	OSM	3	1		"Komyod W, Mol Cancer Res 2007, 5:271-81"	SOCS3 inhibition seems to act through STAT1 activation by phosphorylation619	Melanoma	SOCS3	Suppressor of cytokine signaling 3	mRNA	downregulated by	SOCS3 siRNA		no relationship with	IFN alpha		3	0		"Komyod W, Mol Cancer Res 2007, 5:271-81"	SOCS3 inhibition seems to act through STAT1 activation by phosphorylation620	Melanoma	SOCS3	Suppressor of cytokine signaling 3	protein	expressed			resistance to	IFN gamma		3	-1		"Fojtova M, Br J Cancer 2007, 97:231-7"	Development of IFN-gamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells621	Melanoma	SLUG	Snail	mRNA	downregulated by	Slug siRNA		sensitivity to	Cisplatin	CDDP	3	1		"Vannini I, Cell Oncol 2007, 29:279-87"	Short interfering RNA directed against the SLUG gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine. Slug inhibition seems to act through PUMA upregulation622	Melanoma	SLUG	Snail	mRNA	downregulated by	Slug siRNA		sensitivity to	Fotemustine		3	1		"Vannini I, Cell Oncol 2007, 29:279-87"	Short interfering RNA directed against the SLUG gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine. Slug inhibition seems to act through PUMA upregulation628	Melanoma	MITF	Microphthalmia-associated transcription factor 		downregulated by	MITF dominant negative		sensitivity to	Cisplatin	CDDP	3	1		"Garraway LA, Nature 2005, 436:117-22"	"MITF amplification is prevalent in metastatic disease and correlates with decreased overall patient survival. Ectopic MITF expression in conjunction with the BRAF(V600E) mutant transform primary human melanocytes, and thus MITF can function as a melanoma oncogene"629	Melanoma	MITF	Microphthalmia-associated transcription factor 		downregulated by	MITF dominant negative		sensitivity to	Docetaxel		3	1		"Garraway LA, Nature 2005, 436:117-22"	"MITF amplification is prevalent in metastatic disease and correlates with decreased overall patient survival. Ectopic MITF expression in conjunction with the BRAF(V600E) mutant transform primary human melanocytes, and thus MITF can function as a melanoma oncogene"632	Melanoma	MUC4			expressed			resistance to	Doxorubicin	Adriamycin (R)	3	-1		"Hu YP, Biochem Pharmacol 2003, 65:1419-25"	"The results indicate that although Muc4(+) cells express less MDR1 and MRP1, they are more resistant to drugs recognized by these transporters"633	Melanoma	MUC4			expressed			resistance to	Paclitaxel	Taxol	3	-1		"Hu YP, Biochem Pharmacol 2003, 65:1419-25"	"The results indicate that although Muc4(+) cells express less MDR1 and MRP1, they are more resistant to drugs recognized by these transporters"634	Melanoma	MUC4			expressed			resistance to	Vinblastine		3	-1		"Hu YP, Biochem Pharmacol 2003, 65:1419-25"	"The results indicate that although Muc4(+) cells express less MDR1 and MRP1, they are more resistant to drugs recognized by these transporters"635	Melanoma	HMW-MAA	"gp240, CSPG4, NG2, High molecular weight melanoma associated antigen"	mRNA	downregulated by	HMW-MAA siRNA		sensitivity to	TNF	Tumor necrosis factor	3	1		"Chekenya M, Oncogene 2008, 27:5182-94"	HMW-MAA inhibition seems to act through inhibition of alpha3beta1 integrin/PI3K signaling 637	Melanoma	PAX3		mRNA	downregulated by	PAX3 antisense oligo		sensitivity to	Cisplatin	CDDP	3	1		"He SJ, Mol Cancer Ther 2005, 4:996-1003"	"PAX3 is a transcription factor normally expressed during embryonic development, and which is critically required for development of neural crest-derivatives, including skin melanocytes"639	Melanoma	PKC epsilon	Protein kinase C epsilon	mRNA	downregulated by	PKC epsilon siRNA		sensitivity to	Docetaxel		3	1		"Mhaidat NM, Mol Cancer Res 2007, 5:1073-81"	Inhibition of PKCepsilon by small interfering RNA molecules resulted in down-regulation of phosphorylated ERK1/2 and sensitization of cells to docetaxel-induced apoptosis640	Melanoma	Oxygen			low (hypoxia)			sensitivity to	Retinoic acid	13-cis retinoic acid	3	1		"Demary K, Endocrinology 2001, 142:2600-5"	"Hypoxia reduces reactive oxygen species (ROS) levels, which diminish DNA binding of retinoid X receptor/RAR heterodimers in vitro, providing a molecular basis for the observed inverse correlation between RAR activity and ROS levels"641	Melanoma	CDK2	Cyclin dependent kinase-2		expressed			sensitivity to	Roscovitine		3	1		"Du J, Cancer Cell 2004, 6:565-76"	Roscovitine is a CDK2 inhibitor. CDK2 levels are upregulated by MITF642	Melanoma	BUBR1			expressed			sensitivity to	Arsenic trioxide	ATO	3	1		"McNeely SC, Toxicol Appl Pharmacol 2008, 231:61-7"	BUBR1 forms the mitotic checkpoint complex (MCC) along with MAD2 and BUB1. Results obtained by both expression level and RNA interference experiments645	Melanoma	CDK	Cyclin dependent kinase		uncharacterized			sensitivity to	Roscovitine		3	1		"Mohapatra S, Mol Cancer Res 2007, 5:145-51"	Roscovitine (a CDK inhibitor) inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma667	Melanoma	Mcl-1		mRNA	downregulated by	Mcl-1 siRNA		sensitivity to	ABT-737		3	1		"Miller LA, J Invest Dermatol 2009, 129:964-71"	"ABT-737: Bcl-2, Bcl-xL and Bcl-W inhibitor (BH3 mimetic). siRNA-mediated inhibition of Mcl-1 expression significantly increased sensitivity to ABT-737"668	Melanoma	Noxa		mRNA	downregulated by	Noxa siRNA		resistance to	ABT-737 + MG-132		3	-1		"Miller LA, J Invest Dermatol 2009, 129:964-71"	"ABT-737: Bcl-2, Bcl-xL and Bcl-W inhibitor (BH3 mimetic); MG-132: proteasome inhibitor. Knocking down Noxa expression protected the cells from cytotoxicity induced by the combination treatment"683	Melanoma	TRF2			downregulated by	TRF2 dominant negative		sensitivity to	RHPS4		3	1		"Biroccio A, Eur J Cancer 2006, 42:1881-8"	Treatment with the G-quadruplex-interacting agent (G4-ligand) RHPS4 sensitises melanoma cells to inhibition of TRF2 (telomere binding protein)690	Melanoma	Mcl-1		mRNA	downregulated by	Mcl-1 antisense oligo		sensitivity to	Radiotherapy		3	1		"Skvara H, Anticancer Res 2005, 25:2697-703"	Mcl-1 blocks radiation-induced apoptosis and inhibits clonogenic cell death694	Melanoma	FLIP	c-FLIP	protein	inhibited by	Cisplatin	CDDP	sensitivity to	TRAIL		3	1		"Song JH, Clin Cancer Res 2003, 9:4255-66"	"Cisplatin inhibits c-FLIP protein expression and phosphorylation to restore TRAIL-induced caspase-8-initiated apoptosis in melanoma cells, thus providing a new combined therapeutic strategy for melanomas"699	Melanoma	Mcl-1		mRNA	downregulated by	Mcl-1 antisense oligo		sensitivity to	Betulinic acid		3	1		"Selzer E, Mol Med 2002, 8:877-84"	Downregulation of Mcl-1 by antisense oligodeoxynucleotides in combination with betulinic treatment led to a synergistic effect regarding growth inhibition703	Melanoma	MYC	c-Myc	mRNA	downregulated by	MYC antisense oligo		sensitivity to	Cisplatin	CDDP	2	1		"Steward DA, Nucleic Acids Res 2002, 30:2565-74"	"Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression"704	Melanoma	p33ING1			expressed			no relationship with	Camptothecin		3	0		"Cheung KJ, Int J Oncol 2002, 20:1319-22"	"The tumor suppressor p33ING1 (shares many biological functions with p53, such as cell cycle arrest, DNA repair, apoptosis, and chemosensitivity) does not affect camptothecin-induced cell death in melanoma cells (cell survival assay and flow cytometry analysis showed no significant difference among cells transfected with vector, p33ING1, and antisense p33ING1)"706	Melanoma	Angiostatin		mRNA	upregulated by	Angiostatin genetic engineering		sensitivity to	Endostatin gene therapy		2	1		"Scappaticci FA, Mol Ther 2001, 3:186-96"	Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity and antitumor efficacy707	Melanoma	Endostatin		mRNA	upregulated by	Endostatin genetic engineering		sensitivity to	Angiostatin gene therapy		2	1		"Scappaticci FA, Mol Ther 2001, 3:186-96"	Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity and antitumor efficacy711	Melanoma	NFkB	Nuclear factor kappa B	mRNA	downregulated by	NFkB siRNA		sensitivity to	Temozolomide	TMZ	3	1		"Chen M, Mol Cancer Res 2009, 7:1946-53"	"Inhibition of NFkB with small interfering RNA mimicked the ability of CEL to sensitize melanoma cells to TMZ, suggesting that inhibition of NF-kappaB may play a role in TMZ/CEL-induced cytotoxicity"713	Melanoma	ATM	Ataxia Telangiectasia Mutated 	mRNA	downregulated by	ATM siRNA		no relationship with	Radiotherapy		3	0		"Moschos SJ, Cancer Biol Ther 2009, 8:1815-25"	"Unlike other malignancies, ATM does not modultate radiosensitivity of melanoma cells"714	Melanoma	MYC	c-Myc		expressed			resistance to	Paclitaxel	Taxol	3	-1		"Gatti G, PLoS One 2009, 4:e5442"	The findings suggest that the use of taxane in antitumor therapeutic strategies should be rationally based on the molecular profile of the individual tumor by specifically analyzing Myc expression levels716	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	PD0325901 + ABT-737		4	1		"Cragg MS, J Clin Invest 2008, 118:3651-9"	U0126: MEK inhibitor. ABT-737: BH3 mimetic. Treatment of B-RAF mutant human melanoma with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic 720	Melanoma	MITF	Microphthalmia-associated transcription factor 	DNA	amplified (gene)			no relationship with	Paclitaxel	Taxol	5	0	116	"Ugurel S, Clin Cancer Res 2007, 13:6344-50"	"Various chemotherapy regimens: gemcitabine + treosulfan, gemcitabine + cisplatin, paclitaxel + doxorubicin, paclitaxel + cisplatin, and paclitaxel alone"721	Melanoma	MYC	c-Myc	mRNA	downregulated by	MYC antisense oligo		sensitivity to	Cisplatin	CDDP	3	1		"Benassi B, Mol Pharmacol 2007, 72:1015-23"	"Specific c-Myc inhibition increased melanoma susceptibility to antineoplastic drugs with different mechanisms of action, such as cisplatin (CDDP), staurosporine (STR), and 5-fluorouracil (5-FU). The effect of MYC is mediated by its target gene g-GCS (glutathione synthesis)"722	Melanoma	MYC	c-Myc	mRNA	downregulated by	MYC antisense oligo		sensitivity to	Staurosporine		3	1		"Benassi B, Mol Pharmacol 2007, 72:1015-23"	"Specific c-Myc inhibition increased melanoma susceptibility to antineoplastic drugs with different mechanisms of action, such as cisplatin (CDDP), staurosporine (STR), and 5-fluorouracil (5-FU). The effect of MYC is mediated by its target gene g-GCS (glutathione synthesis)"723	Melanoma	MYC	c-Myc	mRNA	downregulated by	MYC antisense oligo		sensitivity to	5-Fluorouracil	5-FU	3	1		"Benassi B, Mol Pharmacol 2007, 72:1015-23"	"Specific c-Myc inhibition increased melanoma susceptibility to antineoplastic drugs with different mechanisms of action, such as cisplatin (CDDP), staurosporine (STR), and 5-fluorouracil (5-FU)"724	Melanoma	g-GCS	Gamma glutamylcysteine synthetase	mRNA	upregulated by	g-GCS genetic engineering		resistance to	Cisplatin	CDDP	3	-1		"Benassi B, Mol Pharmacol 2007, 72:1015-23"	g-GCS (glutathione synthesis) mediates the Myc response to anticancer drugs producing reactive oxygen species (ROS)725	Melanoma	g-GCS	Gamma glutamylcysteine synthetase	mRNA	upregulated by	g-GCS genetic engineering		resistance to	Staurosporine		3	-1		"Benassi B, Mol Pharmacol 2007, 72:1015-23"	g-GCS (glutathione synthesis) mediates the Myc response to anticancer drugs producing reactive oxygen species (ROS)726	Melanoma	g-GCS	Gamma glutamylcysteine synthetase	mRNA	upregulated by	g-GCS genetic engineering		no relationship with	5-Fluorouracil	5-FU	3	0		"Benassi B, Mol Pharmacol 2007, 72:1015-23"	g-GCS (glutathione synthesis) mediates the Myc response to anticancer drugs producing reactive oxygen species (ROS): 5-FU does not lead to increased levels of ROS727	Melanoma	BRAF	B-Raf	DNA	wild type (vs mutated)			no relationship with	PD0325901		4	0		"Ciuffreda L, Neoplasia 2009, 11:720-31"	PD0325901 is a MEK inhibitor with significant anti-melanoma activity independently of BRAF mutational status728	Melanoma	MEK			expressed			sensitivity to	PD0325901		4	1		"Ciuffreda L, Neoplasia 2009, 11:720-31"	"PD0325901 exerts potent growth-inhibitory, proapoptotic, and antiangiogenic activity in melanoma (regardless of BRAF mutation status)"729	Melanoma	E-cadherin		mRNA	upregulated by	E-cadherin genetic engineering		sensitivity to	Staurosporine		3	1		"Kippenberger S, Melanoma Res 2006, 16:393-403"	Restoration of E-cadherin sensitizes human melanoma cells to apoptosis731	Melanoma	Bcl-2			expressed			no relationship with	Oblimersen		3	0		"Benimetskaya L, Clin Cancer Res 2004, 10:8371-9"	"The mechanism whereby G3139 produces drug-induced cytotoxicity in the 518A2 melanoma line is not dependent on levels of Bcl-2, which emphasizes the non-sequence specific effects of this phosphorothioate oligonucleotide"733	Melanoma	EGFR	ERBB1		expressed			sensitivity to	AG1478		3	1		"Ivanov VN, Oncogene 2005, 24:616-26"	AG1478: EGFR inhibitor734	Melanoma	EGFR	ERBB1		expressed			sensitivity to	PD153035		3	1		"Ivanov VN, Oncogene 2005, 24:616-26"	PD153035: EGFR inhibitor735	Melanoma	AKT	PKB	mRNA	upregulated by	AKT genetic engineering		resistance to	LY294002	AKT inhibitor	3	-1		"Ivanov VN, Oncogene 2005, 24:616-26"	LY294002: PI3K inhibitor. Overexpression of AKT protects WM9 melanoma cells from apoptosis induced by LY294002 or AG1478 736	Melanoma	AKT	PKB	mRNA	upregulated by	AKT genetic engineering		resistance to	AG1478		3	-1		"Ivanov VN, Oncogene 2005, 24:616-26"	AG1478: EGFR inhibitor (tyrosine kinase receptor small molecule inhibitor). Overexpression of AKT protects WM9 melanoma cells from apoptosis induced by LY294002 or AG1478 737	Melanoma	MYC	c-Myc	mRNA	upregulated by	MYC genetic engineering		sensitivity to	Radiotherapy		3	1		"Peltenburg LT, Melanoma Res 2004, 14:3-12 "	c-Myc is able to sensitize human melanoma cells to diverse apoptotic triggers738	Melanoma	MYC	c-Myc	mRNA	upregulated by	MYC genetic engineering		sensitivity to	Etoposide	VP-16	3	1		"Peltenburg LT, Melanoma Res 2004, 14:3-12 "	c-Myc is able to sensitize human melanoma cells to diverse apoptotic triggers739	Melanoma	MYC	c-Myc	mRNA	upregulated by	MYC genetic engineering		sensitivity to	5-Fluorouracil	5-FU	3	1		"Peltenburg LT, Melanoma Res 2004, 14:3-12 "	c-Myc is able to sensitize human melanoma cells to diverse apoptotic triggers740	Melanoma	NFkB	Nuclear factor kappa B		expressed			resistance to	Arsenic trioxide	ATO	3	-1		"Ivanov VN, J Biol Chem 2004, 279:22747-58"	Apoptosis induced by ATO is mediated by TNF744	Melanoma	Hydrogen ion	pH		high (low pH)			sensitivity to	Hyperthermia		3	1		"Coss RA, Mol Cancer Ther 2003, 2:383-8"	"Significant decrease in the intracellular pH of melanoma can selectively sensitize the cells to 42°C hyperthermia, possibly through the inhibition of HSP expression"745	Melanoma	Glucosylceramide synthase 	GCS		expressed			no relationship with	Doxorubicin	Adriamycin (R)	1	0		"Veldman RJ, FASEB J 2003, 17:1144-6"	"Alterations of the cellular ceramide glycosylation capacity failed to sensitize melanoma cells to anticancer drugs, therefore moderating the importance of ceramide glucosylation in drug-resistance mechanisms. Results were based on both expression levels, forced expression and pharmacological inhibition experiments"746	Melanoma	Glucosylceramide synthase 	GCS		expressed			no relationship with	Vinblastine		1	0		"Veldman RJ, FASEB J 2003, 17:1144-6"	"Alterations of the cellular ceramide glycosylation capacity failed to sensitize melanoma cells to anticancer drugs, therefore moderating the importance of ceramide glucosylation in drug-resistance mechanisms. Results were based on both expression levels, forced expression and pharmacological inhibition experiments"747	Melanoma	Glucosylceramide synthase 	GCS		expressed			no relationship with	Paclitaxel	Taxol	1	0		"Veldman RJ, FASEB J 2003, 17:1144-6"	"Alterations of the cellular ceramide glycosylation capacity failed to sensitize melanoma cells to anticancer drugs, therefore moderating the importance of ceramide glucosylation in drug-resistance mechanisms. Results were based on both expression levels, forced expression and pharmacological inhibition experiments"748	Melanoma	Glucosylceramide synthase 	GCS		expressed			no relationship with	Cytarabine	Cytosine arabinoside	1	0		"Veldman RJ, FASEB J 2003, 17:1144-6"	"Alterations of the cellular ceramide glycosylation capacity failed to sensitize melanoma cells to anticancer drugs, therefore moderating the importance of ceramide glucosylation in drug-resistance mechanisms. Results were based on both expression levels, forced expression and pharmacological inhibition experiments"751	Melanoma	E1A (adenoviral oncogene)		mRNA	upregulated by	E1A genetic engineering		sensitivity to	TRAIL		3	1		"Routes JM, J Immunol 2000, 165:4522-7"	Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL)752	Melanoma	EMAP-II	Endothelial monocyte-activating polypeptide II	mRNA	upregulated by	EMAP-II genetic engineering		sensitivity to	TNF	Tumor necrosis factor	4	1		"Gnant MF, Cancer Res 1999, 59:4668-74"	Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus753	Melanoma	PI3K			expressed			sensitivity to	ZSTK474		2	1		"Yaguchi S, J Natl Cancer Inst 2006, 98:545-56"	ZSTK474 is an orally bioavailable PI3K inhibitor with strong antitumor activity against human cancer xenografts without toxic effects in critical organs757	Melanoma	APAF1			expressed			sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Soengas MS, Nature 2001, 409:207-11"	APAF1-negative melanomas are chemoresistant and are unable to execute a typical apoptotic programme in response to p53 activation: restoring physiological levels of Apaf-1 through gene transfer or 5aza2dC treatment markedly enhances chemosensitivity 758	Melanoma	APAF1			expressed			no relationship with	Cisplatin	CDDP	3	0		"Zanon M, Cancer Res 2004, 64:7386-94"	Results in melanoma cells expressing or not expressing APAF-1 suggest that the response of human melanoma cells to different proapoptotic agents may be independent of their APAF1 expression levels759	Melanoma	APAF1			expressed			no relationship with	Camptothecin		3	0		"Zanon M, Cancer Res 2004, 64:7386-94"	Results suggest that the response of human melanoma cells to different proapoptotic agents may be independent of their APAF1 expression levels760	Melanoma	APAF1			expressed			no relationship with	Celecoxib		3	0		"Zanon M, Cancer Res 2004, 64:7386-94"	Results suggest that the response of human melanoma cells to different proapoptotic agents may be independent of their APAF1 expression levels761	Melanoma	APAF1			expressed			sensitivity to	Etoposide	VP-16	3	1		"Zanon M, Cancer Res 2004, 64:7386-94"	"Using melanoma cells expressing or not expressing APAF1, investigators found that response to high dose etoposide is better in APAF1 positive cells"762	Plasma/serum	VEGF	Vascular endothelial growth factor	protein	expressed			resistance to	IL-2	Interleukin-2	5	-1	59	"Sabatino M, J Clin Oncol 2009, 27:2645-52"	High-dose IL-2. Vascular endothelial growth factor (VEGF) and fibronectin were identified as independent predictors of response (high levels were correlated with lack of clinical response) 763	Plasma/serum	Fibronectin		protein	expressed			resistance to	IL-2	Interleukin-2	5	-1	59	"Sabatino M, J Clin Oncol 2009, 27:2645-52"	High-dose IL-2. Vascular endothelial growth factor (VEGF) and fibronectin were identified as independent predictors of response (high levels were correlated with lack of clinical response) 764	Melanoma	Arpc1b		mRNA	expressed			resistance to	Radiotherapy		3	-1		"Kumagai K, Invest Ophthalmol Vis Sci 2006, 47:2300-4"	Uveal melanoma. Arpc1b gene is a candidate prediction marker for choroidal malignant melanomas sensitive to radiotherapy765	Plasma/serum	RASSF1A		DNA	methylated			resistance to	Biochemotherapy		5	-1	47	"Mori T, J Clin Oncol 2005, 23:9351-8"	"Circulating methylated RASSF1A was significantly less frequent for responders than non-responders to mixed regimens containing DTIC, temozolomide, cisplatin, vinblastine, IFN alpa-2b, interleukin-2, tamoxifen "766	Plasma/serum	S100B		protein	expressed			resistance to	Biochemotherapy		5	-1	53	"Hamberg AP, Melanoma Res 2003, 13:45-9"	Biochemotherapy: TMZ + IFN alpha + GM-CSF + IL-2767	Plasma/serum	Autoantibodies		protein	expressed			no relationship with	IFN alpha		5	0	543	"Bouwhuis MG, J Natl Cancer Inst 2009, 101:869-77"	"Serum levels of anticardiolipin, antithyroglobulin, and antinuclear antibodies measured before and during adjuvant IFN alpha treatment were not associated with disease-free survival in two randomized controlled trials"836	Melanoma	ROS	Reactive oxygen species		downregulated by	N-acetylcysteine	NAC	resistance to	Elesclomol		3	-1		"Kirshner JR, Mol Cancer Ther 2008, 7:2319-27"	Elesclomol is a small molecule inducing oxidative stress by increasing ROS levels837	Melanoma	NRAS	N-Ras	DNA	mut G13D			sensitivity to	17-AAG	Tanespimycin (17-allylamino-17-demethoxygeldanamycin)	5	1	6	"Banerji U, Mol Cancer Ther 2008, 7:737-9"	"17-AAG: HSP90 inhibitor. The only patient who had a NRAS mutation (together with wild type BRAF) had a prolonged time to progression of 49 months, which is in excess of what is clinically predicted for metastatic melanoma"838	Melanoma	MET	c-Met		expressed			sensitivity to	SU11274	MET inhibitor	3	1		"Puri N, Clin Cancer Res 2007, 13:2246-53"	SU11274: MET inihbitor (tyrosine kinase receptor small molecule inhibitor). Cell lines expressing higher MET levels were more sensitive839	Melanoma	ABCB5			expressed			sensitivity to	ABCB5 antibody		4	1		"Schatton T, Nature 2008, 451:345-9"	The anti-ABCB5 antibody is directed against melanoma stem cells 840	Immune cells	CD91	HSP receptor		uncharacterized			no relationship with	HSP90 vaccine	gp96 vaccine (Vitespen (R))	6	0	322	"Testori A, J Clin Oncol 2008, 26:955-62"	CD91 is the receptor of HSP90. Phase III RCT of HSP based vaccine versus physicin choice (metastatic setting). No overall survival difference between arms. Patient receiving more vaccine doses survived longer841	Immune cells	IFNAR	IFN alpha receptor		uncharacterized			sensitivity to	IFN alpha		7	1	8122	"Mocellin S, J Natl Cancer Inst 2010, Epub ahead of print"	Significantly increased overall and disease free survival for patients treated with IFN as compared to observation (adjuvant setting)842	Melanoma	"miR-221, miR-222"	"miRNA-221, miRNA-222"		expressed			sensitivity to	mir-221 + mir-222 antagomir		4	1		"Felicetti F, Cancer Res 2008, 68:2745-54"	Antagomir: antisense oligo against microRNA (miRNA)843	Melanoma	ERBB3	HER3		expressed			sensitivity to	HER3 antibody (antagonist)		3	1		"Reschke M, Clin Cancer Res 2008, 14:5188-97"	"Monoclonal antibodies specific for the extracellular portion of HER3 efficiently block heregulin-induced proliferation, migration, and invasion of melanoma cell lines"844	Melanoma	GRM1	Metabotropic glutamate receptor-1	mRNA	upregulated by	GRM1 genetic engineering		sensitivity to	GRM1 downregulation		2	1		"Ohtani Y, Oncogene 2008, 27:7162-70"	Conditional expression model845	Endothelial cells	HMW-MAA	"gp240, CSPG4, NG2, High molecular weight melanoma associated antigen"		uncharacterized			sensitivity to	HMW-MAA vaccine		2	1		"Maciag PC, Cancer Res 2008, 68:8066-75"	"The vaccine worked against melanoma cells both engineered and nor engineered to express HMW-MAA: the hypothesis is that the vaccine could be targeting pericytes, which are important for tumor angiogenesis"846	Melanoma	SRC	c-Src	mRNA	expressed			sensitivity to	SRC siRNA		4	1		"Boukerche H, Proc Natl Acad Sci USA 2008, 105:15914-9"	"c-SRC activation promotes the formation of an active FAK/c-Src signaling complex, leading to enhanced tumor cell invasion and metastatic spread"847	Melanoma	Tbx3		mRNA	expressed			sensitivity to	Tbx3 siRNA		3	1		"Rodriguez M, Cancer Res 2008, 68:7872-81"	TBX3 promotes melanoma progression by inhibiting both p21/CIP1 (cell senescence) and E-cadherin (cell adhesion) expression848	"Melanoma, immune cells"	STAT3	Signal transducer and activator of transcription 3 		expressed			sensitivity to	WP1066		2	1		"Kong LY, Clin Cancer Res 2008, 14:5759-68"	WP1066: STAT3 inhibitor. The antitumor cytotoxic effects of WP1066 and its ability to induce antitumor immune responses suggest that this compound has potential for the effective treatment of melanoma 849	Immune cells	EBI3	IL27B		expressed			sensitivity to	EBI3 knockout		2	1		"Sauer KA, J Immunol 2008, 181:6148-57"	"EBI-3, which codes for a soluble type I receptor homologous to the p40 subunit of IL-12, reveals immunosuppressive properties that make EBI-3 a potential therapeutic target "850	Melanoma	Notch1			expressed			sensitivity to	DAPT		4	1		"Bedogni B, J Clin Invest 2008, 118:3660-70"	DAPT: secretase inhibitor that inhibits Notch signaling. Authors demonstrated similar results with Notch siRNA. Akt regulates Notch1 via NFkB851	Melanoma	NFkB (p50/p105/NFKB1)	Nuclear factor kappa B		expressed			sensitivity to	NFkB1 siRNA		4	1		"Karst AM, Int J Cancer 2009, 124:494-501"	p50 favors melanoma angiogenesis/progression at least in part by enhancing IL-6 expression852	Melanoma	LIF	Leukemia inhibitory factor	mRNA	upregulated by	LIF genetic engineering		sensitivity to	LIF siRNA		4	1		"Maruta S, Clin Exp Metastasis 2009, 26:133-41"	Results suggest a potential role for LIF in the melanoma-induced bone metastasis: LIF might therefore be a potentially effective drug target 853	Melanoma	CD44			expressed			sensitivity to	ADAM10		3	1		"Anderegg U, J Invest Dermatol 2009, 129:1471-82"	ADAM10 is the sheddase of CD44 (hyaluronic acid receptor): the resulting soluble form of CD44 can abolish the cell proliferation-promoting effect of hyaluronic acid on melanoma cells. Enhancement of ADAM10 activity might be a novel therapeutic approach 854	Melanoma	MFG-E8	Milk fat globule EGF-8		expressed			sensitivity to	MFG-E8 siRNA		3	1		"Jinushi M, Cancer Res 2008, 68:8889-98"	MFG knockdown causes human melanoma cell apoptosis855	Melanoma	MFG-E8	Milk fat globule EGF-8	mRNA	downregulated by	MFG-E8 siRNA		sensitivity to	AG538		3	1		"Jinushi M, Cancer Res 2008, 68:8889-98"	"AG538: IGF1R inhibitor. MFG-E8 augments melanoma cell resistance to apoptosis, triggers an epithelial-to-mesenchymal transition (EMT) and stimulates immune suppression"856	Melanoma	MFG-E8	Milk fat globule EGF-8	mRNA	downregulated by	MFG-E8 siRNA		sensitivity to	SU11274	MET inhibitor	3	1		"Jinushi M, Cancer Res 2008, 68:8889-98"	"SU11274: c-Met inhibitor. MFG-E8 augments melanoma cell resistance to apoptosis, triggers an epithelial-to-mesenchymal transition (EMT) and stimulates immune suppression"859	Melanoma	PAR-1	Protease activated receptor 1 (thombin receptor)	mRNA	expressed			sensitivity to	PAR1 siRNA		4	1		"Villares GJ, Cancer Res 2008, 68:9078-86"	"PAR1 is overexpressed in highly metastatic melanoma cell lines and in patients with metastatic lesions; its activation leads to upregulation of genes involved in adhesion, invasion and angiogenesis (e.g. connexin-43 as described by the same group in: Villares GJ, Cancer Res 2009, 69:6730-7)"860	Melanoma	GAS1			downregulated			sensitivity to	GAS1 gene therapy		2	1		"Gobeil S, Genes Dev 2008, 22:2932-40"	GAS1 is often downregulated in melanoma and contributes to metastasis as demonstrated by gene therapy and knockdown experiments 861	Melanoma	IKKG	IKB kinase gamma (NEMO)	protein	expressed			sensitivity to	IKK inhibitor	NBD peptide	3	1		"Ianaro A, Cancer Lett 2009, 274:331-6"	"A cell-permeable peptide spanning the NEMO binding domain (NBD) of IKK-beta disrupts the IKK heterotrimer (IKK-alpha + IKK-beta + NEMO/IKK-gamma), inhibits NFkB activity and leads to apoptosis of a melanoma cell line (with high NFkB levels)"862	Melanoma	Galectin-3		mRNA	expressed			sensitivity to	Galectin-3 siRNA		4	1		"Mourad-Zeidan AA, Am J Pathol 2008, 173:1839-52"	Galectin-3 promotes vasculogenic mimicry863	Melanoma	FAK	Focal adhesion kinase	mRNA	expressed			sensitivity to	FAK antisense oligo		3	1		"Smith CS, Melanoma Res 2005, 15:357-62"	"In BL melanoma cells, treatment with FAK antisense oligonucleotide was associated with a 2.5-fold increase in cell death compared with treatment with control oligonucleotide "864	Melanoma	Melanotransferrin	MTf	protein	expressed			sensitivity to	MTf antibody (antagonist)	L235	4	1		"Rolland Y, Pigment Cell Melanoma Res 2009, 22:86-98"	Melanotransferrin is a melanoma surface antigen that promotes melanoma metastasis865	Melanoma	Methionine cycle pathway			uncharacterized			sensitivity to	TMECG	Epicatechin-3-gallate derivative	3	1		"Sánchez-del-Campo L, Int J Cancer 2008, 123:2446-55"	"TMECG: methionine cycle inhibitor; it inhibits also DHFR (DNA synthesis, target of methotrexate). Methionine is an essential amino acid involved in: protein synthesis, glutathione synthesis, polyamine synthesis, DNA methylation, folic acid cycle (DNA synthesis) and adenosine cycle (purine synthesis). Methionine cycle enzymes are overexpressed in many melanomas. "867	Melanoma	B-catenin	Beta catenin	mRNA	expressed			sensitivity to	B-catenin overexpression		2	1		"Takahashi Y, Int J Cancer 2008, 123:2315-20"	Gene silencing of beta-catenin in melanoma cells retards their growth but promotes the formation of pulmonary metastasis in mice. In this model b-catenin acts as a tumor suppressor gene868	Immune cells	CTLA4			uncharacterized			sensitivity to	Ipilimumab	CTLA4 antibody (antagonist)	5	1	23	"Weber JS, J Clin Oncol 2008, 26:5950-6"	"In this phase I-II trial, a 39% disease control rate was achieved in patients with metastatic melanoma"869	Melanoma	miR-34a	miRNA-34a		downregulated			sensitivity to	mir-34a gene therapy		3	1		"Yan D, Invest Ophthalmol Vis Sci 2009, 50:1559-65"	Uveal melanoma. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met870	Melanoma	let-7a			downregulated			sensitivity to	Let-7a gene therapy		3	1		"Müller DW, Oncogene 2008, 27:6698-706"	The repressed expression of integrin beta(3) accompanies with reduced invasive potential of melanoma cells transfected with synthetic let-7a molecules observed in Boyden chamber assays871	Melanoma	MYC	c-Myc	mRNA	expressed			sensitivity to	MYC siRNA		3	1		"Zhuang D, Oncogene 2008, 27:6623-34"	"In vitro data suggest that one of the major functions of c-MYC overexpression in melanoma progression is to continuously suppress BRAF(V600E)- or NRAS(Q61R)-dependent senescence programs. Accordingly, MYC knockdown leads to cell cycle arrest or apoptosis"872	Plasma/serum	Thrombin		protein	expressed			sensitivity to	Hirudin		2	1		"Niers TM, Clin Exp Metastasis 2009, 26:171-8"	Hirudin is an inhibitor of coagulation factor thrombin 873	Melanoma	"PAR-1, CD24"			expressed			sensitivity to	Hirudin		2	1		"Niers TM, Clin Exp Metastasis 2009, 26:171-8"	The effect of anticoagulant hirudin is dependent on cancer cell expression of CD24 and PAR-1874	Miscellany	"Antithrombin III, selectin"			uncharacterized			sensitivity to	LHD	LMWH-deoxycholic acid conjugate 	2	1		"Lee DY, Clin Cancer Res 2008, 14:2841-9"	"LHD is an orally bioavailable low molecular weight heparin conjugated with deoxycholic acid. Heparins inhibit coagulation by activating antithrombin III. LHD inhibits the metastatic process by interrupting of the interactions between melanoma cells and both platelets and endothelial cells by blocking selectin-mediated interactions. Similar findings in: Lee DY, Pharm Res 2009, 26:2667-76"875	Melanoma	HMW-MAA	"gp240, CSPG4, NG2, High molecular weight melanoma associated antigen"		expressed			sensitivity to	HMW-MAA antibody		4	1		"Wagner S, Clin Cancer Res 2008, 14:8178-83"	Passive immunotherapy with this antibody shows therapeutic potential876	Immune cells	DEC-205		protein	expressed			sensitivity to	gp100/DEC-205 fusion protein		2	1		"Johnson TS, Clin Cancer Res 2008, 14:8169-77"	"This fusion protein targets melanoma antigen gp100 to dendritic cells, which express DEC-205 (an antigen receptor): this immunotheapy is more effective than gp100 peptide vaccination"877	Melanoma	Wnt5A			expressed			resistance to	Lymphocyte lysis (immunotherapy)		3	-1		"Dissanayake SK, Cancer Res 2008, 68:10205-14"	"CTL activation studies showed that increases in Wnt5A correspond to decreased CTL activation and vice versa, suggesting that targeting Wnt5A before immunotherapy may lead to the enhancement of current targeted immunotherapy. Melanosomal antigen expression is governed by MITF, PAX3 and SOX10, and is inhibited upon STAT3 activation by Wnt5A, via decreases in PAX3 and subsequently MITF expression "878	Melanoma	PTPRD	Protein tyrosine phosphatase receptor type D	DNA	mut G446E			sensitivity to	PTPRD gene therapy		3	1		"Solomon DA, Cancer Res 2008, 68:10300-6"	Transfection of melanoma cells harboring this missense mutation with wild type PTPRD led to significant growth inhibition and decrease in cell viability as well as a substantial increase in apoptotic cells 879	Melanoma	PTPRD	Protein tyrosine phosphatase receptor type D	DNA	mut V1565I			sensitivity to	PTPRD gene therapy		3	1		"Solomon DA, Cancer Res 2008, 68:10300-6"	Transfection of melanoma cells harboring this missense mutation with wild type PTPRD led to significant growth inhibition and decrease in cell viability as well as a substantial increase in apoptotic cells 880	Melanoma	GNAQ		DNA	mut Q209L			sensitivity to	GNAQ siRNA		3	1		"Van Raamsdonk CD, Nature 2009, 457:599-602"	"Uveal melanoma. GNAQ is mutationally activated in many uveal (but not skin) melanomas and acts as an oncogene (is a member of the q class of G-protein alpha subunits involved in mediating signals between G-protein coupled receptors, GPCR)"882	Melanoma	SOCS1	Suppressor of cytokine signaling 1		downregulated			sensitivity to	SOCS1 gene therapy		4	1		"Huang FJ, Cancer Res 2008, 68:9634-42"	"In vivo studies demonstrate that suppressor of cytokine signaling 1 (SOCS1) acts as a suppressor of melanoma metastatic potential, likely by inhibiting the activity of STAT3 (which leads to increased expression of MMP-2, bFGF and VEGF)"883	Melanoma	HIF1 alpha	Hypoxia inducible factor 1 alpha	mRNA	expressed			sensitivity to	HIF1alpha siRNA		4	1		"Liu Y, Mol Ther 2009, 17:269-77"	"In an in vivo model, inhibition of hypoxia inducible factor-1 alpha (HIF-1 alpha) by means of short harpin RNA (shRNA) linked to transferrin (whose receptor is expressed on malignant cells) shows anti-melanoma activity"884	Melanoma	TSP2	Thrombospondin 2		downregulated			sensitivity to	TSP2 gene therapy		4	1		"Chijiwa T, Int J Oncol 2009, 34:5-13"	"In a xenograft model, human melanoma cells transfected with the thrombospondin-2 gene show significantly reduced metastatic potential, which is likely due to thrombospondin-2 upregulation of anti-angiogenenic plasminogen activator inhibitors (PAI)"886	Melanoma	PPAR gamma	Peroxisome proliferator activated receptor gamma	protein	expressed			sensitivity to	Ciglitazone		4	1		"Botton T, J Invest Dermatol 2009, 129:1208-18"	"In a human xenograft model of melanoma, ciglitazone - a PPARgamma synthetic ligand of the thiazolidinedione family - dramatically inhibits tumor development, by inducing apoptosis and cell cycle arrest selectively in malignant cells"887	Melanoma	NRAS	N-Ras	DNA	mut Q61R			sensitivity to	NRASmutQ61R siRNA		3	1		"Eskandarpour M, Int J Cancer 2009, 124:16-26"	"Suppression of mutationally activated oncogenic NRAS by siRNA can induce growth arrest and inhibit invasion of human melanoma cells by downregulating the levels of cyclin E2, cyclin D1, EphA2, uPAR, leupaxin, paxillin and vinculin"888	Melanoma	CYLD			downregulated			sensitivity to	CYLD gene therapy		4	1		"Massoumi R, J Exp Med 2009, 206:221-32"	"Transcription factor Snail1 inhibits expression of the tumor suppressor CYLD in melanoma: as a direct consequence, the proto-oncogene BCL-3 translocates into the nucleus and activates Cyclin D1 and N-cadherin promoters, resulting in proliferation and invasion of melanoma cells. Rescue of CYLD expression in melanoma cells reduced proliferation and invasion in vitro and tumor growth and metastasis in vivo"889	Melanoma	ANXA1	Annexin A1	mRNA	expressed			sensitivity to	ANXA1 siRNA		1	1		"Rondepierre F, Biochim Biophys Acta 2009, 1794:61-9"	"In a murine melanoma model, siRNA based inhibition of Annexin-A1 expression decreases melanoma cell invasiveness (Matrigel coated chamber invasion test)"890	Immune cells	IL18R	Interleukin-18 receptor		uncharacterized			no relationship with	IL-18	Interleukin-18	5	0	64	"Tarhini AA, Cancer 2009, 115:859-68"	"In a phase II trial of recombinant interleukin-18 (an immunostimulatory cytokine), no significant tumor response was observed among 64 patients with metastatic melanoma (1 partial response + 4 stable disease)"891	Endothelial cells	CXCR2			expressed			sensitivity to	CXCR2 knockout		4	1		"Singh S, Cancer Res 2009, 69:411-5"	"Nude mice knockout for CXCR2. In this human xenograft melanoma model, host CXCR2 (receptor for angiogenic factor IL-8) depletion inhibits tumor growth and metastasis"892	Melanoma	Rap1GAP		DNA	methylated			sensitivity to	Decitabine	5-aza-2'-deoxycytidine 	3	1		"Zheng H, Cancer Res 2009, 69:449-57"	"Rap1GAP (an inhibitor of RAS family member RAP1A/KREV1) is suppressed in melanoma via promoter hypermethylation, which leads to malignant cell survival, proliferation and migration through activation of ERK and integrin pathways"893	Melanoma	MAGE-11		mRNA	expressed			sensitivity to	MAGE11 siRNA		3	1		"Aprelikova O, Cancer Res 2009, 69:616-24"	"MAGE11 activates the hypoxia response (including angiogenesis) by inhibiting PHD2, the prolyl hydroxylase that targets HIF1-alpha to proteasomal degradation. Knockdown of MAGE-11 results in decreased hypoxic induction of HIF-1alpha and its target genes, which may provide a valuable tool for therapeutic intervention because of the restricted expression of the MAGE gene family in cancers"894	Melanoma	AKT	PKB		expressed			sensitivity to	BI-69A11		4	1		"Gaitonde S, Pigment Cell Melanoma Res 2009, 22:187-95"	BI-69A11 is an AKT inhibitor; the effect of BI-69A11 was more pronounced in cells that express an active form of AKT895	Melanoma	Wnt3A			downregulated			sensitivity to	Wnt3A gene therapy		3	1		"Chien AJ, Proc Natl Acad Sci USA 2009, 106:1193-8"	"As opposed to colon cancer, in melanoma the Wnt3A/beta-catenin pathway seems to increase cell differentiation and decrease cell proliferation"896	Melanoma	IKB gamma	IKBg	mRNA	expressed			sensitivity to	IKBgamma ribozyme		2	1		"Torabian SZ, Am J Pathol 2009, 174:1009-16"	Ribozyme-mediated targeting of IkB-gamma (a member of a family of proteins that inhibit the nuclear localization of NFkB) inhibits melanoma invasion and metastasis899	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	PLX4032	RG7204	3	1		"Halaban R, Pigment Cell Melanoma Res 2010, 23:190-200"	"PLX4032 is a BRAF inhibitor with high selectivity for mutated BRAF V600E. While PLX4032 has antitumor effect against BRAF V600E melanoma cells, it can activate the ERK pathway and enhances cell migration and proliferation of BRAF wild type melanoma cells"900	Melanoma	MIC1	Macrophage inhibitory cytokine 1 (GDF15)	mRNA	expressed			sensitivity to	MIC1 siRNA		4	1		"Boyle GM, J Invest Dermatol 2009, 129:383-91"	"MIC1 is overexpressed in melanoma, is under the transcriptional control of MITF and represents a potential therapeutic target"901	Melanoma	PDSS2	Prenyl diphosphate synthase subunit 2		expressed			sensitivity to	PDSS2 gene therapy		4	1		"Fung JM, Clin Cancer Res 2009, 15:797-803"	PDSS2 is often downregulated in melanoma and is a potential tumor suppressor gene as demonstrated by forcing its expression in melanoma cells902	Melanoma	VEGFR2	VEGF receptor 2	protein	expressed			sensitivity to	Sorafenib + Carboplatin + Paclitaxel		5	1	46	"Jilaveanu L, Clin Cancer Res 2009, 15:1076-85"	Sorafenib is a BRAF CRAF VEGFR and PDGFR inhibitor. VEGFR2 expression was significantly higher in pretreatment specimens from patients with a complete or partial response to this regimen (metastatic setting)903	Melanoma	ERK		protein	expressed			resistance to	Sorafenib + Carboplatin + Paclitaxel		5	-1	46	"Jilaveanu L, Clin Cancer Res 2009, 15:1076-85"	Sorafenib is a BRAF CRAF VEGFR and PDGFR inhibitor. ERK1/2 expression was significantly higher in pretreatment specimens from patients who did not respond to this regimen (metastatic setting)904	Melanoma	Cadherin-7			downregulated			sensitivity to	Cadherin-7 gene therapy		3	1		"Winklmeier A, Cancer Sci 2009, 100:261-8"	Cadherin-7 interacts with melanoma inhibitory activity (MIA) protein and negatively modulates melanoma cell migration905	Melanoma	TGF beta 2	Transforming growth factor beta 2	mRNA	expressed			sensitivity to	TGFbeta-2 siRNA 		2	1		"Zhang C, Cancer Res 2009, 69:828-35"	These data show that TGF-beta2 expression by murine melanoma cells is necessary for the establishment and growth of metastases in the brain parenchyma906	Melanoma	CXCR4		mRNA	expressed			sensitivity to	CXCR4 siRNA		4	1		"Bartolomé RA, Am J Pathol 2009, 174:602-12"	CXCR4 is required at early phases of melanoma cell arrival in the lungs907	Melanoma	MT1-MMP		mRNA	expressed			sensitivity to	MT1-MMP siRNA		4	1		"Bartolomé RA, Am J Pathol 2009, 174:602-12"	"MT1-MMP is not needed for these initial steps of melanoma metastatization to the lungs, but it does promotes subsequent invasion and dissemination of the tumor with CXCR4"908	Melanoma	Autotaxin	ATX	mRNA	expressed			sensitivity to	Autotaxin siRNA		3	1		"Gaetano CG, Mol Carcinog 2009, 48:801-9"	Inhibition of autotaxin expression blocks lysophosphatidylcholine-induced migration of human melanoma cells909	Melanoma	miR-182	miRNA-182	mRNA	expressed			sensitivity to	mir-182 antisense oligo		3	1		"Segura MF, Proc Natl Acad Sci USA 2009, 106:1814-9"	"Aberrant mir-182 expression promotes melanoma metastasis by repressing FOXO3 and MITF expression (as demonstrated also in vivo in a mouse model), which suggests that miRNA silencing may be a worthwhile therapeutic strategy"910	Melanoma	AKT3	PKB	protein	expressed			sensitivity to	Isoselenocyanate		4	1		"Sharma A, Clin Cancer Res 2009, 15:1674-85"	Synthetic isoselenocyanates are therapeutically effective for inhibiting melanoma tumor development by targeting Akt3 signaling to increase apoptosis in melanoma cells with negligible associated systemic toxicity911	Melanoma	CtBP1	C-terminal binding protein 1		downregulated			sensitivity to	CtBP1 gene therapy		3	1		"Winklmeier A, BMC Cancer 2009, 9:52"	CtBP1 expression is often lost in melanoma and correlates with increased melanoma inhibitory activity (MIA) expression. Functional studies support CtBP1 involvement in melanoma invasive potential912	Melanoma	ATP1A1	Sodium pump alpha 1 subunit	protein	expressed			sensitivity to	UNBS1450		4	1		"Mathieu V, J Cell Mol Med 2009, Epub ahead of print"	UNBS1450 is a cardenolide that inhibits ATP1A1913	Melanoma	EphA2		mRNA	expressed			sensitivity to	EphA2 siRNA		4	1		"Margaryan NV, Cancer Biol Ther 2009, Epub ahead of print"	"EphA2, a protein tyrosine kinase receptor commonly expressed in epithelial cells, has been found to be overexpressed and constitutively active in melanoma tumor cells having a metastatic phenotype. In this model EphA2 is shown to be a potential therapeutic target "914	Melanoma	HAX-1	HS1-associated protein X-1	mRNA	expressed			sensitivity to	HAX-1 siRNA		3	1		"Li WB, Cell Biol Int 2009, 33:548-54"	"The data indicate that Hax-1 plays a role in suppression of apoptosis and promotion of melanoma cell growth, suggesting that this Hax-1 siRNA has a therapeutic indication in control of melanoma"915	Melanoma	FGF-2	Fibroblast growth factor 2 (bFGF)	protein	expressed			sensitivity to	FGF2 antibody (antagonist)		3	1		"Lefevre G, Invest Ophthalmol Vis Sci 2009, 50:1047-57"	"Uveal melanoma. Proliferation was strongly reduced by the antisense oligonucleotide-mediated depletion of endogenous FGF2, immunoneutralization of secreted FGF2, and pharmacologic inhibition of FGFR1"916	Melanoma	ID2	Inhibitor of DNA binding 2	mRNA	expressed			sensitivity to	ID2 siRNA		3	1		"Su F, Graefes Arch Clin Exp Ophthalmol 2009, 247:411-9"	Uveal melanoma. Knockdown of ID2 by RNA interference abrogates vasculogenic mimicry and VE-cadherin expression in highly aggressive uveal melanoma cells920	Melanoma	Rnd3		mRNA	expressed			sensitivity to	Rnd3 siRNA		3	1		"Klein RM, Cancer Res 2009, 69:2224-33 "	Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions921	Melanoma	NOX4	NADPH oxidase 4	mRNA	expressed			sensitivity to	NOX4 siRNA		3	1		"Yamaura M, Cancer Res 2009, 69:2647-54"	The findings suggest that Nox4-generated ROS are required for transformation phenotype of melanoma cells and contribute to melanoma growth through regulation of G(2)-M cell cycle progression922	Melanoma	E-cadherin			downregulated			sensitivity to	E-cadherin gene therapy		3	1		"Molina-Ortiz I, J Biol Chem 2009, 284:15147-57"	Overexpression of E-cadherin on melanoma cells inhibits chemokine-promoted invasion involving p190RhoGAP/p120ctn-dependent inactivation of RhoA923	Melanoma	GGT	Gamma glutamyl transferase		expressed			resistance to	Arsenic trioxide	ATO	3	-1		"Giommarelli C, Free Radic Biol Med 2009, 46:1516-26"	"The gamma-glutamyltransferase-overexpressing clone exhibited a low susceptibility to arsenic trioxide-induced apoptosis, associated with low reactive oxygen species induction and increased catalase activity. The combination of arsenic trioxide with subtoxic concentrations of ascorbic acid resulted in a sensitization to apoptotic cell death"924	Melanoma	"PI3K, mTOR"		protein	expressed			sensitivity to	NVP-BEZ235		2	1		"Marone R, Mol Cancer Res 2009, 7:601-13 "	"NVP-BEZ235 is a dual mTOR/PI3K inhibitor. In a syngeneic B16 mouse melanoma tumor model, orally administered NVP-BBD130 and NVP-BEZ235 efficiently attenuated tumor growth at primary and lymph node metastatic sites with no obvious toxicity"925	Melanoma	"PI3K, mTOR"		protein	expressed			sensitivity to	NVP-BBD130		2	1		"Marone R, Mol Cancer Res 2009, 7:601-13 "	"NVP-BBD130 is a dual mTOR/PI3K inhibitor. In a syngeneic B16 mouse melanoma tumor model, orally administered NVP-BBD130 and NVP-BEZ235 efficiently attenuated tumor growth at primary and lymph node metastatic sites with no obvious toxicity"926	Melanoma	PPAR gamma	Peroxisome proliferator activated receptor gamma	protein	expressed			sensitivity to	Rosiglitazone		3	1		"Smith AG, Int J Biochem Cell Biol 2009, 41:844-52 "	Rosiglitazone is a PPAR gamma agonist that shows antiproliferative activity in this model927	Melanoma	PPAR gamma	Peroxisome proliferator activated receptor gamma	protein	expressed			sensitivity to	Troglitazone		3	1		"Smith AG, Int J Biochem Cell Biol 2009, 41:844-52 "	Troglitazone is a PPAR gamma agonist that shows antiproliferative activity in this model928	"Melanoma, endothelial cells, immune cells"	"CXCR1, CXCR2"		protein	expressed			sensitivity to	SCH-479833		4	1		"Singh S, Clin Cancer Res 2009, 15:2380-6"	SCH-479833: CXCR1/CXCR2 inhibitor. Selectively targeting CXCR2/CXCR1 with orally active small-molecule inhibitors is a promising therapeutic approach for inhibiting melanoma growth and angiogenesis929	"Melanoma, endothelial cells, immune cells"	"CXCR1, CXCR2"		protein	expressed			sensitivity to	SCH-527123		4	1		"Singh S, Clin Cancer Res 2009, 15:2380-6"	SCH-527123: CXCR1/CXCR2 inhibitor. Selectively targeting CXCR2/CXCR1 with orally active small-molecule inhibitors is a promising therapeutic approach for inhibiting melanoma growth and angiogenesis931	Melanoma	SYK	Spleen tyrosine kinase	DNA	downregulated			sensitivity to	SYK gene therapy		3	1		"Bailet O, Cancer Res 2009, 69:2748-56"	Re-expression of Syk in melanoma cells induces a p53-dependent expression of the cyclin-dependent kinase (cdk) inhibitor p21 and a senescence program; moreover reintroduction of Syk in melanoma cells dramatically reduces clonogenic survival and three-dimensional tumor spheroid growth and invasion932	Melanoma	"P2Y1, P2X7"		protein	expressed			sensitivity to	ATP	Adenosine tri-phosphate	4	1		"White N, Purinergic Signal 2009, 5:327-33"	"In this model, extracellular ATP shows anti-melanoma activity in vivo (50% tumor response), likely through engagement of P2Y(1) and P2X(7) purinergic receptors"933	Melanoma	Minerva	FAM129B	mRNA	expressed			sensitivity to	Minerva siRNA		3	1		"Old WM, Mol Cell 2009, 34:115-31"	FAM129B (a target of BRAF phosphorylation) belongs to a protein family with unknown function and enhances melanoma cell invasion into three-dimensional collagen matrix936	Melanoma	SRC	c-Src	protein	expressed			sensitivity to	PD173955		3	1		"Putnam AJ, Cell Commun Signal 2009, 7:10"	SRC enhances the integrin alpha V beta 3 mediated invasiveness of melanoma cells937	Melanoma	SRC	c-Src	protein	expressed			sensitivity to	PD180970		3	1		"Putnam AJ, Cell Commun Signal 2009, 7:10"	SRC enhances the integrin alpha V beta 3 mediated invasiveness of melanoma cells938	Melanoma	PKC alpha	Protein kinase C alpha	mRNA	expressed			sensitivity to	PKCalpha siRNA		3	1		"Putnam AJ, Cell Commun Signal 2009, 7:10"	PKC alpha (but not PKC delta) enhances the integrin alpha V beta 3 mediated invasiveness of melanoma cells939	Melanoma	H-cadherin			downregulated			sensitivity to	H-cadherin gene therapy		4	1		"Kuphal S, Pigment Cell Melanoma Res 2009, 22:296-306"	H-cadherin re-expression reduces invasion of malignant melanoma941	Immune cells	PD1	"PDCD1, CD279"		expressed			sensitivity to	PD-1 antibody (antagonist)		3	1		"Fourcade J, J Immunol 2009, 182:5240-9"	"Blockade of the PD1/PD1 ligand pathway favors anti-melanoma CTL expansion and might be used in cancer patients to restore melanoma antigen specific CD8(+) T cell number and functions, thus increasing the likelihood of tumor regression"943	Melanoma	PI3K (p85)	PI3K subunit p85	protein	expressed			no relationship with	LY294002	AKT inhibitor	3	0		"Aziz SA, Clin Cancer Res 2009, 15:3029-36"	"Pretreatment pS6 levels correlated with sensitivity to the PI3K inhibitor, LY294002, whereas PI3K and pAkt did not, suggesting that full activation of the PI3K pathway is needed for sensitivity to PI3K inhibition"944	Melanoma	PI3K (p110 alpha)	PI3K subunit p110 alpha	protein	expressed			no relationship with	LY294002	AKT inhibitor	3	0		"Aziz SA, Clin Cancer Res 2009, 15:3029-36"	"Pretreatment pS6 levels correlated with sensitivity to the PI3K inhibitor, LY294002, whereas PI3K and pAkt did not, suggesting that full activation of the PI3K pathway is needed for sensitivity to PI3K inhibition"945	Melanoma	AKT	PKB	protein	phosphorylated (activated)			no relationship with	LY294002	AKT inhibitor	3	0		"Aziz SA, Clin Cancer Res 2009, 15:3029-36"	"Pretreatment pS6 levels correlated with sensitivity to the PI3K inhibitor, LY294002, whereas PI3K and pAkt did not, suggesting that full activation of the PI3K pathway is needed for sensitivity to PI3K inhibition"946	Melanoma	RSK1	Ribosomal S6 kinase (RS6K)	protein	"phosphorylated (Ser-235, Ser-240)"			sensitivity to	LY294002	AKT inhibitor	3	1		"Aziz SA, Clin Cancer Res 2009, 15:3029-36"	"Pretreatment pS6 levels correlated with sensitivity to the PI3K inhibitor, LY294002, whereas PI3K and pAkt did not, suggesting that full activation of the PI3K pathway is needed for sensitivity to PI3K inhibition"949	Melanoma	Rictor		mRNA	downregulated by	Rictor siRNA		sensitivity to	Rapamycin + LY294002		3	1		"Werzowa J, Br J Dermatol 2009, 160:955-64"	mTORC2 (mTOR complexed with Rictor) inhibition avoids AKT phosphorylation due to PI3K and mTORC1 inhibition (following activation of regulatory loops involving RS6K and IRS1)951	Melanoma	EB1		mRNA	expressed			sensitivity to	EB1 siRNA		1	1		"Schober JM, Cancer Lett 2009, 284:30-6"	Migration and actin protrusion in melanoma cells are regulated by EB1 protein (microtubule end binding protein)952	Melanoma	SMS1	Sphingomyelin synthase 1	mRNA	upregulated by	SMS1 genetic engineering		resistance to	Jaspine-B		3	-1		"Salma Y, Biochem Pharmacol 2009, 78:477-85"	"Jaspine-B inteferes with ceramide metabolism by inhibiting SMS (an enzyme that converts de novo ceramide into the membrane lipid sphingomyelin), which leads to melanoma cell apoptosis. Whereas Jaspine-B induced cell death was enhanced in SMS1-depleted cells, it was strongly inhibited in cells that stably overexpress SMS1"953	Platelets	Integrin alpha IIb beta 3 			expressed			sensitivity to	Heparin (modified)		4	1		"Zhang C, Int J Cancer 2009, 125:2058-65"	Modified heparins can inhibit adhesion of melanoma cells (that express heparin-like proteoglycans) to platelets (that express integrin alpha IIb beta 3) in vitro and in vivo and thus can inhibit the metastatic process954	Melanoma	FAK	Focal adhesion kinase		expressed			sensitivity to	Doxycycline		2	1		"Sun T, Cancer Lett 2009, 285:141-50"	Doxycycline inhibits the adhesion and migration of melanoma cells by inhibiting the expression and phosphorylation of focal adhesion kinase (FAK)955	Melanoma	hTERT			expressed			sensitivity to	hTERT antisense oligo		2	1		"Noreen F, Oligonucleotides 2009, 19:169-78"	"In a murine in vivo melanoma model, small double-stranded oligodeoxynucleotides targeting telomerase RNA show anti-melanoma activity"956	Melanoma	HDAC	Histone deacetylase		uncharacterized			no relationship with	Plitidepsin	Aplidin	5	0	35	"Eisen T, Melanoma Res 2009, 19:185-92"	Plitidepsin (a marine depsipeptide) is a HDAC inhibitor. In this trial plitidepsin yielded 5.7% partial response and 14.3% stable disease rates as second line treatment of metastatic melanoma957	Melanoma	EGFR	ERBB1		expressed			sensitivity to	Gefitinib	ZD1839 (Iressa (R))	3	1		"Djerf EA, Melanoma Res 2009, 19:156-66"	Gefitinib is a small molecule tyrosine kinase inhibitor; ZD1839 interferes with the growth of human malignant melanoma cells by cytostatic effects958	Melanoma	COX	Cyclooxygenase		expressed			sensitivity to	Ibuprofen		3	1		"Redpath M, Br J Dermatol 2009, 161:25-33"	Melanoma cell migration (induced in vitro by TNF alpha) can be reduced by ibuprofen959	Melanoma	MET	c-Met		expressed			sensitivity to	NK4	HGF inhibitor	2	1		"Kishi Y, Cancer Sci 2009, 100:1351-8"	"NK4 is a competitive inhibitor of HGF, the natural ligand for MET. In htis model NK4 was expressed by means of gene therapy"960	Melanoma	GRM1	Metabotropic glutamate receptor-1		expressed			sensitivity to	Riluzole		5	1	12	"Yip D, Clin Cancer Res 2009, 15:3896-902"	"In this phase 0 trial, all patients expressed GRM1; some tumor regressions were observed. The ectopic expression of metabotropic glutamate receptors may be important in the pathogenesis of human melanoma, and targeting this pathway may be an effective therapy"962	Melanoma	WFDC1			downregulated			sensitivity to	WFDC1 gene therapy		4	1		"Liu S, Clin Exp Metastasis 2009, 26:739-49"	"The tumor suppressive function of WFDC1 may be partially a result of upregulated Dkk1 gene expression, which is known to be a potent inhibitor of the Wnt signaling pathway"964	Immune cells	IDO	"Indoleamine 2,3-dioxygenase"		expressed			sensitivity to	5I IDO inhibitor		2	1		"Yue EW, J Med Chem 2009, 52:7364-7"	"5I is an IDO inhibitor. IDO is believed to mediate immune suppression and tumor immune escape. 5l in mice demonstrated pharmacodynamic inhibition of IDO, as measured by decreased kynurenine levels (>50%) in plasma and dose dependent efficacy in mice bearing GM-CSF-secreting B16 melanoma tumors"965	Microenvironment (fibroblasts)	MMP13	Matrix metalloproteinase 13	mRNA	expressed			sensitivity to	MMP13 knockout		2	1		"Zigrino P, J Invest Dermatol 2009, 129:2686-93"	"Tumor growth was significantly impaired in MMP13(-/-) mice and most significant at early time points as compared with wild-type littermates, which shows that stromal expression of MMP-13 is required for melanoma invasion and metastasis"966	Melanoma	TLR3	Toll like receptor 3		expressed			sensitivity to	Phenylmethimazole	C10	4	1		"Schwartz AL, Clin Cancer Res 2009, 15:4114-22"	C10 is a TLR3 antagonist. Constitutive TLR3 expression is associated with constitutive Wnt5a in human melanoma cell lines; C10 can decrease constitutive TLR3/Wnt5a expression and signaling (suggesting they are interrelated signal systems) and inhibit tumor growth in vivo967	Melanoma	RARg	Retinoic acid receptor gamma		expressed			sensitivity to	RARg agonist	CD666	1	1		"Zhao X, Cancer Res 2009, 69:5218-25"	RARgamma upregulates CHST10 (a sulfotransferase that forms HNK-1 glycan on neural cell adhesion proteins) expression in a significant subset of human melanoma cells and three-dimensional cell culture migration assays suggest that CHST10 functions as a suppressor of invasiveness (but not proliferation) in these cells. Induction of CHST10 by RARgamma-activating retinoids may present a novel therapeutic strategy to inhibit tumor invasiveness in a subset of melanoma patients970	Melanoma	EpoR	Erythropoietin receptor	protein	expressed			sensitivity to	EpoR inhibition		3	1		"Mirmohammadsadegh A, J Invest Dermatol 2010, 130:201-10"	"Overexpression of functional EpoR expression in about half of the analyzed clinical melanoma metastasis specimens is associated with anti-apoptotic as well as pro-migratory effects of Epo, which is of importance for the treatment of anemia in advanced melanoma"971	Melanoma	DNMT3a	DNA methyltransferase 3A	mRNA	expressed			sensitivity to	DNMT3a siRNA		2	1		"Deng T, Biochem Biophys Res Commun 2009, 387:611-6"	Inhibition of DNMT3a expression by stable transfection of a DNMT3a-RNA interference (RNAi) construct inhibited melanoma growth and metastasis in mouse melanoma models972	Immune cells	CSF2R	GMCSF receptor		uncharacterized			sensitivity to	GMCSF		5	1	98	"Spitler LE, J Immunother 2009, 32:632-7"	Granulocyte-macrophage colony stimulating factor (GM-CSF) administered as adjuvant therapy in 98 patients with stage II-IV melanoma yielded a 60% 5-year disease-specific survival rate973	Melanoma	HMW-MAA	"gp240, CSPG4, NG2, High molecular weight melanoma associated antigen"		expressed			sensitivity to	HMW-MAA immunotoxin		3	1		"Risberg K, Int J Cancer 2009, 125:23-33"	"The melanoma specific 9.2.27PE immunotoxin (which recognizes the high molecular weight melanoma associated antigen, HMW-MAA) efficiently recognizes and kills melanoma cells in vitro"974	Melanoma	SKI		mRNA	expressed			sensitivity to	SKI siRNA		4	1		"Chen D, Pigment Cell Melanoma Res 2009, 22:761-72"	"In a human melanoma xenograft model, RNA interference mediated knockdown of SKI (an antagonist of TGF-beta signaling) inhibits tumor growth"979	Melanoma	SRC	c-Src	protein	expressed			sensitivity to	PP1	SRC inhibitor	3	1		"Maat W, Br J Cancer 2009, 101:312-9"	Uveal melanoma. SRC levels are higher in primary UM and lower in metastatic UM: SRC inhibition (by PP1 or siRNA) is effective in primary but not metastatic UM cell lines980	Melanoma	Tubulin			expressed			sensitivity to	EM011		2	1		"Aneja R, Int J Cancer 2010, 126:256-65"	"In a syngeneic murine in vivo model, the tubulin-binding agent EM011 shows significant anti-melanoma activity with no toxicity"982	Melanoma	GD2 ganglioside			uncharacterized			no relationship with	EMD 273063		5	0	9	"Ribas A, J Transl Med 2009, 7:68"	"In a phase I-II trial (n=9), a humanized anti-GD2 monoclonal antibody fused to interleukin-2 (EMD 273063) increased tumor infiltration by T-cells but did not induced tumor response in stage IV melanoma patients"983	Melanoma	Plexin B1			downregulated			sensitivity to	PlexinB1 gene therapy		4	1		"Argast GM, Oncogene 2009, 28:2697-709"	Plexin B1 (receptor for SEMA4D) is repressed by oncogenic BRAF signaling and functions as a tumor suppressor in human melanoma cells984	Melanoma	14-3-3 sigma		DNA	methylated			sensitivity to	5-azacytidine + Phenylbutyric acid	5-AZA + PBA	3	1		"Schultz J, Mol Cancer 2009, 8:53"	"Epigenetic silencing of 14-3-3sigma might contribute to melanoma progression via loss of cell cycle control, impaired cellular senescence program and support of migratory capacity. Induction of 14-3-3sigma expression by demethylating agent 5-AZA + HDAC inhibitor PBA leads to almost complete inhibition of cell proliferation"987	Melanoma	PDGFRA	PDGF receptor alpha		downregulated			sensitivity to	PDGFRA gene therapy		2	1		"Faraone D, Neoplasia 2009, 11:732-42"	"PDGFRA expression is found to be low in melanoma. In a mouse melanoma model, platelet-derived growth factor receptor alpha gene therapy inhibits tumor growth in vivo"988	Melanoma	"RIG-I, MDA-5"			expressed			sensitivity to	pppRNA + Poly(I:C)		4	1		"Besch R, J Clin Invest 2009, 119:2399-411"	pppRNA and Poly(I:C) are ligands of RIG-I and MDA-5 respectively. Proapoptotic signaling induced by activation of RIG-I and MDA-5 pathways results in type I interferon-independent apoptosis in human melanoma cells and leads to anti-melanoma effect in vivo 989	Melanoma	miR-155	miRNA-155		downregulated			sensitivity to	mir-155 gene therapy		3	1		"Levati L, Int J Oncol 2009, 35:393-400"	"In vitro, mir-155 ectopic expression inhibits melanoma cell proliferation and promotes apoptosis"997	Endothelial cells	TEM-8	Tumor endothelial marker 8		expressed			sensitivity to	TEM8 knockout (gene therapy)		2	1		"Cullen M, Cancer Res 2009, 69:6021-6"	"In a mouse melanoma model, tumor growth is delayed in tumor endothelial marker 8 (TEM8)-deficient animals"998	Melanoma	SPARC	Secreted protein acidic and rich in cysteine 	mRNA	expressed			sensitivity to	SPARC siRNA		3	1		"Maloney SC, Anticancer Res 2009, 29:3059-64"	Uveal melanoma. SPARC is expressed in human uveal melanoma and its abrogation reduces tumor cell proliferation999	Melanoma	MDA-5		protein	expressed			sensitivity to	Poly(I:C) delivered with PEI	TLR3 agonist	4	1		"Tormo D, Cancer Cell 2009, 16:103-14"	Polyinosine-polycytidylic acid (poly(I:C)) - a double strand RNA mimic that binds to MDA-5 - induces melanoma autophagy and leads to anti-melanoma effect in vivo if co-administered with PEI (polyethyleneimine)1000	Melanoma	PEDF	Pigment epithelium derived factor		downregulated			sensitivity to	PEDF gene therapy		2	1		"Yang H, Invest Ophthalmol Vis Sci 2010, 51:28-34"	Uveal melanoma. Lentivirus-mediated gene transfer of PEDF decreased the growth of ocular melanoma and its hepatic micrometastasis in a mouse ocular melanoma model1007	Melanoma	ERBB4		DNA	mut R544W			sensitivity to	Lapatinib		3	1		"Prickett TD, Nat Genet 2009, 41:1127-32"	Melanoma cells expressing mutationally activated ERBB4 had reduced cell growth after treatment with the ERBB inhibitor lapatinib1008	Melanoma	ERBB4		DNA	mut E563K			sensitivity to	Lapatinib		3	1		"Prickett TD, Nat Genet 2009, 41:1127-32"	Melanoma cells expressing mutationally activated ERBB4 had reduced cell growth after treatment with the ERBB inhibitor lapatinib1009	Melanoma	ERBB4		DNA	mut E317K			sensitivity to	Lapatinib		3	1		"Prickett TD, Nat Genet 2009, 41:1127-32"	Melanoma cells expressing mutationally activated ERBB4 had reduced cell growth after treatment with the ERBB inhibitor lapatinib1010	Melanoma	ERBB4		DNA	mut E452K			sensitivity to	Lapatinib		3	1		"Prickett TD, Nat Genet 2009, 41:1127-32"	Melanoma cells expressing mutationally activated ERBB4 had reduced cell growth after treatment with the ERBB inhibitor lapatinib1011	Melanoma	ERBB4		DNA	mut E317K			sensitivity to	ERBB4 siRNA		3	1		"Prickett TD, Nat Genet 2009, 41:1127-32"	Melanoma cells expressing mutationally activated ERBB4 had reduced cell growth after treatment with small interfering RNA against ERBB41012	Melanoma	ERBB4		DNA	mut E452K			sensitivity to	ERBB4 siRNA		3	1		"Prickett TD, Nat Genet 2009, 41:1127-32"	Melanoma cells expressing mutationally activated ERBB4 had reduced cell growth after treatment with small interfering RNA against ERBB41013	Melanoma	ERBB4		DNA	mut E452K/E872K			sensitivity to	ERBB4 siRNA		3	1		"Prickett TD, Nat Genet 2009, 41:1127-32"	Melanoma cells expressing mutationally activated ERBB4 had reduced cell growth after treatment with small interfering RNA against ERBB41014	Endothelial cells	"VEGFR, PDGFR, KIT, RET"			expressed			sensitivity to	Sunitinib	Sutent (R)	4	1		"Ebos JM, Cancer Cell 2009, 15:232-9"	"Sunitinib is a small molecule inhibitor of various receptor tyrosine kinases such as VEGFR, PDGFR, KIT, RET. Sunitinib induces potent tumor growth inhibition in nu/nu mice bearing orthotopically growing human MeWo melanoma tumors that were treated with sustained sunitinib therapy; this is in contrast to the increased metastasis observed in the lungs of mice 58 days after i.v. inoculation of tumor cells immediately following short-term sunitinib therapy "1015	Melanoma	SRC	c-Src		expressed			sensitivity to	Dasatinib		3	1		"Homsi J, Melanoma Res 2009, 19:167-75"	Dasatinib is a SRC inhibitor1016	Melanoma	SRC	c-Src		expressed			sensitivity to	Bosutinib		3	1		"Homsi J, Melanoma Res 2009, 19:167-75"	Bosutinib is a SRC inhibitor1017	Melanoma	SRC	c-Src		expressed			sensitivity to	Dasatinib		3	1		"Buettner R, Mol Cancer Res 2008, 6:1766-74"	Dasatinib (a dual Src/Abl inhibitor) blocks migration and invasion of human melanoma cells without affecting proliferation and survival1018	Melanoma	SRC	c-Src		expressed			sensitivity to	Dasatinib		3	1		"Eustace AJ, J Transl Med 2008, 6:53"	"Dasatinib inhibited growth of three of the five melanoma cell lines. Dasatinib inhibition of proliferation was associated with reduced phosphorylation of Src kinase, while decreased phosphorylation of FAK was implicated in dasatinib-mediated inhibition of migration and invasion in melanoma cells"1019	Endothelial cells	VEGFR2	VEGF receptor 2		expressed			sensitivity to	Vandetanib	ZD6474 (Zactima (R))	2	1		"Wedge SR, Cancer Res 2002, 62:4645-55"	"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration"1022	Host	RET		DNA	polymorphism G691S			sensitivity to	GDNF inhibition		3	1		"Narita N, Oncogene 2009, 28:3058-68"	"RET proto-oncogene encodes a receptor tyrosine kinase whose ligand is glial cell line-derived neurotrophic factor (GDNF): GDNF significantly amplified cell proliferation, migration and invasion in RETp variant, but not in RETwt melanoma cells"1023	Melanoma	GSTP1-1	Glutathione transferase P1-1	protein	expressed			sensitivity to	NBDHEX		4	1		"Pellizzari Tregno F, Eur J Cancer 2009, 45:2606-17"	NBDHEX is an inhibitor of glutathione transferase P1-1 (GSTP1-1) and causes the disruption of the complex between GSTP1-1 and c-Jun N-terminal Kinase (JNK). This induces JNK activation and apoptosis in melanoma1024	Melanoma	CXCR1		protein	expressed			sensitivity to	CXCR1 antibody (antagonist)		3	1		"Gabellini C, Eur J Cancer 2009, 45:2618-27"	"CXCL8 is the ligand of CXCR1 and CXCR2: CXCL8 induces cell proliferation and angiogenesis through both receptors. The cell proliferation of both M20 and A375SM lines, expressing similar levels of both CXCR1 and CXCR2 but secreting low and high amounts of CXCL8, respectively, was significantly enhanced by CXCL8 exposure and reduced by CXCL8, CXCR1 and CXCR2 neutralising antibodies, indicating the autocrine/paracrine role of CXCL8 in melanoma cell proliferation "1025	Melanoma	CXCR2		protein	expressed			sensitivity to	CXCR2 antibody (antagonist)		3	1		"Gabellini C, Eur J Cancer 2009, 45:2618-27"	"CXCL8 is the ligand of CXCR1 and CXCR2: CXCL8 induces cell proliferation and angiogenesis through both receptors. The cell proliferation of both M20 and A375SM lines, expressing similar levels of both CXCR1 and CXCR2 but secreting low and high amounts of CXCL8, respectively, was significantly enhanced by CXCL8 exposure and reduced by CXCL8, CXCR1 and CXCR2 neutralising antibodies, indicating the autocrine/paracrine role of CXCL8 in melanoma cell proliferation "1026	Melanoma	hTERT			expressed			sensitivity to	RHPS4		4	1		"Leonetti C, Clin Cancer Res 2008, 14:7284-91"	The formation of G-quadruplex structures at telomeric DNA sequences blocks telomerase activity: the pentacyclic acridinium salt RHPS4 is one of the most effective and selective G4 ligands able to rapidly disrupt telomere architecture1031	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	mRNA	upregulated by	MGMT genetic engineering		resistance to	Carmustine		3	-1		"Passagne I, Toxicol Appl Pharmacol 2006, 211:97-105"	O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin-C1032	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	mRNA	upregulated by	MGMT genetic engineering		resistance to	Streptozotocin		3	-1		"Passagne I, Toxicol Appl Pharmacol 2006, 211:97-105"	O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin-C1033	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	mRNA	upregulated by	MGMT genetic engineering		resistance to	Fotemustine		3	-1		"Passagne I, J Pharmacol Exp Ther 2003, 307:816-23"	MGMT-transfected cells were 7 to 9 times less sensitive to fotemustine than parent cells1034	Melanoma	Bik	Nbk		downregulated			sensitivity to	Bik gene therapy		4	1		"Oppermann M, Oncogene 2005, 24:7369-80"	Stably transfected melanoma cells were subcutaneously injected into nude mice: significantly delayed tumor growth was the result when mice received doxycycline for induction of Nbk/Bik expression1035	Melanoma	Bcl-xS			downregulated			sensitivity to	Bcl-xS gene therapy		4	1		"Hossini AM, FEBS Lett 2003, 553:250-6"	In nude mice growth of melanoma xenotransplants derived from stably transfected cells was significantly reduced after induction of Bcl-XS by doxycycline1037	Melanoma	Integrin beta 1			expressed			sensitivity to	Lumcorin		3	1		"Zeltz C, FEBS Lett 2009, 583:3027-32"	"Lumcorin is a peptide derived from lumican, an extracellular matrix proteoglycan binding to integrin beta 1 (D’Onofrio, Biochem Biophys Res Commun 2008, 365:266-72) and inhibiting melanoma cell migration"1038	Host	VKORC1	Vitamin K epoxide reductase complex subunit 1		uncharacterized			sensitivity to	4-hydroxycoumarin	4-HC	2	1		"Salinas-Jazmín N, Cancer Chemother Pharmacol 2010, 65:931-40"	"4-HC is a vitamin K antagonist believed to act by inhibiting vitamin K epoxide reductase. VCORK1 is the catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K: the main result is decreased synthesis of coagulation factors II, VII, IX and X, as well as the regulatory factors protein C and protein S. Clotting factors are believed to affect the metastatic process"1039	Melanoma	Syndecan-1		mRNA	expressed			sensitivity to	Syndecan-1 siRNA		3	1		"O'Connell MP, J Biol Chem 2009, 284:28704-12"	"Syndecan 1 and syndecan 4 expression correlated to Wnt5A expression and melanoma malignancy. Knockdown of syndecan 1 or 4 caused decreases in cell invasion, which could be restored by treating the cells with recombinant Wnt5A"1040	Melanoma	Syndecan-4		mRNA	expressed			sensitivity to	Syndecan-4 siRNA		3	1		"O'Connell MP, J Biol Chem 2009, 284:28704-12"	"Syndecan 1 and syndecan 4 expression correlated to Wnt5A expression and melanoma malignancy. Knockdown of syndecan 1 or 4 caused decreases in cell invasion, which could be restored by treating the cells with recombinant Wnt5A"1041	Melanoma	Frizzled-5	Fzd5		expressed			sensitivity to	Fzd5 antibody (antagonist)		3	1		"Weeraratna AT, Cancer Cell 2002, 1:279-88"	"Wnt5A forced expression leads to no increase in beta-catenin expression or nuclear translocation was observed: however, a dramatic increase in activated PKC and melanoma cell invasiveness was observed. Blocking this pathway using antibodies to Frizzled-5, the receptor for Wnt5a, inhibited PKC activity and cellular invasion"1042	Melanoma	Claudin-1	CLDN1		expressed			sensitivity to	Claudin-1 siRNA		3	1		"Leotlela PD, Oncogene 2007, 26:3846-56"	"Claudin-1 is overexpressed in melanoma, is positively regulated by PKC and contributes to melanoma cell motility (and thus melanoma progression)"1043	Melanoma	Wnt5A		mRNA	expressed			sensitivity to	Wnt5A siRNA		3	1		"Dissanayake SK, J Biol Chem 2007, 282:17259-71"	"Using genetic manipulation of Wnt5A expression, these investigators showed that the Wnt5A/PKC pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors (e.g., E-cadherin) and initiation of an epithelial to mesenchymal transition"1044	Melanoma	SIAH2		protein	expressed			sensitivity to	Menadione		4	1		"Shah M, Pigment Cell Melanoma Res 2009, 22:799-808"	"Menadione is a specific inhibitor of SIAH2 ubiquitin ligase (implicated in the regulation of the hypoxia response, as well as in the control of Ras, JNK/p38/NF-kappaB signaling pathways); in vivo, it inhibits the growth of xenograft melanoma"1046	Host	AGTR1	Angiotensin receptor 1	protein	expressed			sensitivity to	Losartan		4	1		"Otake AH, Cancer Chemother Pharmacol 2010, 66:79-87"	Inhibition of AGTR1 (receptor for angiotensin II) by losartan has therapeutic effect in this model. The reduction in tumor growth was accompanied by a twofold decrease in tumor-associated microvessel density and by a decrease in CD31 mRNA levels1049	Melanoma	CREB	cAMP response element binding protein	mRNA	expressed			sensitivity to	CREB siRNA		4	1		"Dobroff AS, J Biol Chem 2009, 284:26194-206"	"Silencing CREB inhibits tumor growth and metastasis of melanoma; CREB promotes melanoma growth and metastasis by downregulating CCN1/CYR61 expression, which acts as a suppressor of melanoma cell motility, invasion and angiogenesis (same group used CREB dominant negative construct in: Xie S, Oncogene 1997, 15:2069-75)"1050	Melanoma	CYR61	CCN1		downregulated			sensitivity to	CYR61 gene therapy		4	1		"Dobroff AS, J Biol Chem 2009, 284:26194-206"	Forced expression of CCN1/CYR61 in A375SM and C8161-c9 cells (which are highly metastatic with low levels of CCN1/CYR61) suppresses the tumorigenicity and metastatic potential of melanoma cells1052	Melanoma	Moesin			expressed			sensitivity to	Moesin siRNA		4	1		"Estecha A, J Cell Sci 2009, 122(Pt 19):3492-501"	Small interfering RNA (siRNA) experiments show that moesin is crucial for invasion by melanoma cells in 3D matrices and in early lung colonization1053	Melanoma	Integrin alpha V beta 3			expressed			sensitivity to	Artemisinin		3	1		"Buommino E, Invest New Drugs 2009, 27:412-8"	Artemisinin reduces human melanoma cell migration by downregulating alpha V beta 3 integrin and reducing metalloproteinase 2 production1055	Melanoma	miR-15b	miRNA-15b		expressed			sensitivity to	mir-15b siRNA		3	1		"Satzger I, Int J Cancer 2009, Epub ahead of print"	"Downregulation of miR-15b in two melanoma cell lines with high miR-15b expression by transfection with anti-miR-15b siRNA was associated with reduced tumor cell proliferation, whereas apoptosis was increased"1056	Melanoma	Survivin	BIRC5		uncharacterized			no relationship with	YM155		5	0	34	"Lewis KD, Invest New Drugs 2011, 29:161-6"	YM155 is a small molecule inhibitor of survivin. In this phase II trial (metastatic setting) YM155 failed to demonstrate significant anti-melanoma activity1057	Melanoma	SNF5		mRNA	downregulated by	SNF5 siRNA		resistance to	Doxorubicin	Adriamycin (R)	3	-1		"Lin H, Clin Cancer Res 2009, 15:6404-11"	"The tumor suppressor SNF5, the core subunit of SWI/SNF complex, has been shown to regulate cell differentiation, cell cycle control, and apoptosis. Knockdown of SNF5 in melanoma cell lines resulted in significant chemoresistance"1058	Melanoma	ROS	Reactive oxygen species		expressed			sensitivity to	CAPE	Caffeic acid phenethyl ester	2	1		"Kudugunti SK, Invest New Drugs 2009, Epub ahead of print"	The induction of oxidative stress by CAPE exploits this unique characteristic of cancer cells by increasing ROS levels beyond a threshold that triggers cell death1059	Melanoma	mTOR	Mammalian target of rapamycin		uncharacterized			sensitivity to	Rapamycin	Sirolimus	2	1		"Yang Z, Cancer Sci 2010, 101:494-500"	"In a mouse syngeneic model, mTOR inhibitor rapamycin inhibits lung metastasis through downregulation of alpha V integrin expression and upregulation of apoptosis signaling"1060	Melanoma	STAT3	Signal transducer and activator of transcription 3 	mRNA	expressed			sensitivity to	STAT3 siRNA		3	1		"Oka M, J Biol Chem 2009, 284:30416-23"	Blockade of STAT3 activity by small interfering RNAs suppressed the growth of WM1205Lu cells containing constitutively activated STAT31061	Immune cells	IFNAR	IFN alpha receptor		uncharacterized			no relationship with	IFN alpha		5	0	363	"Lane AM, Ophthalmology 2009, 116:2206-12"	"Uveal melanoma. In a non randomized trial, low dose adjuvant interferon alpha provides no survival benefit to patients with high risk uveal melanoma (historical controls)"1062	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	IGFBP7		4	1		"Wajapeyee N, Mol Cancer Ther 2009, 8:3009-14"	"In human melanomas containing an activating BRAF mutation (BRAF-positive melanomas), IGFBP7 is epigenetically silenced, which seems to be a critical step in melanoma genesis. Restoration of IGFBP7 function by the administration of recombinant IGFBP7 induces apoptosis in BRAF-positive human melanoma cell lines suppresses the growth of BRAF-positive primary tumors in xenografted mice"1063	Melanoma	IGFBP7			downregulated			sensitivity to	IGFBP7		4	1		"Wajapeyee N, Mol Cancer Ther 2009, 8:3009-14"	"In human melanomas containing an activating BRAF mutation (BRAF-positive melanomas), IGFBP7 is epigenetically silenced, which seems to be a critical step in melanoma genesis. Restoration of IGFBP7 function by the administration of recombinant IGFBP7 induces apoptosis in BRAF-positive human melanoma cell lines and suppresses the growth of BRAF-positive primary tumors in xenografted mice"1064	Melanoma	STAT3	Signal transducer and activator of transcription 3 	mRNA	expressed			sensitivity to	STAT3 antisense oligo RNA		4	1		"Yang L, Cancer Biol Ther 2009, 8:2065-72"	"Novel antisense RNA oligonucleotides targeting the STAT3 mRNA were 2'-O-methyl modified, strongly inhibited the target gene expression in the melanoma cells and resulted in increase cell apoptosis. Furthermore, these RNA oligonucleotides could significantly inhibit melanoma cell proliferation and xenografts growth in nude mice "1065	Immune cells	CD25			uncharacterized			no relationship with	CD25 antibody (antagonist)		2	0		"Kimpfler S, J Immunol 2009, 183:6330-7"	"Although anti-CD25 mAb injections resulted in efficient depletion of T regulatory (Treg) cells from lymphoid organs of RET transgenic mice, melanoma progression was not significantly affected. Therefore, effective melanoma immunotherapy should include the inhibition of Treg migration into the tumor combined with neutralization of other immunosuppressive cells and factors in the tumor microenvironment"1066	Melanoma	MAP2	Microtubule associated protein 2		downregulated			sensitivity to	MAP2 gene therapy		3	1		"Soltani MH, Am J Pathol 2005, 166:1841-50"	"Viral vector based forced expression of MAP2 in metastatic melanoma cell lines leads to microtubule stabilization, cell cycle arrest in G2-M phase and growth inhibition"1068	Melanoma	NFkB	Nuclear factor kappa B	protein	expressed			sensitivity to	DHMEQ	NFkB inhibitor	3	1		"Dror R, Invest Ophthalmol Vis Sci 2010, 51:1811-6"	Uveal melanoma. DHMEQ: NFkB inhibitor. Pharmacological inhibition of NFkB reduces proliferation and induces apoptosis of human uveal metastatic melanoma cells in vitro1069	Melanoma	NFkB	Nuclear factor kappa B	protein	expressed			sensitivity to	BMS-345541	NFkB inhibitor	3	1		"Dror R, Invest Ophthalmol Vis Sci 2010, 51:1811-6"	Uveal melanoma. BMS-345541: NFkB inhibitor. Pharmacological inhibition of NFkB reduces proliferation and induces apoptosis of human uveal metastatic melanoma cells in vitro1070	Melanoma	TM9SF4			expressed			sensitivity to	TM9SF4 siRNA		3	1		"Lozupone F, EMBO Rep 2009, 10:1348-54"	Tumor cannibalism is a characteristic of malignancy and metastatic behavior. TM9SF4 is highly expressed in human metastatic malignant melanoma cells whereas it is undetectable in healthy human tissues. TM9SF4 silencing induced marked inhibition of cannibal activity. TM9SF4 represents a potential new target for anti-tumor strategies1071	Melanoma	HIF1 alpha	Hypoxia inducible factor 1 alpha	mRNA	expressed			sensitivity to	HIF1alpha siRNA		3	1		"Mills CN, Mol Cancer 2009, 8:104"	Knockdown of HIF-1alpha expression by siRNA in the MET WM9 melanoma cell line resulted in a large decrease in both soft agar colony formation and matrigel invasion relative to cells treated with non-specific siRNA. Overexpression of HIF-1alpha resulted in a small increase in soft agar colony formation and a large increase in matrigel invasion relative to control transfected cells1072	Melanoma	Netrin-1		mRNA	expressed			sensitivity to	Netrin-1 siRNA		3	1		"Kaufmann S, Cell Oncol 2009, 31:415-22"	"Melanoma cells treated with Netrin siRNA showed no changes in proliferation or apoptosis, however, a strong reduction of migratory properties was observed suggesting that Netrin-1 promotes melanoma invasiveness"1073	Melanoma	JWA		mRNA	downregulated by	JWA siRNA		sensitivity to	JWA gene therapy		1	1		"Bai J, Oncogene 2010, 29:1227-37"	"JWA, a newly identified novel microtubule-associated protein (MAP), suppresses melanoma metastasis by inhibiting integrin alpha V beta 3 signaling. JWA knockdown B16 cells were transiently transfected with pEGFP-C1-JWA to produce JWA-rescued B16 cells, which recovered JWA expression and recovered their ability in cell adhesion and invasion to a level comparable to the vector-control B16 cells "1076	Melanoma	PKC beta	Protein kinase C beta		downregulated			sensitivity to	PKCbeta gene therapy		3	1		"Voris JP, Pigment Cell Melanoma Res 2010, 23:216-24"	"Authors found reduced PKCbeta and increased PKCzeta and PKCiota expression at both the protein and mRNA levels in human melanoma cell lines. Re-expression of PKCbeta in melanoma cells inhibited colony formation in soft agar, indicating that PKCbeta loss in melanoma is important for melanoma growth"1077	Immune cells	CTLA4			uncharacterized			sensitivity to	Ipilimumab	CTLA4 antibody (antagonist)	5	1	217	"Wolchok JD, Lancet Oncol 2010, 11:155-64"	"Phase II randomized dose ranging study (metastatic setting). Ipilimumab elicited a dose-dependent effect on efficacy (P for trend: 0.0015) and safety measures in pretreated patients with advanced melanoma, lending support to further studies at a dose of 10 mg/kg. The best overall response rate was 11.1%"1078	Melanoma	ABCA1	ATP binding cassette A1		expressed			resistance to	Curcumin		3	-1		"Bachmeier BE, Mol Cancer 2009, 8:129"	Overexpression of the ATP binding cassette gene ABCA1 determines resistance to Curcumin in M14 melanoma cells (ABCA1 should be considered as response marker)1079	Melanoma	PLP2	Phospholipid protein 2	mRNA	expressed			sensitivity to	PLP2 downregulation		2	1		"Sonoda Y, Oncol Rep 2010, 23:371-6"	"Forced expression of PLP2 enhanced proliferation, adhesion, invasion, and MMP-2 secretion in vitro, and tumor metastasis in vivo. PLP2 acts as an oncogene and thus represents a potential therapeutic target"1082	Melanoma	Bim		mRNA	downregulated by	BIM siRNA		resistance to	CI-1040	PD184352	3	-1		"Cartlidge RA, Pigment Cell Melanoma Res 2008, 21:534-44"	CI-1040: MEK inhibitor. Inhibition of BIM expression by RNA interference provided partial protection from apoptosis induced by MEK inhibitor CI-10401083	Melanoma	TYRP1	Tyrosinase-related protein 1		expressed			sensitivity to	TYRP1 antibody	20D7	4	1		"Patel D, Hum Antibodies 2007, 16:127-36"	The antitumor activity of 20D7 was tested in human melanoma xenografts and mouse metastatic melanoma models in athymic nude mice. Growth of s.c. human melanoma tumors and metastatic nodules of murine B16 tumor were significantly suppressed by 20D7 compared to human IgG control.1084	Melanoma	HDAC	Histone deacetylase		expressed			sensitivity to	Butyric acid	HDAC inhibitor	1	1		"Kuwajima A, Anticancer Res 2007, 27(6B):4163-9"	Butyrate as well as trichostatin A inhibited the cell growth mainly by arresting the cell cycle. The cell invasion of Matrigel was inhibited by butyrate and trichostatin A1085	Melanoma	HDAC	Histone deacetylase		expressed			sensitivity to	Trichostatin A	HDAC inhibitor	1	1		"Kuwajima A, Anticancer Res 2007, 27(6B):4163-9"	Butyrate as well as trichostatin A inhibited the cell growth mainly by arresting the cell cycle. The cell invasion of Matrigel was inhibited by butyrate and trichostatin A1086	Melanoma	SSTR	Somatostatin receptor		expressed			sensitivity to	TT-232	Somatostatic analogue	4	1		"Tejeda M, Anticancer Res 2007, 27(6B):4015-9"	The somatostatin structural derivative (TT-232) showed in vivo antitumor activity against mouse and human melanoma tumor models1087	Melanoma	JAK			expressed			sensitivity to	AG490		3	1		"Kreis S, Mol Cancer Res 2007, 5:1331-41"	AG490: JAK inhibitor. This compound decreased proliferation and induced apoptosis of human melanoma cells likely by reducing STAT3 activation (JAK phosphorylates and activates STAT)1088	Melanoma	MIF	Macrophage migration inhibitory factor		expressed			sensitivity to	MIF siRNA		2	1		"Culp WD, Mol Cancer Res 2007, 5:1225-31"	"MIF is a pleiotropic cytokine with proinflammatory, proangiogenic, and protumorigenic properties: its inhibition has therapeutic potential likely by upragulating  thrombospondin-1 (TSP-1)"1089	Melanoma	HDAC	Histone deacetylase		expressed			sensitivity to	Plitidepsin	Aplidin	3	1		"Munoz-Alonso MJ, J Pharmacol Exp Ther 2008, 324:1093-101"	"Plitidepsin has a dual effect on the human SK-MEL-28 and UACC-257 melanoma cell lines; at low concentrations (</=45 nM), it inhibits the cell cycle by inducing G(1) and G(2)/M arrest, whereas at higher concentrations it induces apoptosis, likely via Rac1/c-Jun NH2-terminal kinase activation  "1092	Melanoma	ARMS	Ankyrin repeat-rich membrane spanning 	mRNA	downregulated by	ARMS siRNA		sensitivity to	UVB	Ultraviolet B light	3	1		"Liao YH, Cancer Res 2007, 67:11547-56"	ARMS silencing sensitizes melanoma cells to ultraviolet radiation induced apoptosis1093	Melanoma	ARMS	Ankyrin repeat-rich membrane spanning 		expressed			sensitivity to	ARMS siRNA		4	1		"Liao YH, Cancer Res 2007, 67:11547-56"	Melanoma growth is inhibited by ARMS silencing in SCID mice1094	Melanoma	FAK	Focal adhesion kinase		expressed			sensitivity to	FAK siRNA		3	1		"Hamamura K, Biochim Biophys Acta 2008, 1780:513-9"	Involvent of FAK in the increased proliferation and invasion in GD3-expressing melanomas was demonstrated by siRNA-mediated knockdown1096	Melanoma	IL24R	Heterodimeric complex of IL20R and IL22R		expressed			no relationship with	IL-24	MDA7	3	0		"Kreis S, PLoS One 2007, 2:e1300"	"None of the investigated cell lines expressed sufficient amounts of functional receptor pairs and therefore did not react to IL-24 stimulation with Jak/STAT activation. Plus, recombinant IL24 did not cause  or increase cell death when compared to appropriate control treatments"1097	Melanoma	IL24R	Heterodimeric complex of IL20R and IL22R		expressed			sensitivity to	IL-24	MDA7	3	1		"Jiang H, Oncogene 1995, 11:2477-86"	Transfection of melanoma cells with IL-24 shows growth inhibitory effects1098	Melanoma	ROS	Reactive oxygen species		expressed			sensitivity to	Elesclomol		3	1		"Kirshner JR, Mol Cancer Ther 2008, 7:2319-27"	The induction of oxidative stress by elesclomol exploits this unique characteristic of cancer cells by increasing ROS levels beyond a threshold that triggers cell death1105	Melanoma	COX-2	Cyclooxygenase 2		expressed			sensitivity to	Amfenac		3	1		"Marshall JC, J Carcinog 2007, 6:17"	Uveal melanoma. Amfenac affected both COX-2 transfected and non-transfected uveal melanoma cells in terms of their proliferation rates as well as their suppressive effects on macrophage cytotoxic activity1106	Melanoma	Livin	ML-IAP		expressed			sensitivity to	Livin siRNA		3	1		"Wang H, Acta Pharmacol Sin 2007, 28:1968-74"	"Silencing livin gene by siRNA leads to apoptosis induction, cell cycle arrest, and proliferation inhibition in malignant melanoma LiBr cells"1107	Melanoma	CD200			expressed			sensitivity to	CD200 siRNA		3	1		"Petermann KB, J Clin Invest 2007, 117:3922-9"	"Melanoma cell lines expressing endogenous CD200 repressed primary T cell activation by DCs, while knockdown of CD200 by shRNA abrogated this immunosuppressive effect, implicating CD200 and its interaction with the CD200 receptor as a potential therapeutic target for MM"1108	Melanoma	BRG1	SWI/SNF chromatin remodeling complex catalytic subunit		expressed			sensitivity to	Brg1 siRNA		3	1		"Vachtenheim J, Biochem Biophys Res Commun 2010, 392:454-9"	Knockdown of Brg1 (SWI/SNF chromatin remodeling complex catalytic subunit) severely compromised MITF expression with a concomitant downregulation of MITF targets and decreased cell proliferation1109	Melanoma	BRG1	SWI/SNF chromatin remodeling complex catalytic subunit	DNA	deleted (null genotype)			sensitivity to	Brm siRNA		3	1		"Vachtenheim J, Biochem Biophys Res Commun 2010, 392:454-9"	"In Brg1-null SK-MEL-5 melanoma cells, depletion of Brm alone was sufficient to abrogate MITF expression and cell proliferation. Brg1 and Brm are catalytic subunits of SWI/SNF chromatin remodeling complex"1110	Immune cells	CTLA4			uncharacterized			no relationship with	Tremelimumab	"CTLA4 antibody (antagonist) CP-675,206"	5	0	251	"Kirkwood JM, Clin Cancer Res 2010, 16:1042-8"	"In this phase II trial (metastatic setting), anti-CTLA4 antibody tremelimumab showed an objective response rate of 6.6%, with all responses being durable > or =170 days since enrollment"1111	Plasma/serum	VEGF	Vascular endothelial growth factor		expressed			sensitivity to	Bevacizumab	Avastin (R)	4	1		"Yang H, Invest Ophthalmol Vis Sci 2010, Epub ahead of print"	Uveal melanoma. Treatment with bevacizumab suppressed in vitro growth and in vivo hepatic micrometastasis of ocular melanoma cells. Bevacizumab is a potential therapeutic agent for the treatment of uveal melanoma micrometastases1112	Melanoma	GLO1	Glyoxalase 1	mRNA	downregulated by	GLO1 siRNA		sensitivity to	Methylglyoxal		3	1		"Bair WB, Melanoma Res 2010, 20:85-96"	"Glyoxalase I (encoded by GLO1) is an ubiquitous cellular defense enzyme overexpressed in melanoma and involved in the detoxification of methylglyoxal, a cytotoxic byproduct of glycolysis. Consistent with an essential role of GLO1 in melanoma cell defense against methylglyoxal cytotoxicity, siRNA interference targeting GLO1 sensitized human metastatic melanoma cells towards the antiproliferative, apoptogenic, and oxidative stress-inducing activity of exogenous methylglyoxal"1113	Melanoma	MMP19	Matrix metalloproteinase 19	mRNA	expressed			sensitivity to	MMP19 downregulation		3	1		"Muller M, Mod Pathol 2010, 23:511-21"	MMP19 is upregulated during melanoma progression and increases invasion of melanoma cells1114	Melanoma	Tubulin			uncharacterized			no relationship with	Ixabepilone	BMS-247550	5	0	23	"Ott PA, PLoS One 2010, 5:e8714"	"In this phase II trial (metastatic setting), ixabepilone (an epothilone B analog) showed no meaningful therapeutic activity in either chemotherapy-naïve (previously untreated) or previously treated patients with metastatic melanoma"1115	Melanoma	IL-1 beta	Interleukin-1 beta	protein	expressed			resistance to	Lymphocyte lysis (immunotherapy)		3	-1		"Kholmanskikh O, Int J Cancer 2010, Epub ahead of print"	"Interleukins 1alpha and 1beta secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens. Accordingly, treating some melanoma cells with IL-1beta reduced by 40-100% their ability to activate antimelanoma cytolytic T lymphocytes"1116	Melanoma	MAP2	Microtubule associated protein 2		downregulated			sensitivity to	MAP2 gene therapy		4	1		"Song Z, Exp Dermatol 2010, Epub ahead of print"	"Forced expression of MAP2 inhibits melanoma cell proliferation, invasion and tumor growth in vitro and in vivo"1117	Melanoma	SPARC	Secreted protein acidic and rich in cysteine 		expressed			sensitivity to	SPARC siRNA		4	1		"Horie K, Cancer Sci 2009, Epub ahead of print"	"When MeWo cells in which SPARC expression was transiently knocked down by SPARC siRNA were implanted in nude mice, the tumor growth was suppressed. These findings suggest that SPARC contributes to cell growth and could be a potential target molecule for melanoma therapy"1118	Melanoma	IL29R	IL10R + IL28R heterodimer		expressed			sensitivity to	IL-29	Interleukin-29	3	1		"Guenterberg KD, Mol Cancer Ther 2010, 9:510-20"	Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis1123	Melanoma	Integrin beta 1			uncharacterized			sensitivity to	Lumican gene therapy		2	1		"Brezillon S, J Physiol Pharmacol 2009, 60 Suppl 4:15-22"	"Lumican inhibits B16F1 melanoma cell lung metastasis. Lumican is an extracellular matrix proteoglycan binding to integrin beta 1 (D’Onofrio, Biochem Biophys Res Commun 2008, 365:266-72) and inhibiting melanoma cell migration"1124	Melanoma	RAGE			expressed			sensitivity to	RAGE antibody (antagonist)		1	1		"Saha A, J Biol Chem 2010, Epub ahead of print"	S100A8 and S100A9 are potent chemoattractants for RAGE-expressing B16F10 cells and pretreatment of these cells with a blocking antibody to RAGE suppressed migration and invasion1125	Melanoma	MMP1	Matrix metalloproteinase 1	mRNA	expressed			sensitivity to	MMP1 siRNA		3	1		"Blackburn JS, Cancer Res 2007, 67:10849-58"	"Compared to shMAMMX control, both cells with MMP-1 and PAR-1 knockeddown had reduced invasive ability (p<0.001) through reconstituted basement membrane (Matrigel)"1126	Melanoma	ATF2			expressed			sensitivity to	Celastrol		4	1		"Abbas S, Clin Cancer Res 2007, 13(22 Pt 1):6769-78"	Celastrol and AIGA have anti-melanoma effects likely by acting as ATF2 inhibitors1127	Melanoma	ATF2			expressed			sensitivity to	AIGA	Acetyl isogambogic acid	4	1		"Abbas S, Clin Cancer Res 2007, 13(22 Pt 1):6769-78"	Celastrol and AIGA have anti-melanoma effects likely by acting as ATF2 inhibitors1130	Melanoma	CXCR4			expressed			sensitivity to	TN14003		3	1		"Di Cesare S, Cancer Cell Int 2007, 7:17"	"Uveal melanoma. TN14003, a synthetic peptide inhibitor that targets the CXCR4 receptor complex (ligand: CXCL12) does not affect cell proliferation but decreases cell migration towards CXCL12"1131	Melanoma	Tyrosinase			expressed			sensitivity to	Quercetin	"3,3',4',5,7-pentahydroxyflavone "	3	1		"Thangasamy T, Nutr Cancer 2007, 59:258-68"	"Quercetin selectively inhibits bioreduction and enhances apoptosis in melanoma cells that overexpress tyrosinase, which catalyzes the formation of 3,3',4',5,7-pentahydroxyflavone (quercetin) into reactive quinone species and subsequent glutathionyl adducts"1133	Melanoma	ROS	Reactive oxygen species		expressed			sensitivity to	Resveratrol		2	1		"Vartanian AA, Melanoma Res 2007, 17:370-9"	"Resveratrol inhibits melanoma vasculogenic mimicry, which correlates with ROS levels"1135	Melanoma	WT1	Wilms tumor protein 1	mRNA	expressed			sensitivity to	WT1 siRNA		1	1		"Zamora-Avila DE, Melanoma Res 2007, 17:341-8"	"As in other tumors, WT1 can be found overexpressed in melanoma and its silencing inhibits cell proliferation and induces apoptosis of murine melanoma cells"1136	Host	CCL2	MCP-1		expressed			sensitivity to	CCL2 dominant negative		2	1		"Koga M, Biochem Biophys Res Commun 2008, 365:279-84"	"Systemic forced expression of dominant negative MCP-1 shows therapeutic potential by inhibiting melanoma angiogenesis and growth, likely by inhibiting recruitment of tumor associated macrophages (TAM)"1137	Melanoma	HO-1	Heme oxygenase 1	mRNA	downregulated by	HO-1 siRNA		sensitivity to	Photodynamic therapy	PDT	3	1		"Frank J, Int J Oncol 2007, 31:1539-45"	Inhibition of heme oxygenase-1 increases responsiveness of melanoma cells to ALA-based photodynamic therapy1138	Melanoma	MITF	Microphthalmia-associated transcription factor 	DNA	amplified (gene)			no relationship with	Dacarbazine	DTIC	3	0		"Ugurel S, Clin Cancer Res 2007, 13:6344-50"	"MITF amplification does not predict chemosensitivity to different chemotherapeutics (dacarbazine, cisplatin, doxorubicin, vindesine, paclitaxel, gemcitabine, treosulfan)"1139	Melanoma	CX3CL1	Fractalkine		expressed			sensitivity to	CX3CL1 siRNA		2	1		"Ren T, Biochem Biophys Res Commun 2007, 364:978-84"	CX3CL1/fractalkine (FKN) promotes cell-cell adhesion by binding with its unique receptor CX3CR1 and its silencing has therapeutic potential likely by inhibiting angiogenesis1140	Melanoma	CCN3			downregulated			sensitivity to	CCN3 gene therapy		3	1		"Fukunaga-Kalabis M, Oncogene 2008, 27:2552-60"	"Forced expression of CCN3 in 1205Lu metastatic melanoma cells did not affect their adhesion to collagen IV: however, CCN3 decreased the transcription and activation of matrix metalloproteinases and suppressed the invasion of 1205Lu melanoma cells in a skin recostruction model"1141	Melanoma	KSP	Kinesin spindle protein		uncharacterized			no relationship with	Ispinesib		5	0	17	"Lee CW, Invest New Drugs 2008, 26:249-55"	No objective response was observed in this pilot trial (metastatic setting)1142	Melanoma	BMP7	Bone morphogenetic protein 7		downregulated			sensitivity to	BMP7 gene therapy		4	1		"Notting I, Invest Ophthalmol Vis Sci 2007, 48:4882-9"	Uveal melanoma. Bone morphogenetic protein 7 inhibits tumor growth of human uveal melanoma in vivo1143	Melanoma	"Rac1, HSP27"			downregulated			sensitivity to	Paclitaxel	Taxol	3	1		"Lee SC, Proteomics 2007, 7:4112-22"	"Dominant negative Rac1 attenuates paclitaxel-induced apoptosis in human melanoma cells through upregulation of heat shock protein 27 (HSP27): if HSP27 is silenced, chemosensitivity is restored"1144	"Melanoma, endothelial cells"	Integrin alpha V beta 3			expressed			sensitivity to	DisBa-01		2	1		"Ramos OH, Clin Exp Metastasis 2008, 25:53-64"	"A novel alpha(v)beta (3)-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis"1145	Melanoma	PKC delta	Protein kinase C delta		expressed			sensitivity to	Docetaxel		3	1		"Mhaidat NM, Mol Cancer Res 2007, 5:1073-81"	"In contrast to PKC epsilon, high levels of activated PKCdelta were associated with activation of the JNK pathway and sensitivity to docetaxel"1147	Melanoma	ABCB1	"MDR1, P-gp"		expressed			sensitivity to	ABCB1 siRNA		3	1		"Colone M, J Invest Dermatol 2008, 128:957-71"	"RNA interference experiments further demonstrated ABCB1 (Pgp) involvement in migration and invasion of resistant melanoma cells, likely by cooperating with CD44 through the activation of ERK1/2 and p38 mitogen-activated protein kinase (MAPK) proteins"1148	Melanoma	MITF	Microphthalmia-associated transcription factor 	DNA	amplified (gene)			no relationship with	Cisplatin	CDDP	3	0		"Ugurel S, Clin Cancer Res 2007, 13:6344-50"	"MITF amplification does not predict chemosensitivity to different chemotherapeutics (dacarbazine, cisplatin, doxorubicin, vindesine, paclitaxel, gemcitabine, treosulfan)"1149	Melanoma	MITF	Microphthalmia-associated transcription factor 	DNA	amplified (gene)			no relationship with	Doxorubicin	Adriamycin (R)	3	0		"Ugurel S, Clin Cancer Res 2007, 13:6344-50"	"MITF amplification does not predict chemosensitivity to different chemotherapeutics (dacarbazine, cisplatin, doxorubicin, vindesine, paclitaxel, gemcitabine, treosulfan)"1150	Melanoma	MITF	Microphthalmia-associated transcription factor 	DNA	amplified (gene)			no relationship with	Vindesine		3	0		"Ugurel S, Clin Cancer Res 2007, 13:6344-50"	"MITF amplification does not predict chemosensitivity to different chemotherapeutics (dacarbazine, cisplatin, doxorubicin, vindesine, paclitaxel, gemcitabine, treosulfan)"1151	Melanoma	MITF	Microphthalmia-associated transcription factor 	DNA	amplified (gene)			no relationship with	Paclitaxel	Taxol	3	0		"Ugurel S, Clin Cancer Res 2007, 13:6344-50"	"MITF amplification does not predict chemosensitivity to different chemotherapeutics (dacarbazine, cisplatin, doxorubicin, vindesine, paclitaxel, gemcitabine, treosulfan)"1152	Melanoma	MITF	Microphthalmia-associated transcription factor 	DNA	amplified (gene)			no relationship with	Gemcitabine		3	0		"Ugurel S, Clin Cancer Res 2007, 13:6344-50"	"MITF amplification does not predict chemosensitivity to different chemotherapeutics (dacarbazine, cisplatin, doxorubicin, vindesine, paclitaxel, gemcitabine, treosulfan)"1153	Melanoma	MITF	Microphthalmia-associated transcription factor 	DNA	amplified (gene)			no relationship with	Treosulfan		3	0		"Ugurel S, Clin Cancer Res 2007, 13:6344-50"	"MITF amplification does not predict chemosensitivity to different chemotherapeutics (dacarbazine, cisplatin, doxorubicin, vindesine, paclitaxel, gemcitabine, treosulfan)"1154	Melanoma	MITF	Microphthalmia-associated transcription factor 	DNA	amplified (gene)			no relationship with	Gemcitabine + Treosulfan		5	0	116	"Ugurel S, Clin Cancer Res 2007, 13:6344-50"	"Various chemotherapy regimens: gemcitabine + treosulfan, gemcitabine + cisplatin, paclitaxel + doxorubicin, paclitaxel + cisplatin, and paclitaxel alone"1155	Melanoma	MITF	Microphthalmia-associated transcription factor 	DNA	amplified (gene)			no relationship with	Paclitaxel + Doxorubicin		5	0	116	"Ugurel S, Clin Cancer Res 2007, 13:6344-50"	"Various chemotherapy regimens: gemcitabine + treosulfan, gemcitabine + cisplatin, paclitaxel + doxorubicin, paclitaxel + cisplatin, and paclitaxel alone"1156	Melanoma	MITF	Microphthalmia-associated transcription factor 	DNA	amplified (gene)			no relationship with	Paclitaxel + Cisplatin		5	0	116	"Ugurel S, Clin Cancer Res 2007, 13:6344-50"	"Various chemotherapy regimens: gemcitabine + treosulfan, gemcitabine + cisplatin, paclitaxel + doxorubicin, paclitaxel + cisplatin, and paclitaxel alone"1157	Melanoma	EphB4			downregulated			sensitivity to	EphB4 gene therapy		2	1		"Huang X, Cancer Res 2007, 67:9800-8"	Forced expression of EphB4 in B16 melanoma cells suppressed tumor growth in a s.c. transplantation tumor model. Histologic examination of these tumors revealed that EphB4 overexpression in B16 cells selectively suppressed arterial ephrinB2 (the EphB4 ligand) positive endothelial cell development1158	Endothelial cells	DARC	"Duffy blood group, chemokine receptor "		downregulated			sensitivity to	DARC gene therapy		2	1		"Horton LW, Cancer Res 2007, 67:9791-9"	"Endothelial cell overexpression of mDARC increased leukocyte trafficking to the tumor, reduced the growth of blood vessels into the tumor, and reduced the growth rate of the tumor"1161	Melanoma	PKR	EIF2AK2		expressed			sensitivity to	PKR siRNA		2	1		"Delgado André N, Cancer Lett 2007, 258:118-25"	Injection of tumor cells transfected with PKR-specific shRNA expressing plasmid resulted in inhibition (85%) of metastatic nodules compared with control. The results suggest that this effect is mediated by the transcription factor NFkB1162	Melanoma	ATF2			expressed			sensitivity to	ATF2 peptide (antagonist)		2	1		"Bhoumik A, J Clin Invest 2002, 110:643-50"	"ATF2 is a transcription factor implicated in melanoma progression and chemoresistance. Expression of a peptide spanning amino acids 50-100 of ATF2 (ATF2(50-100)) reduces ATF2 transcriptional activities while increasing the expression and activity of c-Jun. Growth and metastasis of SW1 and B16F10 mouse melanomas were inhibited by ATF2(50-100) to varying degrees depending on the mode (inducible, constitutive, or adenoviral delivery) of its expression"1170	Melanoma	CDK	Cyclin dependent kinase		expressed			sensitivity to	PHA-848125 		3	1		"Caporali S, Pharmacol Res 2010, 61:437-448"	The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide1171	Melanoma	hTERT			expressed			sensitivity to	hTERT dominant negative		3	1		"Tentori L, Mol Pharmacol 2003, 63:192-202"	Inhibition of telomerase by DN-hTERT resulted in reduced growth rate of melanoma cells1172	Melanoma	PARP-1	Poly ADP-ribose polymerase 1		expressed			no relationship with	Temozolomide	TMZ	3	0		"Augustine CK, Clin Cancer Res 2009, 15:502-10"	"PARP1, POLB, APEX1, LIG1 and MPG showed no correlation with sensitivity to TMZ, suggesting that BER does not significantly contribute to TMZ resistance in melanoma"1173	Melanoma	POLB	DNA polymerase beta		expressed			no relationship with	Temozolomide	TMZ	3	0		"Augustine CK, Clin Cancer Res 2009, 15:502-10"	"PARP1, POLB, APEX1, LIG1 and MPG showed no correlation with sensitivity to TMZ, suggesting that BER does not significantly contribute to TMZ resistance in melanoma"1174	Melanoma	APEX1			expressed			no relationship with	Temozolomide	TMZ	3	0		"Augustine CK, Clin Cancer Res 2009, 15:502-10"	"PARP1, POLB, APEX1, LIG1 and MPG showed no correlation with sensitivity to TMZ, suggesting that BER does not significantly contribute to TMZ resistance in melanoma"1175	Melanoma	LIG1	Ligase 1		expressed			no relationship with	Temozolomide	TMZ	3	0		"Augustine CK, Clin Cancer Res 2009, 15:502-10"	"PARP1, POLB, APEX1, LIG1 and MPG showed no correlation with sensitivity to TMZ, suggesting that BER does not significantly contribute to TMZ resistance in melanoma"1176	Melanoma	MPG	N-methylpurine DNA glycosylase		expressed			no relationship with	Temozolomide	TMZ	3	0		"Augustine CK, Clin Cancer Res 2009, 15:502-10"	"PARP1, POLB, APEX1, LIG1 and MPG showed no correlation with sensitivity to TMZ, suggesting that BER does not significantly contribute to TMZ resistance in melanoma"1177	Melanoma	"Gene set 2: ARHGAP29, DKK1, EVI2A, PAWR, PPAP2C, RRAGD, SFN, SLC43A3"			expressed			resistance to	Temozolomide	TMZ	3	-1		"Augustine CK, Clin Cancer Res 2009, 15:502-10"	This set of genes resulted more highly expressed in resistant melanoma cell lines1178	Melanoma	"Gene set 1: ABCC3, APLP2, BCL2L1, BTN3A2, CXADR, DNMBP, DSP, EEF1A2, FLNB, FTH1, FTS, G6PD, H1F0, IRS1, ITGA3, ITGB4, KIBRA, LAMA5, LGR4, LPXN, NDN, PCBD1, PLS1, PTPRF, RRAGD, SDC1, SFN, SLC43A3, TCF7L2, TXNRD1"			expressed			sensitivity to	Temozolomide	TMZ	3	1		"Augustine CK, Clin Cancer Res 2009, 15:502-10"	This set of genes resulted more highly expressed in sensitive melanoma cell lines1180	Melanoma	PARP	Poly ADP-ribose polymerase 		expressed			no relationship with	ABT-888		2	0		"Palma JP, Anticancer Res 2008, 28:2625-36"	"ABT-888 enhanced TMZ antitumor activity, in a dose-proportional manner with no observed toxicity (44-75% tumor growth inhibition vs. TMZ monotherapy), but did not show single agent activity (identical results in Donawho, Clin Cancer Res 2007, 13:2728-37)"1181	Melanoma	PARP-1	Poly ADP-ribose polymerase 1		expressed			sensitivity to	PARP1 siRNA		2	1		"Tentori L, Eur J Cancer 2008, 44:1302-14"	"Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth, likely by inhibiting tumor angiogenesis"1182	Melanoma	WT1	Wilms tumor protein 1		expressed			sensitivity to	WT1 siRNA		3	1		"Wagner N, Pflugers Arch 2008, 455:839-47"	WT1 silencing significantly reduced the expression of Nestin and Zyxin and resulted in inhibition of melanoma cell proliferation as determined by a reduced BrdU incorporation1183	Host	CCR5		DNA	polymorphism delta32			resistance to	Immunotherapy (miscellany)		5	-1	139	"Ugurel S, Cancer Immunol Immunother 2008, 57:685-91"	The presence of the CCR5Delta32 polymorphism in patients with stage IV melanoma results in a decreased survival following immunotherapy and may help to select patients less likely to benefit from this type of treatment1185	Melanoma	Melanin			targeted by	Heptapeptide		sensitivity to	Radiotherapy		4	1		"Howell RC, Bioconjug Chem 2007, 18:1739-48"	Phage display library derived peptides bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma. Administration of one of the generated heptapeptides to A2058 human metastatic melanoma-bearing nude mice resulted in significant retardation of the tumor growth1186	Melanoma	PRKAR1	PKA regulatory subunit 1		expressed			sensitivity to	PRKAR1 siRNA		3	1		"Mantovani G, Oncogene 2008, 27:1834-43"	Human melanomas are characterized by a high R1/R2 ratio (ratio between PKA regulatory subunits R1 and R2) and pharmacological or genetic manipulations able to revert this unbalanced expression (in this case silencing R1) cause significant antiproliferative and proapoptotic effects in melanoma cells1187	Melanoma	PRKAR2	PKA regulatory subunit 2		expressed			sensitivity to	8-Cl-cAMP	cAMP analogue	3	1		"Mantovani G, Oncogene 2008, 27:1834-43"	Human melanomas are characterized by a high R1/R2 ratio (ratio between PKA regulatory subunits R1 and R2) and pharmacological or genetic manipulations able to revert this unbalanced expression (in this case activating R2) cause significant antiproliferative and proapoptotic effects in melanoma cells1190	Melanoma	Fatty acid synthase			expressed			sensitivity to	Cerulenin		3	1		"Ho TS, Biomed Pharmacother 2007, 61:578-87"	Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells1191	Melanoma	Rac1			expressed			sensitivity to	Rac1 siRNA		3	1		"Bauer NN, Exp Cell Res 2007, 313:3832-9"	"Rac1 activity in FEMX cells regulates cell proliferation and invasion, in part via activation of NFkB, which indicates Rac1 as a key molecule in melanoma progression and metastasis"1192	Melanoma	IL1R	IL-1 receptor		expressed			sensitivity to	IL1R antagonist (microsphere formulation)		2	1		"Lavi G, J Control Release 2007, 123:123-30"	The sustained delivery of IL1R antagoinst from biodegradable microspheres inhibited tumor growth and significantly prolonged mice survival. In vitro cytokine release and bioactivity studies in cultured melanoma B16 cells revealed the microspheres to be capable of sustained IL-1Ra release on a daily level that could inhibit cell proliferation for at least 7 days1193	Immune cells	PD1	"PDCD1, CD279"		expressed			sensitivity to	PD-1 antibody (antagonist)		3	1		"Wong RM, Int Immunol 2007, 19:1223-34"	Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific cytotoxic T lymphocytes (CTL): This correlated with increased frequencies of IFN-gamma-secreting antigen-specific cells and augmented lysis of gp100+/MART-1+ melanoma targets1195	Host	HPSE	Heparanase		uncharacterized			no relationship with	PI-88	Heparanase inhibitor	5	0	44	"Lewis KD, Invest New Drugs 2008, 26:89-94"	"A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma: one (2.4%) patient achieved a partial response, six (14.6%) patients had stable disease as best response, and 30 (73.2%) had progressive disease"1196	Melanoma	ROS	Reactive oxygen species		downregulated by	ROS scavenger		resistance to	Evodiamine		3	-1		"Yang J, Free Radic Res 2007, 41:1099-108"	Critical role of reactive oxygen species in mitochondrial permeability transition in mediating evodiamine-induced human melanoma A375-S2 cell apoptosis1197	Melanoma	"MDH, Carbonic anhydrase"	"Malate dehydrogenase, Carbonic anhydrase"		uncharacterized			no relationship with	E7070	Indisulam	5	0	28	"Smyth JF, Ann Oncol 2005, 16:158-161"	In this phase II trial there were only minor responses on independent radiological review. E7070 (a MDH and carbonic anhydrase inhibitor) does not warrant further development as a single agent for the treatment of metastatic melanoma1198	Melanoma	"Gene set 3: NDUFB8, NDUFS1, NDUFV1, ACADVL "			downregulated			sensitivity to	E7070	Indisulam	5	1	1	"Baur M, Melanoma Res 2007, 17:329-31"	Clinical complete long-term remission of a patient with metastatic malignant melanoma under therapy with indisulam and with low expression of subsets of genes involved in mitochondrial energy metabolism1199	Melanoma	NFkB	Nuclear factor kappa B		expressed			sensitivity to	Curcumin		1	1		"Marin YE, Melanoma Res 2007, 17:274-83"	"Curcumin, a natural and safe compound, inhibits NFkB activity and the expression of its downstream target genes, and also selectively induces apoptosis of melanoma cells but not normal melanocytes. These encouraging in vitro results support further investigation of curcumin for treatment of melanoma in vivo"1200	Melanoma	bTrCP	Beta transducin repeat containing 		expressed			sensitivity to	bTrCP dominant negative		4	1		"Kumar KG, Cancer Biol Ther 2007, 6:1437-41"	"bTrCP regulates the ubiquitination and degradation of different proteins, but these Authors suggest that the main target might be IFNAR: thus they suggest to combine IFN alpha with drugs that stabilize IFNAR "1205	Melanoma	"BRAF, CRAF, VEGFR, PDGFR"			expressed			sensitivity to	Sorafenib	Nexavar (R)	3	1		"Liu J, Oncogene 2007, 26:1954-8"	"Inhibition of BRAF signaling using either a broad-spectrum Raf inhibitor (Sorafenib) or by selective knockdown of BRAF(V600E) expression by RNA interference in human melanoma cells leads to decreased beta-Trcp expression, stabilization of IkB, decreased IKK activity, inhibition of NFkB transcriptional activity and sensitization of these cells to apoptosis"1206	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	BRAF V600E siRNA		3	1		"Liu J, Oncogene 2007, 26:1954-8"	"Inhibition of BRAF signaling using either a broad-spectrum Raf inhibitor (Sorafenib) or by selective knockdown of BRAF(V600E) expression by RNA interference in human melanoma cells leads to decreased beta-Trcp expression, stabilization of IkB, decreased IKK activity, inhibition of NFkB transcriptional activity and sensitization of these cells to apoptosis"1207	Melanoma	CCL2	MCP-1		downregulated			sensitivity to	CCL2 gene therapy		2	1		"Hu K, Immunol Lett 2007, 113:19-28"	"Inoculation of mice with CCL2-B16 cells prolonged mice survival time when they were reinjected with wildtype B16 cells, implying that CCL2 can activate immuno-memory in mice"1208	Melanoma	MTA1	Metastasis associated gene 1		expressed			sensitivity to	MTA1 siRNA		2	1		"Qian H, Biol Cell 2007, 99:573-81"	Studies in vivo confirmed downregulation of MTA1 suppressed the growth and experimental metastasis of B16F10 melanoma cells1209	Melanoma	"Integrin alpha 5 beta 1, Integrin alpha V beta 3"			expressed			sensitivity to	Jarastatin		2	1		"Oliva IB, Toxicon 2007, 50:1053-63"	This RGD disintegrin inhibits melanoma growth both in vitro and in vivo1210	Melanoma	Integrin alpha 5 beta 1			expressed			sensitivity to	Flavoridin		2	1		"Oliva IB, Toxicon 2007, 50:1053-63"	This RGD disintegrin inhibits melanoma growth both in vitro and in vivo1211	Melanoma	MMP2	Matrix metalloprotease 2		expressed			sensitivity to	Chitosan		3	1		"Gorzelanny C, Biomacromolecules 2007, 8:3035-40"	Specific interaction between chitosan and matrix metalloprotease 2 decreases the invasive activity of human melanoma cells1212	Host	DAP10			expressed			sensitivity to	NK cell lysis (immunotherapy)		2	1		"Hyka-Nouspikel N, J Immunol 2007, 179:3763-71"	"Mice lacking DAP10 (DAP10KO), showed enhanced immunity against melanoma malignancies due to hyperactive functioning of NK1.1+CD3+ NKT cells"1215	Melanoma	STAT1	Signal transducer and activator of transcription 1 	protein	phosphorylated (activated)			sensitivity to	IFN alpha		3	1		"Lesinski GB, Clin Cancer Res 2007, 13:5010-9"	IFN alpha-induced p-STAT1 correlated with the antiproliferative effects of IFN alpha. IFN alpha induced significantly lower levels of p-STAT1 in melanoma cells compared with matched PBMC. Melanoma cells and human melanocytes required 10-fold higher IFN alpha doses to exert p-STAT1 levels comparable with PBMC 1216	Melanoma	ASK	Dbf4		expressed			sensitivity to	ASK siRNA		3	1		"Nambiar S, Carcinogenesis 2007, 28:2501-10"	Small interfering RNA-mediated depletion of ASK/Dbf4 retarded melanoma cell survival and proliferation1218	Melanoma	ROS	Reactive oxygen species		downregulated by	N-acetylcysteine	NAC	resistance to	Oxymatrine		3	-1		"Zhang Y, Anticancer Drugs 2010, Epub ahead of print"	"Oxymatrine (a natural quinolizidine alkaloid) dose-dependently increased the generation of reactive oxygen species in A375 cells, and N-acetylcysteine, a reactive oxygen species production inhibitor, almost completely blocked oxymatrine-induced apoptosis"1219	Melanoma	ROCK			expressed			sensitivity to	Y-27632		2	1		"Routhier A, Oncol Rep 2010, 23:861-7"	Y-27632 (small molecule ROCK inhibitor) treatment decreases invasion and alters cell survival of cultured melanoma cells. IP injection of Y-27632 in tumor-bearing mice resulted in a reduction in melanoma tumor volume compared to control treated mice1220	Melamoma	Ribosome			uncharacterized			sensitivity to	scRIP	Single chain ribosome inactivating protein	3	1		"Cheung MC, Mol Cancer 2010, 9:28"	"scRIP (derived from the cytotoxic A subunit of Shiga like toxin 1, SLT-1A) kill 7 of 8 human melanoma cell lines through the blockage of protein synthesis and apoptosis in such cells"1224	Melanoma	SMO (Hedgehog pathway)	Smoothened homologue		expressed			sensitivity to	Cyclopamine		2	1		"Geng L, Angiogenesis 2007, 10:259-67"	"Hedgehog ligands (Sonic, Desert, Indian) bind to and inhibit the Hedgehog receptor Patched-1 (PTCH1), which then cannot inhibit Smootened (SMO); SMO can thus activate glioma associated oncogene (GLI), which in turn transactivates Hedgehog target genes.  This study suggests that inhibiting Hedgehog signaling can have therapeutic potential by inhibiting melanoma related vascular formation and function"1225	Melanoma	Integrin alpha 10			expressed			sensitivity to	Integrin alpha 10 antibody (antagonist)		3	1		"Wenke AK, Cell Oncol 2007, 29:373-86"	"Proliferation assays and colony forming assays revealed no differences comparing antisense integrin alpha10 cell clones with control and wild type melanoma cells, respectively. However, antisense integrin alpha10 cell clones and Mel Im cells treated with an inhibitory antibody against integrin alpha10 showed a reduced migratory potential"1226	Melanoma	Osteonectin			expressed			sensitivity to	Osteonectin siRNA		3	1		"Smit DJ, Int J Cancer 2007, 121:2653-60"	"Melanoma cells overexpressing Osteonectin displayed increased invasive potential, whereas ablation of Osteonectin gene transcription using siRNA suppressed the invasive potential of these cells and resulted in the upregulation of E-cadherin"1227	Melanoma	FGF-2	Fibroblast growth factor 2 (bFGF)		expressed			sensitivity to	FGF-2 antibody (antagonist)		3	1		"Nikitovic D, Int J Biochem Cell Biol 2008, 40:72-83"	Treatment of human melanoma cell lines with a neutralizing FGF-2 antibody inhibited the proliferation rate1228	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	BRAF V600E siRNA		3	1		"Hao H, Mol Cancer Ther 2007, 6:2220-9"	"The growth rate of melanoma cells (but not colon carcinoma) harboring BRAF V600E is inhibited by BRAF V600E siRNA. The growth rate of the BRAF wild type control cell line (MEL 505) was not significantly affected by the expression of BRAF V600E siRNA, indicating that these effects were specific to suppression of mutant BRaf (V600E) expression"1231	Melanoma	"Eri-1, Adar-1"		mRNA	downregulated by	Eri-1 siRNA + Adar-1 siRNA		sensitivity to	MYC siRNA		2	1		"Hong J, Biochem Biophys Res Commun 2007, 361:373-8."	Eri-1 and Adar-1 genes negatively regulate RNA interference. The data strongly suggest that silencing of eri-1 and adar-1 homologs of human being should be concerned for cancer therapy by RNAi approach1233	Melanoma	MC1R	Melanocortin receptor 1	protein	targeted by	MSH		sensitivity to	Radiotherapy		2	1		"Miao Y, Cancer Biother Radiopharm 2007, 22:333-41"	Radiolabeled MSH yielded quantitative therapeutic effects in B16/F1 melanoma-bearing mice and appeared to be a promising radiolabeled peptide for the targeted radionuclide therapy of melanoma1234	Melanoma	PKC	Protein kinase C		expressed			sensitivity to	H7		2	1		"Tsubaki M, Clin Exp Metastasis 2007, 24:431-8"	"H7: PKC inhibitor. The protein kinase C inhibitor, H7, inhibits tumor cell invasion and metastasis in mouse melanoma via suppression of ERK1/2"1235	Melanoma	MEK	"MEK1, MEK2"		expressed			sensitivity to	U0126	MEK inhibitor	2	1		"Tsubaki M, Clin Exp Metastasis 2007, 24:431-8"	"U0126: MEK inhibitor. U0126, a MEK1/2 inhibitor, inhibited B16BL6 cell invasion and metastasis"1236	Melanoma	Tubulin			uncharacterized			no relationship with	Vinflunine		5	0	33	"Olver IN, Eur J Cancer 2007, 43:1829-32"	"In this phase II trial, tubulin assembly inhibitor vinflunine was not active against metastatic melanoma (3% response rate)"1237	Melanoma	PKC beta II	Protein kinase C beta II		downregulated			sensitivity to	PKC beta II gene therapy		3	1		"Oka M, J Invest Dermatol 2008, 128:188-95"	"Hepatocyte growth factor (HGF) signaling process from Gab1 to PI3K is negatively regulated by PKC beta II, whose loss is critical for melanoma cells to gain invasive potential."1238	Melanoma	SPARC	Secreted protein acidic and rich in cysteine 		expressed			sensitivity to	SPARC siRNA		4	1		"Prada F, J Invest Dermatol 2007, 127:2618-28"	Downregulation of SPARC expression in melanoma cells induced their rejection in vivo through a mechanism mediated exclusively by host polymorphonuclear cells1240	Melanoma	MSH2		mRNA	downregulated by	MSH2 siRNA		resistance to	UVB	Ultraviolet B light	3	-1		"Seifert M, J Invest Dermatol 2008, 128:203-13"	The DNA-mismatch repair enzyme hMSH2 modulates UVB-induced cell cycle arrest and apoptosis in melanoma cells1241	Melanoma	SSTR	Somatostatin receptor		expressed			no relationship with	Octreotide		3	0		"Martinez-Alonso M, J Int Med Res 2009, 37:1813-22"	"Although human melanoma cells express the somatostatin receptor, their proliferation and survival are not affected by somatostatin analogues octreotide or SOM230"1242	Melanoma	SSTR	Somatostatin receptor		expressed			no relationship with	SOM230		3	0		"Martinez-Alonso M, J Int Med Res 2009, 37:1813-22"	"Although human melanoma cells express the somatostatin receptor, their proliferation and survival are not affected by somatostatin analogues octreotide or SOM230"1243	Immune cells	CTLA4			uncharacterized			no relationship with	Ipilimumab	CTLA4 antibody (antagonist)	5	0	155	"O'Day S, Ann Oncol 2010, Epub ahead of print"	"In a multicenter single-arm phase II trial of ipilimumab (monotherapy) for pretreated advanced melanoma (n=155), the best overall response rate was 5.8% and the disease control rate was 27%. The median overall survival was 10.2 months (7.6-16.3). The Authors state: ""Ipilimumab demonstrated clinical activity with encouraging long-term survival in a previously treated advanced melanoma population"" "1244	Melanoma	GRM1	Metabotropic glutamate receptor-1		expressed			sensitivity to	CPCCOEt 		3	1		"Haas HS, Oncol Rep 2007, 17:1399-404"	The non-competitive metabotropic glutamate receptor-1 antagonist CPCCOEt inhibits the in vitro growth of human melanoma1245	Melanoma	MEK			expressed			sensitivity to	AZD6244		3	1		"Haass NK, Clin Cancer Res 2008, 14:230-9"	"AZD6244: MEK inhibitor. In two-dimensional cell culture, AZD6244 was cytostatic and reduced the growth of melanoma cells in a concentration-dependent fashion through the induction of G(1)-phase cell cycle arrest"1246	Melanoma	BRM		mRNA	expressed			sensitivity to	BRM siRNA		3	1		"Keenen B, Oncogene 2010, 29:81-92"	Downregulation of the ATPase BRM in SK-MEL5 cells inhibited expression of both differentiation-specific and pro-proliferative MITF target genes and inhibited tumorigenicity in vitro1247	Melanoma	STAT1	Signal transducer and activator of transcription 1 		expressed			sensitivity to	STAT1 siRNA		2	1		"Khodarev NN, PLoS One 2009, 4:e5821"	Stable knockdown of STAT1 reversed the aggressive phenotype and decreased both lung colonization and resistance to genotoxic stress1249	Melanoma	PKC delta	Protein kinase C delta	mRNA	downregulated by	PKC delta siRNA		resistance to	Oncostatin-M	OSM	3	-1		"Lacreusette A, J Pathol 2009, 217:665-76"	Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin M resistance in metastatic melanoma cells1250	Melanoma	"KIT, PDGFR"		protein	expressed			no relationship with	Imatinib	Gleevec (R)	3	0		"Mayorga ME, Melanoma Res 2006, 16:127-35"	"Imatinib: small molecule inhibitor of tyrosine kinase receptors (TKR) such as KIT and PDGFR. This study supports an antiproliferative effect of imatinib (STI571) on cultured human cutaneous melanoma-derived cell lines: however, no relationship could be established between the expression of c-Kit, ABL, PDGFR-alpha or PDGFR-beta and the response of cell lines to STI571. The identification of an unknown target of STI571 in human cutaneous melanoma cells would allow the selection of patients who could benefit from this treatment"1253	"Melanoma, Host"	"VEGFR1, VEGFR2, VEGFR3"		protein	expressed			sensitivity to	PTK787/ZK222584	PTK/ZK	2	1		"Sini P, Cancer Res 2008, 68:1581-92"	Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases 1255	Melanoma	"KIT, PDGFR"			expressed			no relationship with	Imatinib	Gleevec (R)	2	0		"Ogawa Y, J Dermatol Sci 2008, 51:190-9"	"Imatinib mesylate enhanced the antitumor effect of dacarbazine on in vivo growth and lung metastases of melanoma cells, although treatment with only imatinib mesylate had no effect"1256	Melanoma	mTOR	Mammalian target of rapamycin		expressed			no relationship with	Temsirolimus	"CCI-779, Torisel (R)"	4	0		"Thallinger C, J Invest Dermatol 2007, 127:2411-7"	Temsirolimus: mTOR inhibitor. CCI-779 monotherapy exerted no statistically significant antitumor effect 1258	Melanoma	TRAILR3	DcR1		expressed			no relationship with	TRAIL		3	0		"Zhang XD, Cancer Res 1999, 59:2747-53"	Surface expression of TRAIL-R1 and -R2 (but not TRAIL-R3 and -R4) showed an overall correlation with TRAIL-induced apoptosis1259	Melanoma	TRAILR4	DcR2		expressed			no relationship with	TRAIL		3	0		"Zhang XD, Cancer Res 1999, 59:2747-53"	Surface expression of TRAIL-R1 and -R2 (but not TRAIL-R3 and -R4) showed an overall correlation with TRAIL-induced apoptosis1260	Melanoma	Bim		mRNA	downregulated by	Bim siRNA		resistance to	CI-1040	PD184352	3	-1		"VanBrocklin MW, Cancer Res 2009, 69:1985-94"	CI-1040: MEK inhibitor. Bim expression is necessary for MEK inhibition to be therapeutically effective1261	Melanoma	Bad		mRNA	downregulated by	Bad siRNA		no relationship with	CI-1040	PD184352	3	0		"VanBrocklin MW, Cancer Res 2009, 69:1985-94"	CI-1040: MEK inhibitor. Expression of BH3-only proteins Bad or Bid did not impact on CI-1040 activity1262	Melanoma	Bid		mRNA	downregulated by	Bid siRNA		no relationship with	CI-1040	PD184352	3	0		"VanBrocklin MW, Cancer Res 2009, 69:1985-94"	CI-1040: MEK inhibitor. Expression of BH3-only proteins Bad or Bid did not impact on CI-1040 activity1263	Melanoma	Bcl-2		mRNA	upregulated by	Bcl-2 genetic engineering		resistance to	CI-1040	PD184352	3	-1		"VanBrocklin MW, Cancer Res 2009, 69:1985-94"	"CI-1040: MEK inhibitor. Lentiviral vectors were used to deliver and express Bcl-2, Bcl-xL, Bfl-1 and Mcl-1: overexpression of any of these proteins in the sensitive cell line M14-MEL resulted in significant protection from apoptosis induced by CI-1040 "1264	Melanoma	Bcl-xL		mRNA	upregulated by	Bcl-xL genetic engineering		resistance to	CI-1040	PD184352	3	-1		"VanBrocklin MW, Cancer Res 2009, 69:1985-94"	"CI-1040: MEK inhibitor. Lentiviral vectors were used to deliver and express Bcl-2, Bcl-xL, Bfl-1 and Mcl-1: overexpression of any of these proteins in the sensitive cell line M14-MEL resulted in significant protection from apoptosis induced by CI-1040 "1265	Melanoma	Bfl-1		mRNA	upregulated by	Bfl-1 genetic engineering		resistance to	CI-1040	PD184352	3	-1		"VanBrocklin MW, Cancer Res 2009, 69:1985-94"	"CI-1040: MEK inhibitor. Lentiviral vectors were used to deliver and express Bcl-2, Bcl-xL, Bfl-1 and Mcl-1: overexpression of any of these proteins in the sensitive cell line M14-MEL resulted in significant protection from apoptosis induced by CI-1040 "1266	Melanoma	Mcl-1		mRNA	upregulated by	Mcl-1 genetic engineering		resistance to	CI-1040	PD184352	3	-1		"VanBrocklin MW, Cancer Res 2009, 69:1985-94"	"CI-1040: MEK inhibitor. Lentiviral vectors were used to deliver and express Bcl-2, Bcl-xL, Bfl-1 and Mcl-1: overexpression of any of these proteins in the sensitive cell line M14-MEL resulted in significant protection from apoptosis induced by CI-1040 "1267	Melanoma	Tyrosinase			expressed			sensitivity to	TMECG	Epicatechin-3-gallate derivative	2	1		"Sánchez-del-Campo L, Mol Pharm 2009, 6:883-94"	TMECG is an anticancer prodrug (dihydrofolate reductase - DHFR - inhibitor; antifolate agent) activated by tyrosinase1268	Melanoma	ADAM10		mRNA	expressed			sensitivity to	ADAM10 siRNA		3	1		"Lee SB, J Invest Dermatol 2010, 130:763-73"	ADAM10 is upregulated in melanoma metastasis compared with primary melanoma and in vitro downregulation of ADAM10 with specific small interfering RNA (siRNA) resulted in a suppression of the anchorage-independent cell growth and reduced the migration of melanoma cells1269	Plasma/serum	VEGF	Vascular endothelial growth factor		expressed			no relationship with	Bevacizumab	Avastin (R)	3	0		"Schicher N, Clin Cancer Res 2009, 15:3495-502"	"Bevacizumab: anti-VEGF antibody. While in vitro no influence on tumor cell proliferation was seen with erlotinib or bevacizumab monotherapy, a decreased invasive potential on erlotinib treatment in a three-dimensional Matrigel assay was observed"1270	Melanoma	EGFR	ERBB1		expressed			sensitivity to	Erlotinib	Tarceva (R)	3	1		"Schicher N, Clin Cancer Res 2009, 15:3495-502"	"Erlotinib: small molecule inhibitor of EGFR. While in vitro no influence on tumor cell proliferation was seen with erlotinib or bevacizumab monotherapy, a decreased invasive potential on erlotinib treatment in a three-dimensional Matrigel assay was observed. EGFR was expressed in all cell lines tested"1271	Melanoma	PPAR alpha	Peroxisome proliferator activated receptor alpha		expressed			sensitivity to	Vitamin D3	Calcitriol	3	1		"Sertznig P, Dermatoendocrinol 2009, 1:232-8"	"PPARalpha and VDR were stronger expressed in the 1,25(OH)(2)D(3)-sensitive melanoma cells (MeWo and in SK-Mel-28) than in the 1,25(OH)(2)D(3)-resistent melanoma cell lines (SK-Mel-5 and SK-Mel-25) or in normal human melanocytes"1274	Melanoma	PAR-1	Protease activated receptor 1 (thombin receptor)		expressed			sensitivity to	PAR1 siRNA		3	1		"Silini A, Clin Exp Metastasis 2010, 27:43-53"	"The migration and invasion capabilities of the melanoma cells expressing high PAR-1 were hampered by genetic and pharmacological interventions. The reduction of PAR-1 expression by siRNA and the inhibition of PAR-1 function by the SCH79797 specific antagonist significantly decreased the melanoma cell motility and invasiveness, down to an extent similar to that of the non-metastatic and low PAR-1 expressing cells"1275	Melanoma	PAR-1	Protease activated receptor 1 (thombin receptor)		expressed			sensitivity to	SCH79797	PAR-1 inhibitor	3	1		"Silini A, Clin Exp Metastasis 2010, 27:43-53"	"The migration and invasion capabilities of the melanoma cells expressing high PAR-1 were hampered by genetic and pharmacological interventions. The reduction of PAR-1 expression by siRNA and the inhibition of PAR-1 function by the SCH79797 specific antagonist significantly decreased the melanoma cell motility and invasiveness, down to an extent similar to that of the non-metastatic and low PAR-1 expressing cells"1276	Melanoma	SOX2		protein	expressed			sensitivity to	SOX2 siRNA		4	1		"Laga AC, Am J Pathol 2010, 176:903-13"	"In human patient melanoma, strong nuclear expression of SOX2 was noted in a subset of tumors. Whereas SOX2 knockdown failed to influence proliferation of cultured melanoma cells in vitro, tumor xenografts generated with the SOX2-knockdown cell line showed significant decrease in mean tumor volume as compared with controls"1277	Melanoma	SOX2		mRNA	expressed			no relationship with	SOX2 siRNA		3	0		"Laga AC, Am J Pathol 2010, 176:903-13"	"In human patient melanoma, strong nuclear expression of SOX2 was noted in a subset of tumors. Whereas SOX2 knockdown failed to influence proliferation of cultured melanoma cells in vitro, tumor xenografts generated with the SOX2-knockdown cell line showed significant decrease in mean tumor volume as compared with controls"1278	Melanoma	Integrin alpha V beta 3			expressed			sensitivity to	Doxorubicin (albumin nanoparticles)		3	1		"Wagner S, Biomaterials 2010, 31:2388-98"	DI17E6 is a monoclonal antibody directed against alphav integrins that inhibits growth of melanomas in vitro and inhibits angiogenesis due to interference with alphavbeta3 integrins. DI17E6-coupled human serum albumin nanoparticles represent a potential delivery system for targeted drug transport into alphavbeta3-positive cells. The avb3 integrin positive melanoma cell line M21 was used for all experiments; the avb3-negative melanoma cell line M21L was used as control 1280	Melanoma	ATF4		mRNA	downregulated by	ATF4 siRNA		resistance to	Fenretinide		3	-1		"Armstrong JL, J Biol Chem 2010, 285:6091-100"	"siRNA-mediated knockdown of ATF4 resulted in a a significant reduction in fenretinide-, bortezomib- or thapsigargin-induced cell death in A375 cells with reduced ATF4 expression, and there was evidence for increased death of A375 cells overexpressing ATF4 in response to treatment with these agents "1281	Melanoma	ATF4		mRNA	downregulated by	ATF4 siRNA		resistance to	Bortezomib	Velcade (R)	3	-1		"Armstrong JL, J Biol Chem 2010, 285:6091-100"	1282	Melanoma	ATF4		mRNA	downregulated by	ATF4 siRNA		resistance to	Thapsigargin		3	-1		"Armstrong JL, J Biol Chem 2010, 285:6091-100"	1283	Melanoma	PPAR gamma	Peroxisome proliferator activated receptor gamma	protein	expressed			no relationship with	15d-PGJ(2)	PPAR gamma agonist	2	0		"Prakash J, Neoplasia 2009, 11:1348-58"	"Anti-melanoma effects were not elicited through PPARgamma-dependent pathways because an irreversible PPARgamma antagonist GW9662 did not inhibit these effects. This study suggests that 15d-PGJ(2) can be an effective therapeutic agent, although its effects seem to be limited to the tumors allowing albumin penetration"1284	Melanoma	IAP-1	Inhibitor of apoptosis protein 1	mRNA	downregulated by	IAP-1 siRNA		sensitivity to	Poly(I:C)	TLR3 agonist	3	1		"Weber A, Cell Death Differ 2010, 17:942-51"	"Poly I:C is a toll like receptor 3 (TLR3) agonist. Sensitisation towards poly I:C-dependent caspase-8 activation and apoptosis in melanoma cells was also achieved by the synthetic Smac mimetic/inhibitor of apoptosis protein (IAP) antagonist, LBW242, or by specific downregulation of cIAP1 by siRNA"1285	Immune cells	IL17RB	Interleukin 17 receptor B		uncharacterized			sensitivity to	IL-25 (IL-17E)	Interleukin-25 (interleukin-17E)	4	1		"Benatar T, Cancer Immunol Immunother 2010, 59:805-17"	"Antitumor efficacy of IL-17E (IL-25) was examined in a variety of human tumor xenograft models, including melanoma, breast, lung, colon, and pancreatic cancers. Injection of recombinant IL-17E every other day resulted in significant antitumor activity in these tumor models. B cells are necessary for IL-17E-mediated antitumor activity"1286	Immune cells	DNAM1	CD226	mRNA	downregulated by	DNAM-1 knockout		resistance to	IL-2	Interleukin-2	2	-1		"Chan CJ, J Immunol 2010, 184:902-11"	"NK cells require DNAM-1 for natural or cytokine (IL-2, IL-12, or IL-21) suppression of tumor metastases "1287	Immune cells	DNAM1	CD226	mRNA	downregulated by	DNAM-1 knockout		resistance to	IL-12	Interleukin-12	2	-1		"Chan CJ, J Immunol 2010, 184:902-11"	"NK cells require DNAM-1 for natural or cytokine (IL-2, IL-12, or IL-21) suppression of tumor metastases "1288	Immune cells	DNAM1	CD226	mRNA	downregulated by	DNAM-1 knockout		resistance to	IL-21	Interleukin-21	2	-1		"Chan CJ, J Immunol 2010, 184:902-11"	"NK cells require DNAM-1 for natural or cytokine (IL-2, IL-12, or IL-21) suppression of tumor metastases "1289	Endothelial cells	Egr-3	Early growth response 3	mRNA	expressed			sensitivity to	Egr-3 siRNA		2	1		"Suehiro J, Blood 2010, 115:2520-32"	"Knockdown of Egr-3 markedly impaired VEGF-mediated proliferation, migration, and tube formation of endothelial cells. Egr-3 knockdown also attenuated melanoma tumor growth in vivo"1291	Melanoma	Tyrosinase			expressed			sensitivity to	4-HEB		3	1		"Vad NM, Chem Biol Interact 2010, 183:462-71"	"Phenolic analogue 4-HEB is a prodrug bioactivated by tyrosinase: it showed selective toxicity towards melanocytic melanoma cell lines which express functional tyrosinase, compared to non-melanoma cells lines and amelanotic melanoma cells, which do not express functional tyrosinase"1292	Melanoma	ING3			downregulated			sensitivity to	ING3 gene therapy		3	1		"Chen G, Oncogene 2010, 29:1498-508"	The tumor suppressor ING3 is degraded by SCF(Skp2)-mediated ubiquitin-proteasome system. Strategies by either silencing Skp2 or overexpressing ING3 significantly arrested MMRU cells at G1 phase1293	Melanoma	CRAF	C-Raf	protein	expressed			sensitivity to	Sorafenib	Nexavar (R)	3	1		"Karreth FA, Mol Cell 2009, 36:477-86"	"Melanoma cells expressing no ectopic C-Raf were more resistant to Sorafenib. Both oncogenic Ras and Sorafenib stabilize B-Raf(V600E)-C-Raf complexes, thereby impairing MAPK activation. This inhibitory function of C-Raf on B-Raf(V600E)-mediated MAPK activation may explain the lack of co-occurrence of B-Raf(V600E) and oncogenic Ras mutations"1294	Melanoma	STAT3	Signal transducer and activator of transcription 3 	mRNA	expressed			sensitivity to	STAT3 siRNA		2	1		"Alshamsan A, Biomaterials 2010, 31:1420-8"	The lipid-modified polyethylenimine (PEI) is a promising carrier for siRNA delivery and downregulation of STAT3 by polymer-mediated siRNA delivery is an effective strategy for melanoma treatment 1295	Melanoma	dGM3	de-N-acetyl GM3 (ganglioside)		expressed			sensitivity to	P4	PPPP (ganglioside synthesis inhibitor)	3	1		"Liu JW, Cancer Res 2009, 69:8662-9"	Depletion of ganglioside d-GM3 by P4 treatment dramatically reduced cell invasion of aggressive metastatic C8161 melanoma cells 1298	Melanoma	Frizzled-5	Fzd5	protein	expressed			sensitivity to	Box5 (Wnt5a hexapeptide)		3	1		"Jenei V, Proc Natl Acad Sci USA 2009, 106:19473-8"	"In two melanoma cell lines (A2058 and HTB63) expressing Frizzled-5, which has been implicated as the receptor for Wnt5a in melanoma cells, inhibition of Wnt pathway with Wnt5a-derived peptide inhibited melanoma cell invasiveness"1300	Immune cells	TNFRSF9	4-1BB		uncharacterized			sensitivity to	TNFSF9 gene therapy	4-1BBL	2	1		"Hui Q, Cancer Biother Radiopharm 2009, 24:597-605"	"Treatment of tumor-bearing mice with 4-1BBL plasmid DNA significantly suppressed the growth and metastasis of melanoma without significant toxicity, compared with mice treated with control-plasmid DNA"1301	Endothelial cells	Uncharacterized			uncharacterized			sensitivity to	Isthmin gene therapy		2	1		"Xiang W, J Cell Mol Med 2009, Epub ahead of print"	Overexpression of isthmin significantly suppressed mouse B16 melanoma tumor growth through inhibition of tumor angiogenesis without affecting tumor cell proliferation1303	Melanoma	AKT2		mRNA	expressed			sensitivity to	AKT2 siRNA		2	1		"Shin SS, Pigment Cell Melanoma Res 2010, 23:103-11"	Metabotropic glutamate receptor 1 (Grm1) acts as an oncogene in vitro and in vivo. A reduction in tumor volume of Grm1-mouse-melanocytic-allografts was detected in the presence of small interfering AKT2 RNA (siAKT2). 1304	Melanoma	Tyrosinase			uncharacterized			sensitivity to	NPrCAP + magnetite nanoparticles		2	1		"Takada T, J Biomed Biotechnol 2009, 2009:457936"	"Melanogenesis substrate, N-propionyl-cysteaminylphenol (NPrCAP, an amine analog of tyrosine), is selectively incorporated into melanoma cells and inhibits their growth by producing cytotoxic free radicals. Magnetite nanoparticles also disintegrate cancer cells and generate heat shock protein (HSP) upon exposure to an alternating magnetic field (AMF). "1305	Melanoma	EGEVGLG peptide		protein	bound to tumor vessels			resistance to	Sunitinib	Sutent (R)	2	-1		"Passarella RJ, Clin Cancer Res 2009, 15:6421-9"	"Using phage display technology, investigators found that this peptide binds ex vivo to the vasculature of tumors responding to sunitinib (small molecule inhibitor of tyrosine kinase receptors VEGFR, PDGFR and c-KIT) such as breast cancer but not to tumors resistant to sunitinib (such as B16 melanoma)"1307	Melanoma	Proliferation pathway			uncharacterized			sensitivity to	4d	"1,2,4 triazole derivative"	3	1		"Bhat KS, Eur J Med Chem 2009, 44:5066-70"	"4d is a 1,2,4-triazole derivative carrying 2,4-dichloro-5-fluorophenyl moiety. This drug shows anti-proliferative effects, but is MoA is unknown"1308	Melanoma	Differentiation pathway			uncharacterized			sensitivity to	Dendrogenin		3	1		"De Medina P, J Med Chem 2009, 52:7765-77"	"Dendrogenin A and B are new alkylaminooxysterols that induced growth control, differentiation, and the death of tumor cell lines representative of various cancers including metastatic melanoma and breast cancer"1309	Melanoma	Filamin A			downregulated			sensitivity to	Radiotherapy		3	1		"Yue J, Cancer Res 2009, 69:7978-85"	"Lack or reduction of filamin-A sensitizes cells to ionizing radiation, slows the removal of DNA damage-induced gammaH2AX nuclear foci, reduces RAD51 nuclear focus formation and recruitment to chromatin in response to irradiation, and results in a 2-fold reduction of homologous recombinational repair of double strand breaks (DSB)"1310	Melanoma	SNF5		mRNA	downregulated by	SNF5 siRNA		resistance to	Etoposide	VP-16	3	-1		"Lin H, Clin Cancer Res 2009, 15:6404-11"	"The tumor suppressor SNF5, the core subunit of SWI/SNF complex, has been shown to regulate cell differentiation, cell cycle control, and apoptosis. Knockdown of SNF5 in melanoma cell lines resulted in significant chemoresistance"1311	Melanoma	SNF5		mRNA	downregulated by	SNF5 siRNA		resistance to	Camptothecin		3	-1		"Lin H, Clin Cancer Res 2009, 15:6404-11"	"The tumor suppressor SNF5, the core subunit of SWI/SNF complex, has been shown to regulate cell differentiation, cell cycle control, and apoptosis. Knockdown of SNF5 in melanoma cell lines resulted in significant chemoresistance"1312	Melanoma	Integrin alpha V beta 3		protein	expressed			sensitivity to	Leberagin-C		3	1		"Limam I, Matrix Biol 2010, 29:117-26"	"Leberagin-C, A disintegrin-like/cysteine-rich protein from Macrovipera lebetina transmediterranea venom, inhibits alphavbeta3 integrin-mediated cell adhesion of melanoma cells to fibrinogen and laminin-1 (no effect was observed neither on type I collagen nor on vitronectin)"1313	Melanoma	Integrin alpha 4 beta 1		protein	expressed			sensitivity to	LDV-doxorubicin		3	1		"Zhong S, Pharm Res 2009, 26:2578-87"	Leucine-Aspartic Acid-Valine (LDV) sequence acts as a targeting ligand and drug carrier for doxorubicin delivery to melanoma cells overexpressing integrin alpha 4 beta 11314	Melanoma	SFPQ	PSF (mouse)		downregulated			sensitivity to	PSF gene therapy		2	1		"Wang G, Proc Natl Acad Sci USA 2009, 106:16794-8"	"This study shows that PSF protein (tumor suppressor gene that inhibits gene transcription) and PSF-binding RNA (VL30, non-coding RNA that inhibit PFS and thus activates gene transcription) have a central role in the reversible regulation of mammalian cell proliferation and tumorigenesis and that increasing PSF expression or decreasing PSF-binding RNA expression in tumor cells is a potential therapeutic strategy for cancer."1315	Melanoma	SFPQ	PSF (mouse)		expressed			sensitivity to	VL30 gene therapy		2	1		"Wang G, Proc Natl Acad Sci USA 2009, 106:16794-8"	This study shows that PSF protein and PSF-binding RNAs have a central role in the reversible regulation of mammalian cell proliferation and tumorigenesis and that increasing PSF expression or decreasing PSF-binding RNA expression in tumor cells is a potential therapeutic strategy for cancer.1316	Melanoma	Integrin alpha V beta 3		protein	expressed			no relationship with	LY294002	AKT inhibitor	3	0		"Tzukert K, Cancer Lett 2010, 290:174-81"	Expression of integrin alpha V beta 3 did not influence sensitivitiy of adherent melanoma cells to AKT small molecule inhibitor1317	Melanoma	KIT 	c-KIT	DNA	mut L576P (exon 11)			sensitivity to	Imatinib	Gleevec (R)	1	1		"Monsel G, Oncogene 2010, 29:227-36"	KIT inhibitor imatinib works against KIT mutant-transformed melanocytes but not against KIT wild type melanocytes1318	Melanoma	KIT 	c-KIT	DNA	mut K642E (exon 13)			sensitivity to	Imatinib	Gleevec (R)	1	1		"Monsel G, Oncogene 2010, 29:227-36"	KIT inhibitor imatinib works against KIT mutant-transformed melanocytes but not against KIT wild type melanocytes1319	Melanoma	KRAS	K-Ras	DNA	mut G12V			no relationship with	Imatinib	Gleevec (R)	1	0		"Monsel G, Oncogene 2010, 29:227-36"	KIT inhibitor imatinib works against KIT mutant-transformed melanocytes but not against KIT wild type or KRAS mutated melanocytes1320	Melanoma	IL-8	Interleukin-8	protein	expressed			no relationship with	IL-8 antibody (antagonist)		3	0		"Araki K, J Biol Chem 2009, 284:32305-11"	"The migratory ability of 1205Lu cells (highly metastatic melanoma) treated with phosphoglucose isomerase/autocrine motility factor (AMF) was unaffected by treatment with the anti-IL-8 neutralizing antibody. Of note, the same antibody did inhibit migration of SBcl-2 cells (early stage melanoma), indicating that IL-8 upregulation by AMF is essential for the induction of migratory ability in early stage melanoma cells but not in metastatic melanoma cells"1321	Immune cells	IL2R	Interleukin-2 receptor		uncharacterized			sensitivity to	IL-2/S4B6	IL-2 immunocomplex	2	1		"Tomala J, J Immunol 2009, 183:4904-12"	In vivo biological activity of IL-2 can be increased by association of IL-2 with anti-IL-2 mAb (S4B6). IL-2/S4B6 mAb immunocomplexes are highly stimulatory for NK and memory CD8(+) T cells and intermediately also for regulatory T cells1322	Melanoma	Topoisomerase I	TOP1		uncharacterized			sensitivity to	MONCPT		2	1		"Yang XC, Invest New Drugs 2010, 28:800-11"	"MONCPT, a topoisomerase I inhibitor, exhibited potent anti-proliferation and anti-angiogenesis activity in vitro and in vivo"1323	Melanoma	Uncharacterized			modulated by	Cyanine	Far-red absorbing disulfonate cyanine	sensitivity to	Photothermal therapy		2	1		"Camerin M, Photochem Photobiol Sci 2009, 8:1422-31"	"A water-soluble disulfonate cyanine was prepared by chemical synthesis and shown to possess photophysical properties which are particularly favourable for the promotion of photothermally sensitised processes. The cyanine exhibited a good selectivity of amelanotic melanoma targeting in C57BL/6 mice, bearing the tumour subcutaneously transplanted in the dorsal area"1324	Endothelial cells	VAP-1	Vascular adhesion protein 1	mRNA	expressed			sensitivity to	VAP-1 gene knockout		2	1		"Marttila-Ichihara F, Cancer Res 2009, 69:7875-83"	"B16 melanoma is smaller in VAP-1-deficient mice than in wild-type controls, tumor angiogenesis being defective in the absence of VAP-1. VAP-1 also selectively enhanced the recruitment of Gr-1+CD11b+ myeloid cells into the tumors"1325	Melanoma	Proliferation pathway			uncharacterized			sensitivity to	Lycorine		2	1		"Lamoral-Theys D, J Med Chem 2009, 52:6244-56"	"Lycorine displayed high potential (in vitro) therapeutic ratio, being at least 15 times more active against cancer than normal cells. Lycorine exerts its in vitro antitumor activity through cytostatic rather than cytotoxic effects. Furthermore, lycorine provided significant therapeutic benefit in mice bearing brain grafts of the B16F10 melanoma model at nontoxic doses"1327	Melanoma	PRL-3	Phosphatase of regenerating liver 3	protein	expressed			sensitivity to	Curcumin		2	1		"Wang L, Mol Pharmacol 2009, 76:1238-45"	"Curcumin (a component of the spice turmeric) acts as an inhibitor of PRL-3. Cells with PRL-3 stably knocked down show less sensitivity to curcumin treatment, which reveals that PRL-3 is the much further upstream target of curcumin"1330	Melanoma	HERG	KCNH2	protein	expressed			sensitivity to	E4301		3	1		"Afrasiabi E, Cell Signal 2010, 22:57-64"	HERG inhibition by E4301 reduces cell proliferation and migration. HERG is a potassium voltage-gated channel family1331	Melanoma	HERG	KCNH2	protein	expressed			sensitivity to	Cisapride		3	1		"Afrasiabi E, Cell Signal 2010, 22:57-64"	HERG inhibition by Cisapride reduces cell proliferation and migration. HERG is a potassium voltage-gated channel family1332	Melanoma	HLA-DR beta		protein	expressed			sensitivity to	31D7 mAb	HLA DR beta antibody	3	1		"Rasmussen N, J Proteome Res 2009, 8:5048-59"	"The monoclonal antibody (mAb) 31D7, which specifically recognized HLA-DR-beta, was capable of inhibiting the growth of MZ2 melanoma cells in vitro"1333	Melanoma	APP	Beta-amyloid precursor protein	mRNA	expressed			sensitivity to	APP siRNA	Beta-amyloid precursor protein siRNA	3	1		"Botelho MG, J Invest Dermatol 2010, 130:1400-10"	"Blocking the expression of APP by RNA interference impairs the proliferation of metastatic melanoma cells and leads to their terminal and irreversible differentiation. In addition, suppressing APP expression in a metastatic melanoma cell line renders the cells susceptible to several chemotherapeutic agents"1334	Melanoma	APP	Beta-amyloid precursor protein	mRNA	downregulated by	APP siRNA		sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Botelho MG, J Invest Dermatol 2010, 130:1400-10"	"Blocking the expression of APP by RNA interference impairs the proliferation of metastatic melanoma cells and leads to their terminal and irreversible differentiation. In addition, suppressing APP expression in a metastatic melanoma cell line renders the cells susceptible to several chemotherapeutic agents"1335	Melanoma	APP	Beta-amyloid precursor protein	mRNA	downregulated by	APP siRNA		sensitivity to	Paclitaxel	Taxol	3	1		"Botelho MG, J Invest Dermatol 2010, 130:1400-10"	"Blocking the expression of APP by RNA interference impairs the proliferation of metastatic melanoma cells and leads to their terminal and irreversible differentiation. In addition, suppressing APP expression in a metastatic melanoma cell line renders the cells susceptible to several chemotherapeutic agents"1336	Melanoma	APP	Beta-amyloid precursor protein	mRNA	downregulated by	APP siRNA		sensitivity to	Temozolomide	TMZ	3	1		"Botelho MG, J Invest Dermatol 2010, 130:1400-10"	"Blocking the expression of APP by RNA interference impairs the proliferation of metastatic melanoma cells and leads to their terminal and irreversible differentiation. In addition, suppressing APP expression in a metastatic melanoma cell line renders the cells susceptible to several chemotherapeutic agents"1337	Melanoma	STAT3	Signal transducer and activator of transcription 3 	protein	phosphorylated (activated)			sensitivity to	TPA	Tetradecanoyl phorbol acetate	3	1		"Oka M, J Biol Chem 2009, 284:30416-23"	"The in vitro growth and DNA synthesis of five melanoma cell lines, whose STAT3 was activated (phosphorylated), was inhibited by TPA, whereas that of WM35 and WM39 cells, whose STAT3 activity was at negligible levels, was considerably slow and not affected by TPA"1338	Peripheral blood	MGMT	O-6-methylguanine-DNA methyltransferase 	mRNA	expressed			no relationship with	Dacarbazine	DTIC	5	0	51	"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9"	"mRNA expression of MGMT, MLH1 and MSH2 in the peripheral blood did not correlate with treatment efficacy"1339	Peripheral blood	MGMT	O-6-methylguanine-DNA methyltransferase 	mRNA	expressed			no relationship with	Temozolomide	TMZ	5	0	51	"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9"	"mRNA expression of MGMT, MLH1 and MSH2 in the peripheral blood did not correlate with treatment efficacy"1340	Peripheral blood	MLH1		mRNA	expressed			no relationship with	Dacarbazine	DTIC	5	0	51	"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9"	"mRNA expression of MGMT, MLH1 and MSH2 in the peripheral blood did not correlate with treatment efficacy"1341	Peripheral blood	MLH1		mRNA	expressed			no relationship with	Temozolomide	TMZ	5	0	51	"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9"	"mRNA expression of MGMT, MLH1 and MSH2 in the peripheral blood did not correlate with treatment efficacy"1342	Peripheral blood	MLH2		mRNA	expressed			no relationship with	Dacarbazine	DTIC	5	0	51	"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9"	"mRNA expression of MGMT, MLH1 and MSH2 in the peripheral blood did not correlate with treatment efficacy"1343	Peripheral blood	MLH2		mRNA	expressed			no relationship with	Temozolomide	TMZ	5	0	51	"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9"	"mRNA expression of MGMT, MLH1 and MSH2 in the peripheral blood did not correlate with treatment efficacy"1344	Host	MSH2		DNA	polymorphism rs2303428			sensitivity to	Dacarbazine	DTIC	5	1	51	"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9"	The genetic variant rs2303428 (MSH2) might serve as a predictive marker for chemotherapy response (test for trend P-value = 0.04)1345	Host	MSH2		DNA	polymorphism rs2303428			sensitivity to	Temozolomide	TMZ	5	1	51	"Boeckmann L, Pharmacogenet Genomics 2009, 19:760-9"	The genetic variant rs2303428 (MSH2) might serve as a predictive marker for chemotherapy response (test for trend P-value = 0.04)1348	Melanoma	Integrin alpha 2		protein	expressed			sensitivity to	Integrin alpha 2 antibody (antagonist)		2	1		"Yoshimura K, Cancer Res 2009, 69:7320-8"	"Blockade of integrin alpha 2 with an antibody decreases liver metastasis in this mouse model. WARNING: the same treatment increased peritoneal metastasis, which could nullify the therapeutic efficacy of this therapeutic approach"1349	Melanoma	MCSP	CSPG4	mRNA	expressed			sensitivity to	MCSP siRNA		3	1		"Yang J, Cancer Res 2009, 69:7538-47"	"Several cell lines expressing endogenous MCSP were treated with siRNA to inhibit the expression of the MCSP core protein. These included WM1341D, WM164 (vertical growth phase) and 1205Lu and A375SM (metastatic) cell lines. Inhibiting MCSP expression in all of these cell lines reduced the activation of Erk-1,2 and anchorage independent growth of these cells, with the exception of MeWo cells, which express low-to-undetectable levels of endogenous MCSP "1350	Melanoma	MET	c-Met	mRNA	expressed			sensitivity to	MET siRNA		3	1		"Yang J, Cancer Res 2009, 69:7538-47"	RNA interference of c-Met expression significantly inhibited motility and anchorage independent growth in the WM1552C/MCSP cells1351	Melanoma	MET	c-Met	protein	expressed			sensitivity to	SU11274	MET inhibitor	3	1		"Yang J, Cancer Res 2009, 69:7538-47"	Enhanced motility produced by increased MCSP/c-Met could be inhibited by using the c-Met inhibitor SU11274 1352	Melanoma	MEK1		protein	expressed			sensitivity to	U0126	MEK inhibitor	3	1		"Yang J, Cancer Res 2009, 69:7538-47"	The addition of Mek-1 inhibitor U0126 decreased anchorage independent growth of WM1552C/MCSP cells 1352	Uncharacterized	FLAP			uncharacterized			sensitivity to	MK886		2	1		"Bachi AL, Mol Cancer Res 2009, 7:1417-24"	"MK886, a FLAP (5-LOX-activating protein) inhibitor, partially hindered tumor growth induced by apoptotic cells or LPS. The hypothesis is that leukotriene B4 (produced by 5-LOX) creates a favorable microenvironment for murine melanoma growth"1353	Uncharacterized	LTB4R	Leukotriene B4 receptor		uncharacterized			sensitivity to	Leukotriene B4	LTB4	2	1		"Bachi AL, Mol Cancer Res 2009, 7:1417-24"	"Addition to the tumor inflammatory microenvironment of leukotriene B5, an eicosapentaenoic acid-derived leukotriene, significantly inhibited tumor development"1354	Melanoma	BRAF	B-Raf	DNA	mut V600E			no relationship with	CRAF siRNA		3	0		"Jilaveanu L, Clin Cancer Res 2009, 15:5704-13"	"C-Raf siRNA knockdown results in decreased viability of YULAC (B-Raf(V600K)) and YUROB (B-Raf(WT)) melanoma cells, likely mediated by Bcl-2 inhibition rather than mitogen-activated protein kinase inhibition"1355	Endothelial cells	Cadherin VE			uncharacterized			sensitivity to	Genistein		4	1		"Cong R, J Exp Clin Cancer Res 2009, 28:124"	Uveal melanoma model. Genistein inhibits vasculogenic mimicry (VM) formation of uveal melanoma cells in vivo and in vitro. One possible underlying molecular mechanism by which Genistein could inhibit VM formation of uveal melanoma is related to down-regulation of VE-cadherin1356	Melanoma	PAR-1	Protease activated receptor 1 (thombin receptor)	mRNA	expressed			sensitivity to	PAR1 siRNA		3	1		"Blackburn JS, Cancer Res 2007, 67:10849-58"	"Compared to shMAMMX control, both cells with MMP-1 and PAR-1 knockeddown had reduced invasive ability (p<0.001) through reconstituted basement membrane (Matrigel)"1357	Melanoma	Tensin-3		mRNA	expressed			sensitivity to	Tensin-3 siRNA		3	1		"Qian X, Cancer Cell 2009, 16:246-58"	"Investigators tested three metastatic melanoma cell lines (mel 553B, mel 1088 and mel 568) in soft agar and cell migration assays for their dependence on tensin-3: as with the NSCLC lines, siRNA-mediated reduction of tensin-3 in the melanoma lines strongly inhibited their growth in agar and cell migration"1358	Melanoma	COX-2	Cyclooxygenase 2		uncharacterized			no relationship with	Lenalidomide		6	0	294	"Glaspy J, Cancer 2009, 115:5228-36"	"Phase II-III RCT comparing 5 mg vs 25 mg lenalidomide, a thalidomide analogue with anti-inflammatory, immunomodulatory and anti-angiogenic properties (although the exact mechanism of action is unknown). The higher dose of lenalidomide did not improve response rate, time to progression, or survival of patients with relapsed/refractory stage IV melanoma"1362	Melanoma	IL15R	IL-15 receptor		uncharacterized			sensitivity to	RLI (IL15-IL15R fusion protein)		2	1		"Bessard A, Mol Cancer Ther 2009, 8:2736-45"	The fusion protein RLI revealed strong anticancer effect in this cancer model overcoming the limited effect of IL-15 by increasing its bioavailability and efficiency1363	Melanoma	Tubulin			uncharacterized			sensitivity to	Compund-37 	"2-(3-benzo[b]thienyl)-6,7-methylenedioxyquinolin-4-one analogue"	3	1		"Chang YH, J Med Chem 2009, 52:4883-91"	"Compound 37 was cytotoxic against HL-60 (leukemia), HCT-116 (colon cancer), Hep 3B (hepatoma), and SK-MEL-5 (melanoma) cells. Results from mechanism of action studies revealed that these new quinolone derivatives function as antitubulin agents"1364	Melanoma	MEK	"MEK1, MEK2"	protein	expressed			sensitivity to	RDEA119	BAY 869766	4	1		"Iverson C, Cancer Res 2009, 69:6839-47"	RDEA119 is an allosteric MEK inhibitor. Melanoma cells (A375) were BRAF V600E mutated. Increasing levels of drug exposure correlated with increased inhibition of phosphorylated ERK (the MEK target). No formal MEK expression/chemosensitivity correlation was performed1365	Melanoma	PAR-1	Protease activated receptor 1 (thombin receptor)	mRNA	expressed			sensitivity to	PAR1 siRNA		3	1		"Melnikova VO, J Biol Chem 2009, 284:28845-55"	"PAR1, PAFR, or MUC18 silencing inhibits the attachment of melanoma cells to human dermal microvascular endothelial cells and the transendothelial migration of tumor cells"1366	Melanoma	PAFR		mRNA	expressed			sensitivity to	PAFR siRNA		3	1		"Melnikova VO, J Biol Chem 2009, 284:28845-55"	"PAR1, PAFR, or MUC18 silencing inhibits the attachment of melanoma cells to human dermal microvascular endothelial cells and the transendothelial migration of tumor cells"1367	Melanoma	MUC18		mRNA	expressed			sensitivity to	MUC18 siRNA		3	1		"Melnikova VO, J Biol Chem 2009, 284:28845-55"	"PAR1, PAFR, or MUC18 silencing inhibits the attachment of melanoma cells to human dermal microvascular endothelial cells and the transendothelial migration of tumor cells"1368	Melanoma	HMW-MAA	"gp240, CSPG4, NG2, High molecular weight melanoma associated antigen"	protein	expressed			sensitivity to	scFvMEL/rGel immunotoxin	NG2 antibody + gelonin	4	1		"Selbo PK, PLoS One 2009, 4:e6691"	The recombinant single-chain fusion construct scFvMEL/rGel is composed of an antibody targeting the progenitor marker HMW-MAA/NG2/MGP/gp240 and the highly effective toxin gelonin (rGel). Immunotoxin delivery was enhanced by photochemical internalization (PCI)1369	Melanoma	CXCL8		protein	expressed			sensitivity to	CXCL8 antibody (antagonist)		3	1		"Gabellini C, Eur J Cancer 2009, 45:2618-27"	"CXCL8 is the ligand of CXCR1 and CXCR2: CXCL8 induces cell proliferation and angiogenesis through both receptors. The cell proliferation of both M20 and A375SM lines, expressing similar levels of both CXCR1 and CXCR2 but secreting low and high amounts of CXCL8, respectively, was significantly enhanced by CXCL8 exposure and reduced by CXCL8, CXCR1 and CXCR2 neutralising antibodies, indicating the autocrine/paracrine role of CXCL8 in melanoma cell proliferation "1370	Melanoma	VASH1	Vasohibin		downregulated			sensitivity to	VASH1 gene therapy		2	1		"Kern J, BMC Cancer 2009, 9:284"	Murine VASH1-overexpressing B16F10 melanomas displayed a reduction in large vessels and vascular area.1371	Melanoma	DEK		mRNA	expressed			sensitivity to	DEK siRNA		3	1		"Khodadoust MS, Cancer Res 2009, 69:6405-13"	DEK (which is often upregulated in melanoma) transactivates Mcl-1. Its downregulation inhibits melanoma cell proliferation1372	Melanoma	KIT 	c-KIT	DNA	mut L576P (exon 11)			resistance to	Nilotinib		3	-1		"Woodman SE, Mol Cancer Ther 2009, 8:2079-85"	"In vitro testing showed that the cell viability of the L576P mutant cell line was not reduced by imatinib, nilotinib, or sorafenib small molecule KIT inhibitors"1373	Melanoma	KIT 	c-KIT	DNA	mut L576P (exon 11)			resistance to	Sorafenib	Nexavar (R)	3	-1		"Woodman SE, Mol Cancer Ther 2009, 8:2079-85"	"In vitro testing showed that the cell viability of the L576P mutant cell line was not reduced by imatinib, nilotinib, or sorafenib small molecule KIT inhibitors"1379	Melanoma	HDAC	Histone deacetylase		uncharacterized			no relationship with	MS-275	HDAC inhibitor	6	0	28	"Hauschild A, Melanoma Res 2008, 18:274-8"	Phase II RCT. Setting: advanced melanoma. No therapeutic effect observed1381	Immune cells	Immunity pathway			uncharacterized			no relationship with	Vaccine (allogeneic)		6	0	689	"Sondak VK, J Clin Oncol 2002, 8:2058-66"	"Phase III RCT. Setting: adjuvant. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine did not improve patients' survival"1382	Immune cells	Immunity pathway			uncharacterized			no relationship with	Vaccine (allogeneic polyvalent)		6	0	1600	"Morton DL, Ann Surg Oncol 2006, 13:5 (Abstract 12). "	Phase III RCT. Setting: adjuvant. Post-surgical vaccination does not impact on survival1383	Immune cells	Immunity pathway			uncharacterized			no relationship with	Vaccine (allogeneic polyvalent)		6	0	106	"Mitchell MS, Proc Am Soc Clin Oncol 1997, 16:494a (Abstract 1778)"	Phase III RCT. Setting: metastatic. Melacine melanoma vaccine (median survival: 9 months) was not better than combination chemotherapy (median survival: 12 months) in the treatment of stage IV melanoma1384	Immune cells	CTLA4			uncharacterized			sensitivity to	Ipilimumab	CTLA4 antibody (antagonist)	6	1	676	"Hodi FS, N Engl J Med 2010, 363:711-23"	"Phase III RCT. Setting: metastatic, all patients were HLA-A0201 positive. Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma"1385	Melanoma	BRAF	B-Raf	DNA	mut V600E			sensitivity to	PLX4032	RG7204	5	1	81	"Flaherty KT, N Engl J Med 2010, 363:809-19"	Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients1386	Melanoma	HMW-MAA	"gp240, CSPG4, NG2, High molecular weight melanoma associated antigen"	protein	expressed			sensitivity to	GrB/scFvMEL		3	1		"Liu Y, Mol Cancer Ther 2003, 2:1341-50"	GrB/scFvMEL: a fusion protein composed of human granzyme B (GrB) and the single-chain antibody scFvMEL (which targets gp240)1387	Melanoma	TLR2	Toll like receptor 2	mRNA	expressed			sensitivity to	TLR2 siRNA		1	1		"Yang HZ, PLoS One 2009, 4:e6520"	"TLR2 knockdown (KD), but not TLR4 KD, significantly inhibited the invasive activity of B16 cells by about 35% compared with the vector control "1388	Melanoma	TLR2	Toll like receptor 2	mRNA	expressed			sensitivity to	TLR2 siRNA		2	1		"Yang HZ, PLoS One 2009, 4:e6520"	"TLR2-silenced B16 markedly decreased the pulmonary metastatic nodes by 5 fold and subsequently greatly reduced animal death (by contrast, TLR4-silenced B16 aggravated the pulmonary metastasis and animal death)"1389	Melanoma	TLR2	Toll like receptor 2	protein	expressed			sensitivity to	TLR2 antibody (antagonist)		2	1		"Yang HZ, PLoS One 2009, 4:e6520"	Blocking TLR2 attenuated the pulmonary metastases of B16 cells and animal death1391	Melanoma	HLA-G5		protein	expressed			resistance to	NK cell lysis (immunotherapy)		3	-1		"Lesport E, Hum Immunol 2009, 70:1000-5"	Human melanoma cells secreting human leukocyte antigen-G5 inhibit natural killer (NK) cell cytotoxicity by impairing lytic granules polarization toward target cell1392	Melanoma	AURK	Aurora kinase	protein	expressed			sensitivity to	SNS-314	Pan aurora kinase inhibitor	4	1		"Arbitrario JP, Cancer Chemother Pharmacol 2010, 65:707-17"	"SNS-314, a pan-Aurora kinase inhibitor, shows potent therapeutic activity in vivo against a variety of cancer types including melanoma"1393	Melanoma	AURK	Aurora kinase	protein	expressed			sensitivity to	SNS-314	Pan aurora kinase inhibitor	3	1		"Arbitrario JP, Cancer Chemother Pharmacol 2010, 65:707-17"	"SNS-314, a pan-Aurora kinase inhibitor, shows potent therapeutic activity in vitro against a variety of cancer types including melanoma"1394	Melanoma	KCNN3	SK3	mRNA	expressed			sensitivity to	KCNN3 siRNA		3	1		"Chantome A, Exp Cell Res 2009, 315:3620-30"	"Knockdown of the KCa2.3 channel led to plasma membrane depolarization, decreased 2D and 3D cell motility"1395	Melanoma	Uncharacterized			uncharacterized			sensitivity to	Gef gene therapy		2	1		"Prados J, Exp Dermatol 2010, 19:363-71"	"The gef gene, a suicide gene from Escherichia coli that probably acts at the cytoplasmic membrane level, had a significant cytotoxic impact on melanoma both in vitro and in vivo"1396	Melanoma	HDAC	Histone deacetylase	protein	expressed			sensitivity to	CG0006	HDAC inhibitor	3	1		"Hwang JJ, Anticancer Drugs 2009, 20:815-21"	"Micromolar levels of CG0006 (a HDAC inhibitor) induced cell death in several breast, central nervous system, colon, hematopoietic, lung, melanoma, ovarian, prostatic, renal, and stomach cancer cell lines"1397	"Melanoma, endothelial cells"	Uncharacterized			uncharacterized			sensitivity to	Sanguinarine		4	1		"De Stefano I, Biochem Pharmacol 2009, 78:1374-81"	This study shows the antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma1398	Melanoma	REV3L	Catalytic subunit of DNA polymerase zeta 	mRNA	downregulated by	REV3L knockout		sensitivity to	Temozolomide	TMZ	1	1		"Roos WP, Mol Pharmacol 2009, 76:927-34"	"These data show that Rev3L contributes to temozolomide and fotemustine resistance, thus acting in concert with O6-methylguanine-DNA methyltransferase, BER, mismatch repair, and double-strand break repair in defense against simple alkylating anticancer drugs"1399	Melanoma	REV3L	Catalytic subunit of DNA polymerase zeta 	mRNA	downregulated by	REV3L knockout		sensitivity to	Fotemustine		1	1		"Roos WP, Mol Pharmacol 2009, 76:927-34"	"These data show that Rev3L contributes to temozolomide and fotemustine resistance, thus acting in concert with O6-methylguanine-DNA methyltransferase, BER, mismatch repair, and double-strand break repair in defense against simple alkylating anticancer drugs"1400	Melanoma	Uncharacterized			uncharacterized			sensitivity to	Genistein		4	1		"Sun Q, Oncol Rep 2009, 22:563-7"	"Uveal melanoma. Genistein, an isoflavone isolated from soybean, shows anti-melanoma activity both in vitro and in vivo"1401	Melanoma	PKC	Protein kinase C	protein	expressed			sensitivity to	TPA	Tetradecanoyl phorbol acetate	3	1		"Mason SA, Invest New Drugs 2010, 28:575-86"	"Two diterpene esters, prototypic PKC-activating drug TPA and the novel PKC-activating drug PEP008, induce growth arrest with characteristics of senescence in solid tumor cell lines derived from a variety of tissue types including melanoma"1402	Melanoma	PKC	Protein kinase C	protein	expressed			sensitivity to	PEP008		3	1		"Mason SA, Invest New Drugs 2010, 28:575-86"	"Two diterpene esters, prototypic PKC-activating drug TPA and the novel PKC-activating drug PEP008, induce growth arrest with characteristics of senescence in solid tumor cell lines derived from a variety of tissue types including melanoma"1403	Melanoma	Cell cycle pathway			uncharacterized			sensitivity to	Hinokitiol		3	1		"Liu S, Cancer Lett 2009, 286:240-9"	"p27-Associated G1 arrest induced by hinokitiol in human malignant melanoma cells is mediated via down-regulation of pRb, Skp2 ubiquitin ligase, and impairment of Cdk2 function"1404	Melanoma	TIMP-2	Tissue inhibitor of MMP2		expressed			resistance to	TNF	Tumor necrosis factor	3	-1		"Sun J, J Mol Signal 2009, 4:4"	The apoptotic cells induced by TNF were less in TIMP-2 over-expression cells compared to those in the parental A2058 cells. TIMP-2 overexpression was able to protect cells from apoptosis likely by increasing NFkB activity1405	Melanoma	PSF-binding RNAs	VL30-1 analogue	non-coding RNA	expressed			sensitivity to	PSF-binding RNAs siRNA		4	1		"Li L, Proc Natl Acad Sci USA 2009, 106:12956-61"	"Protein PSF represses proto-oncogene transcription, and VL30-1 RNA, a mouse noncoding retroelement RNA, binds and releases PSF from a proto-oncogene, activating transcription. This study shows that human non-coding RNAs act just like VL30-1"1406	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	DNA	methylated			no relationship with	Fotemustine		5	0	34	"Voelter V et al, Int J Cancer 2008, 123:1215-8"	Uveal melanoma. These results do not support MGMT methylation status or protein expression as predictive markers for treatment outcome to intra-arterial chemotherapy with alkylating agents1408	Melanoma	Tyrosinase			expressed			sensitivity to	4-mercaptophenol derivative		1	1		"Ruzza P, J Med Chem 2009, 52:4973-6"	"4-[(4-hydroxyphenyl)sulfanyl]but-3-en-2-one is a compound designed as a potential bifunctional antimelanoma agent, bearing both a tyrosinase-activatable phenolic moiety and a GSH-reactive alpha,beta-unsaturated carbonyl group. Both the E (1) and Z (2) isomers of the synthesized compound proved to be very good substrates of mushroom tyrosinase, reacted quickly with GSH at physiological pH, and showed a significant cytotoxic activity against B16F1 murine melanoma cells"1409	Melanoma	EGFR	ERBB1		downregulated			no relationship with	Gefitinib	ZD1839 (Iressa (R))	2	0		"Iivanainen E, Microvasc Res 2009, 78:278-85"	"To characterize tumor cell-independent stromal effects of EGFR targeting, mice were injected with B16 melanoma cells not expressing significant quantities of EGFR. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels"1409	Melanoma	AQP1		mRNA	expressed			sensitivity to	AQP1 siRNA		3	1		"Monzani E, PLoS One 2009, 4:e6167"	"Using targeted silencing of AQP1 gene expression, an impairment in the organization of F-actin and a reduced migration capacity was demonstrated in human endothelial and melanoma cell lines"1409	Melanoma	NFkB	Nuclear factor kappa B	protein	expressed			sensitivity to	Dimethylfumarate	DMF	2	1		"Yamazoe Y, Cell Biol Int 2009, 33:1087-94"	"DMF inhibited B16BL6 cell invasion and metastasis by suppressing the expression and activities of MMPs. DMF also inhibited the nuclear entry of NF-kappaB/p65, thus inhibiting B16BL6 cell invasion and metastasis"1410	Melanoma	Uncharacterized			uncharacterized			sensitivity to	Gallium complex KP46 		3	1		"Valiahdi SM, Melanoma Res 2009, 19:283-93"	The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines1411	Melanoma	HDAC	Histone deacetylase		uncharacterized			sensitivity to	Apicidin		3	1		"Noh JH, Int J Mol Med 2009, 24:205-26"	Apicidin is a histone deacetylase inhibitor1413	Microenvironment (fibroblasts)	IL-1 beta	Interleukin-1 beta	mRNA	expressed			sensitivity to	IL-1 beta siRNA		3	1		"Li L, Int J Cancer 2009, 125:1796-804"	"A role for fibroblast-secreted IL-1B in the invasion of melanoma was demonstrated in vitro, where siRNA silencing of IL-1B in melanoma-stimulated fibroblasts resulted in a diminution of melanoma invasion"1414	Melanoma	SRC	c-Src	mRNA	expressed			sensitivity to	SRC siRNA		3	1		"Maat W, Br J Cancer 2009, 101:312-9"	Uveal melanoma. SRC levels are higher in primary UM and lower in metastatic UM: SRC inhibition (by PP1 or siRNA) is effective in primary but not metastatic UM cell lines1416	Melanoma	Protein synthesis pathway			uncharacterized			sensitivity to	Saporin gene therapy		2	1		"Zavorni N, Methods Mol Biol 2009, 542:261-83"	"Saporin (from common soapwort, Saponaria officinalis) is one of the new genes useful in suicide gene therapy as they encode toxins such as plant ribosome-inactivating proteins (RIPs), which can irreversibly block protein synthesis, triggering apoptotic cell death"1417	Host	IL-17	Interleukin-17	mRNA	expressed			sensitivity to	IL-17 knockout		2	1		"Wang L, J Exp Med 2009, 206:1457-64"	"IL-17 has been shown to be elevated in several types of cancer, but how it might contribute to tumor growth is still unclear: this work shows that growth of B16 melanoma (and MB49 bladder carcinoma) is reduced in IL-17(-/-) mice"1418	Melanoma	HMG CoA reductase	HMGCR		uncharacterized			sensitivity to	Simvastatin	HGMCR inhibitor	3	1		"Minichsdorfer C, Br J Pharmacol 2009, 157:1278-90"	"Simvastatin and atorvastatin are capable of triggering an 'autocrine' suicide factor, which amplifies apoptosis via the extrinsic pathway in human melanoma cells. This pro-apoptotic stimulus implies possible therapeutic potential"1419	Melanoma	HMG CoA reductase	HMGCR		uncharacterized			sensitivity to	Atorvastatin	HGMCR inhibitor	3	1		"Minichsdorfer C, Br J Pharmacol 2009, 157:1278-90"	"Simvastatin and atorvastatin are capable of triggering an 'autocrine' suicide factor, which amplifies apoptosis via the extrinsic pathway in human melanoma cells. This pro-apoptotic stimulus implies possible therapeutic potential"1420	Melanoma	GLI1		mRNA	expressed			sensitivity to	GLI1 siRNA		4	1		"Das S, J Biol Chem 2009, 284:22888-97"	"Transcriptional silencing of GLI1 negatively impacts osteopontin (OPN) expression and compromises the ability of melanoma cells to proliferate, migrate, and invade in vitro and interferes with their ability to grow as xenografts and spontaneously metastasize in nude mice"1421	Melanoma	PLK1	Polo-like kinase 1	protein	expressed			sensitivity to	GW843682X	PLK1 inhibitor	3	1		"Schmit TL, J Invest Dermatol 2009, 129:2843-53"	Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells1422	Melanoma	PLK1	Polo-like kinase 1	mRNA	expressed			sensitivity to	PLK1 siRNA		3	1		"Schmit TL, J Invest Dermatol 2009, 129:2843-53"	Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells1423	Melanoma	GOLPH3		mRNA	expressed			sensitivity to	GOLPH3 siRNA		4	1		"Scott KL, Nature 2009, 459:1085-90"	GOLPH3 acts as an oncogene as it promotes tumorigenesis in a xenograft melanoma model. Its inhibition decreases anchorage-independent growth in vitro in melanoma cell lines overexpressing GOLPH3 (but not in those not expressing it)1424	Melanoma	GOLPH3		mRNA	expressed			sensitivity to	Rapamycin	Sirolimus	4	1		"Scott KL, Nature 2009, 459:1085-90"	"Using siRNA technology, these authors show that GOLPH3-expressing tumors are significantly more sensitive to rapamycin in vivo.Since GOLPH3 acts as an oncogene, they conclude that GOLPH3’s biochemical effect on mTOR signaling is a critical aspect of its oncogenic function, as inhibition by rapamycin effectively blocked the growth advantage conferred by GOLPH3 in vivo "1425	Melanoma	CXCR4		mRNA	expressed			sensitivity to	CXCR4 siRNA		4	1		"Li H, Invest Ophthalmol Vis Sci 2009, 50:5522-8"	Uveal melanoma. Blocking CXCR4 gene expression by transfection with CXCR4 siRNA inhibited both the chemotactic and the invasive properties of uveal melanoma cells exposed to factors produced by human livers. Uveal melanoma cells transfected with CXCR4 siRNA produced fewer liver metastases than untreated uveal melanoma cells or uveal melanoma cells transfected with control siRNA1426	Melanoma	MC1R	Melanocortin receptor 1	protein	expressed			sensitivity to	MSH-RGD conjugate		1	1		"Yang J, Bioconjug Chem 2009, 20:1634-42"	MSH targets melanoma cells and allows to deliver the cytotoxic RGD peptide1427	Melanoma	Notch1		protein	active (high activity)			sensitivity to	Notch1 inhibition		3	1		"Pinnix CC, Cancer Res 2009, 69:5312-20"	Activated Notch1 acts as an oncogene by transforming melanocytes in vitro; this new information launches a realm of possibilities for drug intervention in this deadly disease1428	Immune cells	p38 MAPK		protein	active (high activity)			resistance to	Immunotherapy (dendritic cell based)		2	-1		"Zhao F, Clin Cancer Res 2009, 15:4382-90"	Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in Ret transgenic mice spontaneously developing melanoma. These data suggest that new strategies of melanoma immunotherapy can include inhibitors of p38 MAPK activity in DCs.1429	Melanoma	Topoisomerase I	TOP1		uncharacterized			sensitivity to	Delimotecan		4	1		"Bigioni M, Int J Cancer 2009, 125:2456-64"	"Delimotecan (MEN 4901/T-0128) is a new cytotoxic prodrug constituted by a camptothecin analog (T-2513) bound to carboxymethyl dextran through a triglycine linker. Classically, camptothecins are TOP1 inhibitors"1430	Endothelial cells	Angiogenesis pathway			uncharacterized			sensitivity to	Ligustrazine		2	1		"Chen L, Biochem Biophys Res Commun 2009, 386:374-9"	"Ligustrazine, a purified and chemically identified component of a Chinese herbal remedy, inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by VEGF"1431	Melanoma	Tyrosinase		mRNA	expressed			sensitivity to	Acetaminophen	Paracetamol	1	1		"Vad NM, Int J Oncol 2009, 35:193-204"	"Using siRNA technology, investigators showed that acetaminophen selectively kills melanoma cells expressing tyrosinase"1432	Melanoma	Integrin alpha 3		protein	expressed			sensitivity to	Integrin alpha 3 antibody (antagonist)		3	1		"Saito N, Pigment Cell Melanoma Res 2009, 22:601-10"	"In an in vitro model, antibody blockage of integrin alpha 3 inhibits migratory ability of melanoma cells"1433	Melanoma	Integrin alpha 6		protein	expressed			sensitivity to	Integrin alpha 6 antibody (antagonist)		3	1		"Saito N, Pigment Cell Melanoma Res 2009, 22:601-10"	"In an in vitro model, antibody blockage of integrin alpha 6 inhibits migratory ability of melanoma cells"1434	Melanoma	CD151		mRNA	expressed			sensitivity to	CD151 siRNA		3	1		"Saito N, Pigment Cell Melanoma Res 2009, 22:601-10"	"In an in vitro model, siRNA mediated downregulation of CD151 inhibits migratory ability of melanoma cells"1435	Melanoma	RhoA		mRNA	expressed			sensitivity to	RhoA dominant negative		3	1		"Garcia MC, J Biol Chem 2009, 284:20936-45"	Inhibition of RhoA signaling with either C3 exoenzyme or dominant negative Rho blocked arachidonic acid-induced melanoma cell adhesion1436	Melanoma	ROCK		mRNA	expressed			sensitivity to	ROCK siRNA		3	1		"Garcia MC, J Biol Chem 2009, 284:20936-45"	Inhibition of the Rho kinase (ROCK) with either small molecule inhibitors or ROCK II-specific small interfering RNA (siRNA) blocked the fatty acid-induced adhesion of melanoma cells1437	Melanoma	Integrin alpha 1 beta 1		protein	expressed			sensitivity to	Viperistatin		3	1		"Staniszewska I, Cancer Biol Ther 2009, 8:1507-16"	Viperistatin and VP12 (isolated from vipera venenom) used separately and simultaneously inhibited pro-metastatic activities of melanoma cells lines. The level of inhibition of MV3 and HS.939T human cell lines in cell adhesion and migration assays by both compounds was correlated with expression of alpha1beta1 and alpha2beta1 integrins on the cell surface1438	Melanoma	Integrin alpha 2 beta 1		protein	expressed			sensitivity to	Viperistatin		3	1		"Staniszewska I, Cancer Biol Ther 2009, 8:1507-16"	Viperistatin and VP12 (isolated from vipera venenom) used separately and simultaneously inhibited pro-metastatic activities of melanoma cells lines. The level of inhibition of MV3 and HS.939T human cell lines in cell adhesion and migration assays by both compounds was correlated with expression of alpha1beta1 and alpha2beta1 integrins on the cell surface1439	Melanoma	Integrin alpha 1 beta 1		protein	expressed			sensitivity to	VP12		3	1		"Staniszewska I, Cancer Biol Ther 2009, 8:1507-16"	Viperistatin and VP12 (isolated from vipera venenom) used separately and simultaneously inhibited pro-metastatic activities of melanoma cells lines. The level of inhibition of MV3 and HS.939T human cell lines in cell adhesion and migration assays by both compounds was correlated with expression of alpha1beta1 and alpha2beta1 integrins on the cell surface1440	Melanoma	Integrin alpha 2 beta 1		protein	expressed			sensitivity to	VP12		3	1		"Staniszewska I, Cancer Biol Ther 2009, 8:1507-16"	Viperistatin and VP12 (isolated from vipera venenom) used separately and simultaneously inhibited pro-metastatic activities of melanoma cells lines. The level of inhibition of MV3 and HS.939T human cell lines in cell adhesion and migration assays by both compounds was correlated with expression of alpha1beta1 and alpha2beta1 integrins on the cell surface1441	Melanoma	Adhesion pathway			uncharacterized			sensitivity to	Lebectin		3	1		"Sarray S, Cancer Lett 2009, 285:174-81"	"Lebectin, a C-type lectin protein (CLP) issued from Macrovipera lebectina snake venom, inhibits integrin-mediated migration of IGR39 melanoma cells. Lebectin promotes N-cadherin/catenin complex reorganization at cell-cell contacts, inducing a strengthening of intercellular adhesion"1442	Melanoma	MC1R	Melanocortin receptor 1		uncharacterized			sensitivity to	MSH	Melanocyte stimulating hormone	2	1		"Kim A, Exp Cell Res 2009,  315:3325-35"	"Treatment with the cAMP-inducing compounds alpha-MSH (alpha-melanocyte stimulating hormone) and IBMX (3-isobutyl-1-methylxanthine) significantly suppressed the in vitro invasiveness and anchorage-independent growth in a semi-solid agar of melanoma cells. In animal experiments, the metastatic potential of the alpha-MSH- or IBMX-treated B16F10 melanoma cells was decreased compared to untreated control cells"1443	Host	PEDF	Pigment epithelium derived factor		downregulated			sensitivity to	PEDF gene therapy		2	1		"Yang LP, J Exp Clin Cancer Res 2009, 28:75"	"The recombinant PEDF adenovirus is able to transfer the PEDF gene to infected cells and successfully produce secretory PEDF protein, which exhibits potent inhibitory effects on HUVEC proliferation. Through inhibiting angiogenesis, Ad-PEDF treatment reduced tumor volume and prolonged survival times of mouse bearing B16-F10 melanoma"1445	Melanoma	NRAS	N-Ras	DNA	mut Q61L			sensitivity to	NRAS siRNA		3	1		"Jaiswal BS, PLoS One 2009, 4:e5717"	This work shows that IPC298 melanoma cell line is dependent on NRAS for proliferation and anchorage-independent growth in vitro1446	Melanoma	NRAS	N-Ras	DNA	mut Q61L			sensitivity to	NRAS siRNA		4	1		"Jaiswal BS, PLoS One 2009, 4:e5717"	This work shows that IPC298 melanoma cell line is dependent on NRAS for growth in vivo1447	Melanoma	NRAS	N-Ras	DNA	mut Q61L			no relationship with	BRAF siRNA		4	0		"Jaiswal BS, PLoS One 2009, 4:e5717"	"In vitro the BRAF-shRNA expressing IPC298 cells showed a 20% decrease in proliferation: however, in vivo, BRAF silencing did not show a statistically significant delay in IPC298 tumor growth"1448	Melanoma	NRAS	N-Ras	DNA	mut Q61L			no relationship with	CRAF siRNA		4	0		"Jaiswal BS, PLoS One 2009, 4:e5717"	"In vitro the CRAF-shRNA expressing IPC298 cells showed a 20% decrease in proliferation: however, in vivo, CRAF silencing did not show a statistically significant delay in IPC298 tumor growth"1449	Melanoma	NRAS	N-Ras	DNA	mut Q61L			sensitivity to	BRAF siRNA + CRAF siRNA		3	1		"Jaiswal BS, PLoS One 2009, 4:e5717"	"In vitro, the double BRAF and CRAF silencing obtained significant decrease in cell proliferation"1450	Melanoma	NRAS	N-Ras	DNA	mut Q61L			sensitivity to	BRAF siRNA + CRAF siRNA		4	1		"Jaiswal BS, PLoS One 2009, 4:e5717"	"In vivo, the double BRAF and CRAF silencing obtained significant decrease in tumor growth"1451	Melanoma	NRAS	N-Ras	DNA	mut Q61L			no relationship with	MEK siRNA		3	0		"Jaiswal BS, PLoS One 2009, 4:e5717"	"Silencing of MEK1, MEK2 or both did not affect proliferation of melanoma cells harboring this NRAS mutation"1452	Melanoma	NRAS	N-Ras	DNA	mut Q61L			no relationship with	PI3K siRNA		4	0		"Jaiswal BS, PLoS One 2009, 4:e5717"	"In vivo, the silencing of PI3K catalytic alpha polypeptide (PIK3CA) did not obtain significant decrease in tumor growth"1453	Melanoma	NRAS	N-Ras	DNA	mut Q61L			sensitivity to	PI3K siRNA + BRAF siRNA		4	1		"Jaiswal BS, PLoS One 2009, 4:e5717"	"In vivo, the double BRAF and PI3K (PIK3CA) silencing obtained significant decrease in tumor growth"1454	Melanoma	NRAS	N-Ras	DNA	mut Q61L			sensitivity to	PI3K siRNA + MEK siRNA		4	1		"Jaiswal BS, PLoS One 2009, 4:e5717"	"In vivo, the double BRAF and MEK silencing obtained significant decrease in tumor growth"1456	Host	OGR1	Ovarian cancer G protein coupled receptor 1		expressed			sensitivity to	OGR1 knockout		2	1		"Li H, PLoS One 2009, 4:e5705"	Melanoma tumorigenesis was significantly inhibited in OGR1 deficient mice1457	Endothelial cells	Angiogenesis pathway			uncharacterized			sensitivity to	Acidic mucopolysaccharide		2	1		"Zhang W, Cancer Biol Ther 2009, 8:1489-99"	"Acidic mucopolysaccharide from Holothuria Leucospilota has antimetastasic properties possibly via its anti-angiogenesis effect induced by downregulation of VEGF and suppression of invasive ability of cancer cells mediated by downregulation of MMP-2, -9 and their activities"1459	Melanoma	FGF-2	Fibroblast growth factor 2 (bFGF)	mRNA	expressed			sensitivity to	FGF-2 inhibition		4	1		"Fontijn D, Cell Oncol 2009, 31:179-90"	Overexpression of FGF-2 in melanoma cells shows that FGF-2 acts as an oncogene and thus is a potential therapeutic target1460	Endothelial cells	PRLR	Prolactin receptor		uncharacterized			sensitivity to	PRL 16K peptide		2	1		"Kinet V, Cancer Lett 2009, 284:222-8"	"Human 16K PRL (16K hPRL) is a potent inhibitor of angiogenesis both in vitro and in vivo. Using a gene transfer method based on cationic liposomes (inoculated s.c. into the peritumoral region) to produce 16K hPRL, these authors demonstrate that 16K hPRL inhibits tumor growth in a subcutaneous B16F10 mouse melanoma model "1461	Melanoma	CHST10	Carbohydrate sulfotransferase 10 		downregulated			sensitivity to	CHST10 activation		3	1		"Zhao X, Cancer Res 2009, 69:5218-25"	RARgamma upregulates CHST10 (a sulfotransferase that forms HNK-1 glycan on neural cell adhesion proteins) expression in a significant subset of human melanoma cells and three-dimensional cell culture migration assays suggest that CHST10 functions as a suppressor of invasiveness (but not proliferation) in these cells. Induction of CHST10 by RARgamma-activating retinoids may present a novel therapeutic strategy to inhibit tumor invasiveness in a subset of melanoma patients1462	Immune cells	SOCS1	Suppressor of cytokine signaling 1	mRNA	expressed			sensitivity to	SOCS1 knockout		2	1		"Hashimoto M, Cancer Sci 2009, 100:730-6"	Silencing of SOCS1 in macrophages suppresses tumor development by enhancing antitumor inflammation. These results suggest that inflammation induced by SOCS1-deficiency in monocytes potentiates antitumor immune responses rather than tumor-promoting inflammation1463	Melanoma	WT1	Wilms tumor protein 1	mRNA	expressed			sensitivity to	WT1 siRNA		2	1		"Zamora-Avila DE, Cancer Gene Ther 2009, 16:892-9"	The Wilms' tumor gene 1 (WT1) is a universal tumor antigen and consequently a good therapeutic target for the development of gene therapy strategies. WT1 gene silencing by aerosol delivery of polyethyleneimine (PEI)-RNAi complexes inhibits B16-F10 lung metastases growth1465	Melanoma	JNK		protein	expressed			sensitivity to	D-JNKI-1	JNK inhibitor	2	1		"Gao YJ, Exp Neurol 2009, 219:146-55"	"Repeated systemic injections of D-JNKI-1, a selective and cell-permeable peptide inhibitor of JNK, suppressed tumor growth in vivo and melanoma cell proliferation in vitro"1466	Immune cells	IL12R	IL-12 receptor		uncharacterized			sensitivity to	IL-12 gene therapy		2	1		"Komita H, Cancer Gene Ther 2009, 16:883-91"	Interleukin (IL)-12 gene therapy delivered intratumorally through ex vivo gene-engineered dendritic cell (DC) is competent to promote the regression of established murine tumors1467	Immune cells	TEM-8	Tumor endothelial marker 8	mRNA	expressed			resistance to	Vaccine (dendritic cells)		5	-1	13	"Venanzi FM, Cancer Immunol Immunother 2010, 59:27-34"	TEM8 expression levels in DC-based therapeutic vaccines would allow the selection of a subgroup of patients who are most likely to benefit from therapeutic vaccination1468	Melanoma	Melanin			expressed			sensitivity to	ICF01012 radiotherapy		4	1		"Bonnet-Duquennoy M, Int J Cancer 2009, 125:708-16"	"ICF01012 is a quinoxaline derivative molecule with specific and long-lasting uptake in melanoma and with rapid clearance from non-target organs, providing a suitable carrier for targeted radiotherapy"1469	Endothelial cells	"Vav-2, Vav-3"	Vav guanine nucleotide exchange factors	mRNA	expressed			sensitivity to	Vav-2 and Vav-3 knockout		2	1		"Brantley-Sieders DM, Mol Cancer Res 2009, 7:615-23"	"Host Vav2/3 deficiency reduced microvascular density, as well as tumor growth and/or survival, in transplanted B16 melanoma and Lewis lung carcinoma models in vivo. These defects were due in part to Vav2/3 deficiency in endothelial cells"1470	Melanoma	ROS	Reactive oxygen species		high			sensitivity to	ROS-inducible suicide gene therapy		4	1		"Policastro LL, Mol Ther 2009, 17:1355-64"	"Increased reactive oxygen species (ROS) production has been reported as a distinctive feature of different pathologies including cancer. Using a chimeric promoter, based on a ROS-response motif located in the VEGF gene promoter placed, in turn, downstream of a second ROS-response motif obtained from the early growth response 1 (Egr-1) gene promoter, these authors showed that transient expression of the thymidine kinase (TK) gene driven by the chimeric promoter, followed by gancyclovir (GCV) administration, inhibited human colorectal cancer and melanoma cell growth in vitro and in vivo"1471	Melanoma	ING4	Inhibitor of growth 4		downregulated			sensitivity to	ING4 gene therapy		3	1		"Cai L, Melanoma Res 2009, 19:1-7"	"Overexpression of ING4 could induce growth suppression and apoptosis enhancement in M14 cells, and also induce the upregulation of p27, Bax and Cyt-c, and the downregulation of cyclinD1, SKP2, Bcl-2, and caspase-3. In conclusion, ING4, as a novel tumor suppressor, has a potential role in growth suppression and apoptosis enhancement of melanoma M14 through the activation of the mitochondrial-induced apoptotic pathway and the hindrance of cell cycle progression"1472	Melanoma	HN1	Hematopoietic and neurologic expressed sequence 1 	mRNA	expressed			sensitivity to	HN1 siRNA		1	1		"Laughlin KM, Differentiation 2009, 78:35-44"	Hematopoietic- and neurologic-expressed sequence 1 (Hn1) depletion in B16.F10 melanoma cells promotes a differentiated phenotype that includes increased melanogenesis and cell cycle arrest1474	Melanoma	MET	c-Met	mRNA	expressed			sensitivity to	MET siRNA		2	1		"VanBrocklin MW, Pigment Cell Melanoma Res 2009, 22:454-60"	"Using a CDKN2A-deficient mouse melanocyte cell line, these authors showed that the MET gene, which encodes a receptor tyrosine kinase implicated in cancer progression, was amplified. RNA interference targeting Met in these tumor cells resulted in a significant delay in tumor growth in vivo compared with the control cells"1475	Plasma/serum	CCL17	TARC		expressed			sensitivity to	Vaccine (dendritic cells)		5	1	20	"Cornforth AN, J Clin Immunol 2009, 29:657-64"	"TARC/CCL17 levels were predictive of progression-free and overall survival, indicating that serum TARC/CCL17 might be of predictive value of response to dendritic cell-based anti-melanoma immunotherapy"1476	Melanoma	Proliferation pathway			uncharacterized			sensitivity to	Saquinavir-NO 		2	1		"Maksimovic-Ivanic D, Mol Cancer Ther 2009, 8:1169-78"	To reduce the toxicity of the HIV protease inhibitor saquinavir and use it for cancer chemotherapy the authors modified the original compound by covalently attaching a nitric oxide (NO) group. Saq-NO drastically reduced B16 melanoma growth in syngeneic C57BL/6 mice with no apparent signs of toxicity1477	Melanoma	AKT	PKB	protein	expressed			no relationship with	Saquinavir-NO 		2	0		"Maksimovic-Ivanic D, Mol Cancer Ther 2009, 8:1169-78"	"Although it has been well documented that Saq decreases tumor cell viability by inhibiting Akt, the anticancer properties of Saq-NO were completely independent of the phosphatidylinositol 3-kinase/Akt signaling pathway"1478	Melanoma	GRP78	Glucose regulated protein 78	protein	expressed			sensitivity to	GRP78 antibody (antagonist)		3	1		"Misra UK, Mol Cancer Ther 2009, 8:1350-62"	"Binding of activated alpha(2)-macroglobulin to GRP78 on the surface of human prostate cancer cells promotes proliferation by activating signaling cascades: antibodies directed against the GRP78 COOH-terminal domain inhibit cellular proliferation while promoting apoptosis in prostate cancer cell lines and A375 melanoma cells, which express GRP78 on their cell surface "1480	Melanoma	PDE1	Phosphodiesterase 1	mRNA	expressed			sensitivity to	Vinpocetin	PDE1 inhibitor	3	1		"Shimizu K, Anticancer Res 2009, 29:1119-22"	PDE1C mRNA is expressed in melanoma cells whose growth was inhibited by the PDE1 inhibitor vinpocetin1482	Melanoma	Mcl-1		mRNA	downregulated by	Mcl-1 siRNA		sensitivity to	ABT-738	Bcl-2 inhibitor	3	1		"Weber A, Transl Oncol 2009, 2:73-83"	ABT-737 on its own was ineffective in melanoma cells unless Mcl-1 was experimentally downregulated1483	Immune cells	"HLA class II, TCR"		protein	expressed			sensitivity to	Immunotherapy + docetaxel		2	1		"Sundstedt A, Int Immunopharmacol 2009, 9:1063-70"	Immunotherapy with tumor-targeted superantigens (TTS; superantigens bind to MHC class II and TCR causing polyclonal activation of T-cells) in combination with docetaxel results in synergistic anti-melanoma effects1484	Melanoma	CXCR1			expressed			sensitivity to	CXCR1 inhibition		4	1		"Singh S, Br J Cancer 2009, 100:1638-46"	"CXCR1- or CXCR2-overexpressing SBC-2 and A375P melanoma cells had enhanced proliferation, chemotaxis and invasiveness in vitro. Interestingly, CXCR1 or CXCR2 overexpression in SBC-2 cells induced tumourigenicity, and A375P cells significantly enhanced tumour growth as examined in vivo"1485	Melanoma	CXCR2			expressed			sensitivity to	CXCR2 inhibition		4	1		"Singh S, Br J Cancer 2009, 100:1638-46"	"CXCR1- or CXCR2-overexpressing SBC-2 and A375P melanoma cells had enhanced proliferation, chemotaxis and invasiveness in vitro. Interestingly, CXCR1 or CXCR2 overexpression in SBC-2 cells induced tumourigenicity, and A375P cells significantly enhanced tumour growth as examined in vivo"1486	Melanoma	Cell cycle pathway			uncharacterized			sensitivity to	AECHL-1		2	1		"Lavhale MS, PLoS One 2009, 4:e5365"	"A novel triterpenoid isolated from the root bark of Ailanthus excelsa Roxb (Tree of Heaven), AECHL-1 is a potential anticancer agent blocking melanoma cells in G1 phase and inducing melanoma regression in vivo"1487	Melanoma	"Cell cycle, apoptosis pathways"			uncharacterized			sensitivity to	Imatinib	Gleevec (R)	3	1		"Sims JT, Cancer Chemother Pharmacol 2009, 64:629-33"	"STI571 inhibited proliferation and increased apoptosis of melanoma cell line MDA-MB-435s, although it does not express any known target of this multikinase inhibitor (KIT, PDGFR, Abl)"1489	Melanoma	NQO1	NADPH quinone oxidoreductase	protein	expressed			resistance to	DCPIP		4	-1		"Cabello CM, Biochem Pharmacol 2009, 78:344-54"	"DCPIP (redox dye 2,6-dichlorophenolindophenol) apoptogenicity observed in the human melanoma cell lines A375 and G361 was inversely correlated with NAD(P)H:quinone oxidoreductase (NQO1) expression levels. NQO1 inhibition by siRNA restores sensitivity to DCPIP. Systemic administration of DCPIP displayed significant antimelanoma activity in the A375 murine xenograft model. These findings suggest feasibility of targeting tumors that display low NQO1 enzymatic activity using DCPIP"1491	Melanoma	Estrogen receptor	ESR1		uncharacterized			sensitivity to	Tamoxifen	Anti-estrogen	2	1		"Matsuoka H, Exp Cell Res 2009, 315:2022-32"	Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways1493	Melanoma	MEK			expressed			sensitivity to	PD98059	MEK inhibitor	2	1		"Basu S, Proc Natl Acad Sci USA 2009, 106:7957-61"	PD98059: selective MEK1-2 inhibitor. Administration of the PD98059-nanoparticles in melanoma-bearing mice inhibits tumor growth and enhances the antitumor efficacy of cisplatin chemotherapy1495	Melanoma	HDAC	Histone deacetylase		expressed			sensitivity to	Butyric acid	HDAC inhibitor	3	1		"Cunneen TS, Arch Ophthalmol 2009, 127:414-20"	"Sodium butyrate and trichostatin induced cell death in melanoma cells, comparable with mitomycin C, with minimal effect on Tenon capsule fibroblasts. These findings support the need for further investigation into the in vivo efficacy of these agents"1496	Melanoma	HDAC	Histone deacetylase		expressed			sensitivity to	Trichostatin A	HDAC inhibitor	3	1		"Cunneen TS, Arch Ophthalmol 2009, 127:414-20"	"Sodium butyrate and trichostatin induced cell death in melanoma cells, comparable with mitomycin C, with minimal effect on Tenon capsule fibroblasts. These findings support the need for further investigation into the in vivo efficacy of these agents"1497	Melanoma	NMI	N-Myc interactor		downregulated			sensitivity to	NMI gene therapy		4	1		"Fillmore RA, Int J Cancer 2009, 125:556-64"	"Constitutive expression of Nmi reduced the ability of tumor cells for the invasion, anchorage independent growth and tumor growth in vivo. Collectively, the data suggest that overexpression of Nmi inhibits the Wnt/beta-catenin signaling via up-regulation of Dkk1 and retards tumor growth"1500	Melanoma	Gab2		mRNA	expressed			sensitivity to	Gab2 siRNA		3	1		"Horst B, Am J Pathol 2009, 174:1524-33"	"Gab2 is an adaptor protein that potentiates the activation of the Ras-Erk and PI3K-Akt pathways: overexpression of Gab2 potentiates, whereas silencing of Gab2 reduces, migration and invasion of melanoma cells"1504	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	DNA	demethylated by	5-azacytidine	5-AZA	resistance to	Temozolomide	TMZ	3	-1		"Fontijn D, Mol Cancer Ther 2007, 6:2807-15"	MGMT causes resistance to TMZ1507	Immune cells	DNAM1	CD226	protein	inhibited by	DNAM1 antibody (antagonist)		resistance to	NK cell lysis (immunotherapy)		4	-1		"Lakshmikanth T, J Clin Invest 2009, 119:1251-63"	"DNAM-1 (as well as natural cytotoxicity receptors, NCR) mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo"1508	Melanoma	hTERT		protein	inhibited by	RHPS4		resistance to	Gemcitabine		3	-1		"Leonetti C, Clin Cancer Res 2008, 14:7284-91"	The formation of G-quadruplex structures at telomeric DNA sequences blocks telomerase activity: the pentacyclic acridinium salt RHPS4 is one of the most effective and selective G4 ligands able to rapidly disrupt telomere architecture1509	Melanoma	hTERT		protein	inhibited by	RHPS4		resistance to	Paclitaxel	Taxol	3	-1		"Leonetti C, Clin Cancer Res 2008, 14:7284-91"	The formation of G-quadruplex structures at telomeric DNA sequences blocks telomerase activity: the pentacyclic acridinium salt RHPS4 is one of the most effective and selective G4 ligands able to rapidly disrupt telomere architecture1510	"Melanoma, endothelial cells"	"BRAF, CRAF, VEGFR, PDGFR"		protein	inhibited by	Sorafenib	Nexavar (R)	resistance to	PI-103	PI3K/mTOR inhibitor	2	-1		"López-Fauqued M, Int J Cancer 2010, 126:1549-61"	"The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells"1511	Melanoma	"PI3K, mTOR"		protein	inhibited by	PI-103		resistance to	Sorafenib	Nexavar (R)	2	-1		"López-Fauqued M, Int J Cancer 2010, 126:1549-61"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells"1512	Melanoma	JNK		protein	inhibited by	SP600125	JNK inhibitor	resistance to	2-acetyl furanonaphthoquinone	FNQ	3	-1		"Rieber M, Cancer Biol Ther 2008, 7:1206-11"	Suppression of JNK activation with the specific inhibitor SP600125 prevented FNQ-mediated cell death1513	Melanoma	ROS	Reactive oxygen species		upregulated by	Imexon		resistance to	Methotrexate	MTX	3	-1		"Scott J, Cancer Chemother Pharmacol 2007, 59:749-57"	Antagonistic combinations with imexon included methotrexate1514	Melanoma	ROS	Reactive oxygen species		upregulated by	Imexon		resistance to	Irinotecan	CPT-11	3	-1		"Scott J, Cancer Chemother Pharmacol 2007, 59:749-57"	Antagonistic combinations with imexon included itrinotecan1515	Melanoma	ROS	Reactive oxygen species		upregulated by	Imexon		resistance to	Doxorubicin	Adriamycin (R)	3	-1		"Scott J, Cancer Chemother Pharmacol 2007, 59:749-57"	Antagonistic combinations with imexon included doxorubicin1516	Melanoma	ROS	Reactive oxygen species		upregulated by	Imexon		resistance to	Mitoxantrone		3	-1		"Scott J, Cancer Chemother Pharmacol 2007, 59:749-57"	Antagonistic combinations with imexon included mitoxantrone1517	Melanoma	ROS	Reactive oxygen species		upregulated by	Imexon		resistance to	Etoposide	VP-16	3	-1		"Scott J, Cancer Chemother Pharmacol 2007, 59:749-57"	Antagonistic combinations with imexon included etoposide1518	Melanoma	JNK		protein	inhibited by	SP600125	JNK inhibitor	resistance to	Paclitaxel	Taxol	3	-1		"Selimovic D, Cell Signal 2008, 20:311-22"	"Pretreatment of melanoma cells with the JNK inhibitor (SP600125) or the p38 inhibitor (SB203580) blocked taxol-induced UCP2 downregulation, ROS generation and apoptosis, whereas the ERK inhibitor (PD98059) had no such effect."1519	Melanoma	p38 MAPK		protein	inhibited by	SB203580		resistance to	Paclitaxel	Taxol	3	-1		"Selimovic D, Cell Signal 2008, 20:311-22"	"Pretreatment of melanoma cells with the JNK inhibitor (SP600125) or the p38 inhibitor (SB203580) blocked taxol-induced UCP2 downregulation, ROS generation and apoptosis, whereas the ERK inhibitor (PD98059) had no such effect."1521	Melanoma	Bcl-2		mRNA	downregulated by	Oblimersen	"Bcl-2 antisense oligo, G3139"	no relationship with	Dacarbazine	DTIC	6	0	771	"Bedikian AY, J Clin Oncol 2006, 24:4738-45"	Phase III RCT. Setting: advanced disease. No overall survival advantage; significant increase of progression free survival and tumor response rate1523	"Melanoma, endothelial cells"	"BRAF, CRAF, VEGFR, PDGFR"		protein	inhibited by	Sorafenib	Nexavar (R)	no relationship with	Paclitaxel + Carboplatin		6	0	270	"Hauschild A, J Clin Oncol 2009, 27:2823-30"	Phase III RCT. Advanced/metastatic melanoma (second line treatment). Sorafenib did not improve either response rate or survival1524	Melanoma	Polyamine oxidase		protein	inhibited by	MDL 72527		sensitivity to	Spermine		3	1		"Agostinelli E, Int J Oncol 2009, 35:485-98"	The MDL72527 lysosomotropic compound sensitizes multidrug resistant melanoma M14 ADR2 cells to the cytotoxicity of spermine oxidation products1525	Melanoma	MEK		protein	inhibited by	U0126		sensitivity to	"5,7-dimethoxycoumarin"		3	1		"Alesiani D, Int J Oncol 2009, 34:1727-35"	"MEK 1/2 inhibitor U0126 significantly potentiated growth inhibition of B16 cells triggered by 5,7-dimethoxycoumarin, suggesting that down-regulation of Raf/Mek/Erk pathway sensitizes melanoma cells to 5,7-dimethoxycoumarin treatment"1526	"Melanoma, endothelial cells"	"BRAF, CRAF, VEGFR, PDGFR"		protein	inhibited by	Sorafenib	Nexavar (R)	sensitivity to	Temozolomide	TMZ	5	1	167	"Amaravadi RK, Clin Cancer Res 2009, 15:7711-7718"	"4-arm phase II trial (metastatic melanoma); no control arm (all patients received sorafenib). The 6-month PFS rate (trial's primary aim) for arms A, B, C, and D were 50%, 40%, 11%, and 23%, respectively. The Authors conclude that the activity of this combination regimen warrants further investigation"1527	Melanoma	Proteasome		protein	inhibited by	Bortezomib	Velcade (R)	sensitivity to	Temozolomide	TMZ	4	1		"Amiri KI, Cancer Res 2004, 64:4912-8"	Bortezomib is a proteasome inhibitor that seems to act mainly through NFkB inhibition1528	Melanoma	Proteasome		protein	inhibited by	Bortezomib	Velcade (R)	sensitivity to	Camptothecin		2	1		"Amschler K, J Invest Dermatol 2010, 130:1073-86"	NFkB inhibition through proteasome inhibition increases the susceptibility of melanoma cells to cytostatic treatment 1529	Melanoma	IKKB	IKB kinase beta	protein	inhibited by	KINK-1		sensitivity to	Camptothecin		2	1		"Amschler K, J Invest Dermatol 2010, 130:1073-86"	"Same results described by the same group in a human model (Schon M, JNCI 2008, 100:862-75)"1530	Melanoma	N-cadherin		protein	inhibited by	ADH-1		sensitivity to	Melphalan	L-PAM	4	1		"Augustine CK, Cancer Res 2008, 68:3777-84"	Model: isolated limb perfusion. ADH-1 is a novel cyclic pentapeptide that contains the cell adhesion recognition site (His-Ala-Val) important in N-cadherin adhesion. ADH-1 synergizes with chemotherapy likely by inhibiting N-cadherin1531	Melanoma	N-cadherin		protein	inhibited by	ADH-1		sensitivity to	Temozolomide	TMZ	4	1		"Augustine CK, Cancer Res 2008, 68:3777-84"	Model: systemic treatment. ADH-1 is a novel cyclic pentapeptide that contains the cell adhesion recognition site (His-Ala-Val) important in N-cadherin adhesion. ADH-1 synergizes with chemotherapy likely by inhibiting N-cadherin.1532	Melanoma	HSP90		protein	inhibited by	17-DMAG		sensitivity to	Imatinib	Gleevec (R)	3	1		"Babchia N, Invest Ophthalmol Vis Sci 2008, 49:2348-56"	Uveal melanoma. Imatinib: c-KIT inhibitor. 17-DMAG: geldanamycin derivative1533	Melanoma	"KIT, PDGFR"		protein	inhibited by	Imatinib	Gleevec (R)	sensitivity to	17-DMAG		3	1		"Babchia N, Invest Ophthalmol Vis Sci 2008, 49:2348-56"	Uveal melanoma. 17-DMAG: HSP90 inhibitor (geldanamycin derivative)1534	Melanoma	TRAILR1	DR4		upregulated by	Decitabine	5-aza-2'-deoxycytidine 	sensitivity to	TRAIL		3	1		"Bae SI, Oncogene 2008, 27:490-8"	"Reexpressing DR4 by 5-AZAdC in melanoma cells in which promoter methylation had suppressed its expression, potentiates apoptosis by IFN-alpha2b, IFN-beta and Apo2L/TRAIL"1535	Melanoma	TRAILR1	DR4		upregulated by	Decitabine	5-aza-2'-deoxycytidine 	sensitivity to	IFN alpha	IFN alpha (2b)	3	1		"Bae SI, Oncogene 2008, 27:490-8"	"Reexpressing DR4 by 5-AZAdC in melanoma cells in which promoter methylation had suppressed its expression, potentiates apoptosis by IFN-alpha2b, IFN-beta and Apo2L/TRAIL"1536	Melanoma	TRAILR1	DR4		upregulated by	Decitabine	5-aza-2'-deoxycytidine 	sensitivity to	IFN beta		3	1		"Bae SI, Oncogene 2008, 27:490-8"	"Reexpressing DR4 by 5-AZAdC in melanoma cells in which promoter methylation had suppressed its expression, potentiates apoptosis by IFN-alpha2b, IFN-beta and Apo2L/TRAIL"1537	Melanoma	MEK		protein	inhibited by	PD98059	MEK inhibitor	sensitivity to	Cisplatin	CDDP	2	1		"Basu S, Proc Natl Acad Sci USA 2009, 106:7957-61"	PD98059: selective MEK1-2 inhibitor. Administration of the PD98059-nanoparticles in melanoma-bearing mice inhibits tumor growth and enhances the antitumor efficacy of cisplatin chemotherapy1538	Melanoma	N-cadherin		protein	inhibited by	ADH-1		sensitivity to	Melphalan	L-PAM	5	1	16	"Beasley GM, Cancer 2009, 115:4766-74"	"ADH-1 was administered systemically, while L-PAM was administered via isolated limb infusion. Although this was a phase I trial, the number of complete responses exceeded expectations, suggesting that targeting N-cadherin may be a new strategy for overcoming melanoma chemoresistance. ADH-1 is a novel cyclic pentapeptide that contains the cell adhesion recognition site (His-Ala-Val) important in N-cadherin adhesion"1539	Melanoma	MEK		protein	inhibited by	U0126		sensitivity to	LY294002	AKT inhibitor	2	1		"Bedogni B, Mol Cancer Ther 2006, 5:3071-7"	LY294002 is a PI3K inhibitor. Transgenic mice with constitutively activated RAS were used. Combined inhibition of MAPK and PI3K/AKT pathways is suggested1540	Melanoma	PI3K		protein	inhibited by	LY294002		sensitivity to	U0126	MEK inhibitor	2	1		"Bedogni B, Mol Cancer Ther 2006, 5:3071-7"	U0126 is a MEK inhibitor. Transgenic mice with constitutively activated RAS were used. Combined inhibition of MAPK and PI3K/AKT pathways is suggested1541	Melanoma	FoxM1		protein	inhibited by	Siomycin A		sensitivity to	ARC		3	1		"Bhat UG, Cell Cycle 2008, 7:1851-5"	ARC is a transcriptional inhibitor (nucleoside analog)1542	Melanoma	ATF2			downregulated by	ATF2 peptide (antagonist)		sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Bhoumik A, Clin Cancer Res 2001, 7:331-42"	"The ATF2 peptide spanning amino acids 50-100 - which acts as an AFT2 inhibitor - elicited the most efficient increase in the sensitivity of human melanoma cells to UV radiation or treatment by Adriamycin, verapamil or UCN-01, as revealed by apoptosis assays"1543	Melanoma	ATF2			downregulated by	ATF2 peptide (antagonist)		sensitivity to	Verapamil		3	1		"Bhoumik A, Clin Cancer Res 2001, 7:331-42"	"The ATF2 peptide spanning amino acids 50-100 - which acts as an AFT2 inhibitor - elicited the most efficient increase in the sensitivity of human melanoma cells to UV radiation or treatment by Adriamycin, verapamil or UCN-01, as revealed by apoptosis assays"1544	Melanoma	ATF2			downregulated by	ATF2 peptide (antagonist)		sensitivity to	UCN-01	7-hydroxystaurosporine 	3	1		"Bhoumik A, Clin Cancer Res 2001, 7:331-42"	"The ATF2 peptide spanning amino acids 50-100 - which acts as an AFT2 inhibitor - elicited the most efficient increase in the sensitivity of human melanoma cells to UV radiation or treatment by Adriamycin, verapamil or UCN-01, as revealed by apoptosis assays"1545	Melanoma	ATF2			downregulated by	ATF2 peptide (antagonist)		sensitivity to	UVR	Ultraviolet radiation	3	1		"Bhoumik A, Clin Cancer Res 2001, 7:331-42"	"The ATF2 peptide spanning amino acids 50-100 - which acts as an AFT2 inhibitor - elicited the most efficient increase in the sensitivity of human melanoma cells to UV radiation or treatment by Adriamycin, verapamil or UCN-01, as revealed by apoptosis assays"1546	Melanoma	"CDK, PDK1"		protein	inhibited by	UCN-01	7-hydroxystaurosporine 	sensitivity to	ATF2 peptide (antagonist)		3	1		"Bhoumik A, Clin Cancer Res 2001, 7:331-42"	"The ATF2 peptide spanning amino acids 50-100 - which acts as an AFT2 inhibitor - elicited the most efficient increase in the sensitivity of human melanoma cells to UV radiation or treatment by Adriamycin, verapamil or UCN-01, as revealed by apoptosis assays"1547	Melanoma	ABCB1	"MDR1, P-gp"	protein	inhibited by	Verapamil		sensitivity to	ATF2 peptide (antagonist)		3	1		"Bhoumik A, Clin Cancer Res 2001, 7:331-42"	"The ATF2 peptide spanning amino acids 50-100 - which acts as an AFT2 inhibitor - elicited the most efficient increase in the sensitivity of human melanoma cells to UV radiation or treatment by Adriamycin, verapamil or UCN-01, as revealed by apoptosis assays"1548	Melanoma	p38 MAPK		protein	inhibited by	SB203580		sensitivity to	ATF2 peptide (antagonist)		3	1		"Bhoumik A, Clin Cancer Res 2001, 7:331-42"	"When combined with an inhibitor of p38 catalytic activity, cells expressing amino acids 50-100 of ATF2 exhibited an increase in the degree of programmed cell death, indicating that combined targeting of ATF2 and p38 kinases is sufficient to induce apoptosis in late-stage melanoma cells"1549	Melanoma	hTERT		protein	inhibited by	RHPS4		sensitivity to	TRF2 dominant negative		3	1		"Biroccio A, Eur J Cancer 2006, 42:1881-8"	Treatment with the G-quadruplex-interacting agent (G4-ligand) RHPS4 sensitises melanoma cells to inhibition of TRF2 (telomere binding protein)1550	Melanoma	NQO1	NADPH quinone oxidoreductase	protein	inhibited by	Dicoumarol		sensitivity to	DCPIP		3	1		"Cabello CM, Biochem Pharmacol 2009, 78:344-54"	Genetic (siRNA) or pharmacological (dicoumarol) antagonism of NQO1 strongly sensitized G361 cells to DCPIP apoptogenic activity1551	Melanoma	CDK	Cyclin dependent kinase	protein	inhibited by	PHA-848125 		sensitivity to	Temozolomide	TMZ	3	1		"Caporali S, Pharmacol Res 2010, 61:437-448"	"The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound"1552	Melanoma	NFkB	Nuclear factor kappa B	protein	inhibited by	Nitrosylcobalamine		sensitivity to	TRAIL		4	1		"Chawla-Sarkar M, J Biol Chem 2003, 278:39461-9"	Nitrosylcobalamine is a nitric oxide donating drug (NODD)1553	Melanoma	NFkB	Nuclear factor kappa B	protein	inhibited by	Celastrol		sensitivity to	Temozolomide	TMZ	3	1		"Chen M, Mol Cancer Res 2009, 7:1946-53"	"Celastrol is a triterpene with anti-oxidant and anti-inflammatory properties. The CEL/TMZ combination synergistically inhibited cell proliferation in melanoma cells. CEL treatment increased the levels of ubiquitinated proteins, reduced the levels of tumor necrosis factor-alpha-induced IkappaB phosphorylation, and blocked NF-kappaB translocation to the nucleus"1554	Melanoma	TRAILR2	DR5		upregulated by	Thapsigargin		sensitivity to	TRAIL		3	1		"Chen LH, Carcinogenesis 2007, 28:2328-36"	Thapsigargin (an endoplasmic reticulum stress inducer) sensitizes human melanoma cells to TRAIL-induced apoptosis by upregulation of TRAIL-R2 through the unfolded protein response1555	Melanoma	DHFR	Dihydrofolate reductase	protein	inhibited by	Pyrimethamine		sensitivity to	Temozolomide	TMZ	3	1		"Chen M, Mol Cancer Res 2009, 7:703-12"	"The authors screened 2,000 compounds from the Spectrum Library in human melanoma cell lines to identify compounds that enhanced the cytotoxic effect of temozolomide"1556	Melanoma	CDK	Cyclin dependent kinase	protein	inhibited by	Roscovitine		sensitivity to	Nutlin-3a		3	1		"Cheok CF, Mol Cancer Res 2007, 5:1133-45"	Nutlins are MDM2 inhibitors (and thus p53 activators)1557	Melanoma	HDM2	MDM2	protein	inhibited by	Nutlin-3a		sensitivity to	Roscovitine		3	1		"Cheok CF, Mol Cancer Res 2007, 5:1133-45"	Roscovitine is a CDK inhibitor1558	Melanoma	PARP	Poly ADP-ribose polymerase 	protein	inhibited by	PJ-34		sensitivity to	Cisplatin	CDDP	3	1		"Chevanne M, J Cell Physiol 2010, 222:401-10"	PJ-34: PARP inhibitor. The ability of PARP activity inhibitors to prevent DNA damage recovery suggest the use of these drugs as chemo- and radio-sensitisers for cancer therapy1559	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 		downregulated by	5-azacytidine	5-AZA	sensitivity to	Fotemustine		3	1		"Christmann M, Int J Cancer 2001, 92:123-9"	"MGMT gene (not promoter) demethylation by 5-AZA inhibits MGMT expression, which increases the therapeutic effect of fotemustine"1560	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	inhibited by	O-6-benzylguanidine		sensitivity to	Fotemustine		3	1		"Christmann M, Int J Cancer 2001, 92:123-9"	Acquired resistance to fotemustine was alleviated by treatment with the MGMT inhibitor O6-benzylguanine demonstrating that reactivation of MGMT is the main underlying cause of acquired alkylating drug resistance1561	Endothelial cells	VEGFR2	VEGF receptor 2	protein	inhibited by	VEGFR2 antibody (antagonist)	DC101	sensitivity to	Vinblastine		4	1		"Cruz-Munoz W, Clin Cancer Res 2009, 15:4867-74"	A combination of metronomic vinblastine therapy and a vascular endothelial growth factor receptor 2-blocking antibody (DC101) results in significant control of metastatic disease and a significant improvement in median survival1562	Immune cells	CTLA4		protein	inhibited by	CTLA4 antibody (antagonist)		sensitivity to	Vaccine (Flt3 expressing melanoma)		2	1		"Curran MA, Cancer Res 2009, 69:7747-55"	Tumor vaccines expressing Flt3 ligand synergize with CTLA-4 blockade to reject preimplanted melanoma1563	Endothelial cells	MetAP2	Methionine aminopeptidase-2	protein	inhibited by	TNP-470		sensitivity to	Cisplatin + IL-12		2	1		"Dabrowska-Iwanicka A, J Cancer Res Clin Oncol 2002, 128:433-42"	"Successful combination of TNP-470 and chemoimmunotherapy suggests that enhanced antitumor activity could be obtained by a concomitant effect on both endothelial, immune and tumor cell compartments"1564	Endothelial cells	Tubulin		protein	inhibited by	OXi4503	CA1P	sensitivity to	Cyclophosphamide (metronomic low dose)	CTX	4	1		"Daenen LG, Mol Cancer Ther 2009, 8:2872-81"	"The combination of the vascular disrupting agent OXi4503 with daily administration of circulating endothelial progenitor (CEP)-inhibiting, low-dose metronomic cyclophosphamide was effective in this model. OXi-4503 (CA1P, a second generation prodrug derivative of Combretastatin A-4 phosphate, CA4P) is a vascular disrupting agent that binds preferentially to endothelial cell associated tubulin, inducing rapid microtubular depolymerization and vascular shutdown in solid tumors "1565	Melanoma	MEK		protein	inhibited by	PD325901		sensitivity to	Rapamycin	Sirolimus	2	1		"Dankort D, Nat Genet 2009, 41:544-52"	Rapamycin is a mTOR inhibitor. Combined treatment with rapamycin and PD325901 led to shrinkage of established melanomas. Model: murine melanoma spontaneously developed following conditional melanocyte-specific expression of BRAF V600E and PTEN loss1566	Melanoma	mTOR	Mammalian target of rapamycin	protein	inhibited by	Rapamycin	Sirolimus	sensitivity to	PD325901		2	1		"Dankort D, Nat Genet 2009, 41:544-52"	PD325901 is a MEK1/2 inhibitor. Combined treatment with rapamycin and PD325901 led to shrinkage of established melanomas. Model: murine melanoma spontaneously developed following conditional melanocyte-specific expression of BRAF V600E and PTEN loss1567	Melanoma	HDAC	Histone deacetylase	protein	inhibited by	Valproic acid		sensitivity to	Karenitecin		4	1		"Daud AI, Clin Cancer Res 2009, 15:2479-87"	Karenitecin: topoisomerase I inhibitor. The same article describes a phase I-II trial in which metastatic disease stabilization was achieved in 47% of 33 evaluable patients1568	Melanoma	Bcl-2		mRNA	downregulated by	Oblimersen	"Bcl-2 antisense oligo, G3139"	sensitivity to	Gimatecan		4	1		"De Cesare M, Eur J Cancer 2005, 41:1213-22"	Gimatecan is a novel lipophilic camptothecin1569	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	inhibited by	BNAG	O6-benzyl-N2-acetylguanosine 	sensitivity to	BCNU		3	1		"Debiton E, Melanoma Res 2002, 12:417-27"	"BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) is a chloroethylnitrosourea"1570	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	inhibited by	BNAG	O6-benzyl-N2-acetylguanosine 	sensitivity to	Cystemustine		3	1		"Debiton E, Melanoma Res 2002, 12:417-27"	Cystemustine is a chloroethylnitrosourea1571	Melanoma	ROS	Reactive oxygen species		upregulated by	Trabectedin	"ET-743, Yondelis (R)"	sensitivity to	Cisplatin	CDDP	4	1		"D'Incalci M, Eur J Cancer 2003, 39:1920-6"	ET-743 is believed to act through formation of anion superoxide in proximity of DNA with consequent DNA damage and induction of apoptosis1572	Melanoma	HDAC	Histone deacetylase	protein	inhibited by	PXD101		sensitivity to	Retinoic acid	13-cis retinoic acid	4	1		"Epping MT, Proc Natl Acad Sci USA 2007, 104:17777-82"	A combination of retinoic acid (RA) and HDACI acted synergistically to activate RA signaling and inhibit tumor growth. These experiments identify the RA pathway as a rate-limiting target of HDACI and suggest strategies to enhance the therapeutic efficacy of HDACI1573	Melanoma	MEK1		protein	inhibited by	PD98059	MEK inhibitor	sensitivity to	SB239063		4	1		"Estrada Y, Pigment Cell Melanoma Res 2009, 22:66-76"	"SB239063: p38MAPK inhibitor. Unlike carcinoma cells, in melanoma cells MAPK-ERK and MAPK-p38 activity is not mutually exclusive and instead synergically increases melanoma migration and proliferation"1574	Melanoma	p38MAPK		protein	inhibited by	SB239063		sensitivity to	PD98059	MEK inhibitor	4	1		"Estrada Y, Pigment Cell Melanoma Res 2009, 22:66-76"	"PD98059: MEK1 inhibitor. Unlike carcinoma cells, in melanoma cells MAPK-ERK and MAPK-p38 activity is not mutually exclusive and instead synergically increases melanoma migration and proliferation"1575	Melanoma	SRC	c-Src	protein	inhibited by	Dasatinib	"BMS-354825, Sprycel"	sensitivity to	Temozolomide	TMZ	3	1		"Eustace AJ, J Transl Med 2008, 6:53"	"Dasatinib in combination with the chemotherapy drug temozolomide showed greater efficacy than either drug alone. Dasatinib inhibition of proliferation was associated with reduced phosphorylation of Src kinase, while decreased phosphorylation of FAK was implicated in dasatinib-mediated inhibition of migration and invasion in melanoma cells"1576	Melanoma	HMG CoA reductase	HMGCR	protein	inhibited by	Lovastatin		sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Feleszko W, Int J Cancer 2002, 100:111-8"	Verified also in vivo in a mouse model1577	Melanoma	COX-2	Cyclooxygenase 2	protein	inhibited by	Amfenac		sensitivity to	Radiotherapy		3	1		"Fernandes BF, Eye (Lond) 2008, 22:701-6"	Uveal melanoma. Amfenac increases the radiosensitivity of uveal melanoma cell lines1578	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	inhibited by	O-6-benzylguanine		sensitivity to	Temozolomide	TMZ	3	1		"Fontijn D, Mol Cancer Ther 2007, 6:2807-15"	MGMT causes resistance to TMZ1579	Melanoma	Proteasome		protein	inhibited by	LLnL		sensitivity to	TRAIL		3	1		"Franco AV, J Immunol 2001, 166:5337-45"	LLnL (a proteasome inhibitor) acts through NFkB inhibition1580	Melanoma	ABCB5		protein	inhibited by	ABCB5 antibody (antagonist)		sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Frank NY, Cancer Res 2005, 65:4320-33"	"Besides expression/sensitivity correlation, ABCB5 inhibition (by a neutralizing antibody) leads to increased sensitivity to doxorubicin "1581	Melanoma	Proteasome		protein	inhibited by	Bortezomib	Velcade (R)	sensitivity to	Rosiglitazone		3	1		"Freudlsperger C, Anticancer Res 2007, 27(1A):207-13"	Rosiglitazone: PPARG ligand1582	Melanoma	XIAP		protein	inhibited by	SMAC mimetic		sensitivity to	TRAIL		3	1		"Fulda S, Nat Med 2002, 8:808-15"	SMAC mimetics are SMAC derived peptides (SMAC physiologically inhibits antiapoptotic factor XIAP)1583	Melanoma	XIAP		protein	inhibited by	SMAC mimetic		sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Fulda S, Nat Med 2002, 8:808-15"	SMAC mimetics are SMAC derived peptides (SMAC physiologically inhibits antiapoptotic factor XIAP)1584	Immune cells	IDO	"Indoleamine 2,3 dioxygenase"	protein	inhibited by	1-methyl-tryptophan	1-MT	sensitivity to	IFN gamma GCNGRC		2	1		"Gasparri AM, Mol Cancer Ther 2008, 7:3859-66"	"Targeted delivery of IFN gamma to tumors was achieved by fusing IFNG with GCNGRC, a tumor neovasculature homing peptide"1585	Immune cells	PD1 ligand	"PDL1, B7H1, CD274"	protein	inhibited by	PDL1 trap		sensitivity to	HSP70 vaccine		2	1		"Geng H, Int J Cancer 2006, 118:2657-64"	"PDL1 is a co-inhibitory molecule. PDL1 trap is a construct encoding the extracellular domain of the PDL1 receptor (PD1), thus acting as a trap"1586	Plasma/serum	VEGF	Vascular endothelial growth factor	protein	inhibited by	VEGF antibody (antagonist)		sensitivity to	Cisplatin	CDDP	2	1		"Ghosh S, Int Immunopharmacol 2007, 7:1598-608"	Experiments show a successful VEGF antibody based combination therapy with cisplatin and suggests that the enhancement of antitumor activity could be explained by a concomitant effect on both endothelial and tumor cell compartment1587	Melanoma	HDAC	Histone deacetylase	protein	inhibited by	SBHA		sensitivity to	TRAIL		3	1		"Gillespie S, Apoptosis 2006, 11:2251-65"	"SBHA (HDAC inhibitor) downregulated Bcl-xL, Mcl-1 and XIAP, but upregulated Bax, Bak and Bim"1588	Melanoma	S100A2			upregulated by	Decitabine	5-aza-2'-deoxycytidine 	sensitivity to	IFN gamma		3	1		"Gollob JA, Clin Cancer Res 2007, 13:5219-25"	Uveal melanoma. Decitabine upregulates S100A2 (a putative tumor suppressor) expression and synergizes with IFN-gamma to kill uveal melanoma cells1589	Melanoma	Proteasome		protein	inhibited by	Bortezomib	Velcade (R)	sensitivity to	IL-29	Interleukin-29	3	1		"Guenterberg KD, Mol Cancer Ther 2010, 9:510-20"	Bortezomib-induced and temozolomide-induced apoptosis was synergistically enhanced following the addition of IL-291590	Melanoma	GRM1	Metabotropic glutamate receptor-1	protein	inhibited by	CPCCOEt 		sensitivity to	Docetaxel		3	1		"Haas HS, Oncol Rep 2007, 17:1399-404"	The non-competitive metabotropic glutamate receptor-1 antagonist CPCCOEt inhibits the in vitro growth of human melanoma and significantly enhanced the tumoricidal effects of docetaxel1591	Melanoma	MEK		protein	inhibited by	AZD6244		sensitivity to	Docetaxel		4	1		"Haass NK, Clin Cancer Res 2008, 14:230-9"	"AZD6244 treatment decreased phospho-ERK in the tumors and significantly suppressed tumor growth. The original tumors remained viable, suggesting that AZD6244 monotherapy was largely cytostatic, and not proapoptotic in this model. Further studies showed that co-administration of AZD6244 (30 mg/kg) with docetaxel (15 mg/kg) led to tumor regression"1592	Melanoma	Proteasome		protein	inhibited by	Bortezomib	Velcade (R)	sensitivity to	Decitabine	"5-AZA, 5-aza-2'-deoxycytidine "	3	1		"Halaban R, PLoS One 2009, 4:e4563"	"Synergistic effect of Bortezomib, a proteasome inhibitor, in enhancing the growth arrest of decitabine in otherwise resistant melanoma cells"1593	Melanoma	"KIT, PDGFR"		protein	inhibited by	Imatinib	Gleevec (R)	sensitivity to	TRAIL		3	1		"Hamai A, Oncogene 2006, 25:7618-34"	Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death1594	Melanoma	NFkB	Nuclear factor kappa B	protein	inhibited by	NFkB inhibitor		sensitivity to	E2F1 gene therapy + Doxorubicin		3	1		"Hao H, Methods Mol Biol 2009, 542:301-13"	Inactivation of NFkB is associated with chemosensitivity in melanoma cells after combination treatment with E2F-1 gene therapy and doxorubicin1595	Melanoma	NFkB	Nuclear factor kappa B	protein	inhibited by	Parthenolide		sensitivity to	Etoposide	VP-16	1	1		"Heon Seo K, Cancer Res 2006, 66:4681-6"	PAF activates NFkB which leads to upregulation of antiapoptotic factors Bcl-2 and Bcl-xL1596	Immune cells	CTLA4		protein	inhibited by	Ipilimumab	CTLA4 antibody (antagonist)	sensitivity to	Dacarbazine	DTIC	5	1	72	"Hersh EM, Invest New Drugs 2010, Epub ahead of print "	"In a phase II trial (n=72), anti-CTLA4 antibody ipilimumab + DTIC yielded a 14.3% tumor response rate in patients with advanced melanoma (ipilimumab alone: 5.4%)"1597	Melanoma	Proteasome		protein	inhibited by	Bortezomib	Velcade (R)	sensitivity to	Fenretinide		4	1		"Hill DS, Clin Cancer Res 2009, 15:1192-8"	Fenretinide is a synthetic retinoid derivative (ATRA derivative). Both agents are capable of inducing endoplasmic reticulum (ER) stress induced apoptosis1598	Melanoma	MMP	Matrix metalloproteinase	protein	inhibited by	MMI-166		sensitivity to	Carboplatin		2	1		"Hojo K, Anticancer Res 2002, 22:3253-9"	"Augmented antitumor activity of the combination treatment was not simply due to the augmentation of direct cytotoxic activity, but was rather an additive effect of the antitumor activities of different mechanisms"1599	Melanoma	MMP	Matrix metalloproteinase	protein	inhibited by	MMI-166		sensitivity to	Paclitaxel	Taxol	2	1		"Hojo K, Anticancer Res 2002, 22:3253-9"	"Augmented antitumor activity of the combination treatment was not simply due to the augmentation of direct cytotoxic activity, but was rather an additive effect of the antitumor activities of different mechanisms"1600	Melanoma	SRC	c-Src	protein	inhibited by	Dasatinib	"BMS-354825, Sprycel"	sensitivity to	Cisplatin	CDDP	3	1		"Homsi J, Melanoma Res 2009, 19:167-75"	"Src inhibitors may be a promising therapy in melanoma, either by themselves or in combination with chemotherapy (especially with platinum compounds)"1601	Melanoma	AKT	PKB	protein	inhibited by	Akti4		sensitivity to	U0126	MEK inhibitor	3	1		"Hou P, PLoS One 2009, 4:e6200"	"U0126 is a MEK inhibitor. Suppression of the MAP kinase and PI3K/Akt pathways showed potent anti-melanoma cell effects, including the inhibition of cell proliferation, transformation and invasion, induction of G(0)/G(1) cell cycle arrest and, when the two pathways were dually suppressed, cell apoptosis"1602	Melanoma	MEK		protein	inhibited by	U0126		sensitivity to	Akti4		3	1		"Hou P, PLoS One 2009, 4:e6200"	"Akti4 is an AKT inhibitor. Suppression of the MAP kinase and PI3K/Akt pathways showed potent anti-melanoma cell effects, including the inhibition of cell proliferation, transformation and invasion, induction of G(0)/G(1) cell cycle arrest and, when the two pathways were dually suppressed, cell apoptosis"1603	Melanoma	"AKT, MEK"		protein	inhibited by	Akti4 + U0126		sensitivity to	Radioiodine		3	1		"Hou P, PLoS One 2009, 4:e6200"	"Suppression of MEK/AKT pathways induced expression of genes that are normally expressed in the thyroid gland, which enabled melanoma cells to take up radioiodide"1604	Melanoma	ATF2		protein	inhibited by	Retinoic acid		sensitivity to	Paclitaxel	Taxol	1	1		"Huang Y, J Mol Signal 2008, 3:3"	Inhibition of ATF-2 phosphorylation by retinoic acid leads to decreased ATF/JUN dimers and increased FOS/JUN dimers1605	Melanoma	HSP90		protein	inhibited by	Geldanamycin		sensitivity to	Hyperthermia		2	1		"Ito A, Cancer Sci 2009, 100:558-64"	"In a murine melanoma in vivo model, geldanamycin (heat shock protein 90 inhibitor) synergically increases the anti-melanoma effect of hyperthermia"1606	Melanoma	ATM	Ataxia telangiectasia mutated (kinase)	protein	inhibited by	KU-55933		sensitivity to	TRAIL		3	1		"Ivanov VN, Cancer Res 2009, 69:3510-9"	Suppression of ATM-dependent and STAT3-mediated antiapoptotic pathway sensitizes human melanoma cells to TRAIL-mediated apoptosis1607	Melanoma	"STAT3, NFkB"		protein	inhibited by	Resveratrol		sensitivity to	TRAIL		3	1		"Ivanov VN, Exp Cell Res 2008, 314:1163-76"	"Resveratrol, a polyphenolic phytoalexin, decreased STAT3 and NFkB activation, which suppressed expression of cFLIP and Bcl-xL proteins and increased sensitivity to exogenous TRAIL in DR5-positive melanomas"1608	Melanoma	PI3K		protein	inhibited by	LY294002		sensitivity to	Arsenic trioxide	ATO	3	1		"Ivanov VN, J Biol Chem 2004, 279:22747-58"	Apoptosis induced by ATO is mediated by TNF1609	Melanoma	MEK		protein	inhibited by	PD98059 	MEK inhibitor	sensitivity to	Arsenic trioxide	ATO	3	1		"Ivanov VN, J Biol Chem 2004, 279:22747-58"	Apoptosis induced by ATO is mediated by TNF1610	Melanoma	MEK		protein	inhibited by	U0126		sensitivity to	Arsenic trioxide	ATO	3	1		"Ivanov VN, J Biol Chem 2004, 279:22747-58"	Apoptosis induced by ATO is mediated by TNF1611	Melanoma	EGFR	ERBB1	protein	inhibited by	AG1478		sensitivity to	Arsenic trioxide	ATO	3	1		"Ivanov VN, Oncogene 2005, 24:616-26"	Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas1612	Melanoma	Bcl-2		mRNA	downregulated by	Oblimersen	"Bcl-2 antisense oligo, G3139"	sensitivity to	Dacarbazine	DTIC	4	1		"Jansen B, Nat Med 1998, 4:232-4"	Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice1613	Melanoma	TRAILR2	DR5		upregulated by	Tunicamycin		sensitivity to	TRAIL		3	1		"Jiang CC, Cancer Res 2007, 67:5880-8"	"Tunicamycin induces ER stress, which in turn leads to TRAILR2 upregulation"1614	Melanoma	MEK		protein	inhibited by	U0126		sensitivity to	Tunicamycin		3	1		"Jiang CC, Cancer Res 2007, 67:9750-61"	Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis. Also MEK1 siRNA increases ER stress mediated apoptosis caused by thapsigargin1615	Melanoma	MEK		protein	inhibited by	U0126		sensitivity to	Thapsigargin		3	1		"Jiang CC, Cancer Res 2007, 67:9750-61"	Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis. Also MEK1 siRNA increases ER stress mediated apoptosis caused by thapsigargin1616	Melanoma	Mcl-1		protein	inhibited by	Obatoclax	GX15-070	sensitivity to	Tunicamycin		3	1		"Jiang CC, Neoplasia 2009, 11:945-55"	Tunicamycin is an endoplasmic reticulum (ER) stress inducer1617	Melanoma	Mcl-1		protein	inhibited by	Obatoclax	GX15-070	sensitivity to	Thapsigargin		3	1		"Jiang CC, Neoplasia 2009, 11:945-55"	Thapsigargin is an endoplasmic reticulum (ER) stress inducer1618	Melanoma	IGF1R	IGF1 receptor	protein	inhibited by	AG538		sensitivity to	MFG-E8 siRNA		3	1		"Jinushi M, Cancer Res 2008, 68:8889-98"	"MFG-E8: Milk fat globule EGF-8. MFG-E8 augments melanoma cell resistance to apoptosis, triggers an epithelial-to-mesenchymal transition (EMT) and stimulates immune suppression"1619	Melanoma	MET	c-Met	protein	inhibited by	SU11274		sensitivity to	MFG-E8 siRNA		3	1		"Jinushi M, Cancer Res 2008, 68:8889-98"	"MFG-E8: Milk fat globule EGF-8. MFG-E8 augments melanoma cell resistance to apoptosis, triggers an epithelial-to-mesenchymal transition (EMT) and stimulates immune suppression"1620	Melanoma	ABCB1	"MDR1, P-gp"	protein	inhibited by	HM30181A		sensitivity to	Paclitaxel	Taxol	2	1		"Joo KM, Int J Oncol 2008, 33:705-12"	HM30181A: P-gp inhibitor. P-gp in the brain microenvironment has crucial roles in the brain metastatic tumor chemoresistance: P-gp inhibitor HM30181A treatment should be considered in the development of brain endothelial cell-targeted chemotherapy1621	Melanoma	HDAC	Histone deacetylase	protein	inhibited by	LAQ824		sensitivity to	Retinoic acid	13-cis retinoic acid	4	1		"Kato Y, Mol Cancer Ther 2007, 6:70-81"	HDAC inhibits the expression of RAR1622	Melanoma	XIAP		protein	inhibited by	Phenoxodiol		sensitivity to	Carboplatin		3	1		"Kluger HM, J Transl Med 2007, 5:6"	"The X-linked inhibitor of apoptosis protein (XIAP) is upregulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization"1623	Melanoma	PI3K		protein	inhibited by	LY294002		sensitivity to	UVR	Ultraviolet radiation	3	1		"Krasilnikov M, Mol Carcinog 1999, 24:64-9"	"Treating melanoma cells with wortmanin or LY294002, two different PI3K inhibitors, decreased PI3K activity and caused a dose-dependent decrease in resistance to ultraviolet radiation"1624	Melanoma	PI3K		protein	inhibited by	Wortmannin		sensitivity to	UVR	Ultraviolet radiation	3	1		"Krasilnikov M, Mol Carcinog 1999, 24:64-9"	"Treating melanoma cells with wortmanin or LY294002, two different PI3K inhibitors, decreased PI3K activity and caused a dose-dependent decrease in resistance to ultraviolet radiation"1625	Melanoma	MEK1		protein	inhibited by	PD098059		sensitivity to	IFN alpha		3	1		"Kumar KG, Cancer Biol Ther 2007, 6:1437-41"	"Pretreatment of 1205Lu cells with MEK1 inhibitor PD098059 noticeably enhanced the anti-proliferative effects of IFN alpha. This is likely due to reduced activity of bTrCP, which in turn leads to increased IFNAR stability"1626	Melanoma	Proteasome		protein	inhibited by	LLnL		sensitivity to	TRAIL		3	1		"Kurbanov BM, Oncogene 2007, 26:3364-77"	"The MoA of LLnL (a proteasome inhibitor) in this model does not seem to be NFkB inhibition, but rather inhibition of TRAILR degradation"1627	Melanoma	mTOR	Mammalian target of rapamycin	protein	inhibited by	Rapamycin	Sirolimus	sensitivity to	Sorafenib	Nexavar (R)	3	1		"Lasithiotakis KG, J Invest Dermatol 2008, 128:2013-23"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells (organotypic culture mimicking the physiological context)"1628	Immune cells	CD4		protein	inhibited by	CD4 antibody (antagonist)		sensitivity to	Adoptive cell therapy (immunotherapy)		2	1		"Lacelle MG, Clin Cancer Res 2009, 15:6881-90"	Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy of adoptive cell transfer1629	"Melanoma, endothelial cells"	"BRAF, CRAF, VEGFR, PDGFR"		protein	inhibited by	Sorafenib	Nexavar (R)	sensitivity to	Rapamycin	Sirolimus	3	1		"Lasithiotakis KG, J Invest Dermatol 2008, 128:2013-23"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells (organotypic culture mimicking the physiological context)"1630	Melanoma	CXCR4		protein	inhibited by	T22 peptide antagonist		sensitivity to	CTLA4 antibody (antagonist)		2	1		"Lee CH, Mol Cancer Ther 2006, 5:2592-9"	"T22 acts as an antagonist of CXCR4, whose natural ligand is CXCL12"1631	Melanoma	CXCR4		protein	inhibited by	T22 peptide antagonist		sensitivity to	Cyclophosphamide	CTX	2	1		"Lee CH, Mol Cancer Ther 2006, 5:2592-9"	"T22 acts as an antagonist of CXCR4, whose natural ligand is CXCL12"1632	Melanoma	hTERT		protein	inhibited by	RHPS4		sensitivity to	Camptothecin		3	1		"Leonetti C, Clin Cancer Res 2008, 14:7284-91"	The formation of G-quadruplex structures at telomeric DNA sequences blocks telomerase activity: the pentacyclic acridinium salt RHPS4 is one of the most effective and selective G4 ligands able to rapidly disrupt telomere architecture. This synergism was most evident when RHPS4 was given after camptothecin1633	Melanoma	Proteasome		protein	inhibited by	Bortezomib	Velcade (R)	sensitivity to	IFN alpha		4	1		"Lesinski GB, Cancer Res 2008, 68:8351-60"	This drug combination works also in Bcl-2 or Mcl-1 expressing tumors1634	Melanoma	IL-8	Interleukin-8	protein	inhibited by	IL-8 antibody (antagonist)		sensitivity to	Dacarbazine	DTIC	3	1		"Lev DC, Mol Cancer Ther 2003, 2:753-63"	Dacarbazine causes transcriptional upregulation of interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF) in melanoma cells: a possible escape mechanism from chemotherapy1635	Melanoma	MEK		protein	inhibited by	PD98059	MEK inhibitor	sensitivity to	219476	CDK4 inhibitor	3	1		"Li J, Cancer Invest 2009, Epub ahead of print "	"219476: CDK4 inhibitor. Investigators examined the effect of cotargeting both pathways with MEK inhibitor PD98059 and CDK4 inhibitor 219476 on human melanoma cells lines, and found that combinatorial treatment dramatically increased apoptosis compared to the single agent treatment"1636	Melanoma	CDK4	Cyclin dependent kinase-4	protein	inhibited by	219476	CDK4 inhibitor	sensitivity to	PD98059	MEK inhibitor	3	1		"Li J, Cancer Invest 2009, Epub ahead of print "	"PD98059: MEK inhibitor. Investigators examined the effect of cotargeting both pathways with MEK inhibitor PD98059 and CDK4 inhibitor 219476 on human melanoma cells lines, and found that combinatorial treatment dramatically increased apoptosis compared to the single agent treatment"1637	Melanoma	"Bcl-2, Bcl-xL"		protein	inhibited by	ABT-737		sensitivity to	Lysis by cytotoxic T lymphocytes (CTL)		3	1		"Lickliter JD, Br J Cancer 2007, 96:600-8"	Lowering the apoptotic threshold enhances immune mediated melanoma cell lysis. ABT-737 does not inhibit Mcl-11638	Melanoma	HDAC	Histone deacetylase	protein	inhibited by	SAHA	Suberoylanilide hydroxamic acid	sensitivity to	TRAIL gene therapy		3	1		"Lillehammer T, J Gene Med 2007, 9:440-51"	Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines1639	Melanoma	TRAILR	TRAIL receptor		upregulated by	2-deoxy-D-glucose	2-DG	sensitivity to	TRAIL		3	1		"Liu H, Mol Cancer 2009, 8:122"	2-DG is a synthetic glucose analog that upregulates TRAILR2 expression through XBP-1 1640	Endothelial cells	Integrin alpha V beta 3		protein	inhibited by	EMD121974		sensitivity to	IL-2-antibody fusion protein		2	1		"Lode HN, Proc Natl Acad Sci USA 1999, 96:1591-6"	EMD121974 is a cyclic peptide. IL2-antibody is a fusion protein made of IL-2 and a tumor targeting antibody1641	Melanoma	MEK1		protein	inhibited by	PD98059	MEK inhibitor	sensitivity to	Cisplatin	CDDP	3	1		"Mandic A, Melanoma Res 2001, 11:11-9"	The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis1642	"Melanoma, endothelial cells"	"BRAF, CRAF, VEGFR, PDGFR"		protein	inhibited by	Sorafenib	Nexavar (R)	sensitivity to	Lenalidomide		3	1		"Mangiameli DP, J Transl Med 2007, 5:38"	"Uveal melanoma. Lenalidomide: derivative of thalidomide. Lenalidomide and sorafenib are effective at targeting endothelial cells, inhibiting growth of ocular melanoma cells and can inhibit growth of tumors in a xenograft model as well as inhibit development of metastases"1643	Immune cells	MARCO		protein	inhibited by	MARCO antibody (antagonist)		sensitivity to	Vaccine (dendritic cells)		2	1		"Matsushita N, Cancer Immunol Immunother 2010, Epub ahead of print "	"In vivo, anti-MARCO antibody treated tumor lysate-pulsed dendritic cells showed better trafficking from the skin injection site to lymph node, enhanced generation of tumor-reactive IFN-gamma producing T cells, and improved therapeutic efficacy against B16 melanoma"1644	Melanoma	Nitric oxide	NO		upregulated by	Glyceryl trinitrate	GTN	sensitivity to	Doxorubicin	Adriamycin (R)	1	1		"Matthews NE, J Natl Cancer Inst 2001, 93:1879-85"	Glyceryl trinitrate (GTN) is a nitric oxide (NO) donor that reduces the resistance to DOXO due to hypoxia. Hypoxia seems to cause chemoresistance by decreasing NO production1645	Melanoma	HMG CoA reductase	HMGCR	protein	inhibited by	Lovastatin		sensitivity to	Tocotrienol		2	1		"McAnallys JA, Exp Biol Med 2007, 232:523-31"	Co-administration of isoprenoids (vitamin E isomers with an isoprenoid moiety) that posttranscriptionally down-regulate tumor reductase may lower the effective dose of statins necessary for antimelanoma activity1646	Melanoma	Estrogen receptor	ESR1	protein	inhibited by	Tamoxifen		sensitivity to	Cisplatin	CDDP	3	1		"McClay EF, Cancer Res 1992, 52:6790-6"	"Combination of tamoxifen with CDDP was highly synergistic, whereas tamoxifen was antagonistic with carmustine and an activated form of dacarbazine"1647	"Melanoma, endothelial cells"	"BRAF, CRAF, VEGFR, PDGFR"		protein	inhibited by	Sorafenib	Nexavar (R)	sensitivity to	Dacarbazine	DTIC	6	1	101	"McDermott DF, J Clin Oncol 2008, 26:2178-85"	Phase II RCT. Setting: advanced melanoma. Increased response rate and progression free survival in patients randomized to combination regimen. Overall survival: not significant but follow up was considered insufficient for meaningful survival analysis1648	"Melanoma, endothelial cells"	"BRAF, CRAF, VEGFR, PDGFR"		protein	inhibited by	Sorafenib	Nexavar (R)	sensitivity to	Wortmannin		3	1		"Meier F, Br J Dermatol 2007, 156:1204-13"	Wortmannin is a PI3K inhibitor. Multiple signaling pathways must be targeted to overcome drug resistance1649	Melanoma	MEK		protein	inhibited by	PD98059	MEK inhibitor	sensitivity to	LY294002	AKT inhibitor	3	1		"Meier F, Br J Dermatol 2007, 156:1204-13"	LY294002 is a PI3K inhibitor. Multiple signaling pathways must be targeted to overcome drug resistance1650	Melanoma	MEK		protein	inhibited by	U0126		sensitivity to	LY294002	AKT inhibitor	3	1		"Meier F, Br J Dermatol 2007, 156:1204-13"	LY294002 is a PI3K inhibitor. Multiple signaling pathways must be targeted to overcome drug resistance1651	Melanoma	PI3K		protein	inhibited by	Wortmannin		sensitivity to	Sorafenib	Nexavar (R)	3	1		"Meier F, Br J Dermatol 2007, 156:1204-13"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor"1652	Melanoma	PI3K		protein	inhibited by	LY294002		sensitivity to	PD98059	MEK inhibitor	3	1		"Meier F, Br J Dermatol 2007, 156:1204-13"	PD98059 is a MEK inhibitor. Multiple signaling pathways must be targeted to overcome drug resistance1653	Melanoma	PI3K		protein	inhibited by	LY294002		sensitivity to	U0126	MEK inhibitor	3	1		"Meier F, Br J Dermatol 2007, 156:1204-13"	U0126 is a MEK inhibitor. Multiple signaling pathways must be targeted to overcome drug resistance1654	Melanoma	mTOR	Mammalian target of rapamycin	protein	inhibited by	Rapamycin	Sirolimus	sensitivity to	Paclitaxel + Carboplatin		5	1	2	"Meier F, J Am Acad Dermatol 2009, 60:863-8"	This report describes two cases of patients with metastatic melanoma who showed significant remission after combination of carboplatin and paclitaxel with the mTOR inhibitor sirolimus1655	Melanoma	"Bcl-2, GSH"			downregulated by	Oblimersen + anti-GSH diet		sensitivity to	Paclitaxel + TNF + IFN gamma + Radiotherapy		2	1		"Mena S, Clin Cancer Res 2007, 13:2658-66"	Bcl-2 and glutathione depletion sensitizes B16 melanoma to combination therapy and eliminates metastatic disease in vivo1656	Melanoma	ROS	Reactive oxygen species	protein	inhibited by	Amifostine	Ethyol	sensitivity to	Fotemustine		3	1		"Merlin JL, Anticancer Drugs 2002, 13:141-7"	ROS inhibits fotemustine effect1657	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	inhibited by	O-6-benzylguanidine		sensitivity to	Temozolomide	TMZ	3	1		"Mhaidat NM, Br J Cancer 2007, 97:1225-33"	Inhibition of MGMT with O6-benzylguanine resulted in decrease in cell viability and this correlated with western blot analysis of MGMT levels in the melanoma cells1658	Melanoma	p53	TP53	protein	inhibited by	Pifithrin alpha 	QB102 (PFT-alpha)	sensitivity to	Temozolomide	TMZ	3	1		"Mhaidat NM, Br J Cancer 2007, 97:1225-33"	It is unclear why inhibition of p53 with PFT-alpha resulted in an increase in apoptosis of human melanoma cells (particularly because apoptosis of TK6 lymphoma cells was inhibited)1659	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	inhibited by	4BTG	O(6)-(4-bromothenyl)guanine 	sensitivity to	Temozolomide	TMZ	4	1		"Middleton MR, Int J Cancer 2000, 85:248-52"	4BTG was less toxic (but equally effective) than O6-benzylguanine1660	Melanoma	PKC	Protein kinase C	protein	inhibited by	PNAE		sensitivity to	Cisplatin	CDDP	3	1		"Mikhaevich IS, Anticancer Drugs 1992, 3:513-7"	The exposure of human melanoma BRO cells in culture simultaneously with cisplatin (1-10 microM) and PNAE(s) (100 microM-1 mM) in a molar ratio of 1/100 for 24 h induced a considerable decrease in the ability of these cells to incorporate [3H]thymidine into DNA. A considerable antiproliferative synergism of these agents was observed1661	Melanoma	Proteasome		protein	inhibited by	MG-132		sensitivity to	ABT-737		3	1		"Miller LA, J Invest Dermatol 2009, 129:964-71"	"ABT-737: Bcl-2, Bcl-xL and Bcl-W inhibitor (BH3 mimetic). ABT-737 combined with MG-132 synergistically induced Noxa-dependent mitochondrial-mediated apoptosis"1662	Melanoma	"Bcl-2, Bcl-xL, Bcl-W"		protein	inhibited by	ABT-737		sensitivity to	MG-132	Proteasome inhibitor	3	1		"Miller LA, J Invest Dermatol 2009, 129:964-71"	MG-132: proteasome inhibitor. ABT-737 combined with MG-132 synergistically induced Noxa-dependent mitochondrial-mediated apoptosis1663	Melanoma	MEK		protein	inhibited by	U0126		sensitivity to	Cisplatin	CDDP	3	1		"Mirmohammadsadegh A, J Invest Dermatol 2007, 127:2207-15"	"ERK1/2 (which is activated by MEK1/2) is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis likely by activating RSK1, which inactivates BAD"1664	Melanoma	Calpain		protein	inhibited by	PD150606		sensitivity to	BSc2118 + Cisplatin		3	1		"Mlynarczuk-Bialy I, Cancer Res 2006, 66:7598-605"	"Cisplatin-resistant cells are more resistant to proteasome inhibition than parental cisplatin-sensitive melanoma cells: however, combined proteasome (BSc2118) and calpain (PD150606) inhibition significantly reduces viability of melanoma cells and helps to overcome the relative proteasome inhibitor resistance of these cells"1665	"Melanoma, Immune cells"	STAT3	Signal transducer and activator of transcription 3 	protein	inhibited by	JSI-124		sensitivity to	CpG oligonucleotide		2	1		"Molavi O, Immunol Cell Biol 2008, 86:506-14"	CpG oligonucleotide: TLR9 agonist. STAT3 activation in tumor and dendritic cells (DC) are believed to contribute to intra-tumoral immunosuppressive environment1666	Melanoma	mTOR	Mammalian target of rapamycin	protein	inhibited by	Rapamycin	Sirolimus	sensitivity to	Sorafenib	Nexavar (R)	3	1		"Molhoek KR, J Transl Med 2005, 3:39"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor"1667	"Melanoma, endothelial cells"	"BRAF, CRAF, VEGFR, PDGFR"		protein	inhibited by	Sorafenib	Nexavar (R)	sensitivity to	Rapamycin	Sirolimus	3	1		"Molhoek KR, J Transl Med 2005, 3:39"	Rapamycin is a mTOR inhibitor1668	Melanoma	HDAC	Histone deacetylase	protein	inhibited by	Trichostatin		sensitivity to	Etoposide	VP-16	3	1		"Monte M, Proc Natl Acad Sci USA 2006, 103:11160-5"	"In melanoma cells with high MAGE-A expression, trichostatin synergizes with etoposide. MAGE-A acts through p53 inhibition in p53 wild type melanoma cells (the MAGE/p53 complex recruits HDAC3, which downregulates the transactivation function of p53)"1669	Melanoma	HDAC	Histone deacetylase	protein	inhibited by	Plitidepsin	Aplidin	sensitivity to	Dacarbazine	DTIC	3	1		"Munoz-Alonso MJ, J Pharmacol Exp Ther 2008, 324:1093-101"	Rac1/JNK activation is critical for cell cycle arrest and apoptosis induction by plitidepsin (a marine depsipeptide) in melanoma cells1670	Melanoma	HDAC	Histone deacetylase	protein	inhibited by	Butyric acid	HDAC inhibitor	sensitivity to	Radiotherapy		3	1		"Munshi A, Clin Cancer Res 2005, 11:4912-22"	HDAC inhibitors radiosensitize human tumor cells by affecting their ability to repair the DNA damage induced by ionizing radiation (gamma-H2AX phosphorylation could be used as a predictive marker of radioresponse)1671	Melanoma	HDAC	Histone deacetylase	protein	inhibited by	Trichostatin		sensitivity to	Radiotherapy		3	1		"Munshi A, Clin Cancer Res 2005, 11:4912-22"	HDAC inhibitors radiosensitize human tumor cells by affecting their ability to repair the DNA damage induced by ionizing radiation (gamma-H2AX phosphorylation could be used as a predictive marker of radioresponse)1672	Melanoma	Proteasome		protein	inhibited by	MG132		sensitivity to	Radiotherapy		3	1		"Munshi A, Mol Cancer Ther 2004, 3:985-92"	MG132 (a proteasome inhibitor) seems to act through NFkB inhibition. Radiotherapy can induce NFkB activity1673	Melanoma	ROCK		protein	inhibited by	Wf-536		sensitivity to	Paclitaxel	Taxol	2	1		"Nakajima M, Cancer Chemother Pharmacol 2003, 52:319-24"	"ROCK phosphorylates and activates DAPK3, which then regulates myosin light chain phosphatase through phosphorylation of MYPT1 thereby regulating the assembly of the actin cytoskeleton, cell migration, invasiveness of tumor cells"1674	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	inhibited by	O-6-benzylguanidine		sensitivity to	Fotemustine		3	1		"Naumann SC, Br J Cancer 2009, 100:322-33"	"MGMT inactivation by O(6)-benzylguanine sensitized all melanoma cell lines expressing MGMT to TMZ and fotemustine-induced apoptosis, and MGMT transfection attenuated the apoptotic response"1675	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	inhibited by	O-6-benzylguanidine		sensitivity to	Temozolomide	TMZ	3	1		"Naumann SC, Br J Cancer 2009, 100:322-33"	"MGMT inactivation by O(6)-benzylguanine sensitized all melanoma cell lines expressing MGMT to TMZ and fotemustine-induced apoptosis, and MGMT transfection attenuated the apoptotic response"1676	Melanoma	Mcl-1		protein	inhibited by	Obatoclax	GX15-070	sensitivity to	Bortezomib	Velcade (R)	1	1		"Nguyen M, Proc Natl Acad Sci USA 2007, 104:19512-7"	Obatoclax is a Bcl-2 family (including Mcl-1) inhibitor that induces apoptosis through Bak and Bax activity; bortezomib is a proteasome inhibitor1677	Melanoma	MEK	"MEK1, MEK2"	protein	inhibited by	U0126		sensitivity to	TNF	Tumor necrosis factor	1	1		"Nishida S, Life Sci 2003, 74:781-92"	"MEK1/2 plays an important role in TNFalpha-resistance and is more important than NFkB, Akt, and p38MAPK in anti-apoptotic PKC signaling; TNFalpha-resistance can be overcome by inhibiting MEK1/2"1678	Melanoma	PKC	Protein kinase C	protein	inhibited by	H7		sensitivity to	TNF	Tumor necrosis factor	1	1		"Nishida S, Life Sci 2003, 74:781-92"	"MEK1/2 plays an important role in TNFalpha-resistance and is more important than NFkB, Akt, and p38MAPK in anti-apoptotic PKC signaling; TNFalpha-resistance can be overcome by inhibiting MEK1/2"1679	Melanoma	ROS	Reactive oxygen species		upregulated by	Elesclomol		sensitivity to	Paclitaxel	Taxol	6	1	81	"O'Day S, J Clin Oncol 2009, 27:5452-8 "	Elesclomol is believed to act by increasing reactive oxygen species (ROS) levels. This phase II RCT showed an increased progression free survival (no increase in overall response rate or overall survival was demonstrated) that warrants further investigation according to the Authors1680	Melanoma	"KIT, PDGFR"		protein	inhibited by	Imatinib	Gleevec (R)	sensitivity to	Dacarbazine	DTIC	2	1		"Ogawa Y, J Dermatol Sci 2008, 51:190-9"	"Imatinib mesylate enhanced the antitumor effect of dacarbazine on in vivo growth and lung metastases of melanoma cells, although treatment with only imatinib mesylate had no effect. Dacarbazine uptake in melanoma was more than three-times increased by treatment with imatinib mesylate, while its uptake in serum or bone marrow was not affected by imatinib mesylate"1681	Melanoma	PARP	Poly ADP-ribose polymerase 	protein	inhibited by	ABT-888		sensitivity to	Temozolomide	TMZ	2	1		"Palma JP, Anticancer Res 2008, 28:2625-36"	"ABT-888 enhanced TMZ antitumor activity, in a dose-proportional manner with no observed toxicity (44-75% tumor growth inhibition vs. TMZ monotherapy), but did not show single agent activity (identical results in Donawho, Clin Cancer Res 2007, 13:2728-37)"1682	"Melanoma, endothelial cells"	"BRAF, CRAF, VEGFR, PDGFR"		protein	inhibited by	Sorafenib	Nexavar (R)	sensitivity to	GSK3B siRNA		3	1		"Panka DJ, J Biol Chem 2008, 283:726-32"	"Sorafenib upregulates GSK3B, which restrains sorafenib therapeutic activity likely by downregulating Noxa"1683	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	inhibited by	O-6-benzylguanidine		sensitivity to	Fotemustine		3	1		"Passagne I, J Pharmacol Exp Ther 2003, 307:816-23"	Coincubation of melanoma cells with O6-benzylguanine significantly increased the cytotoxicity of fotemustine1684	Immune cells	CD25		protein	inhibited by	CD25 antibody		sensitivity to	CTLA4 antibody (antagonist) + vaccine		2	1		"Peggs KS, J Exp Med 2009, 206:1717-25"	"Vaccine/CTLA4 mAb drives CD4+ effector T cell into the cell cycle, but also induces expansion of the Treg cell compartment in the periphery: therapeutic CD25-targeted Treg cell depletion controls the systemic accumulation of Treg cells, facilitating immune mediated tumor rejection"1685	Plasma/serum	VEGF	Vascular endothelial growth factor	protein	inhibited by	Bevacizumab	Avastin (R)	sensitivity to	Paclitaxel + Carboplatin		5	1	53	"Perez DG, Cancer 2009, 115:119-27"	"In this phase II trial (metastatic melanoma), bevacizumab + carboplatin + paclitaxel yielded partial response in 17% of cases and stable disease in 30% of cases"1686	Melanoma	Proteasome		protein	inhibited by	Bortezomib	Velcade (R)	sensitivity to	Mcl-1 siRNA		3	1		"Qin JZ, Cancer Res 2006, 66:9636-45"	In this model bortezomib seems to act by increasing NOXA levels1687	Melanoma	Mcl-1		protein	inhibited by	Fludarabine		sensitivity to	Bortezomib	Velcade (R)	3	1		"Qin JZ, Cancer Res 2006, 66:9636-45"	In this model bortezomib seems to act by increasing NOXA levels and fludarabine by decreasing Mcl-1 levels1688	Melanoma	Proteasome		protein	inhibited by	Bortezomib	Velcade (R)	sensitivity to	Fludarabine		3	1		"Qin JZ, Cancer Res 2006, 66:9636-45"	In this model bortezomib seems to act by increasing NOXA levels and fludarabine by decreasing Mcl-1 levels1689	Melanoma	H2AX		protein	phosphorylated	Dbait	DNA damage mimic	sensitivity to	Radiotherapy		4	1		"Quanz M, Clin Cancer Res 2009, 15:1308-16"	Dbait is a small molecule mimicking DNA damage (it causes H2AX phosphorylation) that inhibits DNA repair and thus sensitizes to radiotherapy1690	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	inhibited by	IBgBZ		sensitivity to	Cystemustine		4	1		"Rapp M, J Pharmacol Exp Ther 2008, 326:171-7"	"IBgBZ is designed as a conjugate of O(6)-(4-iododbenzyl)guanine (IBg) as the MGMT inactivator and a N,N-diethylaminoethylenebenzamido (BZ) moiety as the carrier to the malignant melanocytes"1691	Melanoma	TRAILR1	DR4		upregulated by	Decitabine	5-aza-2'-deoxycytidine 	sensitivity to	IFN beta		4	1		"Reu FJ, J Clin Oncol 2006, 24:3771-9"	Xenograft model was tested only for IFN beta1692	Immune cells	CTLA4		protein	inhibited by	Tremelimumab	CTLA4 antibody (antagonist)	sensitivity to	Vaccine (dendritic cells)		5	1	16	"Ribas A, Clin Cancer Res 2009, 15:6267-76"	The combination of MART-1 peptide-pulsed DC and tremelimumab results in objective and durable tumor responses (4/16) at the higher range of the expected response rate with either agent alone. No direct demonstration of synergism (phase I-II trial)1693	Melanoma	FKBP51	FK506 binding protein 51	protein	inhibited by	Rapamycin	Sirolimus	sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Romano MF, Eur J Cancer 2004, 40:2829-36"	"Doxorubicin is a NFkB inducer. Rapamycin inhibits FKBP51 that activates IKK (which inhibits IkB, the NFkB inhibitor)"1694	Melanoma	Autotaxin	ATX	protein	inhibited by	VPC8a202		sensitivity to	Paclitaxel	Taxol	3	1		"Samadi N, Oncogene 2009, 28:1028-39"	"ATX converts extracellular lysophosphatidylcholine (LPC) into lysophosphatidate (LPA), which strongly antagonized Taxol-induced apoptosis through stimulating phosphatidylinositol 3-kinase (PI3K) and inhibiting the formation of ceramide (a proapoptotic agent)"1695	Melanoma	Methionine cycle pathway		protein	inhibited by	TMECG		sensitivity to	S-adenosylmethionine 	SAM	3	1		"Sánchez-del-Campo L, Int J Cancer 2008, 123:2446-55"	"TMECG and SMA interfere with the methionine cycle, which is overactivated in malignant cells"1696	Melanoma	Geranylgeranyl transferase		protein	inhibited by	GGTI-298		sensitivity to	IFN gamma		3	1		"Sarrabayrouse G, PLoS One 2010, 5:e9043"	Co-administration of IFN-gamma and geranylgeranyl transferase inhibitor GGTI-298 enhance generation and activity of melanoma-specific cytotoxic T cells (CTL)1697	Melanoma	EGFR	ERBB1	protein	inhibited by	Erlotinib	Tarceva (R)	sensitivity to	Bevacizumab	Avastin (R)	4	1		"Schicher N, Clin Cancer Res 2009, 15:3495-502"	"Bevacizumab: anti-VEGF antibody. In vivo, in a severe combined immunodeficient mouse xenotransplantation model, reduction in tumor volume under combined treatment with erlotinib and bevacizumab was superior to the additive effect of both single agents"1698	Plasma/serum	VEGF	Vascular endothelial growth factor	protein	inhibited by	Bevacizumab	Avastin (R)	sensitivity to	Erlotinib	Tarceva (R)	4	1		"Schicher N, Clin Cancer Res 2009, 15:3495-502"	"Erlotinib: small molecule inhibitor of EGFR. In vivo, in a severe combined immunodeficient mouse xenotransplantation model, reduction in tumor volume under combined treatment with erlotinib and bevacizumab was superior to the additive effect of both single agents"1699	Melanoma	IKKB	IKB kinase beta	protein	inhibited by	KINK-1		sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Schon M, J Natl Cancer Inst 2008, 100:862-75"	KINK-1 ultimately acts by inhibiting NFkB (which is upregulated by some chemotherapeutic drugs). KINK-1 worked also in mice with syngeneic melanoma. The synergism was demonstrated also in an in vivo mouse model1700	Melanoma	IKKB	IKB kinase beta	protein	inhibited by	KINK-1		sensitivity to	Camptothecin		3	1		"Schon M, J Natl Cancer Inst 2008, 100:862-75"	KINK-1 ultimately acts by inhibiting NFkB (which is upregulated by some chemotherapeutic drugs). KINK-1 worked also in mice with syngeneic melanoma. The synergism was demonstrated also in an in vivo mouse model1701	Melanoma	Proteasome		protein	inhibited by	Bortezomib	Velcade (R)	sensitivity to	Dendritic cell immunotherapy		2	1		"Schumacher LY, J Immunol 2006, 176:4757-65"	"Established subcutaneous B16 tumors had significantly decreased tumor outgrowth when treated with a combination of bortezomib and dendritic cells, regardless of whether the dendritic cells were loaded or not with a tumor Ag"1702	Melanoma	ROS	Reactive oxygen species		upregulated by	Imexon		sensitivity to	Cisplatin	CDDP	3	1		"Scott J, Cancer Chemother Pharmacol 2007, 59:749-57"	"The consistent synergy seen for imexon and alkylating agents may relate to the sulfhydryl-lowering effect of imexon, which would render cells more sensitive to electrophilic species from the alkylators"1703	Melanoma	ROS	Reactive oxygen species		upregulated by	Imexon		sensitivity to	Cytarabine	Cytosine arabinoside	3	1		"Scott J, Cancer Chemother Pharmacol 2007, 59:749-57"	The marked synergy noted with pyrimidine-based antimetabolites was unexpected and may relate to the induction of cell cycle arrest in S-phase1704	Melanoma	ROS	Reactive oxygen species		upregulated by	Imexon		sensitivity to	Dacarbazine	DTIC	3	1		"Scott J, Cancer Chemother Pharmacol 2007, 59:749-57"	"The consistent synergy seen for imexon and alkylating agents may relate to the sulfhydryl-lowering effect of imexon, which would render cells more sensitive to electrophilic species from the alkylators"1705	Melanoma	ROS	Reactive oxygen species		upregulated by	Imexon		sensitivity to	Docetaxel		3	1		"Scott J, Cancer Chemother Pharmacol 2007, 59:749-57"	Docetaxel and Imexon synergically killed melanoma cells1706	Melanoma	ROS	Reactive oxygen species		upregulated by	Imexon		sensitivity to	5-Fluorouracil	5-FU	3	1		"Scott J, Cancer Chemother Pharmacol 2007, 59:749-57"	The marked synergy noted with pyrimidine-based antimetabolites was unexpected and may relate to the induction of cell cycle arrest in S-phase1707	Melanoma	ROS	Reactive oxygen species		upregulated by	Imexon		sensitivity to	Gemcitabine		3	1		"Scott J, Cancer Chemother Pharmacol 2007, 59:749-57"	The marked synergy noted with pyrimidine-based antimetabolites was unexpected and may relate to the induction of cell cycle arrest in S-phase1708	Melanoma	ROS	Reactive oxygen species		upregulated by	Imexon		sensitivity to	Melphalan	L-PAM	3	1		"Scott J, Cancer Chemother Pharmacol 2007, 59:749-57"	"The consistent synergy seen for imexon and alkylating agents may relate to the sulfhydryl-lowering effect of imexon, which would render cells more sensitive to electrophilic species from the alkylators"1709	Immune cells	IDO	"Indoleamine 2,3-dioxygenase"	protein	inhibited by	1-methyl-tryptophan	1-MT	sensitivity to	Vaccine		2	1		"Sharma MD, Blood 2009, 113:6102-11"	"In vivo, using a model of established B16 melanoma, the combination of an IDO-inhibitor drug plus antitumor vaccine caused upregulation of IL-6 in dendritic cells and in situ conversion of a majority of Tregs to the TH17 phenotype, with marked enhancement of CD8+ T-cell activation and antitumor efficacy"1710	Melanoma	MEK		protein	inhibited by	CI-1040		sensitivity to	LY294002	AKT inhibitor	3	1		"She QB, Cancer Cell 2005, 8:287-97"	LY294002 is a PI3K inhibitor. Both MEK and PI3K/AKT must be inhibited to restore BAD pro-apoptotic activity. The cell line used is PTEN deficient1711	Melanoma	PI3K		protein	inhibited by	LY294002		sensitivity to	CI-1040	PD184352	3	1		"She QB, Cancer Cell 2005, 8:287-97"	CI-1040 is a MEK inhibitor. Both MEK and PI3K/AKT must be inhibited to restore BAD pro-apoptotic activity. The cell line used is PTEN deficient1712	Melanoma	"VEGFR1, VEGFR2, VEGFR3"		protein	inhibited by	PTK787/ZK222584	PTK/ZK	sensitivity to	Cisplatin	CDDP	1	1		"Sini P, Cancer Res 2008, 68:1581-92"	PTK/ZK is a small molecule inhibitor of the 3 VEGFR1713	Melanoma	"VEGFR1, VEGFR2, VEGFR3"		protein	inhibited by	PTK787/ZK222584	PTK/ZK	sensitivity to	Oxaliplatin		1	1		"Sini P, Cancer Res 2008, 68:1581-92"	PTK/ZK is a small molecule inhibitor of the 3 VEGFR1714	Melanoma	Tyrosinase		protein	inhibited by	D-penicillamine		sensitivity to	Cyclophosphamide	CTX	3	1		"Slominski A, Int J Cancer 2009, 124:1470-7"	"The inhibition of melanogenesis by blocking tyrosinase sensitized melanoma cells towards cytotoxic action of cyclophosphamide, and amplified immunotoxic activities of IL-2 activated lymphocytes. D-penicillamine (and N-phenylthiourea) inhibit melanogenesis and tyrosinase activity in SKMEL-188 melanoma cells"1715	Melanoma	Tyrosinase		protein	inhibited by	D-penicillamine		sensitivity to	Immunotherapy (IL-2 activated lymphocytes)		3	1		"Slominski A, Int J Cancer 2009, 124:1470-7"	"The inhibition of melanogenesis by blocking tyrosinase sensitized melanoma cells towards cytotoxic action of cyclophosphamide, and amplified immunotoxic activities of IL-2 activated lymphocytes. D-penicillamine (and N-phenylthiourea) inhibit melanogenesis and tyrosinase activity in SKMEL-188 melanoma cells"1716	Melanoma	Farnesyl transferase (RAS)		protein	inhibited by	SCH66336		sensitivity to	Cisplatin	CDDP	3	1		"Smalley KS, Int J Cancer 2003, 105:165-75"	Farnesyl transferase inhibitors interfere with RAS signaling1717	Melanoma	PI3K		protein	inhibited by	LY294002		sensitivity to	U0126	MEK inhibitor	3	1		"Smalley KS, Mol Cancer Ther 2006, 5:1136-44"	U0126 is a MEK inhibitor. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases1718	Melanoma	MEK		protein	inhibited by	U0126		sensitivity to	LY294002	AKT inhibitor	3	1		"Smalley KS, Mol Cancer Ther 2006, 5:1136-44"	LY294002 is a PI3K inhibitor. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases1719	Immune cells	CTLA4		protein	inhibited by	CTLA4 antibody (antagonist)		sensitivity to	CD25 antibody (antagonist)		2	1		"Sutmuller RP, J Exp Med 2001, 194:823-32"	CD25 antibody leads to depletion of CD25+ Treg cells (immunosuppressive cells). CTLA4: co-inhibitory molecule1720	Immune cells	CD25		protein	inhibited by	CD25 antibody		sensitivity to	CTLA4 antibody (antagonist)		2	1		"Sutmuller RP, J Exp Med 2001, 194:823-32"	CD25 antibody leads to depletion of CD25+ Treg cells (immunosuppressive cells). CTLA4: co-inhibitory molecule1721	Melanoma	Nitric oxide	NO		downregulated by	c-PTIO		sensitivity to	Cisplatin	CDDP	3	1		"Tang CH, J Biol Chem 2004, 279:288-98"	Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines1722	Melanoma	Integrin alpha V		protein	inhibited by	Cilengitide		sensitivity to	Temozolomide	TMZ	2	1		"Tentori L, Oncol Rep 2008, 19:1039-43"	The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma1723	Melanoma	mTOR	Mammalian target of rapamycin	protein	inhibited by	Temsirolimus	CCI-779	sensitivity to	Dacarbazine	DTIC	4	1		"Thallinger C, J Invest Dermatol 2007, 127:2411-7"	"CCI-779 has the potential to increase the chemotherapeutic efficacy, as the combination of CCI-779 plus DTIC proved to be more efficacious compared to DTIC monotherapy in two out of three melanoma cell lines in vivo"1724	Melanoma	mTOR	Mammalian target of rapamycin	protein	inhibited by	Temsirolimus	CCI-779	sensitivity to	Cisplatin	CDDP	4	1		"Thallinger C, Pharmacology 2007, 79:207-13"	CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model1725	Melanoma	XIAP		protein	inhibited by	UVB	Ultraviolet B light	sensitivity to	TRAIL		3	1		"Thayaparasingham B, Oncogene 2009, 28:345-62"	"UVB cause XIAP degradation, which enhances TRAIL effect. Quite unexpectedly, UVB sensitization is mediated by NFkB, which mediates XIAP downregulation"1726	Melanoma	PARP-1	Poly ADP-ribose polymerase 1	protein	inhibited by	PARP-1 inhibitors (benzimidazole-based)		sensitivity to	Temozolomide	TMZ	2	1		"Tong Y, J Med Chem 2009, 52:6803-13"	"Compounds 24 and 44, featuring an oxadiazole and a pyridine moiety, respectively, demonstrated balanced potency and pharmacokinetics profiles: these two molecules exhibited potent oral in vivo efficacy in potentiating the cytotoxic agent temozolomide in a B16F10 murine melanoma model"1727	Melanoma	HDAC	Histone deacetylase	protein	inhibited by	Butyric acid	HDAC inhibitor	sensitivity to	PUVA	Psoralen + UVA	3	1		"Toyooka T, Cancer Res 2009, 69:3492-500"	Histone deacetylase inhibitor sodium butyrate enhances the cell killing effect of psoralen plus UVA by attenuating nucleotide excision repair1728	Melanoma	AKT	PKB	protein	inhibited by	Ceramide		sensitivity to	Sorafenib	Nexavar (R)	4	1		"Tran MA, Clin Cancer Res 2008, 14:3571-81"	"Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor"1729	"Melanoma, endothelial cells"	"BRAF, CRAF, VEGFR, PDGFR"		protein	inhibited by	Sorafenib	Nexavar (R)	sensitivity to	Ceramide		4	1		"Tran MA, Clin Cancer Res 2008, 14:3571-81"	Ceramide is an AKT inhibitor1730	Melanoma	"KIT, PDGFR"		protein	inhibited by	Imatinib	Gleevec (R)	sensitivity to	Temozolomide	TMZ	4	1		"Triozzi PL, Melanoma Res 2008, 18:420-30"	Imatinib causes TMZ resistance in vitro while it is synergistic with TMZ in vivo1731	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	inhibited by	O-6-benzylguanidine		sensitivity to	Temozolomide	TMZ	4	1		"Ueno T, Mol Cancer Ther 2006, 5:732-8"	Isolated limb infusion model (locoregional therapy)1732	Melanoma	HDAC	Histone deacetylase	protein	inhibited by	Valproic acid		sensitivity to	Etoposide	VP-16	3	1		"Valentini A, Cancer Biol Ther 2007, 6:185-91"	Valproate chemosensitizes melanoma in association with upregulation of p161733	Melanoma	HDAC	Histone deacetylase	protein	inhibited by	Valproic acid		sensitivity to	Cisplatin	CDDP	3	1		"Valentini A, Cancer Biol Ther 2007, 6:185-91"	Valproate chemosensitizes melanoma in association with upregulation of p161734	Melanoma	NFkB (p65/RelA)	Nuclear factor kappa B	protein	inhibited by	Dimethylfumarate	DMF	sensitivity to	Dacarbazine	DTIC	4	1		"Valero T, J Invest Dermatol 2010, 130:1087-94"	"DMF is believed to act through NFkB inhibition (Vandermeeren M, J Invest Dermatol 2001, 116:124-30). DTIC + DMF therapy significantly reduced mRNA expression and protein concentration of the promigratory chemokines CXCL2 and CXCL11"1735	Immune cells	CTLA4		protein	inhibited by	CTLA4 antibody (antagonist)		sensitivity to	Vaccine (GMCSF producing tumor cells)		2	1		"van Elsas A, J Exp Med 2001, 194:481-9"	The combination therapy induced tumor rejection and skin depigmentation in B cell-deficient and in CD4(+) T cell-depleted mice. Both effects of the treatment absolutely required CD8(+) T cells1736	Melanoma	"Bcl-2, Bcl-xL, Mcl-1"		protein	inhibited by	TW-37		sensitivity to	U0126	MEK inhibitor	4	1		"Verhaegen M, Cancer Res 2006, 66:11348-59"	U0126 is a MEK inhibitor. This combination regimen is tumor selective through ROS/p53 activation (which does not occur in normal melanocytes)1737	Melanoma	MEK		protein	inhibited by	U0126		sensitivity to	TW-37		4	1		"Verhaegen M, Cancer Res 2006, 66:11348-59"	"TW-37 inhibits Bcl-2, Bcl-xL and Mcl-1. This combination regimen is tumor selective through ROS/p53 activation (which does not occur in normal melanocytes)"1738	Melanoma	HDAC	Histone deacetylase	protein	inhibited by	LAQ824		sensitivity to	Adoptive cell therapy (immunotherapy)		2	1		"Vo DD, Cancer Res 2009, 69:8693-9"	This study showed enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824 (melanoma cells used for the challenge were previously treated with LAQ824)1739	Melanoma	Proteasome		protein	inhibited by	MG132		sensitivity to	Evodiamine		3	1		"Wang C, Toxicol In Vitro 2010, 24:898-904"	Evodiamine is a major alkaloidal component of Evodiae fructus 1740	Melanoma	IAP (family)	Inhibitor of apoptosis protein (family)	protein	inhibited by	LBW242	Smac mimetic	sensitivity to	Poly(I:C)	TLR3 agonist	3	1		"Weber A, Cell Death Differ 2010, 17:942-51"	"Poly I:C is a toll like receptor 3 (TLR3) agonist. Sensitisation towards poly I:C-dependent caspase-8 activation and apoptosis in melanoma cells was also achieved by the synthetic Smac mimetic/inhibitor of apoptosis protein (IAP) antagonist, LBW242, or by specific downregulation of cIAP1 by siRNA"1741	Melanoma	Bcl-2		protein	inhibited by	ABT-737		sensitivity to	Dacarbazine	DTIC	3	1		"Weber A, Transl Oncol 2009, 2:73-83"	"Strong synergistic proapoptotic effect of the Bcl-2 family inhibitor ABT-737 and the standard antimelanoma drugs, namely, dacarbazine and fotemustine, and the experimental agent, imiquimod. This synergism depends on Noxa, as demonstrated by experiments with Noxa-specific siRNA"1742	Melanoma	Bcl-2		protein	inhibited by	ABT-738		sensitivity to	Fotemustine		3	1		"Weber A, Transl Oncol 2009, 2:73-83"	"Strong synergistic proapoptotic effect of the Bcl-2 family inhibitor ABT-737 and the standard antimelanoma drugs, namely, dacarbazine and fotemustine, and the experimental agent, imiquimod. This synergism depends on Noxa, as demonstrated by experiments with Noxa-specific siRNA"1743	Melanoma	Bcl-2		protein	inhibited by	ABT-738		sensitivity to	Imiquimod	TLR agonist	3	1		"Weber A, Transl Oncol 2009, 2:73-83"	"Strong synergistic proapoptotic effect of the Bcl-2 family inhibitor ABT-737 and the standard antimelanoma drugs, namely, dacarbazine and fotemustine, and the experimental agent, imiquimod. This synergism depends on Noxa, as demonstrated by experiments with Noxa-specific siRNA"1744	Melanoma	"mTOR, PI3K"		protein	inhibited by	Rapamycin + LY294002		sensitivity to	Rictor siRNA		3	1		"Werzowa J, Br J Dermatol 2009, 160:955-64"	mTORC2 (mTOR complexed with Rictor) inhibition avoids AKT phosphorylation due to PI3K and mTORC1 inhibition (following activation of regulatory loops involving RS6K and IRS1)1745	Melanoma	Mcl-1		protein	inhibited by	Gossypol		sensitivity to	Bortezomib	Velcade (R)	4	1		"Wolter KG, Cell Death Differ 2007, 14:1605-16"	"Gossypol inhibits Bcl-2, Bcl-xL and Mcl-1, but siRNA experiments showed that Mcl-1 must be inhibited to synergize with bortezomib. Mcl-1 is induced by bortezomib, which reduces its therapeutic activity."1746	Melanoma	TLR2	Toll like receptor 2	protein	inhibited by	TLR2 antibody (antagonist)		sensitivity to	Gemcitabine		2	1		"Yang HZ, PLoS One 2009, 4:e6520"	Combining the TLR2 Ab and chemotherapeutic agent GC significantly improved the therapeutic efficacy of treating the pulmonary metastasis of B16 cells and the survival rate of tumor-bearing mice compared to mice treated with GC alone1747	Melanoma	IKKB	IKB kinase beta	protein	inhibited by	BMS-345541	NFkB inhibitor	sensitivity to	Temozolomide	TMZ	4	1		"Yang J, Mol Cancer Ther 2009, 8:636-47"	"BMS-345541 is an IKKB inhibitor and thus a NFkB inhibitor (IKKB inhibits IKB, which in turn inhibits NFkB)"1748	Melanoma	FLIP	c-FLIP	protein	inhibited by	UVB	Ultraviolet B light	sensitivity to	TRAIL		3	1		"Zeise E, J Invest Dermatol 2004, 123:746-54"	Resistance of human melanoma cells against the death ligand TRAIL is reversed by ultraviolet-B radiation via downregulation of FLIP1749	Melanoma	MEK		protein	inhibited by	U0126		sensitivity to	TRAIL		3	1		"Zhang XD, Oncogene 2003, 22:2869-81"	Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria1750	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 		downregulated by	IL-24	Interleukin-24	sensitivity to	Temozolomide	TMZ	3	1		"Zheng M, Mol Cancer Ther 2008, 7:3842-51"	Interleukin-24 overcomes temozolomide resistance and enhances cell death by downregulation of O6-methylguanine-DNA methyltransferase in human melanoma cells1751	Melanoma	JNK		protein	inhibited by	SP600125	JNK inhibitor	resistance to	Celastrol		1	-1		"Abbas S, Clin Cancer Res 2007, 13(22 Pt 1):6769-78"	"Celastrol and AIGA have anti-melanoma effects likely by acting as ATF2 inhibitors, which seems to require JNK activity"1752	Melanoma	JNK		protein	inhibited by	SP600125	JNK inhibitor	resistance to	AIGA	Acetyl isogambogic acid	1	-1		"Abbas S, Clin Cancer Res 2007, 13(22 Pt 1):6769-78"	"Celastrol and AIGA have anti-melanoma effects likely by acting as ATF2 inhibitors, which seems to require JNK activity"1753	Immune cells	Immunity pathway			modulated by	BCG	Bacillus Calmette-Guerin	no relationship with	Dacarbazine	DTIC	6	0	734	"Agarwala SS, Cancer 2004, 100:1692–8"	"In this phase III RCT, immunostimulation with BCG did not increase the therapeutic effect of DTIC in patients with stage I-III skin melanoma"1754	Immune cells	IFNAR	IFN alpha receptor	protein	activated by	IFN alpha	Interferon alpha	sensitivity to	Diosmine		2	1		"Alvarez N, Cancer Biother Radiopharm 2009, 24:347-52"	"In an in vivo murine model, diosmin (a flavonoid) and interferon-alpha showed synergic anti-melanoma activity"1755	Melanoma	ERK		protein	inhibited by	PD98059	MEK inhibitor	resistance to	IL-1	Interleukin-1	3	-1		"Arakawa T, Int Immunopharmacol 2008, 8:80-9"	"A selective inhibitor of ERK1/2 pathway, PD98059 and a selective inhibitor of p38MAPK, SB203580 each alone significantly reversed the IL-1-induced growth inhibition of A375-6 cells. Co-treatment with PD98059 and SB203580 completely reversed the IL-1-induced growth inhibition"1756	Melanoma	p38 MAPK		protein	inhibited by	SB203580		resistance to	IL-1	Interleukin-1	3	-1		"Arakawa T, Int Immunopharmacol 2008, 8:80-9"	"A selective inhibitor of ERK1/2 pathway, PD98059 and a selective inhibitor of p38MAPK, SB203580 each alone significantly reversed the IL-1-induced growth inhibition of A375-6 cells. Co-treatment with PD98059 and SB203580 completely reversed the IL-1-induced growth inhibition"1757	Immune cells	"CCR1, CCR3, CCR5"		protein	activated by	CCL5	Rantes	sensitivity to	gp100 vaccine		2	1		"Aravindaram K, Gene Ther 2009, 16:1329-39"	"In a mouse in vivo melanoma model, vaccination with chemokine RANTES and gp100 is more effective than gp100 alone"1758	Immune cells	TLR2	Toll like receptor 2	protein	activated by	Pam3		sensitivity to	Adoptive cell therapy (immunotherapy)		2	1		"Asprodites N, FASEB J 2008, 22:3628-37"	"Adoptive OT-1 T-cell transfer into wild-type and MyD88(-/-) mice, followed by injection with TLR1/2 ligand, resulted in a synergistic antitumor effect"1759	Immune cells	"IL2R, IFNAR"	"IL-2 receptor, IFN alpha receptor"	protein	activated by	IL-2 + IFN alpha		no relationship with	Cisplatin + Vinblastine + Dacarbazine	CVD	6	0	415	"Atkins MB, J Clin Oncol 2008, 26:5748-54"	IL2 + IFN alpha do not increase the therapeutic effect of CVD regimen in terms of overall survival1760	Endothelial cells	IFNAR	IFN alpha receptor	protein	activated by	IFN alpha 2b		sensitivity to	Thalidomide		4	1		"Bauer JA, J Interferon Cytokine Res 2003, 23:3-10"	IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis1761	"Melanoma, endothelial cells, immune cells"	TNFR	TNF receptor	protein	activated by	TNF	Tumor necrosis factor	sensitivity to	Melphalan	L-PAM	4	1		"Bauer TW, Surgery 2003, 133:420-8"	Isolated limb perfusion model (locoregional therapy)1762	Melanoma	COX-2	Cyclooxygenase 2	protein	inhibited by	Celecoxib		no relationship with	Paclitaxel (metronomic schedule)	Taxol	5	0	20	"Bhatt RS, Cancer 2010, 116:1751-6"	"In this phase II trial (metastatic setting), low-dose, continuous intravenous infusion paclitaxel and oral celecoxib produced one partial response (5%) and three (15%) disease stabilizations in heavily pretreated patients with melanoma"1763	Melanoma	COX-2	Cyclooxygenase 2	protein	downregulated by	Celecoxib		no relationship with	Paclitaxel (metronomic schedule)	Taxol	5	0	20	"Bhatt RS, Cancer 2010, 116:1751-6"	"In this phase II trial (metastatic setting), low-dose, continuous intravenous infusion paclitaxel and oral celecoxib produced one partial response (5%) and three (15%) disease stabilizations in heavily pretreated patients with melanoma"1764	Endothelial cells	Angiogenesis pathway			modulated by	Angiostatin + Endostatin gene therapy		sensitivity to	"Vaccine (pDNA encoding gp100, TRP2, Ii-PADRE)"		2	1		"Chan RC, Oncol Rep 2009, 22:1197-203"	"This study shows that the anti-tumor efficacy of vaccination with pDNAs encoding gp100, TRP2 and Ii-PADRE was enhanced by co-delivery of pDNAs encoding Angiostatin and/or Endostatin"1765	Immune cells	TLR9	Toll like receptor 9	protein	activated by	CpG oligonucleotide		sensitivity to	IL-18	Interleukin-18	2	1		"Chaudhry UI, Cancer Res 2006, 66:10497-504"	Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth1766	Immune cells	IL18R	Interleukin-18 receptor	protein	activated by	IL-18	Interleukin-18	sensitivity to	CpG oligonucleotide		2	1		"Chaudhry UI, Cancer Res 2006, 66:10497-504"	Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth1767	Melanoma	IFNAR	IFN alpha receptor	protein	activated by	IFN beta	Interferon beta	sensitivity to	TRAIL		3	1		"Chawla-Sarkar M, J Immunol 2002, 169:847-55"	IFN-beta and TRAIL/Apo2L combination treatment had more potent apoptotic and anti-growth effects when compared with either cytokine alone in melanoma cells lines1768	Melanoma	TRAILR	TRAIL receptor	protein	activated by	TRAIL		sensitivity to	IFN beta		3	1		"Chawla-Sarkar M, J Immunol 2002, 169:847-55"	IFN-beta and TRAIL/Apo2L combination treatment had more potent apoptotic and anti-growth effects when compared with either cytokine alone in melanoma cells lines1769	Melanoma	Tyrosinase		protein	inhibited by	1-phenyl-2-thiourea		resistance to	Cisplatin	CDDP	3	-1		"Chen KG, J Natl Cancer Inst 2009, 101:1259-71"	"Tyrosinase is a melanosome related protein; its inhibition leads to the formation of immature melanosomes, which in turn promotes chemoresistance (similar article by the same investigators: Chen KG, Proc Natl Acad Sci USA 2006, 103:9903-7)"1770	Melanoma	Tyrosinase		protein	inhibited by	1-phenyl-2-thiourea		resistance to	Cisplatin	CDDP	3	-1		"Chen KG, J Natl Cancer Inst 2009, 101:1259-71"	"Tyrosinase is a melanosome related protein; its inhibition leads to the formation of immature melanosomes, which in turn promotes chemoresistance (similar article by the same investigators: Chen KG, Proc Natl Acad Sci USA 2006, 103:9903-7)"1771	Melanoma	Ribosome		protein	inhibited by	scRIP	Single chain ribosome inactivating protein	sensitivity to	Dacarbazine	DTIC	4	1		"Cheung MC, Mol Cancer 2010, 9:28"	"Co-administration of scRIP (derived from the cytotoxic A subunit of Shiga like toxin 1, SLT-1A) with DTIC resulted in tumor regression and greatly increased survival in a mouse xenograft model in comparison to DTIC or scRIP treatment alone "1772	Immune cells	IL18R	Interleukin-18 receptor	protein	activated by	IL-18	Interleukin-18	sensitivity to	B7-1 gene therapy		2	1		"Cho D, J Invest Dermatol 2000, 114:928-34"	Melanoma cells were forced to express costimulatory molecule B7-1 (CD80)1773	Immune cells	CD137	4-1BB	protein	activated by	4-1BB antibody (agonist)	CD137 antibody (agonist)	sensitivity to	CD4+ cell depletion		2	1		"Choi BK, Cancer Res 2007, 67:8891-9"	"The combination of the two mAbs, agonistic anti-4-1BB and depleting anti-CD4, results in enhanced antimelanoma activity"1774	Melanoma	Estrogen receptor	ESR1		uncharacterized			no relationship with	Cisplatin + Dacarbazine + Carmustine 		6	0	184	"Creagan ET, J Clin Oncol 1999, 17:1884-90 "	"In this phase III RCT of the combination of cisplatin, dacarbazine and carmustine with or without tamoxifen in patients with advanced malignant melanoma no significant therapeutic benefit was observed by adding the anti-estrogen tamoxifen to polychemotherapy"1775	Endothelial cells	CD13	Aminopeptidase N	protein	targeted by	NGR peptide		sensitivity to	TNF + EMAP-II		2	1		"Crippa L, Cancer Res. 2008 Feb 15;68(4):1154-61"	"NGR peptide is a ligand for CD13, which is expressed by tumor vessels. NGR-TNF is a peptide-TNF conjugate able to target tumor blood vessels. EMAP-II sensitizes tumor vasculature to TNF"1776	Immune cells	GITR	TNFRSF18	protein	activated by	GITR antibody (agonist)		sensitivity to	Vaccine		2	1		"Duan F, Cancer Res 2009, 69:3545-53"	"B16 tumors expressing mutations that generate strongly immunogenic epitopes naturally induce T-cell responses, which are insufficient to reject tumors. Immune modulation, such as inducing GITR signaling, is required to enhance CD8(+) T-cell responses to specific mutations and to lead to tumor rejection"1777	Immune cells	Dipeptidyl peptidase	DPP	protein	inhibited by	Talabostat		no relationship with	Cisplatin	CDDP	5	0	40	"Eager RM, BMC Cancer 2009, 9:263"	"In a phase II trial of cisplatin + talabostat (an immunostimulatory dipeptidyl peptidase inhibitor) in stage IV melanoma patients, no advantage was observed over cisplatin alone (historical comparison)"1778	Immune cells	"IFNAR, IL2R"		protein	activated by	IFN alpha + IL-2		no relationship with	Cisplatin + Vinblastine + Dacarbazine 		6	0	190	"Eton O, J Clin Oncol 2002, 20:2045-52 "	"In this phase III RCT of the combination of cisplatin, dacarbazine and vinblastine with or without IFN-alpha and IL-2 in patients with advanced malignant melanoma no significant therapeutic benefit was observed by adding the two cytokines to polychemotherapy (biochemotherapy was not superior to polychemotherapy in terms of overall survival, although higher tumore response rates and time to progression was reported)"1779	Immune cells	CSF2R	GMCSF receptor	protein	activated by	GMCSF	CSF2	resistance to	Vaccine (allogeneic)		6	-1	97	"Faries MB, Clin Cancer Res 2009, 15:7029-35"	Adjuvant setting. GM-CSF is not helpful as an immune adjuvant in this dose and schedule and raise concern that it may be harmful (early melanoma deaths and a trend toward worse survival with GM-CSF were observed)1780	Melanoma	A3 adenosine receptor		protein	activated by	Cl-IB-MECA		sensitivity to	Cyclophosphamide	CTX	2	1		"Fishman P, Exp Cell Res 2001, 269:230-6"	Cl-IB-MECA: A3 adenosine receptor agonist1781	Melanoma	PPAR gamma	Peroxisome proliferator activated receptor gamma	protein	activated by	Rosiglitazone		sensitivity to	Bortezomib	Velcade (R)	3	1		"Freudlsperger C, Anticancer Res 2007, 27(1A):207-13"	Bortezomib is a proteasome inhibitor1782	Melanoma	IFNAR	IFN alpha receptor	protein	activated by	IFN alpha	Interferon alpha	no relationship with	Dacarbazine	DTIC	6	0	444	"Garbe C, Ann Oncol 2008, 19:1195-201"	Adjuvant setting; IFN alone increased survival1783	Melanoma	TRAILR	TRAIL receptor	protein	activated by	TRAIL		sensitivity to	SBHA		3	1		"Gillespie S, Apoptosis 2006, 11:2251-65"	"SBHA (HDAC inhibitor) downregulated Bcl-xL, Mcl-1 and XIAP, but upregulated Bax, Bak and Bim"1784	Melanoma	ERK		protein	inhibited by	U0126		resistance to	Nitroprusside	Nitric oxide(NO)-donating drug	3	-1		"Gomez-Sarosi LA, Cancer Biol Ther 2009, 8:1173-82"	"Constitutive ERK activation, characteristic of cancer cells, increases nitroprusside (SNP)-induced apoptosis: pretreatment with U0126 protected from SNP-mediated cell death "1785	Melanoma	ERK		protein	inhibited by	U0126		resistance to	Nitroprusside	Nitric oxide(NO)-donating drug	3	-1		"Gomez-Sarosi LA, Cancer Biol Ther 2009, 8:1173-82"	"Constitutive ERK activation, characteristic of cancer cells, increases nitroprusside (SNP)-induced apoptosis: pretreatment with U0126 protected from SNP-mediated cell death "1786	Melanoma	VDR	Vitamin D receptor	protein	activated by	Vitamin D3		no relationship with	Doxorubicin	Adriamycin (R)	3	0		"Gruber BM, Acta Pol Pharm 2003, 60:363-6"	Vitamin D3 metabolites calcidiol and calcitriol did not stimulate apoptotic events in the cells studied and did not influence apoptosis induction in the cells treated with adriamycin1787	Host	Hyaluronan		protein	inhibited by	Pep-1	Hyaluronan specific binding peptide	sensitivity to	IL-2	Interleukin-2	2	1		"Guan H, J Immunol 2007, 179:3715-23"	"Blocking hyaluronan (a large glycosaminoglycan, abundant in the extracellular matrix and on the cell surface) with Pep-1 dramatically inhibited IL-2-induced VLS (vascular leak syndrome, a life-threatening toxicity induced during IL-2 treatment of cancer patients) in both normal mice as well as in mice bearing melanoma. Moreover, Pep-1 treatment maintained the effectiveness of IL-2 and prevented the metastasis of melanoma"1788	Melanoma	IL29R	IL10R + IL28R heterodimer	protein	activated by	IL-29	Interleukin-29	sensitivity to	Bortezomib	Velcade (R)	3	1		"Guenterberg KD, Mol Cancer Ther 2010, 9:510-20"	Bortezomib-induced and temozolomide-induced apoptosis was synergistically enhanced following the addition of IL-291789	Melanoma	IL29R	IL10R + IL28R heterodimer	protein	activated by	IL-29	Interleukin-29	sensitivity to	Temozolomide	TMZ	3	1		"Guenterberg KD, Mol Cancer Ther 2010, 9:510-20"	Bortezomib-induced and temozolomide-induced apoptosis was synergistically enhanced following the addition of IL-291790	Plasma/serum	Thrombin		protein	inhibited by	Hirudin		sensitivity to	Vinblastine		2	1		"Guo RR, Biol Pharm Bull 2008, 31:696-702"	"Hirudin, a recombinant peptide inhibiting thrombin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of murine melanoma"1791	Melanoma	TRAILR	TRAIL receptor	protein	activated by	TRAIL		sensitivity to	Imatinib	Gleevec (R)	3	1		"Hamai A, Oncogene 2006, 25:7618-34"	Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death1792	"Melanoma, endothealial cells"	Integrin alpha V beta 3		protein	inhibited by	Etaracizumab		no relationship with	Dacarbazine	DTIC	6	0	112	"Hersey P, Cancer 2010, 116:1526-1534"	A randomized phase II study (metastatic setting) showed that dacarbazine does not add therapeutic benefit to etaracizumab (a monoclonal antibody against integrin alpha V beta 3) and that survival results in both treatment arms of this study were considered unlikely to result in clinically meaningful improvement over dacarbazine alone1793	Melanoma	RAR	Retinoic acid receptor	protein	activated by	Fenretinide	4-HPR	sensitivity to	Bortezomib	Velcade (R)	4	1		"Hill DS, Clin Cancer Res 2009, 15:1192-8"	Fenretinide is a synthetic retinoid derivative that seems to act also through RAR independent mechanisms. Bortezomib is a proteasome inhibitor. Both agents are capable of inducing endoplasmic reticulum (ER) stress induced apoptosis1794	Immune cells	OX40	TNFRSF4	protein	activated by	OX40 antibody (agonist)		sensitivity to	Cyclophosphamide	CTX	2	1		"Hirschhorn-Cymerman D, J Exp Med 2009, 206:1103-16"	"Combined use of the alkylating agent cyclophosphamide (CTX) and an agonist antibody targeting the co-stimulatory receptor OX40 (OX86) provides potent antitumor immunity capable of regressing established, poorly immunogenic B16 melanoma tumors"1795	Melanoma	SRC	c-Src	protein	inhibited by	Dasatinib	"BMS-354825, Sprycel"	no relationship with	Paclitaxel	Taxol	3	0		"Homsi J, Melanoma Res 2009, 19:167-75"	Dasatinib does not act synergically with paclitaxel1796	Melanoma	SRC	c-Src	protein	inhibited by	Dasatinib	"BMS-354825, Sprycel"	no relationship with	Temozolomide	TMZ	3	0		"Homsi J, Melanoma Res 2009, 19:167-75"	Dasatinib does not act synergically with temozolomide1797	Melanoma	IFNAR	IFN alpha receptor	protein	activated by	IFN beta	Interferon beta	sensitivity to	Mezerein		3	1		"Huynh KM, Gene 2009, 433:32-9"	"Metastatic human melanoma cells treated with IFN-beta plus mezerein (phorbol ester analog from the plant Daphne mezereum) undergo irreversible growth arrest and terminal differentiation followed by apoptosis, which is accompanied by downregulation of cell cycle related genes"1798	Melanoma	TRAILR	TRAIL receptor	protein	activated by	TRAIL		sensitivity to	KU-55933		3	1		"Ivanov VN, Cancer Res 2009, 69:3510-9"	KU-55933: ATM inhibitor. Suppression of ATM-dependent and STAT3-mediated antiapoptotic pathway sensitizes human melanoma cells to TRAIL-mediated apoptosis1799	Immune cells	IFNAR	IFN alpha receptor	protein	activated by	IFN alpha	Interferon alpha	no relationship with	Chemotherapy (miscellany)		7	0	1260	"Ives NJ, J Clin Oncol 2007, 25:5426-34"	This meta-analysis of 8 trials shows no overall survival advantage for the addition of IFN to chemotherapy1800	Immune cells	"IL2R, IFNAR"	"IL-2 receptor, IFN alpha receptor"	protein	activated by	IL-2 + IFN alpha		no relationship with	Chemotherapy (miscellany)		7	0	1206	"Ives NJ, J Clin Oncol 2007, 25:5426-34"	This meta-analysis of 8 trials shows no overall survival advantage for the addition of IL2 + IFN to chemotherapy1801	Melanoma	ER stress pathway			activated by	Tunicamycin		sensitivity to	Obatoclax		3	1		"Jiang CC, Neoplasia 2009, 11:945-55"	Obatoclax is a Mcl-1 inhibitor; tunicamycin is an endoplasmic reticulum (ER) stress inducer1802	Melanoma	ER stress pathway			activated by	Thapsigargin		sensitivity to	Obatoclax		3	1		"Jiang CC, Neoplasia 2009, 11:945-55"	Obatoclax is a Mcl-1 inhibitor; thapsigargin is an endoplasmic reticulum (ER) stress inducer1803	Melanoma	Bax		protein	inhibited by	Silibinin		resistance to	Mitomycin-C	MMC	3	-1		"Jiang YY, J Pharmacol Sci 2009, 111:137-46"	"Preincubation with silibinin prior to mitomycin C treatment substantially suppressed cell apoptosis, likely by blocking the translocation of Bax to mitochondrial outer membrane"1804	Melanoma	RAR	Retinoic acid receptor	protein	activated by	Retinoic acid		sensitivity to	LAQ824		4	1		"Kato Y, Mol Cancer Ther 2007, 6:70-81"	LAQ824 is a HDAC inhibitor. HDAC inhibits the expression of RAR 1805	Immune cells	IFNAR	IFN alpha receptor	protein	activated by	IFN alpha	Interferon alpha	no relationship with	Temozolomide	TMZ	6	0	294	"Kaufmann R, J Clin Oncol 2005, 35:9001-7"	Phase III RCT. Setting: advanced disease. No therapeutic benefit was observed by adding INF1805	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	inhibited by	Lomeguatrib		no relationship with	Temozolomide	TMZ	5	0	32	"Kefford RF, Br J Cancer 2009, 100:1245-9"	"In this phase I study of extended dosing with lomeguatrib with TMZ in patients with advanced melanoma, only limited clinical activity was seen, suggesting no advantage for this regimen over conventional TMZ administration in the treatment of melanoma"1806	Immune cells	CD137	4-1BB	protein	activated by	4-1BB antibody (agonist)	CD137 antibody (agonist)	sensitivity to	Cyclophosphamide	CTX	2	1		"Kim YH, Mol Cancer Ther 2009, 8:469-78"	CTX creates an environment in which anti-4-1BB actively promotes the differentiation and expansion of tumor-specific CTLs1807	Melanoma	RXR		protein	activated by	LGD1069 (rexinoid)		sensitivity to	Rosiglitazone		4	1		"Klopper JP, Mol Cancer 2009, 8:16"	Rosiglitazone: PPARG ligand1808	Melanoma	PPAR gamma	Peroxisome proliferator activated receptor gamma	protein	activated by	Rosiglitazone		sensitivity to	LGD1069 (rexinoid)		4	1		"Klopper JP, Mol Cancer 2009, 8:16"	Rexinoid: RXR ligand1809	Melanoma	"BRAF, CRAF, VEGFR, PDGFR"		protein	inhibited by	Sorafenib	Nexavar (R)	resistance to	IFN alpha		3	-1		"Kumar KG, Cancer Biol Ther 2007, 6:1437-41"	"Despite stabilizing IFNAR, Sorafenib - while inhibiting melanoma cell growth by itself - attenuated the anti-proliferative effects of IFN alpha, likely by inhibiting the IFN signaling in 1205Lu human melanoma cells (e.g., inhibits JAK activity)"1810	Melanoma	IFNAR	IFN alpha receptor	protein	activated by	IFN alpha	Interferon alpha	resistance to	Sorafenib	Nexavar (R)	3	-1		"Kumar KG, Cancer Biol Ther 2007, 6:1437-41"	"Despite stabilizing IFNAR, Sorafenib - while inhibiting melanoma cell growth by itself - attenuated the anti-proliferative effects of IFN alpha, likely by inhibiting the IFN signaling in 1205Lu human melanoma cells (e.g., inhibits JAK activity)"1811	Melanoma	IFNAR	IFN alpha receptor	protein	activated by	IFN alpha	Interferon alpha	sensitivity to	PD098059		3	1		"Kumar KG, Cancer Biol Ther 2007, 6:1437-41"	"Pretreatment of 1205Lu cells with MEK1 inhibitor PD098059 noticeably enhanced the anti-proliferative effects of IFN alpha. This is likely due to reduced activity of bTrCP, which in turn leads to increased IFNAR stability"1812	Immune cells	TLR3	Toll like receptor 3	protein	activated by	Poly(I:C)	Poly(inosine:cytosine)	sensitivity to	Radiotherapy		2	1		"Le UM, Radiother Oncol 2009, 90:273-9"	Poly(I:C) is a toll like receptor (TLR) agonist1813	Melanoma	Estrogen receptor	ESR1	protein	inhibited by	Tamoxifen		no relationship with	Chemotherapy (miscellany)		7	0	912	"Lens MB, Cancer 2003, 98:1355-61"	"Meta-analysis of 6 trials involved a combined total of 912 patients. The findings demonstrated that tamoxifen does not improve the overall response rate, complete response rate, or survival rate when administered along with combined chemotherapy regimens"1814	Melanoma	hTERT		protein	inhibited by	RHPS4		no relationship with	Cisplatin	CDDP	3	0		"Leonetti C, Clin Cancer Res 2008, 14:7284-91"	The formation of G-quadruplex structures at telomeric DNA sequences blocks telomerase activity: the pentacyclic acridinium salt RHPS4 is one of the most effective and selective G4 ligands able to rapidly disrupt telomere architecture1815	Melanoma	hTERT		protein	inhibited by	RHPS4		no relationship with	Doxorubicin	Adriamycin (R)	3	0		"Leonetti C, Clin Cancer Res 2008, 14:7284-91"	The formation of G-quadruplex structures at telomeric DNA sequences blocks telomerase activity: the pentacyclic acridinium salt RHPS4 is one of the most effective and selective G4 ligands able to rapidly disrupt telomere architecture1816	Melanoma	IFNAR	IFN alpha receptor	protein	activated by	IFN alpha	Interferon alpha	sensitivity to	Bortezomib	Velcade (R)	4	1		"Lesinski GB, Cancer Res 2008, 68:8351-60"	This drug combination works also in Bcl-2 or Mcl-1 expressing tumors1817	Melanoma	TRAILR	TRAIL receptor	protein	activated by	TRAIL (adenoviral vector)		sensitivity to	Dacarbazine	DTIC	3	1		"Lillehammer T, J Gene Med 2007, 9:440-51"	Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines1818	Melanoma	TRAILR	TRAIL receptor	protein	activated by	TRAIL (adenoviral vector)		sensitivity to	SAHA		3	1		"Lillehammer T, J Gene Med 2007, 9:440-51"	SAHA: HDAC inhibitor. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines1818	Melanoma	HMW-MAA	"gp240, CSPG4, NG2, High molecular weight melanoma associated antigen"		expressed			sensitivity to	Doxorubicin + GrB/scFvMEL		4	1		"Liu Y, Neoplasia 2006, 8:125-35"	GrB/scFvMEL: a fusion protein composed of human granzyme B (GrB) and the single-chain antibody scFvMEL (which targets gp240)1819	Melanoma	HMW-MAA	"gp240, CSPG4, NG2, High molecular weight melanoma associated antigen"		expressed			sensitivity to	Vincristine + GrB/scFvMEL		4	1		"Liu Y, Neoplasia 2006, 8:125-35"	GrB/scFvMEL: a fusion protein composed of human granzyme B (GrB) and the single-chain antibody scFvMEL (which targets gp240)1820	Melanoma	HMW-MAA	"gp240, CSPG4, NG2, High molecular weight melanoma associated antigen"		expressed			sensitivity to	Cisplatin + GrB/scFvMEL		4	1		"Liu Y, Neoplasia 2006, 8:125-35"	GrB/scFvMEL: a fusion protein composed of human granzyme B (GrB) and the single-chain antibody scFvMEL (which targets gp240)1821	Immune cells	CSF2R	GMCSF receptor	protein	activated by	GMCSF	CSF2	no relationship with	Docetaxel + Oxaliplatin		5	0	19	"Locke F, Cancer Chemother Pharmacol 2010, 65:509-14"	A phase II trial demonstrated that combining oxaliplatin + docetaxel + GM-CSF yields no objective tumor response in previously treated advanced melanoma patients1822	Melanoma	p53	TP53	protein	activated by	CP-31398		no relationship with	Cisplatin	CDDP	3	0		"Luu Y, Anticancer Res 2003, 23(1A):99-105 "	CP-31398 can stabilize wild-type p53 and rescue mutant p53 to enhance its transcriptional activity1823	Melanoma	p53	TP53	protein	activated by	CP-31398		no relationship with	Camptothecin		3	0		"Luu Y, Anticancer Res 2003, 23(1A):99-105 "	CP-31398 can stabilize wild-type p53 and rescue mutant p53 to enhance its transcriptional activity1824	Melanoma	p53	TP53	protein	activated by	CP-31398		no relationship with	Vincristine		3	0		"Luu Y, Anticancer Res 2003, 23(1A):99-105 "	CP-31398 can stabilize wild-type p53 and rescue mutant p53 to enhance its transcriptional activity1825	Immune cells	CTLA4		protein	inhibited by	CTLA4 antibody (antagonist)		no relationship with	IL-2	Interleukin-2	5	0	36	"Maker AV, Ann Surg Oncol 2005, 12:1005-16"	"In this phase I-II trial, there is no evidence to support a synergistic effect of CTLA-4 blockade plus IL-2 administration, because the 22% objective response rate is that expected from the sum of these two agents administered alone"1826	Immune cells	IL2R	Interleukin-2 receptor	protein	activated by	IL-2	Interleukin-2	no relationship with	CTLA4 antibody (antagonist)		5	0	36	"Maker AV, Ann Surg Oncol 2005, 12:1005-16"	"In this phase I-II trial, there is no evidence to support a synergistic effect of CTLA-4 blockade plus IL-2 administration, because the 22% objective response rate is that expected from the sum of these two agents administered alone"1827	Melanoma	PRKAR2	PKA regulatory subunit 2	protein	activated by	8-Cl-cAMP		sensitivity to	Cisplatin	CDDP	3	1		"Mantovani G, Oncogene 2008, 27:1834-43"	Human melanomas are characterized by a high R1/R2 ratio (ratio between PKA regulatory subunits R1 and R2) and pharmacological or genetic manipulations able to revert this unbalanced expression (in this case activating R2) cause significant antiproliferative and proapoptotic effects in melanoma cells and increases the activity of chemotherapeutics1828	Melanoma	PRKAR2	PKA regulatory subunit 2	protein	activated by	8-Cl-cAMP		sensitivity to	Vinblastine		3	1		"Mantovani G, Oncogene 2008, 27:1834-43"	Human melanomas are characterized by a high R1/R2 ratio (ratio between PKA regulatory subunits R1 and R2) and pharmacological or genetic manipulations able to revert this unbalanced expression (in this case activating R2) cause significant antiproliferative and proapoptotic effects in melanoma cells and increases the activity of chemotherapeutics1828	Melanoma	TNFR	TNF receptor	protein	activated by	TNF	Tumor necrosis factor	sensitivity to	Radiotherapy		2	1		"Mauceri HJ, Cancer Gene Ther 2009, 16:373-81"	Tumor-associated endothelium is the principal target for TNF radiosensitization and implicate TNF signaling in tumor radiosensitivity1829	Melanoma	RAR	Retinoic acid receptor	protein	activated by	Fenretinide	4-HPR	sensitivity to	Safingol		3	1		"Maurer BJ, J Natl Cancer Inst 2000, 92:1897-909"	Safingol: modulator of ceramide metabolism1830	Melanoma	Estrogen receptor	ESR1	protein	inhibited by	Tamoxifen		resistance to	Carmustine		3	-1		"McClay EF, Cancer Res 1992, 52:6790-6"	"Combination of tamoxifen with CDDP was highly synergistic, whereas tamoxifen was antagonistic with carmustine and an activated form of dacarbazine"1831	Melanoma	Estrogen receptor	ESR1	protein	inhibited by	Tamoxifen		resistance to	Dacarbazine	DTIC	3	-1		"McClay EF, Cancer Res 1992, 52:6790-6"	"Combination of tamoxifen with CDDP was highly synergistic, whereas tamoxifen was antagonistic with carmustine and an activated form of dacarbazine"1832	Immune cells	"IFNAR, IL2R, HRH1"		protein	activated by	IFN-alpha + IL-2 + istamine		no relationship with	Dacarbazine	DTIC	6	0	241	"Middleton M, Ann Oncol 2007, 18:1691-7 "	"Phase III RCT. Setting: metastatic. No improvement in survival by adding immunotherapy agents (IFN, IL2, histamine) to DTIC"1833	Melanoma	IL1R	Interleukin-1 receptor	protein	activated by	IL-1 alpha	Interleukin-1 alpha	sensitivity to	Doxorubicin	Adriamycin (R)	3	1		"Mimnaugh EG, Oncol Res 1992, 4:401-12"	Synergistic antiproliferative effects of the combination of interleukin-1 alpha and doxorubicin against human melanoma cells1834	Melanoma	EpoR	Erythropoietin receptor	protein	activated by	Erythropoietin		resistance to	Cisplatin	CDDP	3	-1		"Mirmohammadsadegh A, J Invest Dermatol 2010, 130:201-10"	"Overexpression of functional EpoR expression in about half of the analyzed clinical melanoma metastasis specimens is associated with anti-apoptotic as well as pro-migratory effects of Epo, which is of importance for the treatment of anemia in advanced melanoma"1835	Melanoma	Rac1		protein	inhibited by	NSC23766		resistance to	Plitidepsin	Aplidin	3	-1		"Munoz-Alonso MJ, J Pharmacol Exp Ther 2008, 324:1093-101"	"Plitidepsin has a dual effect on the human SK-MEL-28 and UACC-257 melanoma cell lines; at low concentrations (</=45 nM), it inhibits the cell cycle by inducing G(1) and G(2)/M arrest, whereas at higher concentrations it induces apoptosis, likely via Rac1/c-Jun NH2-terminal kinase activation  "1836	Melanoma	"JNK, p38 MAPK"		protein	inhibited by	SB203580		resistance to	Plitidepsin	Aplidin	3	-1		"Munoz-Alonso MJ, J Pharmacol Exp Ther 2008, 324:1093-101"	"Plitidepsin has a dual effect on the human SK-MEL-28 and UACC-257 melanoma cell lines; at low concentrations (</=45 nM), it inhibits the cell cycle by inducing G(1) and G(2)/M arrest, whereas at higher concentrations it induces apoptosis, likely via Rac1/c-Jun NH2-terminal kinase activation  "1837	Melanoma	MEK		protein	inhibited by	PD184352		no relationship with	Radiotherapy		3	0		"Munshi A, Mol Cancer Ther 2004, 3:985-92"	PD184352 is a MEK inhibitor1838	Melanoma	HDAC	Histone deacetylase	protein	inhibited by	Vorinostat		no relationship with	Doxorubicin	Adriamycin (R)	5	0	6	"Munster PN, Br J Cancer 2009, 101:1044-50"	In this phase I trial (dose finding) both melanoma (n=6) and non-melanoma (n=26) patients were enrolled; the two partial responses were observed in non-melanoma patients1839	Melanoma	ALK2		protein	activated by	BMP7		sensitivity to	Cisplatin	CDDP	3	1		"Na YR, Cancer Sci 2009, 100:2218-25"	ALK2: BMP receptor. BMP7 induces mesenchymal-to-epithelial transition in melanoma cells and reduces melanoma resistance to CDDP1840	Immune cells	TLR	Toll like receptor	protein	activated by	CpG oligonucleotide		sensitivity to	Dacarbazine	DTIC	2	1		"Najar HM, J Invest Dermatol 2008, 128:2204-10"	Topical (intraperitoneal) administration of CpG oligos increases therapeutic effect of DTIC1841	Immune cells	IFNAR		protein	activated by	IFN alpha	Interferon alpha	sensitivity to	EGCG	Epigallocatechin-3-gallate	4	1		"Nihal M, Cell Cycle 2009, 8:2057-63"	Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma1842	Melanoma	AKT	PKB	protein	inhibited by	LY294002		no relationship with	TNF	Tumor necrosis factor	1	0		"Nishida S, Life Sci 2003, 74:781-92"	"MEK1/2 plays an important role in TNFalpha-resistance and is more important than NFkB, Akt, and p38MAPK in anti-apoptotic PKC signaling; TNFalpha-resistance can be overcome by inhibiting MEK1/2"1843	Melanoma	p38 MAPK		protein	inhibited by	SB203580		no relationship with	TNF	Tumor necrosis factor	1	0		"Nishida S, Life Sci 2003, 74:781-92"	"MEK1/2 plays an important role in TNFalpha-resistance and is more important than NFkB, Akt, and p38MAPK in anti-apoptotic PKC signaling; TNFalpha-resistance can be overcome by inhibiting MEK1/2"1844	Immune cells	IL18R	Interleukin-18 receptor	protein	activated by	IL-18	Interleukin-18	sensitivity to	Alpha-galactosylceramide		2	1		"Nishio S, Cancer Sci 2008, 99:113-20"	"alpha-Galactosylceramide (alpha-GalCer) shows antitumor effects by activating natural killer (NK) cells indirectly through stimulation of the secretion of cytokines by NKT cells, whereas interleukin (IL)-18 shows antitumor effects by activating NK cells directly"1845	Immune cells	Inflammation pathway			modulated by	Thalidomide		no relationship with	Dacarbazine	DTIC	5	0	15	"Ott PA, Chemotherapy 2009, 55:221-7"	Metastatic setting. The addition of thalidomide to dacarbazine in metastatic melanoma yielded activity insufficient to proceed with additional trials of this combination1846	Plasma/serum	Antithrombin III		protein	inhibited by	Heparin-deoxycholic acid (conjugate)	HD	sensitivity to	Doxorubicin	Adriamycin (R)	2	1		"Park K, Pharm Res 2008, 25:268-76"	"Combination therapy of heparin-deoxycholic acid conjugate and doxorubicin against B16F10 melanoma is effective in vivo, likely through a potent antiangiogenic effect"1847	Immune cells	IL21R	IL-21 receptor	protein	activated by	IL-21	Interleukin-21	sensitivity to	Chemoimmunotherapy (cyclophosphamide + adoptive cell therapy)		2	1		"Petersen CC, Cytokine 2010, 49:80-8"	mIL-21 enhances chemoimmunotherapy: it amplifies the number of tumor-specific T cells in the circulation and also stunts early tumor growth1848	Melanoma	RIG-I	DDX58	protein	activated by	3p-siRNA		sensitivity to	Bcl-2 siRNA		2	1		"Poeck H, Nat Med 2008, 14:1256-63"	"Anti-Bcl-2 3p-siRNA can both inhibit Bcl-2 expression and activate Rig-I, the immunostimulating cytosolic antiviral helicase retinoic acid-induced protein I"1849	Immune cells	"CD3, CD28"		protein	activated by	CD3 and CD28 antibodies (activating)		sensitivity to	Temozolomide	TMZ	4	1		"Radfar S, J Immunol 2009, 183:6800-7"	CD4+ T cells activated with anti-CD3 and anti-CD28 antibodies dramatically enhance chemotherapeutic melanoma responses in vitro and in vivo1850	Melanoma	MGMT	O-6-methylguanine-DNA methyltransferase 	protein	inhibited by	Lomeguatrib		no relationship with	Temozolomide	TMZ	6	0	104	"Ranson M, J Clin Oncol 2007, 25:2540-5"	RCT of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. The efficacy of LM and TMZ in the current dosing schedule is similar to that of TMZ alone1851	Melanoma	"COX-2, PPAR gamma"		protein	"inhibited by, activated by"	Rofecoxib + Pioglitazone		sensitivity to	Trofosfamide		6	1	76	"Reichle A, Melanoma Res 2007, 17:360-4"	"In this phase II RCT (advanced melanoma), combination therapy was associated with significantly improved progression free survival. Note: rofecoxib has been withdrawn from the market due to cardiovascular toxicity"1852	Melanoma	Melanin			expressed			sensitivity to	6D2 antibody radioimmunotherapy		4	1		"Revskaya E, Clin Cancer Res 2009, 15:2373-9"	6D2 is an anti-melanin antibody that delivers radioactive agents to melanin-containing cells1853	Immune cells	"IFNAR, IL2R"		protein	activated by	IFN alpha + IL-2		no relationship with	Cisplatin + Dacarbazine		6	0	176	"Ridolfi R, J Clin Oncol 2002, 20:1600-7"	"In this phase III RCT of cisplatin plus DTIC with or without the 2 cytokines, no significant improvement of survival was observed"1854	Melanoma	HDAC	Histone deacetylase	protein	inhibited by	Valproic acid		no relationship with	Dacarbazine + IFN alpha		5	0	29	"Rocca A, Br J Cancer 2009, 100:28-36"	"In a phase I-II trial of valproic acid (histone deacetylase [HDAC] inhibitor) plus chemoimmunotherapy (DTIC + IFN-alpha), this combination regimen did not produce results overtly superior to standard therapy in patients with advanced melanoma"1855	Melanoma	ATM	Ataxia Telangiectasia Mutated 	protein	inhibited by	ATM inhibitor		resistance to	Etoposide	VP-16	3	-1		"Rudolf K, Cancer Invest 2009, 27:704-17"	ATM silencing inhibits apoptosis induced by etoposide1856	Endothelial cells	CD13	Aminopeptidase N	protein	targeted by	NGR peptide		sensitivity to	Doxorubicin	Adriamycin (R)	2	1		"Sacchi A, Cancer Res 2004, 64:7150-5"	"NGR peptide is a ligand for CD13, which is expressed by tumor vessels. NGR-TNF is a peptide-TNF conjugate able to target tumor blood vessels"1857	Melanoma	TLR3	Toll like receptor 3	protein	activated by	Poly(I:C)	Poly(inosine:cytosine)	sensitivity to	IFN alpha		3	1		"Salaun B, Clin Cancer Res 2007, 13(15 Pt 1):4565-74"	Activation of IFNAR and TLR3 shows synergistic therapeutic potential (inhibition of melanoma cell survival)1858	Melanoma	IFNAR	IFN alpha receptor	protein	activated by	IFN alpha	Interferon alpha	sensitivity to	Poly(I:C)	TLR3 agonist	3	1		"Salaun B, Clin Cancer Res 2007, 13(15 Pt 1):4565-74"	Activation of IFNAR and TLR3 shows synergistic therapeutic potential (inhibition of melanoma cell survival)1858	Melanoma	IFNGR	IFN gamma receptor	protein	activated by	IFN gamma	Interferon gamma	sensitivity to	GGTI-298		3	1		"Sarrabayrouse G, PLoS One 2010, 5:e9043"	Co-administration of IFN-gamma and geranylgeranyl transferase inhibitor GGTI-298 enhance generation and activity of melanoma-specific cytotoxic T cells (CTL)1859	Melanoma	Uncharacterized			activated by	IP6	Inositol 6 phosphate	sensitivity to	Pterostilbene		3	1		"Schneider JG, Am J Surg 2009, 198:679-84"	Pterostilbene produces caspase-dependent apoptosis in melanoma cell lines. Combination treatment with IP6 produces synergistic growth inhibition. Both compounds have significant potential for a therapeutic role in the treatment of melanoma1860	Melanoma	IKKB	IKB kinase beta	protein	inhibited by	KINK-1		no relationship with	Cisplatin	CDDP	3	0		"Schon M, J Natl Cancer Inst 2008, 100:862-75"	KINK-1 did not increase the therapeutic activity of cisplatin1861	Melanoma	Integrin beta 1		protein	activated by	Contortrostatin	Disintegrin family member	sensitivity to	Cytarabine	Cytosine arabinoside	4	1		"Schwartz MA, Clin Cancer Res 2008, 14:6193-7"	Contortrostatin is a member of the disintegrin family that activates integrin signaling (unlike other disintegrins)1862	Melanoma	Integrin beta 1		protein	activated by	TS2/16 antibody		sensitivity to	Cytarabine	Cytosine arabinoside	4	1		"Schwartz MA, Clin Cancer Res 2008, 14:6193-7"	TS2/16 is an activating anti-integrin beta 1 antibody1864	Immune cells	CSF2R	GMCSF receptor	protein	activated by	GMCSF	CSF2	sensitivity to	Oncolytic herpesvirus		5	1	50	"Senzer NN, J Clin Oncol 2009, 27:5763-71"	"In this non-comparative phase II clinical trial of a GMCSF-encoding oncolytic herpesvirus, promising tumor response (26%) and survival (52% at 2 years) rates were observed in patients with metastatic melanoma"1864	Melanoma	ERK		protein	inhibited by	PD98059	MEK inhibitor	no relationship with	Paclitaxel	Taxol	3	0		"Selimovic D, Cell Signal 2008, 20:311-22"	"Pretreatment of melanoma cells with the JNK inhibitor (SP600125) or the p38 inhibitor (SB203580) blocked taxol-induced UCP2 downregulation, ROS generation and apoptosis, whereas the ERK inhibitor (PD98059) had no such effect."1865	Melanoma	PPAR	Peroxisome proliferator activated receptor	protein	activated by	Bezafibrate		resistance to	Vitamin D3	Calcitriol	3	-1		"Sertznig P, Anticancer Res 2009, 29:3647-58"	"Simultaneous treatment with bezafibrate and 1,25(OH)2D3 resulted in a statistically significant partial antagonisation of the 1,25(OH)2D3-induced inhibition of MeWo cell proliferation"1866	Endothelial cells	TNFR	TNF receptor	protein	activated by	TNF	Tumor necrosis factor	sensitivity to	Doxorubicin (liposome formulation)	Caelyx (R)	2	1		"Seynhaeve AL, Cancer Res 2007, 67:9455-62"	"Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response: likely TNF renders more tumor vessels permeable, leading to a more homogeneous distribution of the liposomes throughout the tumor, which is crucial for an optimal tumor response"1867	Immune cells	IFNAR		protein	activated by	IFN alpha	Interferon alpha	sensitivity to	Vaccine (gp100 peptide)		2	1		"Sikora AG, J Immunol 2009, 182:7398-407"	"IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. These results demonstrate the efficacy of IFN-alpha as an adjuvant for peptide vaccination, give insight into its mechanism of action, and provide a rationale for clinical trials in which vaccination is combined with standard-of-care IFN-alpha therapy for melanoma"1868	Melanoma	"VEGFR1, VEGFR2, VEGFR3"		protein	inhibited by	PTK787/ZK222584	PTK/ZK	no relationship with	5-Fluorouracil	5-FU	1	0		"Sini P, Cancer Res 2008, 68:1581-92"	PTK/ZK is a small molecule inhibitor of the 3 VEGFR1869	Immune cells	IFNAR	IFN alpha receptor	protein	activated by	IFN alpha 2b pegylated	PEG interferon	no relationship with	Temozolomide	TMZ	5	0	124	"Spieth K, Ann Oncol 2008, 19:801-6"	Overall response rate: 18% (not greater than expected with DTIC alone)1870	Immune cells	TLR	Toll like receptor	protein	activated by	CpG oligo + Poly(I:C)		sensitivity to	CD40L gene therapy		2	1		"Stone GW, PLoS One 2009, 4:e7334"	"Stimulation of CD40 and Toll-Like Receptors (TLR) can be synergistic, resulting in even stronger dendritic cell (DC) and CD8+ T cell responses and anticancer activity"1871	Immune cells	CD40	CD40L receptor	protein	activated by	CD40L gene therapy		sensitivity to	CpG oligo + Poly(I:C)		2	1		"Stone GW, PLoS One 2009, 4:e7334"	"Stimulation of CD40 and Toll-Like Receptors (TLR) can be synergistic, resulting in even stronger dendritic cell (DC) and CD8+ T cell responses and anticancer activity"1872	Melanoma	Proteasome		protein	inhibited by	Bortezomib	Velcade (R)	no relationship with	Temozolomide	TMZ	5	0	19	"Su Y, Clin Cancer Res 2010, 16:348-57"	In this phase I trial (dose-finding study) only one partial response (8 months) and three with stable disease >or=4 months were observed. A significant reduction in proteasome-specific activity was observed 1 hour after infusion at all bortezomib doses1873	Immune cells	IL2R	Interleukin-2 receptor	protein	activated by	IL-2	Interleukin-2	no relationship with	Temozolomide	TMZ	5	0	38	"Tarhini AA, Cancer 2008, 113:1632-40"	IL-2: high dose. The overall response rate and the durability of responses with this combination did not exceed those of single-agent HD IL-21874	Melanoma	mTOR	Mammalian target of rapamycin	protein	inhibited by	Rapamycin	Sirolimus	no relationship with	Dacarbazine	DTIC	4	0		"Thallinger C, Pharmacology 2008, 82:233-8"	"The combination of rapamycin and DTIC was not superior to rapamycin monotreatment (while rapamycin exerts a relevant antineoplastic effect, which appeared more pronounced in DTIC less sensitive melanoma xenografts)"1875	Melanoma	"KIT, PDGFR"		protein	inhibited by	Imatinib	Gleevec (R)	resistance to	Temozolomide	TMZ	3	-1		"Triozzi PL, Melanoma Res 2008, 18:420-30"	Imatinib causes TMZ resistance in vitro while it is synergistic with TMZ in vivo1876	Melanoma	"KIT, PDGFR"		protein	inhibited by	Imatinib	Gleevec (R)	resistance to	Temozolomide	TMZ	3	-1		"Triozzi PL, Melanoma Res 2008, 18:420-30"	Imatinib causes TMZ resistance in vitro while it is synergistic with TMZ in vivo1877	Melanoma	IL1R	Interleukin-1 receptor	protein	activated by	IL-1 alpha	Interleukin-1 alpha	sensitivity to	Etoposide	VP-16	3	1		"Usui N, J Natl Cancer Inst 1989, 81:1904-9"	Synergistic antitumor activity of etoposide and human interleukin-1 alpha against human melanoma cells1878	Immune cells	IFNAR	IFN alpha receptor	protein	activated by	IFN alpha	Interferon alpha	no relationship with	Thalidomide		5	0	18	"Vaishampayan UN, Anticancer Drugs 2007, 18:1221-6"	"In this phase II trial, no objective responses were noted; three patients demonstrated disease stabilization. This combination failed to demonstrate clinical efficacy in pretreated metastatic malignant melanoma"1879	Immune cells	IFNAR	IFN alpha receptor	protein	activated by	IFN alpha	Interferon alpha	no relationship with	Bevacizumab	Avastin (R)	6	0	32	"Varker KA, Ann Surg Oncol 2007, 14:2367-76"	This phase II RCT showed that addition of IFN to bevacizumab was not associated with clinical benefit in patients with metastatic melanoma1880	Melanoma	TLR3	Toll like receptor 3	protein	activated by	Poly (I:C)	Poly(inosine:cytosine)	sensitivity to	LBW242	Smac mimetic	3	1		"Weber A, Cell Death Differ 2010, 17:942-51"	"LBW242 is a SMAC mimetic and thus a IAP inhibitor. Sensitisation towards poly I:C-dependent caspase-8 activation and apoptosis in melanoma cells was also achieved by the synthetic Smac mimetic/inhibitor of apoptosis protein (IAP) antagonist, LBW242, or by specific downregulation of cIAP1 by siRNA"1881	Immune cells	TLR	Toll like receptor	protein	activated by	PF-3512676	CpG oligonucleotide	no relationship with	Dacarbazine	DTIC	6	0	184	"Weber JS, Cancer 2009, 115:3944-54"	"In a phase II-III RCT, the addition of CpG oligodeoxynucleotide PF-3512676 does not add significant tumor response advantage to dacarbazine alone in patients with advanced melanoma"1882	Immune cells	TLR9	Toll like receptor 9	protein	activated by	CpG oligonucleotide		sensitivity to	CD40 antibody (agonist)		2	1		"Wells JW, J Immunol 2008, 181:3422-31"	Peptide-based vaccine works better when both TLR and CD40 stimulation is achieved1883	Immune cells	CD40	CD40L receptor	protein	activated by	CD40 antibody (agonist)		sensitivity to	CpG oligonucleotide		2	1		"Wells JW, J Immunol 2008, 181:3422-31"	Peptide-based vaccine works better when both TLR and CD40 stimulation is achieved1884	Melanoma	PI3K		protein	inhibited by	LY294002		no relationship with	Rapamycin	Sirolimus	3	0		"Werzowa J, Br J Dermatol 2009, 160:955-64"	"Both PI3K inhibition (by LY294002) and mTORC1 (mTOR complexed with Raptor) inhibition (by rapamycin) leads to AKT phosphorylation by mTORC2 (mTOR complexed with Rictor) activation, which lilekly explains the lack of synergism between the two drugs"1885	Melanoma	mTOR	Mammalian target of rapamycin	protein	inhibited by	Rapamycin	Sirolimus	no relationship with	LY294002	AKT inhibitor	3	0		"Werzowa J, Br J Dermatol 2009, 160:955-64"	"Both PI3K inhibition (by LY294002) and mTORC1 inhibition (by rapamycin) leads to AKT phosphorylation by mTORC2 activation, which lilekly explains the lack of synergism between the two drugs"1886	Immune cells	IL12R	Interleukin-12 receptor	protein	activated by	IL-12	Interleukin-12	sensitivity to	4-1BB antibody (agonist)	CD137 antibody (agonist)	2	1		"Xu D, Int J Cancer 2004, 109:499-506"	"NK cell depletion significantly reduced both tumor-specific CTL activity and the number of tumor-specific IFN-gamma-producing cells, suggesting that this synergistic effect requires the participation of both NK and CD8(+) T cells"1887	Immune cells	CD137	4-1BB	protein	activated by	4-1BB antibody (agonist)	CD137 antibody (agonist)	sensitivity to	IL-12	Interleukin-12	2	1		"Xu D, Int J Cancer 2004, 109:499-506"	"NK cell depletion significantly reduced both tumor-specific CTL activity and the number of tumor-specific IFN-gamma-producing cells, suggesting that this synergistic effect requires the participation of both NK and CD8(+) T cells"1888	Melanoma	BRAF	B-Raf	protein	inhibited by	BAY 54-9085	BRAF inhibitor	no relationship with	BMS-345541	NFkB inhibitor	4	0		"Yang J, Mol Cancer Ther 2009, 8:636-47"	"BMS-345541 is an IKKB inhibitor and thus a NFkB inhibitor (IKKB inhibits IKB, which in turn inhibits NFkB)"1889	Melanoma	IKKB	IKB kinase beta	protein	inhibited by	BMS-345541	NFkB inhibitor	no relationship with	BAY 54-9085	BRAF inhibitor	4	0		"Yang J, Mol Cancer Ther 2009, 8:636-47"	BAY 54-9085 is a BRAF inhibitor1890	Melanoma	Caspase		protein	inhibited by	Caspase inhibitors		resistance to	Magnolol		3	-1		"You Q, Arch Pharm Res 2009, 32:1789-94"	"Pan-caspase inhibitor (z-VADfmk), caspase-3 inhibitor (z-DEVD-fmk), capase-8 inhibitor (z-IETD-fmk), caspase-9 inhibitor (z-LEHD-fmk) and caspase-10 inhibitor (z-AEVD-fmk) inhibited magnolol-induced A375-S2 cell apoptosis"1891	Immune cells	IL18R	Interleukin-18 receptor	protein	activated by	IL-18	Interleukin-18	sensitivity to	Oncolytic adenovirus		4	1		"Zheng JN, Cancer Gene Ther 2010, 17:28-36"	Oncolytic adenoviral vector encoding IL-18 showed greater anti-melanoma activity than oncolytic virus or IL-18 gene therapy alone1891	Melanoma	p53	TP53	protein	inhibited by	Pifithrin-alpha	QB102 (PFT-alpha)	resistance to	Elafin		4	-1		"Yu KS, Int J Cancer 2009, Epub ahead of print"	Elafin is a protein that acts as a protease inhibitor; inhibition of p53 inhibits elafin anti-melanoma activity1893	Melanoma	NDRG2			downregulated			sensitivity to	NDRG2 gene therapy		2	1		"Kim A, Carcinogenesis 2009, 30:927-36"	"NDRG2 affects invasion through suppression of nuclear factor kappa B (NFkB) activity. In animal experiments, subcutaneously injected B16F10-NDRG2 cells showed delayed tumor growth compared with B16F10-mock cells"1894	Host	eNOS	"NOS3, endothelial nitric oxide synthase"	mRNA	expressed			sensitivity to	eNOS knockout		2	1		"Lahdenranta J, Cancer Res 2009, 69:2801-8"	Genetic deletion of eNOS in the host also leads to a decrease in T241 tumor cell dissemination to the lymph nodes and macroscopic lymph node metastasis of B16F10 melanoma1896	Melanoma	Topoisomerase I	TOP1	uncharacterized	inhibited by	Karenitecin		sensitivity to	Valproic acid	HDAC inhibitor	4	1		"Daud AI, Clin Cancer Res 2009, 15:2479-87"	Karenitecin: topoisomerase I inhibitor. The same article describes a phase I-II trial in which metastatic disease stabilization was achieved in 47% of 33 evaluable patients1898	Melanoma	Bcl-2		mRNA	downregulated by	Oblimersen	"Bcl-2 antisense oligo, G3139"	sensitivity to	d-(KLAKLAK)(2)	Proapoptotic peptide	2	1		"Ko YT, Mol Pharm 2009, 6:971-7"	Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 show synergistic anticancer therapy1899	Melanoma	Tyrosinase		protein	expressed			sensitivity to	NPrCAP/M		2	1		"Sato M, J Invest Dermatol 2009, 129:2233-41"	"NPrCAP/M is a nanoparticle that, like NPrCAP, is integrated as a substrate in the oxidative reaction by tyrosinase. It shows anti-melanoma activity when heated to 43 degrees C by an external alternating magnetic field (AMF)"1900	Melanoma	MUC4		protein	expressed			resistance to	Cisplatin		3	-1		"Workman HC, Cancer Res 2009, 69:2845-52"	Membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms1902	Immune cells	Immunity pathway			modulated by	HemoHIM		sensitivity to	Cisplatin	CDDP	2	1		"Park HR, BMC Cancer 2009, 9:85"	"HemoHIM was prepared by adding the ethanol-insoluble fraction to the total water extract of a mixture of 3 edible herbs, Angelica Radix, Cnidium Rhizoma and Paeonia Radix. HemoHIM administration enhanced both NK cell and Tc cell activity in mice and synergized with CDDP"1904	Melanoma	PPAR gamma	Peroxisome proliferator activated receptor gamma	protein	activated by	Ciglitazone	PPAR gamma agonist	sensitivity to	Retinoid IIF	6-OH-11-O-hydroxyphenantrene 	3	1		"Papi A, Oncol Rep 2009, 21:1083-9"	Enhanced effects of PPARgamma ligands and RXR selective retinoids (IIF) in combination to inhibit migration and invasiveness in melanoma cells1906	Melanoma	RXR	Retinoid X receptor	protein	activated by	Retinoid IIF	6-OH-11-O-hydroxyphenantrene 	sensitivity to	Ciglitazone	PPAR gamma agonist	3	1		"Papi A, Oncol Rep 2009, 21:1083-9"	Enhanced effects of PPARgamma ligands and RXR selective retinoids (IIF) in combination to inhibit migration and invasiveness in melanoma cells1907	Melanoma	Calcineurin		protein	expressed			sensitivity to	Cyclosporine	CsA	3	1		"Juhász T, Int J Oncol 2009, 34:995-1003"	"CsA lowered the enzyme activity by 50% and caused elevation in both mRNA and protein expression of calcineurin. Cell proliferation was diminished, as well as the cellular morphology and the actin organization were altered in both cell lines. CsA increased cell death moderately in both cell lines and reduced the metabolic activity of HT168 cells, but not that of WM35 cells. CsA also elevated the expressions of both Bcl-2 and ERK1/2"1908	Endothelial cells	Angiogenesis pathway			inhibited by	Combretastatin A4	CA4P	sensitivity to	Doxorubicin (liposomial)		2	1		"Mitrus I, Acta Biochim Pol 2009, 56:161-5"	Combination of combretastatin A4 phosphate (a vascular-disruptive drug) and doxorubicin-containing liposomes affects growth of B16-F10 tumors1910	Melanoma	Hyaluronan synthase		protein	expressed			sensitivity to	4-Methylumbelliferone	4-MU	3	1		"Kultti A, Exp Cell Res 2009, 315:1914-23"	"4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3, which leads to significant inhibition of cell migration, proliferation and invasion, supporting the importance of hyaluronan synthesis in cancer, and the therapeutic potential of hyaluronan synthesis inhibition"1911	Melanoma	HRH1	Histamine receptor H1	protein	expressed			sensitivity to	Histamine		3	1		"Medina VA, Free Radic Biol Med 2009, 46:1510-5"	Histamine inhibits melanoma cell proliferation likely by increasing hydrogen peroxide levels1912	Melanoma	Biot2	CCDC7	mRNA	expressed			sensitivity to	Biot2 siRNA		1	1		"Wang CT, Cell Mol Biol Lett 2009, 14:363-76"	Treating B16 murine melanoma and CT26 murine colorectal adenocarcinoma with shRNA targeting Biot2 can significantly reduce the proliferation rate of these tumor cell lines in vitro. The tumorigenicity of the CT26 cells transfected with shRNA targeting Biot2 was also decreased distinctly in vivo compared with control. It was therefore concluded that Biot2 plays a key role in tumorigenesis and could be a potential target for biotherapy1913	Melanoma	ARF6	ADP ribosylation factor 6	mRNA	expressed			sensitivity to	ARF6 dominant negative		4	1		"Muralidharan-Chari V, Cancer Res 2009, 69:2201-9"	Mice injected with tumor cells expressing a dominantly inhibitory ARF6 mutant exhibited a lower incidence and degree of invasion and lung metastasis compared with control animals1914	Melanoma	BRAF		protein	mut V600E			sensitivity to	GDC-0879	RAF inhibitor	4	1		"Hoeflich KP, Cancer Res 2009, 69:3042-51"	Anti-melanoma efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAF(V600E) mutational status and sustained extracellular signal-regulated kinase (ERK) / mitogen-activated protein kinase (MAPK) pathway suppression1915	Immune cells	IL21R	IL-21 receptor	protein	uncharacterized			no relationship with	IL-21		5	0	24	"Davis ID, Clin Cancer Res 2009, 15:2123-9"	"Setting: metastatic. Phase II trial. Tumor response rate < 10% (2/24, 1 complete + 1 partial)"1917	Endothelial cells	Tie2	TEK	protein	inhibited by	Soluble Tie2		sensitivity to	Sorafenib	Nexavar (R)	2	1		"Tsai JH, Mol Cancer Res 2009, 7:300-10"	"Soluble Tie2 inhibits the Tie2 pathway (Tie2 is the receptor for angiopoietin-1). Tie2Ex failed to inhibit the growth of established K1735 tumors. These tumors were additionally treated with sorafenib, a multikinase inhibitor that inhibits tumor endothelial cell ERK activation but not AKT activation. Combining Tie2Ex and sorafenib decreased both endothelial cell AKT and ERK activation, decreased endothelial cell survival and proliferation, and significantly inhibited growth of established tumors"1919	"Melanoma, endothelial cells"	"BRAF, CRAF, VEGFR, PDGFR"		protein	inhibited by	Sorafenib	Nexavar (R)	sensitivity to	Soluble Tie2		2	1		"Tsai JH, Mol Cancer Res 2009, 7:300-10"	"Soluble Tie2 inhibits the Tie2 pathway (Tie2 is the receptor for angiopoietin-1). Tie2Ex failed to inhibit the growth of established K1735 tumors. These tumors were additionally treated with sorafenib, a multikinase inhibitor that inhibits tumor endothelial cell ERK activation but not AKT activation. Combining Tie2Ex and sorafenib decreased both endothelial cell AKT and ERK activation, decreased endothelial cell survival and proliferation, and significantly inhibited growth of established tumors"1921	Melanoma	MEK		protein	inhibited by	U0126		sensitivity to	Metabolic stress (glucose starvation)		3	1		"Esteve-Puig R, PLoS One 2009, 4:e4771"	"BRAF(V600E) melanoma cells are less sensitive to apoptosis from metabolic stress (mediated by the LKB1-AMPKalpha energy sensor): the inhibition of the RAS pathway (with U0126) in BRAF(V600E) mutant melanoma cells recovered the complex formation and rescued the LKB1-AMPKalpha metabolic stress-induced response, increasing apoptosis in cooperation with glucose starvation"1923	Melanoma	Glucose			low (hypoglycemia)			sensitivity to	U0126	MEK inhibitor	3	1		"Esteve-Puig R, PLoS One 2009, 4:e4771"	"BRAF(V600E) melanoma cells are less sensitive to apoptosis from metabolic stress (mediated by the LKB1-AMPKalpha energy sensor): the inhibition of the RAS pathway (with U0126) in BRAF(V600E) mutant melanoma cells recovered the complex formation and rescued the LKB1-AMPKalpha metabolic stress-induced response, increasing apoptosis in cooperation with glucose starvation"1924	Melanoma	SOX9		mRNA	downregulated			sensitivity to	SOX9 gene therapy		3	1		"Passeron T, J Clin Invest 2009, 119:954-63"	SOX9 is often downregulated in melanoma. Melanoma cell lines transfected with SOX9 showed a significant decrease in proliferation compared with controls 1925	Melanoma	SOX9		protein	upregulated by	SOX9 gene therapy		sensitivity to	Retinoic acid		3	1		"Passeron T, J Clin Invest 2009, 119:954-63"	SOX9 is often downregulated in melanoma. Melanoma cell lines transfected with SOX9 (but not controls) are sensitive to retinoic acid1927	Melanoma	PTDGR	PGD2 receptor	protein	activated by	PGD2	Prostaglandin D2	sensitivity to	Retinoic acid		3	1		"Passeron T, J Clin Invest 2009, 119:954-63"	SOX9 is often downregulated in melanoma. Upregulating SOX9 expression with PGD2 renders melanoma cells sensitive to retinoic acid1930	Melanoma	RAR	Retinoic acid receptor	protein	activated by	Retinoic acid		sensitivity to	SOX9 gene therapy		3	1		"Passeron T, J Clin Invest 2009, 119:954-63"	SOX9 is often downregulated in melanoma. Melanoma cell lines transfected with SOX9 (but not controls) are sensitive to retinoic acid1932	Melanoma	RAR	Retinoic acid receptor	protein	activated by	Retinoic acid		sensitivity to	PGD2	Prostaglandin D2	3	1		"Passeron T, J Clin Invest 2009, 119:954-63"	SOX9 is often downregulated in melanoma. Upregulating SOX9 expression with PGD2 renders melanoma cells sensitive to retinoic acid1933	Melanoma	RXR gamma		mRNA	downregulated by	RXR gamma siRNA		resistance to	LGD1069 (rexinoid)		3	-1		"Klopper JP, Mol Cancer 2009, 8:16"	Rexinoid: RXR ligand1934	Melanoma	PPAR gamma	Peroxisome proliferator activated receptor gamma	mRNA	downregulated by	PPAR gamma siRNA		resistance to	Rosiglitazone		3	-1		"Klopper JP, Mol Cancer 2009, 8:16"	Rosiglitazone: PPARG ligand1935	Immune cells	STAT3	Signal transducer and activator of transcription 3 	mRNA	downregulated by	STAT3 knockout		sensitivity to	CpG oligonucleotide		2	1		"Kortylewski M, Cancer Res 2009, 69:2497-505"	Targeting Stat3 in immune cells (hematopoietic system) can drastically improve CpG-based immunotherapeutic approaches